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2 Chapter 1
Fig.l. Schematic representation of a GPCR, a heterotrimeric G protein and effector enzym.
since deletion or modification of this region results in a receptor that still binds ligands but can
not generate a response. Besides the third cytoplasmatic loop, other cytoplasmatic domains
(e.g. second intracellular loop and cytoplasmatic tail) were also found to contribute to receptor
G-protein interaction (Gudermann et al., 1995, Moro et al., 1993, Zhu et al., 1994).
Upon agonist binding, the GPCR is thought to form ahigh affinity complex with the
agonist and the heterotrimeric G-protein, consisting of an ex, ~ and y subunit (ternary complex
model, Fig. 1) (De Lean, 1980). This receptor G-protein interaction causes the release of GDP
from the guanine nucleotide binding site on the Gex-subunit, allowing GTP to bind. The GTP-
bound form of the G-protein (ex subunit) dissociates from the receptor and activates a specific
effector protein, which in tum is responsible for the modulation of cellular activity. In recent
years it has become evident that different G-proteins (Bimbaumer, 1993, Spiegel, 1992) exist,
whereas also ~y subunits were found to be responsible for the activation of various cellular
processes (Clapham and Neer, 1993, see also section 1.3.1). Moreover, also effector enzymes
such as adenylyl cyclase and phospholipase C consist of a large family of isoenzymes
(Cockcroft and Thomas, 1992, Iyengar, 1993, Tang and Gilman, 1992). The interaction of the
GPCRs with the intracellular biochemical pathways is clearly very complex (Milligan, 1993).
As such, the class of GPCRs can drastically influence the cellular activity. It is therefore
important for the responsiveness of the biological system to be tightly controlled. GPCRs have
long been known to be under control of negative feedback mechanisms (Collins, 1993, Lohse,
1993). These negative feedback mechanisms cause a loss of cellular responsiveness despite
activation of the GPCR, a process referred to as desensitization. This phenomenon may also
become apparent under pathophysiological conditions and after drug therapy (see section 1.3).
As such it may have consequences for the development of effective drug therapy.
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1.1.2 Histamine receptors
One of the many neurotransmitters acting via GPCRs is the monoamine histamine. In the CNS
this amine is synthesized in a restricted population of neurons located in the tuberomammillary
nucleus of the posterior hypothalamus (Airksinen et aI., 1992). These neurons project
diffusely to most cerebral areas and have been implicated in several functions of the brain of
mammalian species (e.g. sleep/wakefullness, hormonal secretion, cardiovascular control,
thermoregulation) (Schwartz et aI., 1991). In various peripheral tissues histamine is stored in
mast cells, basophils, enterochromaffin cells and probably also in specific neurons. In e.g. the
gastric mucosa histamine is, depending on the species, stored in enterochromaffin-like cells or
specific mast cells, which in response to gastrin and acetylcholine release the amine
(Rangachari et aI., 1992). Histamine in tum stimulates the gastric acid secretion by parietal
cells through interaction with specific receptors (Bertaccini and Coruzzi, 1992).
Histamine stored in mast cells also plays an important role in the pathogenesis of various
allergic conditions. After mast cell degranulation, release of histamine leads to various of the
well-known symptoms of allergic conditions in the skin and the airway system (Barnes, 1991,
Ring et ai., 1985). Based on these observations histamine is considered as one of the
important mediators of allergy and inflammation.
Initially, research in the histamine field was completely focussed on the role of histamine in
allergic diseases indeed and this intensive research resulted in the development of several potent
"anti-histamines" (e.g. mepyramine), which were useful in inhibiting certain symptoms of
allergic conditions (see for references Janssens, 1993). The observation that these "anti-
histamines" could not antagonize histamine-induced effects at the stomach and the heart, led
Ash and Schild in 1966 to the hypothesis that histamine should act via at least two distinct
receptor subtypes, referred to as the histamine HI and H2 receptor (Table 1) (Ash and Schild,
1966). This hypothesis became generally accepted when Black et al. (1972) succeeded in the
synthesis of a series of new compounds (e.g. burimamide), which were able to block the
effects of histamine on the stomach and the heart. These H2 receptor antagonists proved to be
very useful in the therapy of gastric ulcers (Bertaccini and Corruzzi, 1992, Deakin and
Williams, 1992). In recent years it became apparent that histamine is not only a mediator of
several pathophysiological conditions, but also functions as a neurotransmitter (see reviews
Hill, 1990, Leurs et ai., 1995a, Schwartz et ai., 1991). As found for many other
neurtransmitter systems, a presynaptic receptor (H3) for histamine appeared to exist (Table 1)
(Arrang et ai., 1983). The identification of this new histaminergic receptor subtype in 1983 by
Arrang and colleagues gave rise to a new field of interest for both pharmacologists and
medicinal chemists. Although the development of the molecular biology of GPCRs has led to a
dramatic increase of receptor subtypes for most of the known neurotransmitters (Savarese and
Fraser, 1992), the subclassification of the histamine receptors is still based on the traditional
pharmacological methods and has not been questioned yet by molecular biological approaches.
Table 1 Pharmacological defInition of the three histamine receptors
HI H2 H3
.j:>.
• smooth muscles in airways, • heart (pos. inotropic, pos.
intestine, blood vessels chronotropic effect)
(contraction) • stomach (gastric acid secretion)
• CNS (sleep/wakefulness, food intake,· uterus (contraction)
thermoregulation) • CNS (neuroendocrinological
• heart (pos. inotropic, processes)
pos. chronotropic effect)
localization
(function)
Effectors
agonists
antagonists
radioligands
IPynAG
2-thiazolylethylamine
2-phenylhistamine
mepyramine
triprolidine
[3H]mepyramine
cAMP (increase)
dimaprit
amthamine
ranitidine
tiotidine
[1251]iodoaminopotentidine
[3H]tiotidine
• CNS (inhibition histamine synthesis,
inhibition neurotransmitter release)
• lung (inhibition histamine synthesis,
inhibition neurogenic contraction)
• intestine (inhibition neurotransmitter
release)
• stomach (inhibition gastric acid
secretion)
?
(R)-<X-methylhistamine
imetit
immepip
thioperamide
clobenpropit
[1251]iodophenpropit
[125l]iodoproxyfan
9{l
~
...
.......
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Histamine H I receptors are found in smooth muscles of airways, intestine and blood
vessels, where activation leads to contraction. They are also present in the central nervous
system (CNS), where they are responsible for e.g. sleep/wakefulness, food intake,
thermoregulation, and in the heart where they induce positive inotropic and chronotropic effects
(Hill, 1990, Leurs et a1., 1995a, Schwartz et a/., 1991). The biological actions of HI
receptors are mediated by stimulation of the phosphoinositide pathway (see section 1.2.2).
Histamine H2 receptors are mostly located in heart, stomach and CNS (McNeill, 1984,
Schwartz et a1., 1991, Traiffort et a/., 1992a). Smooth muscles of airways and blood vessels
also contain H2 receptors (Barnes, 1991, Toda, 1987). The effects, including positive
chronotropic and inotropic effects on the heart, activation of gastric acid secretion, inhibition of
contraction of the uturus, relaxation of smooth muscle preparations and involvement in
neuroendocrinological processes in the brain are thought to be mediated by activation of the
adenylyl cyclase system (Hill, 1990, Leurs et a/., 1995a, Schwartz et a/., 1991) (see section
1.2.2). Histamine H3 receptors are primarely located on neQrons in the CNS, intestine, lung
and stomach. In the brain H3 receptor stimulation leads to the inhibition of histamine synthesis
and also inhibits the release of several neurotransmitters (histamine, dopamine, serotonin,
noradrenaline, acetylcholine) (Hill, 1990, Leurs et a1., 1995a, Schwartz et a1., 1993). At
present the signal transduction pathway for the H3 receptor-mediated actions is not known,
although radioligand binding studies suggest a role for a G-protein in the H3 receptor activation
mechanism (Jansen et a1., 1994). Moreover, an inhibition of the phosphoinositide metabolism
has been reported in HGT-I gastlic carcinoma cells (Chelifi et a/., 1992).
Pharmacological studies (radioligand binding studies, biochemical measurements) have
indicated that the histamine HI and H2 receptor, and most likely also the H3 receptor, belong
to the family of GPCRs. Evidence for these findings was provided by the cloning of the genes
encoding the HI and H2 receptor from different species (see section 1.2.1 and 1.2.1). The
predicted amino acid sequences revealed that both receptor proteins belong to the GPCR
family. The availibility of the genes encoding the histamine HI and H2 receptor provide the
possibility to obtain stable cell lines expressing high densities of the cloned histamine receptors
(Fukushima et a1., 1993, Leurs et a/., 1994a,c, Iredale et a1., 1993, Traiffort et a1., 1992b).
Detailed pharmacological characterization of the histamine HI and H2 receptor in tissues or cell
lines expressing endogenous histamine receptors was often hampered by the low expression of
receptor proteins and lack of homogeneity in case of tissue preparations. The use of transfected
cell lines and mutant receptors now provide the opportunity to examine structural requirements
and mechanisms underlying regulation of histamine receptor function. By means of site-
directed mutagenesis studies amino acids have been identified involved in the binding of
histaminergic ligands to the HI and H2 receptor (Gantz et a1., 1992, Leurs et a1., 1994b,
Ohta et a1., 1994). Future studies will further define the ligand-binding domain and determine
the receptor regions involved in G-protein coupling.
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In the following section attention is paid to the molecular properties of both the histamine
HI and H2 receptor (section 1.2.1), describing the biochemical aspects of the receptor proteins
and recent findings revealed by molecular biological techniques. The signal transduction
pathways activated by both receptors are outlined in section 1.2.2. The phenomena of receptor
regulation of the family of GPCRs are described in section 1.3.1 which is followed by a
description of the regulation of the histamine HI and H2 receptors (section 1.3.2). The clinical
aspects of desensitization and implications for drug therapy will be discussed in section 1.3.3.
The aim of this thesis will be outlined in the fmal section 104.
1.2 Molecular aspects of the histamine H1 and~ receptor
1.2.1 Molecular properties of the histamine HI and H2 receptor
Over the past few years, remarkable advances have been made in our understanding of the
molecular properties of the histamine HI and H2 receptor. First, the availibity of HI and H2
receptor photoaffinity labels resulted in an improvement of our knowledge concerning the
biochemical properties of the respective receptor proteins (Ruat et al., 1988, Ruat et al.,
1990b, Yamashita et al., 1991b). Thereafter, molecular biological approaches have been
implemented in histamine research. In the last four years the genes encoding for the HI (De
Backer et al., 1993, Fujimoto et al., 1993, Fukui, et al., 1994, Horio et at., 1993,
Moguilevsky et at., 1994, Traiffort et al., 1994, Yamashita et at., 1991a) and H2 receptor
(Gantz et al., 1991a,b, Ruat et al., 1991) from several species have been cloned. The
molecular biological approach has provided, and will do so in the future, the opportunity to
examine many aspects of histamine receptor function, including structural features required for
ligand binding, G-protein coupling and receptor regulation.
The HI receptor protein
Using [125I]-iodoazidophenpyramine the HI receptor proteins in rat, guinea-pig and mouse
brain were irreversibly labelled (Ruat and Schwartz, 1989, Ruat et al., 1988, 1990a).
Following SDS-PAGE analysis of the labelled proteins, two main polypeptides (56 and 41-47
kDa) were found to be specifically labelled (Ruat and Schwanz, 1989). Based on experiments
with protease inhibitors, it was suggested that the HI receptor binding protein was represented
by the 56 kDa peptide, whereas the other labelled peptide was probably a result of proteases
action (Ruat and Schwartz, 1989). Using [3H]-azidobenzamide, Yamashita et al. (1991b)
recently found receptor peptides of similar size (53-58 kDa) to be labelled in bovine adrenal
medulla membranes. Whereas the 56 kDa peptide was also found in guinea-pig lung and ileum,
a peptide with a substantially higher molecular weight (68 kDa) was labelled in guinea-pig heart
tissue (Ruat et al., 1990a). Although at present no pharmacological differences have been
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observed between the H I receptors from guinea-pig heart and brain tissue, these results
suggest the occurrence of several isoforms for the HI receptor. Moreover, the molecular
weight found for the HI receptor after photoaffinity labelling is in sharp contrast with the
reported weight (38-40 kDa) of a purified [3HJ-mepyramine binding protein from DDTIMF-2
smooth muscle cells (Mitsuhashi and Payan, 1989). Since several highly potent HI receptor
antagonists possess only a moderate affinity for this binding protein, it is not yet clear whether
the binding of [3Hl-mepyramine to these cells really represents HI receptor binding
(Mitsuhashi and Payan, 1989, Dickenson and Hill, 1994).
Yamashita et al. (199Ia) were the first to succeed in the cloning of the cDNA encoding for
the bovine HI receptor. Using the approach of expression cloning (injection mRNA in
Xenopus oocytes) a cDNA clone from a cDNA library of bovine adrenal medulla was isolated
and expressed in both Xenopus oocytes and COS-7 cells (Yamashita et al., 1991a). The
expressed receptor protein specifically binds [3Hl-mepyramine and shows in displacement
studies typical HI receptor characteristics (Yamashita et al., 1991a). The cloned cDNA
encodes for a 491 amino acid receptor protein (apparent molecular weight 56 kDa) with all of
the structural features of a GPCR (seven transmembrane domains, N-terminal glycosylation
sites, phosphorylation sites for protein kinase A and C, Fig. 2). Since it is known from
biochemical studies that the HI receptor protein from guinea-pig brain is glycosylated (Garbarg
et al., 1985), the predicted molecular weight of 56 kDa is certainly underestimated.
Using the sequence information of the bovine HI receptor cDNA (Yamashita et ai., 1991)
the genes/cDNAs for the rat (Fujimoto et ai., 1993), guinea-pig (Horio et ai., 1993, Traiffort
et al., 1994) and human (De Backer et ai., 1993, Fukui, et ai., 1994, Moguilevsky et al.,
1994) HI receptor have been cloned. These genes are all intronless and encode for proteins of
respectively 486 (rat), 488 (guinea-pig) and 487 (human) amino acids. The homology between
the several receptor proteins is quite high in the intracellular domains (- 90 %), but differs
importantly in the long third intracellular loop and also in the extracellular N-terminal tail. The
various cloned genes should be regarded as real species homologues, although some small
changes in pharmacology are noticed (De Backer et ai., 1993, Fujimoto et al., 1993, Fukui,
et al., 1994, Horio et ai., 1993, Moguilevsky et ai., 1994, Traiffort et al., 1994, Yamashita
et ai., 1991a).
With the availability of the cloned genes new possibilities have emerged in the field of
histamine research. Application of molecular biological techniques has allowed investigation of
the structure-function relationships of the HI receptor protein (Ohta et ai., 1994, Leurs et al.,
1994b). On the basis of results of site-directed mutagenesis studies of various other aminergic
receptors it is generally accepted that the binding of these small neurotransmitters mainly occurs
in the transmembrane domains (Savarese and Fraser, 1992). With respect to the HI receptor
recognition of histamine it was shown that an aspartate residue in the third transmembrane
domain functions as a binding site for the protonated amino-function of histamine (Ohta et
Guinea-pig H1 receptor
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Fig. 2. Schematic representation of the guinea-pig histamine HI receptor. The amino acids are indicated by the single letter notation. A consensus
sequence for asparagine-linked glycosylation is indicated. Moreover, possible PKA and PKC phosphorylation sites are indicated with an asterisk
and arrows respectively.
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aI., 1994). Based on the findings on binding of catecholamines to the ~2-adrenergic receptor
(Savares and Fraser, 1992), a threonine and asparagine in the fifth transmembrane domain
have beensuggested to be responsible for binding the imidazole moiety (Timmerman, 1992).
Site-directed mutagenesis studies, substituting these amino acids to non-functional alanines
showed that the threonine residue does not seem to be very important for the interaction with
either agonist or antagonist (Leurs et al., 1994b). In contrast, the asparagine residue appears
to be very important for the interaction with histamine and 2-methylhistamine, a moderately
selective H1 receptor agonist, interacting most likely with the Nt-nitrogen of the imidazole ring
of histamine. Whereas on the basis of the agonist actions of various analogues, the Nt-nitrogen
of the imidazole ring of histamine has always been regarded as relatively non-functional, these
ideas should now be reconsidered. In addition, the affinity of the selective agonist 2-(3-
bromophenyl)histamine and the non-imidazole agonists 2-pyridylethylamine and 2-
thiazolylamine for the Asn207Ala mutant was only slightly affected (Leurs et at., 1994b),
indicating that histamine and the non-imidazole agonists use different functionalities to bind to
the receptor. More detailed studies should identify the amino acid residues of the HI receptor
protein that are involved in the interaction with the aromatic ring of the 2-phenylhistamines and
the N't-nitrogen of the HI receptor agonists.
The H2 receptor protein
Detailed biochemical information for the H2 receptor has initially also been obtained by
photoaffinity labelling studies. Using [125I]-iodoazidopotentidine Ruat et at. (1990b) showed
that the H2 receptor binding peptide is probably a 59 kDa protein, although the purification of a
[3H]-tiotidine binding protein from human HGT-1 cells resulted in the identification of a 70
kDa protein (Reyl-Desmars et at., 1991). Yet, the H2 receptor nature of the [3H]-tiotidine
binding protein from these cells has not clearly been defmed. Using an antipeptide antibody
against the C-terminal sequence of the cloned canine H2 receptor Fukushima et at. (1993)
identified a band with an apparent molecular mass of 63 kDa to 95 kDa in the membranes from
transfected Chinese Hamster Ovary (CHO) cells. The reason for this apparent heterogeneity is
at present not clear, but could perhaps be explained by the use of different techniques to
solubilize the receptor protein (MJ. Smit unpublished observations).
The eDNA sequence/genes encoding for the H2 receptor has been elucidated for several
species including man (Gantz et al., 1991a,b, Ruat et al., 1991, Traiffort et al., 1995).
Using the polymerase chain reaction with degenerate primers, based on the known sequence
similarity of various GPCRs, and canine gastric parietal eDNA, Gantz et al. obtained the
eDNA encoding for the canine H2 receptor (Gantz et at., 1991b). Soon thereafter, the
intronless gene encoding for the rat (Ruat et at., 1991) and the human H2 receptor (Gantz et
at., 1991a) were rapidly cloned by means of homology screening. The cDNAs and various
genes show considerable homology (80-90%) and are probably real species homologues
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Fig. 3. Schematic representation of the rat histamine H2 receptor. The amino acids are indicated by the single letter notation. A consensus
sequence for asparagine-linked glycosylation is indicated. Moreover, possible PKC phosphorylation sites are indicated with arrows.
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(Gantz et al., 1991a,b, Ruat et aI., 1991, Traiffort et aI., 1995). The DNA sequences encode
for a 359 (dog, man, guinea-pig) or 358 (rat) amino acid receptor protein, containing many of
the structural features of GPCRs and apparent molecular weights of approximately 40 kDa.
Since in the N-terminal extracellular tail a consensus sequence for N-linked glycosylation is
present (Fig. 3), the actual molecular weight of the receptor will be significantly higher.
Expression of the human and rat receptor gene in CHO cells was followed by an extensive
pharmacological characterization (Leurs et al., 1994a, Traiffort et aI., 1992b). Using the
highly selective and potent radioligand [125I]-iodoaminopotentidine Traiffort et al. (1992b)
and Leurs et al. (1994b) revealed that respectively the rat and human H2 receptor show a
similar pharmacological profIle as the H2 receptor in guinea-pig heart, the commonly accepted
H2 receptor reference system, or in human brain. Although for the dog receptor protein
extensive pharmacological data are not yet available it is very likely that the gene Gantz et al.
(l991b) identified encodes for a classical H2 receptor.
Site-directed mutagenesis of the canine H2 receptor by Gantz et al. (1992) showed that an
aspartate residue in the third transmembrane domain is also involved in the binding of the
protonated amino function of histamine and H2 receptor antagonists. Mutations of the aspartate
and threonine residues located in the fifth transmembrane domain of the H2 receptor protein to
alanine residues resulted in a loss of [3H]-tiotidine binding and a reduction of the histamine-
induced cAMP production (Gantz et aI., 1992), indicating that the aspartate and threonine
residues likely interact with histamine and the antagonist [3H]-tiotidine. The interaction of the
two residues with the antagonist is, based on studies with other biogenic amine receptors,
however rather unexpected and certainly deserves future attention. Moreover, also the
interaction of the two amino acids with histamine is not well defined; the mutated receptors
require more detailed investigations with e.g. the recently developed non-imidazole agonists
amthamine and amselamine (Eriks et aI., 1992, Van der Goot et aI., 1994).
1.2.2 Transmembrane signalling of the histamine Ht and H2
receptor
As already stated in section 1.1 efficient communication pathways exist between and within
cellular entities. Histamine may be considered as a 'chemical messenger' , responsible for the
intercellular communication, whereas complex biochemical pathways are involved in the
intracellular communication. GPCRs communicate with heterotrimeric G-proteins to direct the
flow of information to effector molecules. The availability of the genes encoding for the
histamine H1 and H2 receptor (see section 1.2.1) has allowed the expression of these receptor
proteins into various cell lines. This approach permits detailed investigations of the several
transmembrane signalling pathways that can be activated by the different receptors. Detailed
insights of these signalling pathways are essential for a good understanding of the action of
histamine in (patho)physiological processes.
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Signal transduction of the HI receptor
The histamine HI receptor is, among other GPCRs, a Ca2+ mobilizing receptor. It is widely
accepted that activation of Ca2+ mobilizing receptors is associated with the phospholipase C
catalyzed hydrolysis of membrane inositide phospholipids (Michel, 1975). Receptor
stimulation leads to the hydrolysis of phosphatidyl 4,5- biphosphate resulting in the formation
of inositol1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 was shown to mobilize
Ca2+ from intracellular stores, whereas DAG was found to activate protein kinase C (PKC).
For a detailed description of the various functions of these second messengers the interested
reader is referred to a review of Berrigde (Berridge, 1992).
In accordance with the above, histamine induces production of inositol phosphates in
several tissues, including brain, airway smooth muscle, intestinal smooth muscle, vascular
smooth muscle and heart tissue (Barnes, 1991, Claro et al., 1989, Donaldson and Hill, 1986,
Orellano et at., 1987, Sakuma et at., 1988, Schwartz et at., 1991). Moreover, guinea-pig
brain regions showing the highest density of HI receptors displayed the largest
phosphoinositide response (Carswell and Young, 1986, Daum et at., 1983). However, in
some tissues, guinea-pig ileum and neonatal brain, the HI response to histamine itself appeared
to be masked by a HI antagonist insensitive component (Bailey et al., 1987, Claro et al.,
1987, Donaldson and Hill, 1985).
In membrane preparations of both rat cerebral cortex and 1321N1 astrocytoma cells, HI
receptor-stimulated phospholipid hydrolysis was found to be dependent on the presence of
guanine nucleotides (Claro et al., 1989, Orellano et al., 1987). Studies in 1321N1
astrocytoma cells (Orellano et al., 1987), HeLa cells (Tilly et at., 1990a) and CHO cells
stably expressing HI receptors (Leurs et at., 1994c), showed the involvement of a pertussis
toxin-insensitive G-protein. The actual nature of the pertussin toxin-insensitive G-protein
remains unclear. However, the recent cloning of the HI receptor as well as identification of
various G-proteins will allow a detailed investigation of this issue.
One of the physiological consequences of the production of inosto1 phosphates is the
elevation of intracellular Ca2+. The use of fluorescent Ca2+ indicators in various isolated cell
systems has clearly demonstrated the increase of the intracellular Ca2+ concentration upon HI
receptor activation (Bloemers et al., 1993, Brown et at., 1986, Jacob et al., 1988, Johnson
et at., 1990, Kotlikoff et at., 1987, Leurs et at., 1994c, Matsumoto et al., 1986,
McDonough et al.. 1988, Oakes et at., 1988, Rotrosen and Gallin, 1986, Smit et al., 1992,
Tilly et at., 1990b). The histamine-induced Ca2+ response is characterized by a rapid transient
rise of the intracellular Ca2+ concentration, which is followed by a sustained elevation of the
C 2+ 0 E 0 0 C 2+ f d· d °th· 0 C 2+ .a concentration. xpenments In a - ree me lUm an Wi InOrganiC a .antagomsts
suggest that the sustained response is highly dependent on the influx of extracellular calcium,
whereas the transient increase is caused by the release of Ca2+ from intracellular Ca2+ stores
(Brown et al., 1986, Jacob et at., 1988, Johnson et at., 1990, Kotlikoff et al., 1987, Leurs
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et al., 1994c, Matsumoto et aI., 1986, McDonough et aI., 1988, Oakes et al., 1988,
Rotrosen and Gallin, 1986, Tilly et at., 1990b).
Since Ca2+ is involved in the regulation of many cellular functions, the increase of the
intracellular Ca2+ concentration can explain a wide variety of pharmacological responses
induced after stimulation of the HI receptor. First of all, elevation of intracellular Ca2+ levels
lead to further stimulation of phospholipase C, most likely the phospholipase C/3 subtype as it
is known to be sensitive to Ca2+ (Cockcroft and Thomas, 1992). Moreover, the histamine-
induced production of inositol phosphates in both brain and tracheal slices (Alexander et aI.,
1990, Baird et al., 1989) and CHO cells stably expressing the guinea-pig HI receptor (Leurs
et al., 1994c) was shown to be highly dependent on the influx of extracellular Ca2+.
Besides the activation of phospholipase C, histamine-induced increase of Ca2+ seems to
induce the production of nitric oxide. In various vascular preparations, endothelium-dependent
relaxation is observed upon HI receptor activation, which appeared to be related to the
production of nitric oxide (Satoh and Inui, 1984, Schoeffter and Godfraind, 1991, Toda,
1987, Van den Voorde and Leusen, 1984). In cultured bovine aortic cells the actual generation
of nitric oxide could be measured after stimulation of histamine (Schmidt et al., 1990). In a
variety of airway and heart preparations HI receptor activation was shown to induce the
production of cGMP, which may be ascribed to generation of nitric oxide (Casale et al., 1985,
Duncan et al., 1980, Hattori et aI., 1988, Leurs et al., 1991a, Sert! et al., 1987, Yuan et
aI., 1993). Thus, some vascular responses to histamine may be explained by the generation of
nitric oxide, which appears to be highly dependent on the mobilization of intracellular Ca2+.
Another consequence of the histamine-induced mobilization of Ca2+ is the generation of
arachidonic acid metabolites, prostacyclin and thromb6xane A2' due to liberation of
arachidonic acid from the phospholipids (Leurs et at., 1994c, Lewis Baenziger et aI., 1980,
Resink et at., 1987). In CHO cells transfected with the guinea-pig HI receptor and HeLa cells
the release of arachidonic acid appeared to be phospholipase A2 dependent (Leurs et aI.,
1994c). In these CHO cells the histamine-induced activation of phospholipase A2 was found to
be partially sensitive to pertussis toxin (Leurs et al., 1994c). In contrast, in these cells the
regulation of phospholipase C was completely insensitive to pertussis toxin (Leurs et aI.,
1994c). These findings are in agreement with the observations described by Murayama et aI.
(1990), who reported that in human and rabbit platelets histamine stimulates the release of
arachidonic acid via a pertussis toxin sensitive pathway without the generation of inositol
phosphates. In HeLa cells, on the other hand, the phospholipase A2 dependent release of
arachidonic acid appeared to be insensitive to pertussis toxin (Leurs et aI., 1994c). Thus, the
HI receptor-mediated activation of phospholipase A2 in transfected CHO cells may be ascribed
to two different pathways; arachidonic acid can be stimulated via an elevation of the
intracellular Ca2+ concentration (as in HeLa cells) and via interaction of phopholipase A2 with
a pertussis toxin sensitive G-protein (as in platelets).
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Last, the increase of intracellular Ca2+ is most likely involved in the regulation of cAMP
levels. HI receptor stimulation seems to modulate cAMP responses via histamine H2,
adenosine A2 and VIP receptors (AI-Gadi and Hill, 1987, Donaldson et ai., 1989, Garbarg
and Schwartz, 1988, Magistrati and Schorderet, 1985, Marley et ai., 1991). The exact
mechanism involved in the elevation cAMP remains to determined, however, a role for both
Ca2+ and PKC has been suggested (Hill and Donaldson, 1992). Yet, recent findings in CHO
cells expressing the guinea-pig HI receptor showed that PKC nor Ca2+ did account for the
observed elevation of cAMP levels (Leurs et at., 1994c). The latter observations could
possibly be explained by stimulation of adenylyl cyclase by G-protein ~y-subunits (Iyengar,
1993).
In conclusion, the histamine HI receptor is coupled to the phospholipase C-dependent
inositol phosphate pathway, thereby inducing a rise in the intracellular Ca2+concentration. The
latter can explain the histamine-induced production of other second messengers such as cGMP,
cAMP and arachidonic metabolites. Yet, it appears that responses such as modulation of cAMP
and phospholipase A2 activity can also be regulated by phospholipase C-independent
pathways. The way, activation of the HI receptor leads to these responses, requires further
detailed mechanistic investigations.
Signal transduction of the "2 receptor
It is generally accepted that the histamine H2 receptor is coupled to the adenylate cyclase
system. A large number of reports showed that histamine increases the levels of cAMP in e.g
brain, stomach and heart tissue of several species, including man (Agullo et at., 1990,
Bristow et at., 1982, Foreman et at., 1986, Hattori et at., 1988, Hegstrand et at., 1976,
Johnson, 1992, Ozawa et at., 1991, Ozawa and Segawa, 1988, Sarem-Aslani et at., 1991,
Schwartz et at., 1991). Since the~ receptor mediates its response through activation of
adeny1ate cyclase in membrane fractions in a guany1 nucleotide-sensitive manner (Johnson,
199Z), an activation model similar to the well-studied ~-adrenergic receptor system is often
presented (Johnson, 199Z). However, it should be emphasized that, although such a model is
highly probable, no direct evidence is at present available for the interaction with a Gs-protein.
In this respect it is interesting that Ozawa and co-workers suggested that a HZ receptor-
stimulated phospholipid methylation is responsible for a subsequent activation of adenylate
cyclase (Ozawa and Segawa, 1988, Ozawa et at., 1991). In both rat brain (Ozawa and
Segawa, 1988, Ozawa et ai., 1987) and guinea-pig heart (Ozawa et at., 1991) histamine was
shown to rapidly stimulate the phospholipid methylation. The cAMP response in both tissues
was significantly slower than the phospholipid methylation and completely dependent on the
presence of the methyldonor S-adenosyl-L-methionine and reduced by an inhibitor of the
phospholipid methyltransferases (Ozawa and Segawa, 1988, Ozawa et al., 1991). Moreover,
in rat brain the regional distribution of the histamine-induced phospholipid methylation closely
paralleled the H2 receptor-mediated cAMP response (Ozawa and Segawa, 1988). These data
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are intriguing and suggest that the phospholipid response might be necessary for an effective
coupling of the receptor to the G-protein responsible for the activation of the cyclase.
Interesting in this respect is that also much earlier for the 13-adrenergic receptor similar
suggestions have been reported by Hirata and Axelrod in 1980. Yet, it should be noticed that
currently, these observations are not drawing much attention, nor are within the field of the 13-
adrenergic receptor.
Although the linkage of the H2 receptor to the adenylate cyclase is rather well accepted,
some findings argue against a universal role of cAMP. In guinea-pig brain the regional
distribution of H2 receptor binding sites does not parallel the observed H2 receptor-mediated
cyclase acivation (Ruat et al., 1990b). Moreover, Haas et al. (1978) observed a denervation
hypersensitivity to histamine at the electrophysiological level, whereas under the same
conditions the cAMP response was unaltered.
In view of these findings it is interesting that new signalling pathways have been described
for the H2 receptor. III differentiated HL-60 cells and HEPA cells, transfected with the canine
H2 receptor, a H2 receptor mediated increase of the intracellular Ca2+ concentration was
observed (Gespach et al., 1982, Delvalle et aI., 1992, Mitsuhashi et al., 1989). The increase
of intracellular Ca2+ was found to result from the release of Ca2+ from intracellular stores
(Delvalle et al., 1992, Mitsuhashi et al., 1989). The H2 receptor-dependent Ca
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mobilization is probably due to the activation of phospholipase C, since histamine induced an
increase of the levels of inositoll,4,5-trisphosphate. In both cell lines these effects were found
to be inhibited by cholera toxin but not by pertussis toxin, suggesting the involvement of a G-
protein (Delvalle et al., 1992, Mitsuhashi et al., 1989). Recent reports in hamster DDTIMF-2
cells and bovine trachea smooth muscle have demonstrated a cAMP-mediated inhibition of the
production of inositol phosphates (Dickenson et al., 1993, Hall and Hill, 1988, Hall et aI.,
1989) The crosstalk between the cAMP cascade and phosphoinositide system could well
explain the observed inhibitory effects induced by cholera toxin. Yet, in the HEPA cells,
forskolin did not inhibit the histamine induced effects, suggesting the involvement of another
mechanism (Delvalle et aI., 1992). The involvement of distinct G-protein can not be excluded.
Another cAMP-independent response was described for the cloned rat H2 receptor
expressed in CHO cells by (Traiffort et al. 1992b). Besides a massive production of cAMP
upon H2 receptor activation, an inhibition of the release of arachidonic acid induced by either
constitutive purinergic receptors or a Ca2+-ionophore was observed. The histamine-induced
inhibition was potently inhibited by ranitidine (Ki = 0.16I!M) and also induced by dimaprit.
Forskolin, prostaglandin El or 8-bromo-cAMP did not mimick the effects induced by
histamine indicating the involvement of a cAMP-independent process (Traiffort et aI., 1992b).
Histamine did not significantly modify the features of the Ca2+-responses to ATP. At present
the actual mechanism for this response is unknown. Yet, one should be aware that this
coupling to a new signalling system could be due to the high expression of receptors in these
cells. In contrast, expression of the gene encoding the human H2 receptor in CHO cells was
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shown to be functionally coupled to adenylate cyclase, but did not influence the inositol
phosphate turnover nor arachidonic acid release (Leurs et al.; 1994a). The expression level of
the human H2 receptor resembles a more physiological level of expression (Leurs et ai.,
1994a, Chapter 7). Moreover, the observed sequence differences, in particular in the
intracellular parts, between the rat and human receptor (Gantz et aI., 1991a, Ruat et at.,
1991b) might also be a possible explanation for the observed differences in signal transduction.
In conclusion, the H2 receptor is coupled to the adenylyl cyclase-dependent production of
cAMP. Yet, the observed breakdown of phosphoinosites, elevation of intracellular Ca2+ levels
and modulation of phospholipase A2 activity upon H2 receptor activation, seem to be regulated
via other cAMP-independent pathways.
1.3 Regulation of receptor function
1.3.1 Regulation of GPCRs
GPCRs are responsible for the generation of various second messengers that affect cellular
functions and gene expression. It is therefore important for the responsiveness of the biological
system to be tightly controlled. A major mechanism involved in the control of GPCRs is
receptor desensitization (see reviews Collins et ai. 1991, Collins, 1993, Lohse, 1993,
Savarese and Fraser, 1992). Desensitization is a general biological phenomenon which is
characterized by a rapid loss of responsiveness over time despite the continuous presence of a
stimulus. At least three mechanistically and temporarily distinct processes are thought to
contribute to the overall phenomenon of desensitization (Collins et al. 1991, Collins, 1993,
Lohse, 1993). The first involves the functional uncoupling of receptors from their effector
system shortly after agonist binding and is referred to as short-term desensitization. The second
mechanism is the translocation of receptors from the cell surface into a membrane-associated
compartment within a few minutes after agonist exposure. Such agonist-promoted endocytosis,
also referred to as internalization or sequestration, has been proposed to playa primary role in
the resensitization of receptors (Pippig et aI., 1995, Von Zastrow and Kobilka, 1992, Yu et
ai., 1993). Finally, long-term exposure of a receptor to an agonist leads to receptor
downregulation (also referred to as long-term desensitization), defined as the breakdown of
receptor proteins.
In this context, it is also important to make a distinction between homologous and
heterologous desensitization. When the loss of stimulatory activity in the pathway is specific
for the receptor being activated, it is termed homologous desensitization. Specific modifications
of the receptor protein itself are believed to be involved in the process of desensitization. In
contrast, if the functions of other receptor systems are affected upon activation of one receptor,
one refers to heterologous desensitization. Such a regulation can also be the result of specific
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modifications of the receptor protein but usually is caused by alterations at levels distal to the
receptor, e.g. G-protein or the effector enzyme.
The mechanisms underlying receptor desensitization have been studied most extensively for
the f32-adrenergic receptor (Collins, 1993). The understanding of this phenomenon has been
facilitated by the early molecular cloning of the f32-adrener~ic receptor gene (Dixon et al.,
1986) and the utilization of site-directed mutagenesis. This receptor therefore often serves as a
model system for the investigation underlying receptor desensitization.
Desensitization
One of the mechanisms underlying short-term receptor desensitization is thought to be
associated with post-translational modification of the receptor protein by phosphorylation
(Hausdorff et at., 1990, Huganir and Greengard, 1990, Lefkowitz et at., 1990). Specific
receptor kinases seem to play crucial roles in the mechanism underlying homologous receptor
desensitization, whereas kinases, such as protein kinase A (PKA) and protein kinase C (PKC)
seem to be important in the heterologous type of desensitization (Huganir and Greengard,
1990, Lefkowitz et al., 1990, Palczewski and Benovic, 1991).
For the f32-adrenergic receptor homologous receptor desensitization was found to be
associated with receptor phosphorylation catalyzed by a specific receptor kinase called 13-
adrenoceptor kinase (f3ARK), which specifically phosphorylates the agonist-occupied form of
the receptor (Hausdorff et al., 1990, Huganir and Greengarq, 1990, Lefkowitz et at., 1990).
Besides f3ARK, a cofactor called f3-arrestin was found to be involved in this process of
desensitization (Lohse et at., 1990, Pippig et al., 1993). f3-arrestin shares reasonable
homology with the a-subunit of the Gs-protein. Moreover, f3-arrestin shows only affinity for
the phosphorylated f32-receptor. Binding of f3-arrestin to the phosphorylated f32-adrenergic
receptors inhibits the receptor-Gs interaction, thereby creating an uncoupled or desensitized
state of the receptor.
Besides phosphorylating the f32-adrenergic receptor, f3ARK was also found to
phosphorylate other GPCRs, such as rhodopsin, the a2A adrenergic receptor, the muscarine
m2, substance P receptor and platelet-activating factor receptor indicating that not only GPCRs
which are positively coupled to adenylyl cyclase are substrate for this kinase (Benovic et at.,
1989, Lefkowitz et al., 1990, Inglese et al., 1993, Haga et at., 1994, Kwatra et at., 1993,
Takano et al., 1994). Application of molecular cloning techniques resulted in the isolation of
related kinases (see for more details reviews Lefkowitz, 1993, Haga et at., 1994). Therefore,
a more general term was introduced: G-protein coupled receptor kinases (GRKs). To date, the
family of GRKs is still expanding. Up to 6 cDNAs encoding GRKs have been isolated (see for
references Lefkowitz, 1993, Haga et at., 1994). The tremendous diversity of the GPCRs,
compared to the limited number of GRKs, raises questions about the receptor specificity of the
various GRKs. The GRKs showed differences in their ability to phosphorylate the 132-
adrenergic receptor or other GPCRs, suggesting that these kinases have distinct substrate
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specificities. In addition, the level of expression and distribution of this class of GRKs differ.
The expression of some GRKs is confined to restricted areas (e.g. GRKI (or rhodopsin
kinase) in retina and pineal gland, GRK4 (or IT11) in brain and testes), implying specific
functions (see for references Lefkowitz, 1993, Haga et al., 1994). Others, such as GRK2, are
widely distrubuted throughout the mammalian central nervous system, suggesting broader
roles in regulating a wide variety of neurotramsmitter receptors (Arriza et ai., 1992).
There is no strict consensus sequence for the phosphorylation by the GRKs, but it seems
that acidic amino acids located 2 or 3 positions N-terminal to a serine or threonine are required
for phosphorylation by GRKs (Onorato et al., 1991). Removal of serine/threonine residues
from the C-terminal tail of the p2-adrenergic receptor by site directed mutagenesis resulted in
decreased phosphorylation of the p2-adrenergic receptor (Bouvier, 1988, Campbell, 1991).
Moreover, removal of these residues by site-specific substitution or truncation of the C-
terminal tail of the P2-, a1B-, substance P neurokinin NK2, adrenergic and platelet-activating
factor receptors were shown to attenuate the homologous desensitization (Alblas et al., 1995,
Lattion et ai., 1994, Lefkowitz, 1993, Sasakawa et ai., 1994, Takano et al., 1994). For the
a2A-adrenergic receptor and m2 muscarinic receptor phosphorylation sites were shown to
reside in the third intracellular loop (Liggett et ai., 1992, Dohlman et ai., 1987, Nakahata et
al., 1994). Recently, four consecutive serines in the third intracellular of the a2A-adrenergic
receptor were shown to be sites for GRK-mediated phosphorylation and to be critical for
agonist-promoted desensitization (Eason et al., 1995).
G-protein Pr subunits (Pr) were shown to playa role in the translocation of some GRKs
from cytosol to the membrane and the stimulation its enzyme activity, thus enhancing agonist-
stimulated receptor phosphorylation and receptor desensitization (Inglese et ai., 1993, Haga
et al., 1994). The mechanism of activation appears to be largely due to the specific interaction
of the isoprenylated Pr complex (the r subunit appears to be isoprenylated) with GRKs 2 and
3, which serves to target the kinases to the plasma membrane. These GRKs appear to possess
Gpybinding domains, containing pleckstrin homology (PH) domains. PH domains,
consisting of 100 amino acids forming a large binding pocket, have only recently been
recognized as sites for interaction between proteins (Yoon et aI., 1994). If the various Pr
complexes show differential affinity for the various GRKs, this could be a mechanism for
directing GRK isoforms to distinct GPCRs.
Unlike GRKs 2 and 3, GRK1 (or rhodopsin kinase) does not require Pr subunits to
translocate to the membrane, as in contrast to GRKs 2 and 3 GRKI is isoprenylated at its C-
terminus and does not require a secondary membrane anchor (Inglese et aI., 1993). GRKs 5
and 6 are also not activated by Pr subunits suggesting a different mechanism for translocation
(Benovic and Gomez, 1993, Kunapuli and Benovic, 1993). Kunapuli et ai. (1994) have
recently demonstrated that phospholipid-stimulated autophosphorylation may provide a new
mechanism for activation of GRK5, as well as a potential meChanism for the in vivo targetting
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to its substrates. Thereafter, DebBurman et ai. (1995) reported that the GRKs 2 and 3 are also
regulated by lipids via a mechanism that does not involve autophosphorylation. The effects of
these lipids were prevented by the Gpybinding protein phosducin, which was found to inhibit
phosphorylation of purified and reconstituted p2-adrenergic receptors earlier (Hekman et ai.,
1994). These findings suggest that the Gpybinding domain (possibly PH domain) of the
GRKs is also a site for lipid-protein interaction. Thus, it seems that both lipids and G-proteins
co-regulate the function of GRKs. Phosducin, on the other hand can be phosphorylated by
PKA upon which the affinity for py subunits decreases (Bauer et ai., 1992). These findings
indicate that this system is quite complex containing various positive and negative feedback
loops.
Also the existence of additional cDNA clones encoding novel p-arrestin-related proteins,
termed p-arrestin2 and 3, have been reported (Attramadal et ai., 1992, Sterne-Marr, 1993).
Questions concerning the receptor specificity of these various arrestins arise also for this family
of proteins. Recently, Gurevich et ai. (1995) have identified structural elements that contribute
to arrestin binding and selectivity using truncated and chimeric arrestins, suggesting a common
molecular mechanism involved in determining receptor binding selectivity. Apparently, GRK-
and arrestin-mediated receptor desensitization reflects a general occuring mechanism with
regard to the GPCRs. The extensive distribution of the different GRKs and arrestins, also in
areas were no pz-adrenergic receptors are located, supports this fact (Arriza et ai., 1992,
Attramadal et ai., 1992).
As already mentioned, several GPCRs can also be phosphorylated by their respective
effector kinases, PKA and PKC (see for references Lohse, 1993). PKA and PKC are
respectively activated by cAMP and DAG, second messengers produced after activation of the
adenylyl cyclase and phosphoinositide pathway respectively. Since PKA and PKC, may be
activated upon stimulation of other receptor systems, they are considered to be responsible for
several,reports of the heterologous type of desensitization.
The region important for the heterologous type of short~term desensitization of the P2-
adrenergic receptor, mediated by PKA, appears to reside in the third intracellular loop and in
the N-terminal part of the C-terminus. At these locations consensus sites for PKA (consensus
sequence: XRRXSX, (X=no specific amino acid, R=arginine, S=serine), Kemp and Pearson,
1990) exist. Both regions, but in particular the third intracellular loop, appear to be involved in
receptor-Gs coupling. Phosphorylation of these sites introduces a highly charged moiety into
these regions leading to important alterations in the conformation of these regions. As for the
phospholipase C-linked receptor systems, PKC consensus sites (consensus sequence:
XRXXSXRX, Kemp and Pearson, 1990) were found to reside in particular in the third
intracellular loop, a region important for G-protein coupling. Several of these receptors appear
to undergo PKC-mediated desensitization (see for references Lohse 1993). Moreover, phorbol
esters, activators of PKC, were found to phosphorylate and desensitize the p2-adrenergic
receptor (Sibley et ai., 1987). PKC and PKA were found to phosphorylate the p2-adrenergic
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receptor at the same site as their effects were not additive (Sibley et aI., 1987). These data
indicate that phospholipase C-linked receptors may also contribute to some forms of
heterologous desensitization of adenylyl cyclase-linked receptors.
The extent of PKA-mediated desensitization of the ~2-adrenergic receptor is comparable to
the extent mediated by the GRKJ~-arrestin mechanism. Yet, the agonist-induced PKA-
mediated desensitization is considerably slower (t1l2 - 2 min) than the GRK-mediated process
(t1l2 - IS secs), but is more sensitive to low agonist concentrations (ECSO - 10 nM vs - 300
nM). It is therefore believed that the PKA-mediated desensitization may be a sensitive
ubiquitous process occurring in response to low agonist concentrations, whereas GRK-
mediated desensitization might occur at regions were high concentrations of neurotransmitters
are to be found, e.g. synapses (Lohse et aI., 1990). In fact, the expression of the GRKs were
shown to be high at post-synaptic locations (Arriza et al., 1992, Attramadal et al., 1992).
Thus, two different patterns of short-term desensitization appear to exist. The first
involves a rapid strict homologous type of desensitization mediated by specific receptor kinases
(GRKs). The heterologous desensitization is somewhat less r-apid but much more sensitive to
low agonist concentrations and is mediated by effector kinases such as PKA and PKC. In view
of the reported heterogeneity of these kinases (Nishizuka, 1988) the complexity of the system
is further enhanced. Yet, at this moment no information is available on the involvement of
specific kinase isoforms.
Besides regulation at the level of the receptor, there is also evidence indicating that
regulation may take place at post-receptor levels as well. In particular at the level of G-proteins,
mechanisms affecting G-protein function and G-protein number can be distinguished. A small
number of intracellular proteins (e.g. GAP-43, ras-GAP, phosducin) have been found to be
responsible for altering G-protein function by activating or inhibiting G-protein-mediated
signalling (see for more information references Lohse, 1993). Moreover, desensitization of
GPCRs was found to induce phosphorylation or alterations in expression of G-protein
subunits, thereby altering G-protein receptor function. Long-term activation of receptors which
are positively coupled to adenylyl cyclase was found to be accompanied by a decrease of Gsa
levels but increase in expression of Gia (see for references Lohse, 1993, Mullaney et aI.,
1993). For the receptors that are negatively coupled to adenyly cyclase and those coupled to
phospholipase C, similar observations were made with regard to downregulation of
respectively Gai and Gaq (see for references Lohse, 1993, Mullaney et al., 1993).
As already stated in section 1.1 the effector enzymes adenylyl cyclase and phospholipase C
consist of a family of isoenzymes, which each appear to be differentially regulated (Cockcroft
and Thomas, 1992, Iyengar, 1993, Tang and Gilman, 1992). Regulation of these isoenzymes
may contribute to the overall phenomenon of receptor desensitization. I3Y subunits for example
were shown to regulate some isoenzymes of the adenylyl cyclase and phospholipase C family
(Iyengar, 1993, Fisher, 1995). Various isoenzymes were even found to be susceptible to
cross-regulation. Activation of PKC or increases of the intracellular Ca2+ concentration, were
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shown to regulate adenylyl cyclase activity either positively or negatively (see Gusovsky and
Gutkind, 1991, Iyengar, 1993). Similarly, heterologous regulation of phospholipase C by
acute activation of adenylyl cyclase-linked receptors has frequently been associated with an
inhibition of receptor-stimulated phosphoinositide hydrolysis (Dickenson et ai., 1993),
although enhancement of phosphoinositide hydrolysis has also been reported (see for
references Fisher, 1995). The mechanism underlying the differential ability of cAMP to either
inhibit or potentiate receptor-stimulated phosphoinositide hydrolysis remains to be determined.
Another class of proteins that may contribute to desensitization of the adenylyl cyclase-
coupled receptors are the cAMP phosphodiesterases. At least five different isoenzyme families
are now recognized, which appear to be differentially expressed, regulated and distributed
(Beavo and Reifsnyder, 1990, Nicholson et at., 1991). There is evidence that these
phosphodiesterases can be rapidly regulated by cAMP- and Ca2+/calmodulin-dependent
protein kinases (see for references Nicholson et at., 1991). A slower cAMP-mediated control
of phosphodiesterase mRNA transcription has also been reported (see for references Nicholson
et at., 1991).
For the phospholipase C-linked receptors, desensitization or downregulation of the IP3
receptor located at intracellular Ca2+ pool or ineffective Ca2+-pump or Ca2+ release
mechanisms due to prolonged agonist-exposure have been proposed to playa possible role in
the process of receptor desensitization (see for references Wojcikiewicz et at., 1993).
Receptor internalization
Besides an uncoupling of GPCRs from their respective G-proteins, agonists can also induce a
translocation of receptors to intracellular sites. The inaccessibility of internalized receptors to
hydrophilic ligands (e.g. the aminergic agonists), but accessibility to hydrophobic ligands, as
well as the occurrence of receptors in fractions lighter than membrane fractions and disruption
of internalization by specific inhibitors, suggest that sequestered receptors are internalized into
intracellular endosomes (Hertel et ai., 1985, Maloteaux and Hermans, 1994, Von Zastrow and
Kobilka, 1992, 1994). More direct evidence for such a hypothesis was given by means of
immunofluorescence confocal microscopy, showing f32-adrenoceptor immunoreactivity in
intracellular vesicles and colocalization with transferrin receptors (Von Zastrow and Kobilka,
1992, 1994). Thereafter, other reports showed similar results for other GPCRs using either
epitope-tagged GPCRs or antibodies raised against the N-. or C-terminus (Garland et at.,
1994, Von Zastrow and Kobilka, 1993). Moreover, using similar techniques recently Mantyh
et ai. (1995) have found evidence for in vivo internalization of the substance P receptor in the
rat striatum, suggesting that the observations made on the internalization and recycling of
GPCRs in transfected cell lines in vitro is applicable in vivo.
At first it was thought that internalization was the major mechanism of receptor
desensitization (Waldo et ai., 1983). However, internalization is a rather slow process
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compared to the rapid phosphorylation and uncoupling of receptors. Moreover, the extent of
receptor internalization can not explain the observed extent of desensitization (Lohse, 1990).
Yet, internalization may be considered as a mechanism of receptor resensitization (Pippig et
aI., 1995, Sibley et aI., 1986, Yu et aI., 1993). Sequestered receptors exhibit a decreased
degree of phosphorylation as compared to surface receptors and vesicles are found to be
enriched with phosphatases (Sibley et aI., 1986). The hypothesis regarding resensitization is
further supported by the finding that prevention of internalization by sucrose or phenylarsine
oxide, known as blockers of internalization, inhibit receptor resensitzation (Hertel et aI., 1985,
Feldman et aI., 1986, Garland et aI., 1994, Palmer et aI., 1994, Pippig et aI., 1995, Yu et
al., 1993) Moreover, internalization-defective ~2-adrenergic receptors (Barak et aI., 1994,
Yu et aI., 1993) do not recover from desensitization.
For the ~2-adrenergic receptors initial studies have shown that second messenger
production, activation of the effector system or phosphorylation by PKA or GRKs do not seem
to be prerequisites for agonist-induced internalization, as mutated receptors showing impaired
Gs-coupling or cellular systems lacking the machinery to activate the G-protein mediated
effector system or receptors lacking potential phosphorylation sites still show internalization
upon agonist exposure (Campbell et aI., 1991, Hausdorff et aI., 1989, Lohse, 1990, Mahan
et aI., 1985, Strader et aI., 1987). Yet, serine- and threonine-rich sequences in the
cytopasmatic tail of the ~2-adrenergic receptor seem to play an important role in the process of
internalization, as receptor mutants lacking these phosphorylation sites show impaired
internalization (Barak et al., 1994, Bouvier et aI., 1988, Campbell et aI., 1991, Hausdorff
et aI., 1991). Internalization has also been reported for other GPCRs, including the cq-
adrenoceptors, the gastrin-releasing peptide, thyroptropin and angiotensin AT1A and
muscarinic receptors (Eva et aI., 1990, Benya et aI., 1993, Hunyady et aI., 1994,
Nussenzveig et al., 1993, Thomas et aI., 1995). For most receptors that couple to
phospholipase C, the production of second messengers appears not to be a prerequisite
(Laduron, 1994, Fisher, 1995, Slowiejko et aI., 1994). However, for the muscarinic m1 and
gastrin-releasing peptide receptors intact receptor-G-protein coupling seems to be important
(Benya et al., 1994, Lameh et aI., 1992. Mutational analysis revealed that for the human m1
muscarinic receptor deletion of the small central region of the third intracellular loop is
sufficient to impair internalization severely (Lameh et al., 1992). Substitution of two amino
acids, which are essential for G-protein coupling, resulted in an attenuation of the agonist-
induced internalization of the gastrin-releasing peptide receptors, indicating that the gastin-
releasing peptide receptor requires intact receptor-G-protein coupling (Benya et aI., 1994).
The C-terminal tail of many GPCRs appears to be an important structural determinant for
receptor internalization. As stated before removal of serineithreonines residues from the C-
terminal tail of the ~2-adrenergic receptor prohibits receptor internalization (Barak et aI., 1994,
Bouvier et aI., 1988, Campbell et aI., 1991, Hausdorff et aI., 1991). Moreover, truncation
of the C-terminal tail of the thyrotropin-releasing hOlmone receptor and angiotensin II receptor
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also resulted in reduction of internalization (Nussenzveig et aI., 1993, Thomas et aI., 1995).
For the f31-adrenergic receptor, a proline-rich region in the third intracellular loop, however,
was found to induce conformational changes that might impair internalization, as removal of
this region increased internalization (Oreen and Liggett, 1994). Insertion of this proline-rich
region into the f32-adrenergic receptor resulted in an impaired internalization. These findings
indicate that different domains of the C-terminal tail can modulate receptor internalization in
opposite directions. This observation is perfectly illustrated by the findings that the
cytoplasmatic tail of the parathyroid hormone receptor contains regions that are implicated in
induction and others in inhibition of internalization (Huang et aI., 1995).
Receptor downregulation
Downregulation is a slow process compared to the two previously described desensitization
phenomena (Collins, 1991, Lohse, 1993). It commonly occurs after many hours and may not
be maximal before 24 hrs continuous agonist exposure. The mechanism of downregulation
remains uriclear but probably involves both enhanced degradation of internalized receptors and
decreased receptor synthesis, induced by changes in gene expression (Von Zastrow and
Kobilka, 1992, Hadcock and Malbon, 1989). One distinguishes two different components in
the process of f32-adrenergic receptor downregulation, Le. an agonist- and PKA-mediated
(heterologous) component. S49 mouse lymphoma cells defective in post-receptor components
(Os' adenylyl cyclase or PKA) were shown to be still susceptible to f32-adrenergic receptor
downregulation, indicating an agonist-dependent mechanism (Allen et aI., 1989, Shear et al.,
1976, Su el al., 1980). Defects in f32-adrenoceptor-Os coupling resulted in impaired receptor
downregulation, suggesting the importance of receptor-Os coupling in the process of receptor
downregulation (Campbell et at., 1991, Hadcock et at., 1989, Mahan et aI., 1985, Shear et
al., 1976, Su et aI., 1980). Addition of exogenous cAMP or phosphodiesterase inhibitors
could not overcome the observed impaired downregulation in these receptor mutants.
Moreover, mutational analysis of the f32-adrenergic receptor have shown that the palmitoylated
cysteine at position 341 (Campbell et al., 1991) and the N-terminal and C-terminal portions of
the third intracellular loop (Campbell et al., 1991) which are involved in Os-coupling, were
found to be important for f32-adrenergic receptor downregulation as well. These findings show
that either a Os-mediated but PKA independent signal is required for receptor downregulation,
or that receptor-Os complexes are preferentially degraded. Moreover, it should be noted that
while mutant receptors in these studies could be fully impaired in Os-coupling, the
downregulation was never fully blocked.
Besides the agonist-induced downregulation, cAMP analogues or forskolin were also
shown to promote receptor f32-adrenergic receptor downregulation, which is referred to as the
PKA-dependent downregulation (Bouvier et aI., 1989). However, the rate at which f32-
adrenergic receptors are lost from the plasma membrane is considerably slower and often less
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pronounced compared to the agonist-induced effects. Site-directed miItagenesis experiments
have shown that phosphorylation of the ~2-adrenergic receptor at a site in the third intracellular
loop by PKA may modestly enhance the rate of ~2-adrenergicreceptor degradation (Bouvier
et aI., 1989).
There are various reports describing downregulation of receptors that are negatively
coupled to adenylyl cylcase and phospholipase C, including e.g. adenosine AI, o,l-adrenergic
and muscarinic receptors (see for references Fisher, 1995, Hadcock and Malbon, 1993).
However, a distinction between agonist-induced and second messenger-induced
downregulation of these receptors remain to be elucidated. In the neuroblastoma N1E-115 cell
line and neuroblastoma/glioma hybrid cell line NG108-15, PKC stimulation with phorbolesters
induces downregulation of respectively muscarinic (Liles et al., 1986) and o-opioid receptors
(Gucker et aI., 1992), suggesting a role of PKC in the proc.ess of receptor downregulation.
Evidence for the involvement of a PKC-dependent mechanism in the process of receptor
downregulation of the gastrin-releasing peptide receptor was provided by mutational analysis,
as removal of the PKC consensus site located in the C-terminal tail resulted in an attenuation of
the agonist-induced downregulation (Benya et al., 1995). Using site-directed mutagenesis,
regions in the third intracellular loop of the muscarinic m1 receptor were found to playa role in
the process of receptor downregulation (Shapiro and Nathanson, 1989).
Finally, the C-terminal tail of many GPCRs appears to be an important structural
determinant for the process of receptor downregulation. Truncation or site-directed
mutagenesis of serine, threonine or tyrosine residues of the C-terminal tail of for e.g. the ~2­
adrenergic receptor and muscarine m3 receptor were shown to decrease the rate"of receptor
downregulation (Valiquette et al., 1990, 1993, Cheung et aI., 1989, Bouvier et aI., 1989,
Campbell et aI., 1991, Yang et aI., 1993). In addition, two isoforms of the somatostatin
(mSSTR2A and mSSTR2B) (Vanetti et al., 1993) and prostaglandin E2 receptor (EP3o, and
EP3~) (Negishi et al., 1993), which differ in their C-terminal tail, showed different patterns
of receptor downreglliation upon agonist exposure. Yet, the role of the C-terminal tail in
receptor downregulation appears to be complex. For the avian ~l-receptor the C-terminal tail
seems to prevent receptor downregulation as truncation of the receptor eliminates the
insensitivity of the ~ I-adrenergic receptor towards receptor downregulation (Hertel et al.,
1990, Parker et al., 1991).
Generally, agonist-induced downregulation of GPCRs is accompanied by a decline of
receptor mRNA levels (see for references review Hadcock and Malbon, 1993). The reduced
levels of mRNA presumably contribute to the overall reduction in receptor number and
responsiveness. Lowering of receptor mRNA levels serves to maintain the downregulated state
by establishing a new steady-state level of receptors. As for the adenylyl cyclase-coupled
receptors, the agonist-promoted downregulation of receptor mRNA appears to require PKA-
activation although partial downregulation may also be induced by functional coupling of the
receptor to Gs. In addition, an additional pathway exists for regulating receptor mRNA that
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does not require elevated cAMP levels but only basal PKA activity (Hadcock and Malbon,
1993). For the phospholipase C-linked receptors the mechanism underlying decline of receptor
mRNA is unclear, but for the alB-adrenergic receptor a decline in receptor mRNA levels may
be induced by PKC (Izzo et at., 1994).
Generally, cAMP- or Ca2+-activated kinases are believed to phosphorylate factors involved
in either repression of receptor gene transcription or selective degradation of receptor mRNA.
In addition, transciptionltranslation of such factors may be induced (Port et at., 1992). The
mRNAs of several GPCRs are relatively short-lived: 30 min to 2 hrs (Collins, 1993), but
breakdown can even be enhanced by agonist exposure. For the ~2-adrenergic receptor in
DDT1MF-2 cells, the ~2-adrenergic receptor expressed into CHW cells and the endothelin
ETB receptor in ROS17/2 rat osteosarcoma cells, the decline in receptor mRNA was ascribed
to destabilization of the mRNA (Bouvier et at., 1989, Hadcock et at., 1989, Sakurai et aI.,
1992). Besides agonist-induced destabilization of mRNA a decrease of gene transcription may
also contribute to the decrease of receptor mRNA levels. For the thyrotropin, luteinizing
gonadotropin, platelet-activating factor, muscarinic m2 and m3 receptors, reduced rates of gene
transcription have been proposed to, be responsible for the lowered steady-state mRNA levels
(Chau et at., 1994, Fukamauchi et at., 1993, Habecker and Nathanson, 1992, Saji et at.,
1992, Wang et at., 1992).
In conclusion, events involving alterations in receptor function, intracellular translocation,
downregulation, expression as well as alterations in the function and expression of G-proteins
are found to contribute to the overall phenomenon of desensitization of GPCRs.
1.3.2 Regulation of histamine receptor function
As discussed in the previous sections receptor desensitization is regarded as one of the
prominent mechanisms of receptor regulation. For the histamine receptors, such processes may
become apparent under several pathophysiological conditions (e.g. asthmatic attack or allergic
reaction), where histamine is released in large quantities, but might also occur under normal
physiological conditions (see section 1.3.3).
Desensitization of the H1 receptor has been reported in vitro in airway preparations
(Anderson et at., 1979, Brink et at., 1982, Krzanowiski et at., 1980, Leurs et at., 1990a),
intestinal smooth muscle preparations (Kenakin and Cook, 1979, Bielkiewicz and Cook, 1984,
Hishinuma and Uchida, 1988, Leurs et at., 1990b, Uchida and Hirano, 1983), cerebral
preparations (Dillon-Carter and Chuang, 1989, Quach et at., 1981, Bristow et at., 1993) and
several isolated cell systems (Brown et at., 1986, Bristow and Zamani, 1993, Cowlen et at.,
1990, Dickenson and Hill, 1993, Lewis Baenzinger et at. 1981, McCreath et at., 1994,
McDonough et at., 1988, Nakahata and Harden, 1987, Smit et at., 1992, Zamani et at.,
1994). Excessive exposure of the histamine HI receptor, located on either airway, intestinal
smooth muscle- or cerebral preparations of the guinea-pig, to a high concentration of histamine
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was found to cause a time- and dose-dependent desensitization to subsequent stimulation
(Bielkiewicz and Cook, 1984, Hishinuma and Uchida, 1988, Leurs, et ai., 1990c).
Desensitization of histamine HI receptors present on cell lines such as BC3H-l-smooth muscle
cells, human 1321NI astrocytoma cells, human vascular endothelial cells, DDTIMF-2 smooth
muscle cells, human umbilical vein endothelial cells and human uterine HeLa cells was
characterized by either an attenuated production of inositol phosphates or reduced capacity of
the HI receptor to increase the intracelluar Ca2+ concentration (Brown et ai., 1986, Bristow
and Zamani, 1993, Cowlen et ai., 1990; Dickenson and Hill, 1993, Lewis Baenzinger et at.
1981, McCreath et at., 1994, McDonough et at., 1988, Nakahata and Harden, 1987, Smit et
at., 1992, Zamani et at., 1994).
Desensitization in canine and monkey tracheal strips in vitro and in human airways in
vivo was suggested to result from a functional antagonism via a cyclooxygenase product
(Anderson etat., 1979, Krzanowiski et at., 1980, Manning et at., 1987). Yet, decrease of
HI responsiveness in guinea-pig parenchymal lung strips could not be explained by the
intervention of relaxing prostaglandines (Leurs et at. 1990a). However, contractions after
KCI-induced membrane depolarization were reduced, suggesting that desensitization might
affect the excitation-contraction coupling. In guinea-pig intestinal smooth muscle, however,
KCI-induced membrane depolmlzation was unaltered, excluding dysfunction of the contractile
apparatus in this preparation (Leurs et at., 1990b).
In several cellular systems desensitization of the HI histamine receptor response appeared
to be clearly restricted to the HI receptor, as other receptor mediated responses, e.g.
muscarinergic, or direct activation of the G-protein by NaF remained unaffected (Cowlen et
ai., 1990, Dickenson and Hill, 1993, Dillon Carter and Chuang, 1989, Hishinuma and
Uchida, 1988, Leurs et at., 1990c, McCreath et at., 1994, Quach et at., 1981, Smit et at.,
1992, Uchida and Hirano, 1983). The observed homologous desensitization implies a
modulation at the level of the receptor. Possible modifications that might be responsible for the
observed homologous desensitization are modulation of receptor binding characteristics (e.g.
agonist affinity), attenuated receptor-G-protein coupling or loss of receptors.
Quach et at. (1981) explained the observed desensitization of the HI receptor-mediated
glycogen breakdown in mouse cerebral cOltex by a small reduction of the [3H]-mepyramine
binding sites. Yet, the loss of receptors could not entirely explain the reduced receptor activity.
Moreover, in the guinea-pig intestine both maximal binding.capacity and binding affinity of
histamine for the histamine HI receptor remained unaltered (Leurs et ai., 1991c). In addition,
in HeLa cells the number of HI receptors measured as [3H]-mepyramine binding sites did not
alter after short-term histamine pretreatment (Smit et at., 1992).
Investigation of the effect of short-term and in particular long-term histamine-treatment on
HI receptor density has been hampered by the lack of suitable model systems, possessing a
reasonable density of HI receptors. The recent cloning of the genes encoding the HI receptor
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(De Backer et al., 1993, Fujimoto et aI., 1993, Fukui et al., 1994, Horio et aI., 1993,
Moguilevsky et al., 1994, Traiffort et aI., 1994) permits the generation of cell lines
expressing sufficient amounts of HI receptors (Ireda1e et al., 1993, Leurs et aI., 1994c).
Chapter 3 of this thesis describes the short-term, and long-term desensitization of the human
HI receptor expressed in Chines Hamster Ovary (CHO) cells.
In contrast to the frequent reports on histamine HI receptor desensitization, relatively little
information is available on histamine H2 receptor desensitization. Desensitization of the
histamine H2 receptor has been described in HL-60 cells and was found to be mainly
homologous, although in some experiments prostaglandin (PGE2) responses were also
affected, indicating a small heterologous component (Johnson and Sawutz, 1984). A
phospholipase A2 inhibitor, reported to be effective against ~-adrenergic receptor
desensitization in astrocytoma cells, inhibited the heterologous induced desensitization in HL-
60 cells (Mallorga et al., 1980). The mechanism of action of this inhibitor is however unclear.
Desensitization in HL-60 cells could not be explained by a loss of H2 receptors nor by the
induction of phosphodiesterase activity. However, in mononuclear leukocytes, histamine
caused a heterologous desensitizatio\1 of the H2 receptor, ~-adrenergic and prostaglandin E2
receptor, which could be explained by enhancement of phosphodiesterase activity (Chan et aI.,
1982, Holden et al., 1987).
In clonal cytolic T lymphocytes histamine was reported to induce an homologous
desensitization of the H2 receptor as no effect on isoproterenol, PGE2 or forsko1in stimulated
cAMP formation was observed (Schreurs et aI., 1984). The half time of desensitization was
less than 10 min, possibly indicating receptor-cyclase uncoupling rather than receptor
intemalisation or downregulation. In addition, in the human gastric cancer cell line HGT-1 H2
receptors have also been reported to be desensitized upon exposure to histamine with a half
time of 20 mins (Prost et al., 1984). Recent reports, however, have demonstrated the
existence of a histamine H2 receptor on HL-60 and HGT-1 cells with a pharmacological profJ.le
distinct from the commonly described H2 receptor (Burde et al., 1989, Mitsuhashi et aI.,
1989, Reyl-Desmars et al., 1991, Seifert et al., 1992). The human monocytic cell line U937,
appeared to express H2 receptors pharmacological identical to the H2 receptor located on the
right atrium of the guinea-pig and was therefore chosen as model system for the investigation
of H2 receptor desensitization in our laboratory (Smit et al., 1994, Chapter 4). The H2
receptors present on this cell line were found to be susceptible to homologous receptor
desensitization as the ~-adrenoceptor-mediated effect remained unaffected (Smit et aI., 1994,
Chapter 4). Homologous desensitization of the H2 receptor has also been observed in the
human gastric carcinoma cell line MKN-45 CArima et al., 1993). The histamine-induced
desensitization in MKN-45 cells did not appear to be associated with a reduction in [3H]-
tiotidine binding. Fukushima et aI., (1993) on the other hand, showed a 25% decrease of
[3H]-tiotidine binding in intact and membranes of CHO cells, expressing the canine H2
receptor, treated with 10 IlM histamine for 1 hr, a condition where H2 receptors were found to
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be desensitized. In contrast, histamine treatment induced no apparent change in H2 receptor
level as assessed by immunoblotting with a antipeptide antibody against the C-terminal tail
sequence of the receptor. Moreover, if one takes into account the technical difficulties
associated with [3H]-tiotidine binding assays (Garbarg et al., 1992), the validity of the
observed decrease of only 25% should be questioned. The introduction of a highly sensitive
H2 antagonist [125I]-aminopotentidine (Ruat et al. 1990b) may give more insight in the effect
of histamine-induced desensitization on H2 receptor expression.
As already discussed for the HI receptor, binding studies with the commonly used cellular
systems are often hampered by the low expression of H2 receptors. The elucidation of DNA
sequences encoding the histamine H2 receptor protein (Gantz et ai., 1991a, Gantz et ai.,
1991b, Ruat et ai., 1991) has made it possible to generate stable cell lines expressing high
densities of H2 receptor protein (Fukumashi et ai., 1993, Leurs et ai., 1994a, Traiffort,
1992b). These model systems enable for the first time investigation of long-term regulatory
mechanisms of the H2 receptor. In Chapters 5 to 9, the effects of long-term exposure of H2
receptors to H2 agonist and antagonists are studied and discussed.
As shown in section 1.3.1 desensitization is thought to be associated with post-translational
modification of the receptor protein by phosphorylation (Hausdorff et ai. 1990, Huganir and
Greengard, 1990, Lefkowitz et al., 1990). Kinases, such as PKA and PKC are responsible
for the heterologous type of receptor desensitization, whereas GRKs seem to play clUcial roles
in the mechanism underlying homologous desensitization (Huganir and Greengard, 1990,
Lefkowitz et ai., 1990, Palczewski and Benovic, 1991, see section 1.3.1).
Indeed, desensitization of the histamine HI receptor appears also to be regulated by
kinases. In various systems PKC has been found to account for a negative feedback on the
histamine receptor-mediated response (Cowlen et al., 1990, Dickenson and Hill, 1993,
Dillon-Carter and Chuang, 1989, Fukui et ai., 1991, Leurs 'et al., 1990c, 1991c, McCreath
et ai., 1994, McDonough et al., 1988, Tilly et al., 1990a,b, Smit et ai., 1992, Volpi and
Berlin, 1988). In some cellular systems exposure of histamine HI receptors to other
stimulating agents, which activate receptors coupled to phospholipase C, resulted also in an
attenuation of HI receptor-mediated responses, referred to as heterologous desensitization
(Hishinuma and Uchida, 1988, Leurs et al., 1990b, McDonough et al., 1988). This type of
desensitization is most likely caused by a commonly activated molecular entity such as the G
protein or alterations at the level of the intracellular Ca2+ pool.
Evidence for the possible involvement of a specific kinase (GRK) in the process of HI
receptor desensitization has been obtained by experiments using Ca2+ fluorescence microscopy
and video digital imaging in human HeLa cells (Smit et ai., 1992, see Chapter 2). In HeLa
cells histamine induces an immediate HI receptor mediated biphasic elevation of the
intracellular Ca2+ concentration. Desensitization, characterized by an impaired release and
influx component of the Ca2+ response, was monitored when the HeLa cells were repeatedly
exposed to histamine. The histamine induced release component appeared to be reduced in a
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selective manner, as neither the caffeine- nor the ATP-induced Ca2+ release components were
found to be affected. The observed inhibition of the influx component can be explained by the
involvement of PKC, as activation of PKC by a phorbolester both affected the histamine- and
ATP-induced Ca2+ response. Yet, inhibition of the Ca2+ release component was still observed
when PKC activity was eliminated, suggesting the involvement of another regulatory
mechanism, possibly a specific receptor kinase (GRK). Based on these experimental data it
was suggested that short-term desensitization of the histamine HI receptor in HeLa cells
evolves from two different processes: aPKC dependent pathway, and a PKC independent
pathway (Smit et aI., 1992).
Also in guinea-pig lung tissue evidence has been obtained for the involvement of a PKC-
independent mechanism of receptor desensitization (Leurs et ai., 1992) The non-selective
kinase inhibitor H-7 was found to attenuate HI receptor desensitization, whereas selective
PKC inhibitors were ineffective. Moreover, H-7 was found to attenuate 13-adrenoceptor-
induced translocation of a GRK-like enzyme from the cytosol to the membrane (Garcia-
Higuerea and Mayor, 1992). Thus, it is tempting to speculate that H-7 interferes with a specific
kinase, inhibiting its translocation to the membrane, leading to HI receptor desensitization.
Moreover, in human umbilical vein endothelial cells and DDTIMF-2 cells the histamine-
induced desensitization appeared to be homologous and insensitive to PKC inhibitors,
excluding a role for PKC and suggesting the involvement of a specific mechanism in this
process (Dickenson and Hill, 1993, McCreath et aI., 1994). Other kinase inhibitors such as
Ca2+/calmodulin or cGMP-dependent kinase inhibitors failed also to modify the histamine-
induced desensitization of HI receptor-mediated responses in human umbilical vein endothelial
cells (McCreath et aI., 1994).
For the H2 receptor there is no direct evidence for the involvement of GRKs, but the
observed homologous desensitiation in U937 and MKN-45 cells suggest such an involvement
(Arima et ai., 1993, Smit et ai., 1994).
Taken together, it is conceivable that agonist-induced, short-term desensitization of the
histamine receptors involves activation of a GRK, analogous to the proposed mechanism for
desensitization of the 13-adrenoceptor system. Recently, the genes encoding the histamine HI
and H2 receptor were cloned (see section 1.2.1). The primary sequence of both the histamine
HI and H2 receptor reveals the existence of several serines and threonines in the third
intracellular loop and cytoplasmatic tail, which may serve as potential phosphorylation sites in
the process of desensitization (Fig. 2 and 3). Moreover, these potential phosphorylation sites
may also be involved in the process of receptor internalization or downregulation. Besides the
serines and threonines, other structural features, which were reported to be important for
regulation of the 132-adrenergic receptor, such as various conserved tyrosine residues, are also
present in the H2 receptor. The histamine HI receptor contains several PKC sites and also a
potential PKA site (Fig. 2). The histamine H2, on the other hand, does not seem to possess
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potential PKA sites (Fig. 3). However, this does not rule out the possibility that the H2
receptor is phosphorylated by PKA, since e.g. nitric oxide synthase was found to be
phosphorylated by PKC despite the absence of a potential PKC site (Bredt et al., 1991).
Clearly, the availibility of the genes encoding the histamine HI and H2 receptor offers new
possibilities with regard to the elucidation of the mechanism underlying receptor desensitization
(Chapters 3, 5 to 9).
1.3.3 Clinical aspects of receptor desensitization and implications
for drug therapy
As shown in previous sections (1.3.1, 1.3.2) receptor regulation is functionally diverse and in
many cases rather complex. Transcriptional, post-transcriptional and post-translational
mechanisms are found to contribute to the overall control of receptor expression and cellular
responsiveness.
Under pathophysiological conditions such mechanisms may become apparent. In e.g.
patients suffering from congestive heart failure, loss of heart function is associated with
increased levels of noradrenaline, decreased neuronal adrenergic uptake and a decreased ~­
adrenoceptor function (Homcy et al., 1991, Hammond, 1993, Stiles, 1991). The latter can be
explained by a decreased sensitivity, due to receptor uncoupling and by a reduction in the
number of myocardial ~l-adrenoceptors (Homey et ai., 1991, Hammond, 1993, Stiles,
1991). First, it was assumed that the hormone sensitive adenylyl cyclase system of the heart in
patients with congestive heart failure is less responsive to catecholamine stimulation in terms of
cAMP generation. However, stimulatory agonists such as histamine and forskolin
demonstrated unaltered activity (see for references Ungerer et ai., 1993). In view of these
findings inotropic H2 agonists are considered as potential drugs which might be used in
treatment of patients with congestive heart failure (Felix et al., 1991). Moreover, Ungerer et
al. have shown that' the diminished response to ~-adrenergic agonist can be ascribed to
increased expression of GRKs (Ungerer et ai., 1993). In addition, it has been found that the
level of the inhibitory G-protein Gi is increased in myocardial tissue from patients with
congestive heart failure (Feldman et ai., 1988, Neuman et al., 1988). Increase in GRK2 as
well as ~-arrestin levels, has also been reported after chronic morphine administration in the rat
locus coeruleus and not in other brain areas, suggesting that elevation of both entities may
contribute to opioid-receptor tolerance which is known to occur in this brain region (Terwilliger
et ai., 1994). In view of the potential use of H2 agonists in the treatment of patients with
congestive heart failure it is important to determine whether the H2 receptor is susceptible to
desensitization mechanisms as found for the ~2-adrenergic receptor (Chapter 4).
For the histamine receptors there are various reports describing in vivo desensitization of
histamine receptor function (Antol et ai., 1988, Manning et ai., 1987, Poulakos and Gertner,
1986). The mechanism underlying the observed desensitization, however, is still unclear.
There are also various reports describing dynamic regulation of H1 receptor density in vivo
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(Iinuma et a!., 1993, Martinez-Mir et a!., 1993, Nakai et a!., 1991, Yanai et at., 1992).
Upon aging the number of HI receptors was shown to decrease (Yanai et a!., 1992). Changes
of HI receptor density have also been reported in the e1ectlic focii in the temporal cortex of
epileptic patients (upregu1ation HI receptors) and in the frontal cortex of patients with chronic
schizophrenia (downregu1ation HI receptors) (linurna et ai., 1993, Nakai et ai., 1991).
Similarly, the H2 receptor density was found to be altered in brain tissue of patients suffering
from Huntington's Chorea disease (downregulation H2 receptors) (Martinez-Mir et ai., 1993).
These examples indicate that HI and H2 receptor expression is susceptible to regulatory
changeS under physiological and pathophysiological conditions.
Desensitization has also been observed during drug therapy (Brodde et ai., 1990,
Motomura et at., 1990, Ghosh et ai., 1991, Homey et ai., 1991, Stiles, 1991). Healthy
volunteers receiving prolonged treatment with ~1 and ~2 agonists display reduced ~­
adrenoceptor function (Brodde et ai., 1990). There are also reports which show altered GPCR
function after antagonist treatment. Upregu1ation of ~1-, ~2-adrenergicand opoid receptors
after chronic antagonist treatment have been reported (Boudoulas et ai., 1977, E1fellah et ai.,
1989, Motomura et a!., 1990, Yoburn et at., 1994). Patients with severe heart failure have
been beneficially treated with low doses of selective ~l-antagonists (Heilbrunn et al., 1989).
The theoretical rationale for such treatment is that ~ I-antagonists can increase ~-adrenergic
density, and thus may restore the previously reduced ~-adrenergic density in these patients. As
for the HI receptors, long-term (l week) treatment of patients with mild atopic asthma with the
HI antagonist cetilizine resulted in a loss of effect of cetilizine itself on histamine-induced
bronchoconstriction, compared to when administerd only once (Ghosh et at., 1991). These
observations were suggested to result from increased sensitivity of HI receptors, caused by a
possible upregu1ation of HI receptors. Based on the results from a study in which patients
were chronically treated with the HI antagonist chlorpheniramine similar suggestions were
made (Taylor et at,. 1985). Similarly, H2 antagonists were shown to lose their antisecretory
effects in patients after prolonged dosing, which might be explained by a possible upregulation
of H2 receptors (Bertaccini et at., 1992, Merki et at., 1994, see Chapter 9). Moreover,
chronic treatment with the H2 antagonists ranitidine resulted in increased palietal cell sensitivity
in consious cats and abrupt withdrawal of histamine H2 receptor blockade led to intragastlic
hyperacidicity (Nwokolo et ai., 1991, Coruzzi et at., 1989), which also may be ascribed to
an increase of H2 receptor density (see Chapter 9). Schizophrenic patients receiving chronic
neuroleptic treatment display increased H2 receptor densities in the globus palllidus (Martinez-
Mir et at., 1993). As some neuroleptics show considerable affinity for the human H2
receptors (Traiffort et ai., 1992b, Leurs et at., 1994a), it is conceivable that neuroleptics may
modulate H2 receptor expression in vivo.
It is evident that the occurence of desensitization after agonist treatment and observed
changes in GPCR function after antagonist treatment may have implications for the
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development of efficient drug therapy. Approximately 50 to 60 % of all clinical relevant drugs
exert their action via GPCRs (Guderman et aI., 1995). In view of the wide use of HI and H2
antagonists in the treatment of allergies (Janssens, 1993) and gastric ulcers respectively
(Bertaccini and Corruzzi, 1992, Deakin and Williams, 1992) and the putative therapeutical
application of H2 receptor agonists in patients suffering from congestive heart failure (Felix et
al., 1991), a detailed study of the mechanisms underlying the regulation of histamine HI and
H2 receptor expression is indispensable (see 1.4 Aim of thesis ).
Effective drug therapy requires detailed knowledge of the phenomena of receptor
regulation. The degree and the development of regulatory phenomena depend on the presence
and expression level of the molecular entities (e.g. GRKs, arrestins) in the cellular environment
of that receptor. As such, regulation of one receptor may differ from cell to cell. Receptor
regulation may even vary within a population, as receptor mutations were found to explain
phenotypic variations leading to altered receptor regulation (Reihsaus et aI., 1993, Green et
al., 1994). Recently, Reihsaus et aI. (1993) have identified in the general population different
polymorphic forms of the ~2-adrenergic receptor, including three forms that are compromized
in the N-terminus of the receptor, encompassing a single mutation. Although there is no clear
idea how this extracellular part of the receptor can influence receptor regulation, in vitro
studies have indicated that these polymorphisms of the ~2-adrenergic receptor impart distinct
patterns of agonist-promoted downregulation; two promoting downregulation, another
inhibiting downregulation (Green et al., 1994). As such, these polymorphisms, occuning at
frequenties ranging from -10% to -50 %, may be responsib~e for the heterogeneity between
individuals in ~2-adrenergic receptor expression and function. Reihsaus et aI. even suggested
that these natural occuring polymorphisms may explain the clinical status of asthmatic patients
(Reihsaus et aI. 1993). It is therefore tempting to speculate that hypersensitivity of asthmatic
patients for histamine is caused by polymorphic variations of the histamine HI receptor within
the population.
All the molecular entities involved in the processes of receptor regulation may form
possible targets for interference to prevent undesired receptor regulation. Potential strategies to
prevent receptor desensitization, include inhibitors of e.g. GRKs or arrestins, as these
molecular entities were shown to contain domains that comprise selectivity (Inglese et aI.,
1992, Haga et al., 1994, Gurevich et al., 1995). Moreover, in vitro studies have shown that
a synthetic peptide corresponding to the last 28 amino acid residues from the C-terminal region
of ~ARK was able to block ~'Y activation of GRK2/3, and may therefore provide a useful
strategy for the inhibition of the enzyme (Koch et aI., 1993). Other possible strategies may be
envisaged so that in the future effective therapy consists of a multitargeting drug approach, in
order to eliminate regulatory changes of GPCR function after agonist or antagonist medication.
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1.4 Aim of thesis
The rapid regulation of receptor function appears to be an integral part of the transmembrane
signalling of many GPCRs (section 1.3). The endogenous compound histamine is one of the
mediators which is frequently released in inflammatory processes, leading to an instantaneous
increase of the histamine concentration. It is therefore conceivable that histaminergic receptor
responses may be affected and become desensitized. This regulatory process may serve as a
protective mechanism, aiming to maintain a certain degree of intercellular communication.
Desensitization of the implicated histamine receptor system may thus be favoured. In contrast,
in tissues where histamine is essential for normal functioning desensitization should be
reduced. Moreover, in view of the widespread use of HI (Janssens, 1993) and H2 (Bertaccini
and Corruzzi, 1992, Deakin and Williams, 1992) antagonists and proposed use of H2 agonists
(Felix et aI., 1991) and H3 receptor ligands (Leurs et aI., 1995) detailed knowledge of the
regulation of the histamine receptors is important for development of effective drug therapy.
Besides, there are various reports describing altered density of histamine receptors in vivo,
observed under pathophysiological but also physiological conditions (see section 1.3.2).
Understanding receptor regulation might give new insights in the respective (patho)
physiological conditions, but might also create new strategies for modulating receptor
desensitization. All molecular entities involved in the process of desensitization represent
possible targets for therapeutic intervention to modify the process of desensitization and thus
cellular communication.
In this thesis the dynamic regulation of the histamine HI and H2 receptor has been
investigated. Previous studies in our laboratory have shown that the histamine HI receptor
located on guinea-pig lung tissue and small intestine is rapidly desensitized upon histamine
exposure (Leurs et ai., 1990a, b, 1991a, b, c, 1992). However, the use of these tissue
preparations was limited as large quantities of material for radioligand binding studies and
second messenger production were required. In addition, these preparations do not represent a
homogeneous population of cells and histamine receptors. In our study we used cell lines
expressing endogenous HI and H2 receptors as a model system to examine the phenomenon of
short-term receptor desensitization (Chapter 2 and 4). For the HI receptor we used the HeLa
cell line, a human uterine carcinoma cell line (Chapter 2), and for the H2 receptor the U937, a
monocytic cell line (Chapter 4). Due to the low expression of histamine receptors in these
cellular systems we subsequently used a transfected cell line (Chinese Hamster Ovary (CHO)
cells) expressing the recently cloned human HI and human and rat H2 receptor to examine
long-term desensitization (Chapter 3 and 5). The pharmacological characterization of the human
HI and H2 receptor expressed in CHO cells is described in Chapters 3 and 7 respectively.
Long-term receptor desensitization (downregulation) of the histamine HI and H2 receptor was
studied in Chapters 3 and 5. H2 receptor mutants were generated to examine the biochemical
mechanisms underlying H2 receptor regulation and to determine the structural requirements for
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H2 receptor downregulation (Chapter 5, 6). In order to visualize the process of H2 receptor
internalization, epitope-tagged human and rat H2 receptor were used and expressed in human
embryonal kidney cells (HEK293) cells (Chapter 8). Besides the examination of short-term and
long-term desensitization of the histamine HI and H2 receptors, the long-term effects of H2
antagonists on H2 receptor expression were examined and discussed in Chapter 9.
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Chapter 2
Short-term desensitization of the histamine B 1
receptor in human BeLa cells: involvement of
protein kinase C dependent and independent
pathways
M. J. Smit, R. Leurs, S. M. B1oemers, L. G. J. Tertoo1en, A. Bast, S. W. de Laat and H.
Timmerman
In this study we have investigated the effects of short-term exposure of cells to histamine on the subsequent HI
receptor responsiveness in HeLa cells, using ea2+ fluorescence microscopy. In HeLa cells histamine (100 J.lM)
induces an irmnediate HI receptor mediated biphasic elevation of the intracellular Ca2+ concentration ([Ca2+]i)
(basal [Ca2+]i: 81 ± 30 nM, histamine-induced Ca2+ response: fIrst phase: 1135 ± 79 nM; second phase: 601 ±
52 nM, n =11). The histamine HI receptors on HeLa cells are readily susceptible to desensitization since
repetitive exposure of the same group of cells to histamine (100 J.lM) markedly affected the release and influx
component of the induced Ca2+ response (-second application of histamine: fIrst phase: 590 ± 92 nM, second
phase: 279 ± 47 nM; third application of histamine: fIrst phase: 454 ± 127 nM, second phase: 240 ± 45 nM, n
=6).
The influx component of the histamine-induced Ca2+ response appeared to be non-selectively reduced as
also the second phase of the ATP response (50 J.lM) was significantly reduced after desensitization with
histamine (control cells: 516 ± 33 nM; desensitized cells: 331 ± 96, n =4). As activation of protein kinase C
(PKC) by PMA was found to inhibit the histamine as well as ATP-induced Ca2+ response in a dose dependent
manner, PKC seems to be responsible for the observed inhibition of the Ca2+ influx component. Moreover, in
PKC downregulated cells the second phase of the histamine induced Ca2+ response was elevated, indicating the
involvement of PKC in tlle negative feedback on the Ca2+ influx (control cells: second phase: 602 ± 52 nM;
PKC downregulated cells: second phase: 837 ± 100 nM, n = 6).
The release component of the histamine-induced ea2+ response appeared to be selectively reduced as neither
the release component of the ATP response (50 J.lM) nor the caffeine-(3 roM) induced Ca2+ release were found
to be affected by desensitization with 100 J.lM histamine. The data indicate the existence of homologous
desensitization. The homologous desensitization of HI receptor responsiveness was still observed in PKC
downregulated cells, implying the rapid activation of a regulatory mechanism other than PKC.
Based on our experimental data we suggest that short-term desensitization of the histamine HI receptor
evolves from two different processes: a selective reduction of the histamine-induced ea2+ release, mediated by a
PKC independent pathway, and a non-selective inhibition of the receptor mediated Ca2+ influx activated by a
PKC dependent pathway.
Introduction
G-protein coupled receptors (GPCRs) show frequently a dynamic regulation of receptor
function. In response to various conditions receptor functionality can either be increased or
diminished by cellular systems. Such a dynamic regulation of receptor responsiveness is not
only observed under in vitro conditions but can also occur in vivo (Homey et aI., 1991,
Manning et aI., 1987) and has been suggested to have serious consequences for drug therapy
(Brodde et aI., 1990, Ghosh et aI., 1991, Homey et aI., 1991, Motomura et aI., 1990,
Stiles et al., 1991).
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Desensitization is regarded as one of the prominent mechanisms of receptor regulation.
This process is charactelized by a loss of receptor responsiveness, despite the continuous
presence of a high concentration of a stimulus (Hausdorff et at., 1990, Huganir and
Greengard, 1990, Lefkowitz et aI., 1990). This process might become apparent during drug
therapy (Brodde et aI., 1990), but plays also a dominant role in several pathophysiological
conditions (Homcy et aI., 1991, Stiles et aI., 1991).
In certain pathologies, e.g. an allergic reaction or asthmatic attack, the biogenic amine
histamine is released in high quantities from either mast cells or basophils, resulting in an
immediate, local increase of the histamine concentration. Thus, histamine receptors located near
these sites are prone to be affected, which might result in receptor desensitization. To date, the
process of desensitization of the HI and H2 receptor has been reported in e.g. smooth muscle
preparations (Anderson et aI., 1979, Bielkiewicz and Cook, 1984, Hishinuma and Uchida
1988, Kenakin and Cook, 1979, Leurs et aI., 1990, 1991b) and various isolated cell systems
(Brown et aI., 1986, Cowlen et at., 1990, Lewis Baenzinger et aI., 1981, McDonough et
at., 1988, Nakahata and Harden, 1987, Sawutz et at., 1984). In earlier studies performed in
our laboratory desensitization of the histamine HI receptor was suggested to be homologous
and caused by an alteration at the level of the histamine HI receptor (Leurs et at., 1990,
1991b). These findings were based on functional studies, measurements of inositol phosphate
production and radioligand binding studies (Leurs et at., 1990b, 1991). Nevertheless, the use
of smooth muscle preparations has its limitations, since large quantities of material are needed
for measurements of inositol phosphate production or radioligand binding studies. Moreover,
since these preparations do not represent a homogeneous population of cells and histamine
receptors, the use of these preparations for detailed mechanistic investigation is rather limited.
These considerations prompted us to search for a well defined cellular system.
In the present study HeLa cells, a human uterine carcinoma cell line, was chosen as a
model system to study the process of histamine HI receptor desensitization. Previous work
from various laboratories has already revealed several characteristics with respect to the
histamine HI receptor. Production of inositol phosphates, changes in ion permeability and
Ca2+ signalling have been well delineated in this cell line after activation of the histamine HI
receptor (Bristow et at., 1991, Hazama et at., 1985, Raymond et at., 1991, Sauve et at.,
1987, 1990, 1991, Tilly et at., 1990a, b, c, Volpi and Berlin, 1988). Since these cells appear
to possess a reasonable number of [3H]-mepyramine binding sites (Bristow and Young,
1991), these cells might be suited to investigate HI receptor regulation.
The present study was undertaken in order to examine the effects of short-term exposure of
HeLa cells to histamine on the subsequent HI receptor responsiveness. As parameter for
receptor activation we used the increase in intracellular Ca2+ levels ([Ca2+h); changes in
[Ca2+h were measured using fluorescence microscopy. Major advantages of this technique are
the high sensitivity of this system and the ability to monitor direct changes in [Ca2+h upon
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receptor activation in a group of 6 to 8 cells. In our experimental set up, changes in [Ca2+h
induced upon second addition of a stimulus can be monitored in the same group of cells. This
feature is especially important with regard to the agonist-induced desensitization. Mter an initial
characterization of the HI receptor desensitization some experiments were performed to
elucidate the underlying mechanism of this process.
Materials and methods
Cell culture Human HeLa cells were cultured at 37 °C in a humified atmosphere with 7.5 % CO2 in Dulbelco's
modified Eagle's medium supplemented with 7.5 % heat-inactivated fetal-calf serum (Integro, The Netherlands),
2 roM L-glutamine, 10 IV Iml penicilin and 10 Jlg/ml streptomycin (Flow Labarotories). The cells were
passaged twice a week, using trypsine (0.05 %)-EDTA (0.2 mg/ml) (Flow laboratories) and grown to sub-
confluency for the fluorescence measurements.
Measurements of lCa2+1i HeLa monolayers, grown on glass coverslips, were loaded with 10 JlM fura-2-AM
ester in a HBS buffer (140 roM NaCI, 5 roM KCl, 2 roM CaCI2' 1 roM MgCI2' 10 roM glucose, 0.2 % BSA
and 10 roM Hepes (pH 7.4» for 30 mins at 37 °C . Ca2+.dependent fura-2 fluorescence was monitored at an
emission wavelength of 510 nm with an excitation wavelength of 340 nm and 380 nm (Grynkiewicz et al.
1985). Fluorescence measurements were carried out at 33 °C in HBS buffer using a fluorescence microscope
(Leitz orthoplan, Ernst Leitz GHMB Wetzlar, Germany) and a SPEX dual wavelength fluorimeter as excitation
source (SPEX Industries Inc., N.Y., U.S.A.). For Ca2+ measurements 6 to 8 cells were selected in all
measurements. HeLa cells were washed evefy 5 mins by completely exchanging the medium by rapid perfusion
during a period of 10 mins. Exposure of cells to a stimulus lasted for a period of 5 mins. Thereafter, cells were
washed rapidly three times and were exposed to another stimulus 5 mins later. The second phase was recorded
after 30 sees of receptor activation with the indicated drug. The background, largely due to autofluorescence, was
measured prior to fura-2-AM loading and was corrected for in the calculation. Minimal fluorescence (Fmin) was
achieved by complexing calcium with 6 roM EGTA in Ca2+-free HBS buffer (pH 8.0) and maximal
fluorescence (Fmax) was measured by permeabilization of cells with 3 JlM ionomycin.
Chemicals Histamine dihydrochloride, methacholine chloride, bradykiniu, phorbol-12-myristate-13-acetate,
ionomycin and ATP (sodium salt) were obtained from Sigma Chemical Company Ltd. (St. Louis, MO,
U.S.A.), fura-2-acetoxymethylester (fura-2-AM) was from Molecular Probes (Eugene, OR, U.S.A). The
enantiomers of cicletanine were kindly donated by the Institute of Henri Beaufour (France).
Statistical analysis All data shown are expressed as mean ± s.e.mean of at least four independent experiments.
Statistical analysis was carried out by Student's t-test. P-values < 0.05 were considered to indicate a significant
difference.
Results
The histamine-induced calcium response in HeLa cells
In HeLa cells 100 IJM histamine induced an immediate biphasic elevation of the intracellular
Ca2+concentration ([Ca2+h) as measured by fura-2 fluorescence microscopy (Fig. 1A). This
response was characterised by a rapid transient rise in [Ca2+h, followed by a sustained
increase in [Ca2+h and lasted until the agonist was removed (Fig. 1). The basal level of
[Ca2+h in Hela cells was 81 ± 30 nM (n =11), whereas after application of 100 pM histamine
[Ca2+h was rapidly elevated to 1135 ±79 nM (first phase, n =11). Mter this initial rapid rise
the [Ca2+h decreased to an elevated level of 601 ±52 nM (second phase, n =11) after 30 sees
of receptor activation with histamine. The initial rise is largely dependent on the release of
intracellular Ca2+, whereas the second phase depends on the influx of extracellular Ca2+ (Tilly
et al., 1990b). As can be seen in Fig 1B the elevation of [Ca2+h by 100 pM histamine was
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effectively blocked by 1~ (-)-cicletanine, an HI receptor antagonist (Schoeffter et at.,
1987). The enantiomer (+)-cicletanine (l ~M), which is not active as an H1 antagonist
(Schoeffter et at., 1987) did not affect the responsiveness of HeLa cells to histamine (Fig.
1C). These data clearly indicate the involvement of the histamine H1 receptor in the response to
histamine.
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Fig. 1. Intracellular free Ca2+ transients induced by histamine (His, IOO~) (a), histamine (100~) in the
presence of (-)-cicIetanine (1 ~) (b) and histamine (lOO~) in the presence of (+)-cicIetanine (1 ~) (c) in a
group of 6 to 8 HeLa cells. The HeLa cells were exposed to the indicated drugs for a period of 5 mins as
indicated by the bars. Typical experiments out of 4 are shown.
Desensitization ofthe HI receptor induced by 100 JiM histamine
Desensitization to histamine was observed when the same group of HeLa cells was repeatedly
exposed to histamine (Fig. 2 B, C). As depicted in Fig. 2 exposure of cells to 100 ~M
histamine for 5 mins markedly affected the subsequent [Ca2+h transient after a washing period
of 5 mins. The intracellular Ca2+ levels of the initial peaks for the second and third application
of 100~ histamine were significantly reduced to respectively 590 ±92 nM (52 % reduction,
n = 6, p < 0.05) and 454 ± 127 nM (65 % reduction, n = 6, p < 0.05). The second phase was
significantly reduced to respecively 279 ±47 nM (62 % reduction, n =6, p < 0.05) and 240 ±
45 nM (70 % reduction, n =6, p < 0.05) after 30 secs and further declined to basal Ca2+
levels (Fig. 2 B, C).
Thus, an incubation of 5 mins with 100~ of histamine seems sufficient to induce a rapid
loss of responsiveness of the histamine HI receptor in HeLa cells. Moreover, histamine-
induced desensitization seem to affect two separate components; the release as well as the
influx component.
In order to establish whether these observations of receptor desensitization were confined
to the histamine HI receptor, we examined the effects of histamine pretreatment on the
responses to other Ca2+-mobilizing agents. Recent studies performed in our laboratory
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Fig. 2. Desensitization of the hisuunine-induced Ca2+ transients in HeLa cells. The cells were repeatedly
exposed to 100~ of histamine for a period of 5 mins. After the first application of hisuunine (a) the HeLa
cells were washed three times by completely exchanging the medium by rapid perfusion. Hisuunine was added
again after 5 mins (b, c). A typical experiment out of 6 is shown.
showed that in HeLa cells bradykinin, carbachol and ATP can also elevate the [Ca2+h levels
(data not shown). The responses to bradykinin (11JM) and carbachol (300 ~M) were found to
be weak, yet, ATP proved to be effective in elevating [Ca2+h. Phannaco10gical investigations
revealed that on He1a cells ATP binds to a "5'-nucleotide" type of purinergic receptor, inducing
a rapid rise in [Ca2+h (Smit et al., 1993). No additivity was monitored when cells were
exposed to histamine (loo IJM) and ATP (50 ~M). Based on these findings, the ATP response
was found to be suitable to study whether the desensitization induced by histamine was
homologous or heterologous.
In HeLa cells 50 IlM ATP-induced a biphasic rise of the [Ca2+h levels (Fig. 3A).This
response was also characterised by a rapid transient rise in [Ca2+h, followed by a sustained
increase in [Ca2+h (Fig. 3A). After application of 50 IJM ATP [Ca2+h was rapidly elevated
from 71 ± 17 nM (n = 6) to 681 ± 140 nM (first phase, n = 6). After this initial rapid rise the
[Ca2+li decreased to an elevated level of 516 ± 33 nM (second phase, n =6) after 30 secs of
receptor activation.
Pretreatment of HeLa cells with 100 IlM histamine for 5 mins did not alter the initial
transient response after application of 50 ~M ATP (Fig. 3C). After the desensitization with
histamine the peak response after stimulation of the ATP receptor was 599 ± 110 nM (n = 4).
This value was not significantly different from the peak response under control conditions (681
± 140 nM, n = 6). However, as for the second and third stimulation with histamine, the second
phase of the ATP response was significantly reduced after desensitization with 100 ~M
histamine (control: 516 ± 33 nM; desensitized: 331 ± 96, n =4, p < 0.05) (Fig. 3C).
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Fig. 3. Intracellular free Ca2+ transients induced by ATP (50 ~) in control cells (a) and after (c)
desensitization with histamine (Hisl, loo~) (b) (exposure 5 mins). Experiments were performed as described
in Fig. 2. A typical experiment out of 4 is shown.
To investigate the involvement of intracellular Ca2+ pools more directly, experiments with
caffeine were performed. Caffeine (3 mM) induced a transient rise in [Ca2+li in HeLa cells
(568 ± 149 nM, n =4). After the histamine-induced desensitization the response to caffeine did
not significantly alter (560 ± 180 nM, n =4). These data indicate that in contrast to the Ca2+
influx the effects of desensitization on the Ca2+ release component are confmed to HI receptor
responsiveness.
Role ofprotein kinase C in the process ofdesensitization
In many cell systems PKC was found to be responsible for a negative feedback on histamine
HI receptor mediated responses (Dillon-Carter and Chuang, 1989, Fukui et aI., 1991, Leurs
et aI., 1990, 1991a, Tilly et al., 1990a,b, Volpi et aI., 1988). Pretreatment of HeLa cells
with increasing concentrations of the protein kinase C (pKC) activator phorbol-12-myristate-
13-acetate (PMA), also resulted in a decrease in subsequent responsiveness to histamine (Fig.
4C). Initial responses of histamine were hardly affected by pretreatment of cells with 20 nM
PMA for 5 mins. Reasonable reduction was observed following pretreatment with 0.2 J.IM
PMA, whereas complete inhibition was achieved at 2 J.IM PMA. Based on these observations,
a concentration of 0.2 11M of PMA was used for further investigation concerning the role of
PKC. Inhibition exerted by PMA on the histamine-induced response resulted particularly in a
decrease of the second phase of the Ca2+ transient (Fig. 4B). After treatment of HeLa cells
with 0.2 J.IM PMA for 5 mins the [Ca2+h levels were only 114 ± 18 nM (n = 6) after 30 secs
of stimulation with 100 11M histamine. This value was significantly lower compared to the
elevation of the [Ca2+h under control conditions (second phase: 601 ± 52 nM). Thus, the
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percentage of inhibition by PMA of this second phase of the histamine response is considerably
larger compared to the effects on the rapid, initial elevation of [Ca2+h (Fig. 4B,C).
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Fig. 4. Intracellular free Ca2+ transient induced by histamine (Hist, 100 J.lM) (a), and by histamine (100 J.lM)
in the presence of 0.2 J.lM of PMA after 5 mins pretreatment of the cells with 0.2 J.lM of PMA (b). Effects of
increasing concentrations of PMA on the first (closed bars) and second phase (open bars) of the histamine-
induced Ca2+ response (100 J.lM) are shown in Fig. 4c. The histamine-induced Ca2+ transients were recorded
after pretreatment of cells with various doses of PMA for 5 mins, and in the presence of the respective PMA
concentration. No histamine-induced Ca2+ response was observed when cells were exposed to 2 J.lM of PMA.
Data shown are the mean ± s.e.mean of 6 experiments.
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Fig. 5. Effects of increasing concentrations of PMA on the fIrst (closed bars) and second phase (open bars) of
the ATP-induced Ca2+ response (100 J.lM). The ATP-induced Ca2+ transients were recorded after pretreatment of
cells with various doses of PMA for 5 mins, and in the presence of the respective PMA concentration. No ATP-
induced Ca2+ response was observed when cells were exposed to 2 J.lM of PMA. Data shown are the mean ±
s.e.mean of 6 experiments. The asterisk indicates a signifIcant difference compared to the control histamine-
induced response.
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To assess the specificity of the inhibitory activity of PMA, we examined the effects of PMA
on the ATP response. Pretreatment of HeLa cells with increasing concentrations of PMA
resulted in a dose dependent inhibition of the ATP response (SO ~) (Fig. 5).
In order to examine the possible involvement of other regulation mechanisms in the process
of desensitization, PKC activity was eliminated by downregulating PKC. This was achieved
by incubating HeLa cells for 20 hrs with 0.2 11M PMA, as was done in earlier studies (Tilly et
aI., 1990a,b). As a control experiment, total exclusion of PKC activity was determined by
pretreating the downregulated cells with 0.2~ PMA for 5 mins (Table 1). Yet, no significant
decrease of the responsiveness to histamine was observed after short PMA treatment, justifying
the elimination ofPKC activity (Table 1).
Table 1 The [Ca2+lj of the first and second phase of the histamine (100 IJM) induced response in control,
PKC downregulated and PKC downregulated cells pretreated with 0.21JM PMA for 5 mins
cell treatment 1st phase [Ca2+lj 2nd phase of [Ca2+lj n
(nM) (nM)
control 1135 ± 79 601 ± 52 (11)
PKC downregulated 1121 ± 124 890± 90 * (10)
PKC downregulated 1011 ± 156 769 ± 46 (4)
+ 5 mins. 0.2 IJM PMA
The second phase was recorded 30 secs after receptor activation with histamine. The asterisk indicates a
significant difference compared to the control response of histamine. n; number of experiments.
As can be seen in Table I, histamine still elicited an initial response, which was comparable to
the initial response in untreated cells. However, the characteristics of the histamine-induced
Ca2+ response changed (Fig. 6A). The second phase of the histamine response in these cells
significantly (p < 0.05) exceeded the Ca2+ level of the histamine response in untreated cells. In
control cells the [Ca2+h levels of the second phase reached 601 ± 52 nM (n = 11), whereas
after downregulation of PKC application of histamine resulted in an increase of the second
phase to 890 ± 90 nM (n =6).
When PKC downregulated cells were exposed to another dose of histamine (100 ~),
marked desensitization was again observed (Fig. 6B). The initial Ca2+ response induced by a
second application of histamine was significantly decreased to 519 ± 139 nM (n =6).
Compared to the initial response of the first application (1121 ± 124 nM, Table 1) this
corresponded to an inhibition of 54 %. These data imply that homologous desensitization of the
histamine HI receptor may result from a regulation mechanism other than PKC activation.
Discussion
The histamine HI receptor belongs to the class of receptors that is coupled to the phosphatidyl
inositol turnover (Haaksma et at., 1990, Hill, 1990). The process of receptor desensitization
of this class of receptors remains to be elucidated. In this study we used fluoremetric Ca2+
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Fig. 6. Histamine-induced Ca2+ responses in PKC downregulated cells. The HeLa cells were incubated for 20
hrs with 0.2 f.lM PMA. After the first application of histamine (Hist, exposure of 5 mins) (a) the cells were
washed for 5 mins. and exposed to another dose of histamine (Hist, exposure of 5 mins) (b). A typical
experiment out of 6 is shown.
measurements to define the mechanism underlying short-term receptor desensitization of the
HI receptor in HeLa cells.
Histamine induces an immediate HI receptor mediated biphasic rise in [Ca2+h in human
HeLa cells (Fig. 1). The HI receptors on HeLa cells seem to be readily susceptible to
desensitization since repetitive exposure of the same group of cells to histamine (100 ~M)
markedly affected the rise in [Ca2+h (Fig. 2). The experimental data show that desensitization
of the histamine HI receptor is associated with the reduction of both the Ca2+ release and
influx component. The histamine-induced release component appears to be reduced in a
selective manner, as neither the caffeine induced Ca2+ release nor the release component of the
ATP response were found to be affected. Thus, desensitization of the HI receptor does not
affect the intracellular Ca2+ pool, as was also reported by Hishinuma and Uchida (1988),
Leurs et al. (1990) and McDonough et al. (1988). The influx component, however, of both
the histamine and ATP response was found to be impaired. These data indicate that
desensitization of the histamine HI receptor evolves from two different mechanisms, a
selective reduction of the histamine-induced Ca2+ release, associated with a homologous
desensitization, and a non-selective inhibition of the receptor mediated Ca2+ influx,
corresponding to a heterologous desensitization.
Receptor desensitization of the GPCRs is thought to be associated with posttranslational
modification of the receptor by phosphorylation reactions (Benovic et al., 1988, Hausdorff et
ai., 1990, Lohse et al., 1990, Sibley et ai., 1987). Kinases, such as PKA, PKC and specific
receptor kinases seem to play crucial roles in the mechanism underlying receptor desensitization
(Huganir and Greengard, 1990, Palczewski and Benovic, 1991). In several receptor systems
PKC was found to account for a negative feedback on the histamine HI receptor mediated
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response (Dillon-Carter et at., 1989, Fukui et at., 1991, Leurs et al., 1990, Tilly et al.,
1990a,b, Volpi et at., 1988). This has led to the proposal of a role for PKC in the process of
desensitization.
PKC was found to inhibit the histamine as well as ATP responses in HeLa cells, affecting
both the Ca2+ release and in particular the Ca2+ influx (Fig. 4 and 5). A decrease of 45Ca2+
influx in HeLa cells upon short-term exposure to PMA was also reported by Marunaka et at.
(1985). Earlier studies showed an impaired formation of inositol phosphates upon HI receptor
stimulation after activation of PKC in HeLa cells (Tilly et at., 1990a,b). The GTPyS induced
formation of inositol phosphates was also found to be reduced, indicating that effects on the G-
protein rather than on the HI receptor might explain these data (Tilly et al., 1990a). These
[mdings may explain the observed reduction of the initial rise in Ca2+ of the histaminergic, as
well as purinergic responses after pretreatment with PMA (Berridge and Irvine, 1989). Based
upon the model proposed by Irvine, coupling the Ca2+ release to the Ca2+ influx, the reduced
Ca2+ release may partly account for the impaired influx of extracellular Ca2+ (Irvine, 1990).
However, the sensitivity of the Ca2+ influx to PMA is much more pronounced, implying that
PKC may exert a negative feedbaCK on other molecular entities, such as the receptor operated
Ca2+ channels. Peppelenbosch et al. (1991) developed a model in which the receptor-operated
Ca2+ influx was suggested to be mediated by transactivation of hyperpolarization-activated
Ca2+ channels and Ca2+-activated K+ channels. In this model activation of PKC was
proposed to have an inhibitory effect on the K+ channels leading to a decrease of the Ca2+
influx (Peppelenbosch et at., 1991). Since the HI receptor activation in HeLa cells is also
associated with hyperpolarization of the cell membrane (Hazama et al., 1985, Sauve et al.,
1987, Tilly et al., 1990b), it is likely the HI receptor is subjected to a similar negative
feedback induced by PKC. This suggestion is further corroborated by the experiments with
PKC downregulated HeLa cells (Fig. 6). In these cells the second phase of the histamine-, as
well as ATP-induced response was found to be elevated, implying the involvement of PKC in
the negative feedback on the influx of extracellular Ca2+.
In contrast to the involvement of PKC in the heterologous desensitization of the Ca2+
influx it is highly unlikely that PKC activation is implicated in the selective reduction of the
initial HI receptor response. Although PKC activation can inhibit the Ca2+ release component
(see above), this effect is clearly not restricted to the HI receptor since also purinergic
responses are inhibited. Furthermore, in the PKC downregulated cells, desensitization of the
HI receptor was still observed (Fig. 6). Based on these data we suggest that during short-term
exposure of HeLa cells to histamine besides PKC another regulatory mechanism is rapidly
activated. This yet unknown mechanism is responsible for a selective desensitization of the HI
receptor response. The number of HI receptors, measured as [3H]-mepyramine binding sites,
did not alter after an incubation of 5 mins with 100 IlM of histamine (unpublished
observations). Similar findings were monitored in smooth muscle preparations (Leurs et al.,
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1991b). It is therefore unlikely that shOlt-term desensitization is associated with receptor
downregulation. The rapid loss of responsiveness is probably caused by alterations in efficacy
of the HI receptor to activate the appropriate G-proteins.
During the preparation of this manuscript, the gene encoding the HI receptor was cloned
by Yamashita et aZ. (1991). Like all other GPCRs, the HI receptor was found to contain seven
putative transmembrane domains. The ~-adrenergic receptor (~AR) is one of the best
characterised receptors of the GPCRs. As extensive structural analogy was found between this
receptor and the other GPCRs, the ~AR provides a model for elucidating characteristics of
receptor regulation mechanisms, such asdesensitization (Benovic et a1., 1988, Hausdorff et
aZ., 1990, Lohse et a1., 1990, Sibley et aZ., 1987). Rapid desensitization of the ~AR is
associated with phosphorylation of the receptor by protein kinase A (PKA) and the ~­
adrenoceptor kinase (~ARK), resulting in the functional uncoupling of the receptor from its
effector system (Benovic et aZ., 1989). These kinases were found to phosphorylate the
receptor at specific serine and threonine residues. The latter kinase is only activated when the
receptor is occupied. The primary sequence of the HI receptor reveals the existence of several
serines and threonines, which may ~erve as potential phosphorylation sites for such kinases
(Yamashita et aZ., 1991). Based on these findings we therefore hypothesize that the
homologous desensitization of the HI receptor is associated with the activation of a receptor
kinase and the non-specific, heterologous, desensitization with activation of PKC. PKC might
playa role comparable to PKA in the process of desensitization. Moreover, up to six ~ARK
related genes have been cloned, implying the existence of a family of receptor kinases, also
referred to as G-protein receptor kinases (GRKs) (see for references Lefkowitz, 1993, Haga
et a1., 1994). These GRKs have distinct substrate specificities (Benovic, 1991). Furthermore,
as other GPCRs were found to be substrates for ~ARK, it is feasible that this class of receptors
is regulated by a general mechanism in which specific receptor kinases are responsible for the
stimulus-dependent phosphorylation (Benovic et aZ., 1989). Differences in the number and
location of potential phosphorylation sites of various cloned GPCRs, suggest that these
receptors might be regulated in distinct ways under different physiological conditions.
In conclusion, results of this study show that histamine induces a rapid HI receptor
mediated Ca2+ response in HeLa cells. PKC appears to be responsible for negative feedback
on the Ca2+ influx. Moreover, HI receptors in HeLa cells are readily susceptible to
desensitization. Based upon our experimental data we suggest that short-term desensitisation of
the HI receptor is mediated by two distinct pathways, a PKC dependent and PKC independent
pathway. In view of future experiments, the recent cloning of the histamine HI receptor
(Yamashita et a1., 1991) offers new possibilities, with regard to the elucidation of the
mechanism underlying receptor desensitization.
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Chapter 3
Regulation of the human histamine HI receptor
stably expressed in Chinese Hamster Ovary cells
M. J. Smit, H. Timmerman, J. C. Hijzelendoom, H. Fukui and R. Leurs
In the present study we characterized the human HI receptor expressed in Chinese Hamster Ovary cells
(CHOhumH1 cells) and examined whether this receptor was susceptible to short-term and long-term receptor
desensitization. The human HI receptor gene expressed in Chinese Hamster Ovary cells encodes a classical
histamine HI receptor with a pharmacology similar to that of the HI receptor found in guinea-pig cerebellum
and the endogenously expressed human HI receptor in 1321N1 astrocytoma cells. Histamine induced a dose-
dependent rise in inositol phosphates (EC50: 2.2 ± 1.0 flM) and a rapid increase of [Ca2+lj, followed by a
sustained increase of [Ca2+lj upon addition of 100 flM histamine.
Short-tem exposure of the human HI receptor to histamine led to an heterologous desensitization of the
agonist-induced Ca2+ response, which may be explained by alterations at the level of the intracellular Ca2+
pool. In CHOhumHl cells the PKC activator, PMA (1 flM), was found to inhibit the histamine (100 flM)- as
well as the ATP (100 flM)-induced Ca2+ reponse only partially and less effective than histamine-pretreatment.
Moreover, in CHOhumHI cells PKC dowuregulation induced by long-term exposure to PMA (I flM) did not
affect the histamine-induced desensitization nor did pretreatment with thePKC inhibitor staurosporine (100 nM),
indicating that in CHOhumHI cells PKC is probably not involved in the heterologous desensitization.
Long-term treatment of CHOhumHI cells with histamine or other HI agonists resulted in a time- and dose-
dependent decrease in the number of HI receptor binding sites (maximal reduction: 47 ± 5%). Long-term
exposure of CHOhumHI cells to ATP or PKC did not affect HI receptor density, indicating that HI receptor
downregnlation is apparently not induced by activation of phospholipase C or PKC. Both histamine (100 flM)-
and ATP (100 flM)-induced Ca2+ responses were affected upon long-term exposure of cells to histamine (100
flM), which might be explained by an alteration at a level distant from the receptor.
Taken together, these findings show that in CHOhumHI cells the human histamine HI receptor is
susceptible to short-term and long-term receptor regulation in which PKC does not seem to playa role. The
CHOhumH1 cells therefore provide an excellent model system to study the mechanism(s) of PKC-independent
HI receptor regulation.
Introduction
The gene encoding the histamine HI receptor was successfully cloned from bovine adrenal
medulla by means of an expression cloning strategy (Yamashita et at., 1991). Soon thereafter,
the guinea-pig (Horio et at., 1993, Traiffort et at., 1994), rat (Fujimoto et at., 1993) and
human homologues (De Backer et at., 1993, Fukui et at., 1994, Moguilevsky et at., 1994)
were cloned by homology screening. The cloning of these genes revealed that the" histamine HI
receptor belongs to the multigene family of G-protein coupled receptors, which putatively all
contain seven hydrophobic transmembrane domains, separated by hydrophilic intra- and
extracellular loops (Collins, 1993).
For several members of the family of G-protein coupled receptors it has been shown that
excessive stimulation of the receptor protein leads to a modulation of the receptor response and
regulation of receptor expression (Collins, 1993, Lohse, 1993). Short-term activation of the
histamine HI receptor is indeed frequently followed by a period of refractoriness, often
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referred to as desensitization. HI receptor desensitization has been observed and studied in
several isolated tissues (Bristow et aI., 1993, Dillon-Carter and Chuang, 1989, Leurs et aI.,
1990, Quach et aI., 1981) and cultured cell lines (Bristow and Zamani, 1993, Brown et al.,
1986, Dickenson and Hill, 1993, McCreath et aI., 1994, McDonough et aI., 1988, Smit et
aI., 1992, Zamani et al., 1994). Moreover, desensitization of HI receptor responses has also
been observed in vivo (Antol et aI., 1988, Manning et aI., 1987, Pou1akos and Gertner,
1986), indicating the importance of this process in physiology. So far no clear mechanistic
details are known, although, depending on the cell type, protein kinase C (PKC)-dependent
and independent mechanisms for short-term HI receptor desensitization have been observed
(Cowlen et aI., 1990, Dickenson and Hill, 1993, Dillon-Carter and Chuang, 1989, Fukui et
al., 1991, Leurs et aI., 1990, McCreath et al., 1994, Smit et aI., 1992). Similarly, both
receptor specific (homologous)- and receptor non-specific (heterologous) desensitization have
been observed in various cellular systems (Brown et al., 1986, Cowlen et aI., 1990,
Dickenson and Hill, 1993, Dillon-Carter and Chuang, 1989, Leurs et al., 1990, McCreath
et aI., 1994, McDonough et al., 1988, Quach et al., 1981, Smit et al., 1992). Homologous
desensitization is usually considered to be due to a specific modification of the receptor protein,
whereas heterologous desensitization is often caused by a modulation of a common signal
transduction pathway.
Prolonged exposure of the G-protein coupled receptors to their respective agonist often
results in a reduction in receptor number (Collins, 1993, Lohse, 1993). For the HI receptor
only one experimental study has been published, reporting a 20% downregulation of the
H1receptor after an in vitro histamine treatment of mouse brain tissue (Quach et al., 1981).
Yet, there are various reports that show that the HI receptor density is dynamically regulated
in vivo. Yanai et al. (1992) showed by means of [llC]-doxepin positron emmission
tomography (PET) studies that the HI receptor density in the brain decreases upon aging.
Using the same technique Iinuma et al. (1993) revealed an upregulation of HI receptors in the
electrical focii in the temporal cortex of epileptic patients. Moreover, in the frontal cortex of
patients with chronic schizophrenia a downregulation of HI receptors was reported (Nakai et
aI., 1991). These examples indicate that the HI receptor expression is susceptible to
regulatory changes under physiological and pathophysiological conditions, emphazising the
need to further delineate the mechanisms underlying the process of HI receptor regulation.
The recent cloning of the gene encoding the histamine HI receptor permits a more detailed
investigation of the molecular mechanisms, related to the HI receptor function. Especially
investigations of the downregulation of the HI receptor have been hampered so far by the lack
of suitable model systems with a reasonable density of HI receptors. We therefore stably
transfected the gene encoding the human HI receptor into Chinese Hamster Ovary (CHO)
cells. First, the expressed human HI receptor was subjected to a pharmacological
characterization. Thereafter this cell line was used to investigate whether the expression of the
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human HI receptor can be modulated by prolonged exposure to histamine. Moreover, we also
studied the effects short-term exposure to histamine to evaluate the use of transfected CHO
cells in mechanistic studies on homologous HI receptor desensitization. In all these studies the
role of protein kinase C in the regulatory processes was evaluated.
Materials and methods
Transfection and cell culture Chinese Hamster Ovary (CHO) cells, deficient in dihydrofolate reductase, were
maintained at 37°C in a humidified incubator with 95% air and 5% C02 in a-minimal essential medium
(aMEM) with ribonucleosides and deoxyribonucleosides supplemented with L-glutamine (2mM), penicillin (50
ill/mI), streptomycin (50 ~g/ml) and 10% (vol/voI) foetal calf serum. CHO cells were stably transfected with
the eukaryotic expression vector pdKCR-dhfr- containing the human HI receptor gene using the calcium
phosphate precipitation method as described previously by Fujimoto et al. (1993). Selection was imposed by
growing the cells in a-MEM without ribonucleosides and deoxyribonucleosides supplemented with L-glutamine
(2mM), penicillin (50 ill/mI), streptomycin (50 ~g/mI) and 10% (vol/vol) dialyzed foetal calf serum, which
resulted in the appearance of several clonal cell lines. Thereafter, these cells were screened for expression of
[3H]-mepyramine binding.
CHO cells stably expressing the human HI receptor were cotransfected with the PKC isoenzymes a, ~I' ~II'
5, £ or ycDNAs, inserted into a pTB vector (Ono et al., 1987), and the pSV2neo vector using the calcium
phosphate method as des(.TIbed previously by Fujimoto et al. (1993). Neomycin resistant clones were selected
by growing the cells in medium containing 500 ~g/ml of 0418. The clones were screened by means of [3H]-
phorbol-12,13-dibutyrate binding.
The human 1321Nl human astrocytoma cells (Nakahata et al., 1985) were grown at 37°C in a humidified
atmosphere with 5% CO2 in Dulheco's Modified Eagle's Medium (DMEM), containing 10% foetal calf serum
and supplemented with 2 mM L-glutamine, 50 ill/ml penicillin and 50 ~g/ml streptomycin.
Membrane preparation CHOhumHI cells and 1321Nl cells were harvested by means of a cell scraper and
recovered by a 10 min centrifugation at 500g. Cells were homogenized in ice-cold 50 mM Na2/K-phosphate
buffer (pH = 7.4) with a Polytron homogenizer (5 sees, maximal speed) and used for radioligand binding studies.
Protein concentrations were determined according to Bradford (1976) (Bradford, 1976) using bovine serum
albumin as a standard.
Histamine HI receptor binding Membranes (60-80 ~g of protein) were incubated for 30 min at 25°C in 50
mM Na21K phosphate buffer in a total volume of 400~ with the indicated concentrations of [3H]-mepyramiue.
In saturation studies increasing concentrations of [3H]-mepyramine were incubated with the membranes in the
absence or presence of 1~ mianserin. In displacement studies membranes were incubated with 2 nM [3H]-
mepyramine and increasing concentrations of competing ligands. The incubations were stopped by rapid dilution
with 3 ml ice-cold 50 mM Na21K phosphate buffer (pH = 7.4). The bound radioactivity was subsequently
separated by filtration with a Brandel cell harvester (Semat, UK) through Whatman GF/B glass fibre filters that
had been treated with 0.3% polyethyleneimine. Filters were washed twice with 3 ml buffer and radioactivity
retained on the filters was measured by liquid scintillation counting. The binding data were evaluated using
LIGAND, a non-linear, weighted, least squares curve-fitting procedure (Munson and Rodbard, 1980).
Changes in HI receptor density were denoted as a percentage dowuregulation compared to non-treated control
cells. During the 24 hrs incubation of cells with various histaminergic ligands or other compounds, cells were
grown in serum-free medium.
[3H]-lnositol plwsphate measurements CHOhumH1 cells were seeded in 12-well plates and cultured overnight
in culture medium. Thereafter, cells were labeled overnight in inositol-free medium supplemented with 1 ~Cilml
[3H]-myo-inositol. Cells were washed twice with Krebs buffer (125 mM NaCI, 4.7 mM KCI, 2.2 mM
CaCI2.2H20, 1.2 mM MgC12.6 H20, 1.2 mM KH2P04.2H20, 11 mM glucose, 15 mM Hepes, 15 mM
NaHC03, pH =7.4 at 37°C), supplememted with 10 mM LiCl, and preincubated for 10 min at 37°C with or
without one of the histaminergic antagonists at the indicated concentrations. Incubations were started by the
addition of histamine. After 10 min incubation at 37 °C the medium was aspired and the reaction was stopped by
addition of 5% TCA. The cells were chilled on ice for 10 mins. Thereafter, 2 ml of water-saturated diethylether
was added to the TCA extract and was mixed for 5 mins. The ether phase was aspired and the procedure was
repeated once more. After aspiration the remaining diethylether was removed by incubation at 37°C. 150 ~l 0.2
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M Tris-HCI was added to neutralize the samples and the [3H]-inositol phosphates were isolated by anion
exchange chromatography (Godfrey, 1992).
Measurements ofintracellularfree Ca2+ concentration ([Ca2+1i) CHOhumHI cells were trypsinized, washed
with aMEM supplemented with 0.2% bovine serum albumin (BSA) and resuspended in aMEMI 0.2%BSA
containing 2~ fura-2-AM and 0.025% Pluronic-F for I hr at 25°C. Thereafter cells were gently washed with
5 ml of aMEMlO.2% BSA, resuspended in I ml of aMEMlO.2% BSA and stored on ice. A 100 !Jl sample was
added to 1.5 ml prewarmed Tyrode solution (2.5 mM KCl. 0.5 mM MgCI2. 137 mM NaC!. 0.36 mM
NaH2P04. 5.6 mM glucose and 10 mM Hepes, pH = 7.4) in a temperature-controlled (30°C) quartz cuvette.
Ca2+-dependent fura-2 fluorescence was monitored at an emission wavelength of 510 um with an excitation
wavelength of 340 and 380 nm in a Shimadzu RF5OOIPC. The intracellular Ca2+ concentration ([Ca2+lj) was
calculated according to the formula derived by Grynkiewicz (1985). Maximal fluorescence was measured (Fmax)
by permeabilization of cells with 0.2% Triton-X-100 and minimal fluorescence (Fmin) was achieved by
complexing calcium with 10 mM EGTA.
Desensitization experiments were carried out with CHOhumHl cells grown on a coverslip. Cells were
loaded with 2~ fura-2-AM in a HBS buffer (140 mM NaCI. 5 mM KCI. 2 mM CaCI2' 1 mM MgCI2. 10
mM glucose. 0.2% BSA, 10 mM Hepes. pH = 7.4) for I hr at 25°C. Thereafter. the coverslip was inserted into
the quartz cuvette and cells were washed by completely exchanging prewarmed HBS buffer (30°C). Fluorescence
was measured as described above.
[3Hl-plwrbol-12.13-dibutyrate binding CHOhumHI cells were seeded in 12-well plates and cultured overnight
in culture medium. Cells were washed with PBS and preincubated for 10 min in aMEM supplemented with
0.1% BSA and 20 mM Hepes (pH 7.0) (binding buffer) at 37°C. Thereafter. cells were incubated in binding
buffer with 5 nM [3H]-phorbol-12,13-dibutyrate in the presence or absence of 10~ PMA for 1 hr at 37°C.
The incubations were stopped by washing with ice-cold PBS buffer supplemented with 0.1% BSA. Next. cells
were incubated with trypsine-EDTA for several hours in order to disrupt the cells. The bound radioactivity was
subsequently separated by filtration through GFIB glass fibre ftlters. Filters were washed with cold PBS and the
radioactivity retained on the filters was counted. The difference in radioactivity measured in cells incubated in the
absence and presence of 10~ PMA was considered as specific phorbolester binding.
Chemicals Histamine dihydrochloride, phorbol-12-myristate-13-acetate. phorbol-12.13-dibutyrate (PdBu). 4a-
phorbol. bovine serum albumin (BSA). caffeine and ATP (disodium salt) were obtained from Sigma Chemical
Company (USA). Dowex AGlx8 (200-400 mesh) formate form was purchased from Bio-rad (Bio-rad laboratories
GmbH. Germany). [3H]-mepyramine ([pyridinyl-5-3H]-pyrilamine. 21 Cilmmol). [3H]-phorbol-12,13-dibutyrate
(15.1 Ci/mmol) and [3H]-myo-inositol (18.8 Ci/mmol) were obtained from Amersham. Fura-2-
acetoxymethylester (fura-2-AM) and Pluronic-F was purchased from Molecular Probes (Eugene. OR, USA). 2-
pyridylethylamine dihydrochloride was taken from laboratory stock. Gifts of mianserin (Organon. The
Netherlands). 2-methylhistamine dihydrochloride. 2-thiazolylethylamine dihydrochloride (SmithKline Beecham.
United Kingdom). the enantiomers of cicletanine (Institute of Heuri Beaufour. France). the enantiomers of
chlorphenirarnine (maleate salts) (Dr. A. Belt, Nijmegen, The Netherlands) and the PKC isoenzyme cDNAs
(Drs. Kikkawa and Ono. Kobe University. Japan) are greatly acknowledged.
Statistical analysis All data shown are expressed as mean ±standard errors (mean ± s.e.mean) of at least three
independent experiments. Statistical analysis was carried out by Student's t-test. P-values < 0.05 were
considered to indicate a significant difference.
Results
Pharmacological characterization ofthe human histamine H] receptor expressed in Chinese
Hamster Ovary cells (CHOhumH])
Transfection of the cDNA encoding the human HI receptor (Fukui et aI., 1994) into CHO
cells resulted in the isolation of several clones, expressing [3H]-mepyramine binding sites.
Untransfected cells did not show any specific [3H]-mepyramine binding. One clonal cell line
(CHOhumH 1) was selected for further analysis. Saturation experiments performed with
CHOhumH I cell membranes revealed the presence of a single population of saturable [3H]-
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mepyramine binding sites with a dissociation constant (Kd) of 1.10 ± 0.09 nM and a maximal
density (Bmax) of 861 ± 41 fmoVmg protein (n =3, mean ± s.e.mean) (Fig. lA). The binding
of 2 nM [3H]-mepyramine to CHOhumHl cell membranes was monophasically and
stereoselectively inhibited by various HI antagonists (Fig. lB, Table 1). For compalison,
binding studies were performed on membranes of human l32lNl astrocytoma cells, which
endogenously express a low level of HI receptors (Nakahata et al., 1985). Saturation
expeliments revealed a Kd value of [3H]-mepyramine of 1.14 ±0.22 nM and a Bmax of 131 ±
46 fmoVmg protein (n =3, mean ± s.e.mean). The pKi values for the different HI antagonists
on CHOhumH1 membranes were found to be consistent with the observed pKi values on
132lNl membranes and reported pKi values determined on guinea-pig cerebellum (Ter Laak
et al., 1993) (Table 1). Histamine displaced the specific [3H]-mepyramine binding to
CHOhumH1 membranes with a pKi value of 4.67 ± 0.02 (n =5, mean ± s.e.mean), a value
that closely corresponds to the pKi-value previously determined with 132lNl astrocytoma
membranes (Nakahata et al., 1985).
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Fig. 1. Binding of [3H]-mepyramine to CHOhnmH1 cell membranes. A, Saturation of [3H]-mepyramine to
CHOhumHl cell membranes. Specific radioligand binding (open circles) was determined by substracting the
binding determined in the presence of 1 j.IM of mianserin (filled squares) from the total binding (filled circles). B,
Displacement of binding of 2 oM [3Hj-mepyramine by increasing concentrations of (-)-cicletanine (open circles)
and (+)-cicletanine (filled circles). Mean ± the s.e.mean values of triplicate determinations of a typical
experiment out of three are shown.
Expeliments with [3H]-myo-inositollabelled CHOhumHI cells showed a dose-dependent
increase in inositol phosphate production when cells were incubated for 10 min with increasing
concentrations of histamine (Fig. 2A). The ECSO value of histamine for this response was 2.2
± 1.0 11M (n = 3, mean ± s.e.mean). A lO-fold stimulation over basal levels of inositol
phosphate production was observed when cells were stimulated with 100 11M histamine. The
H I antagonist mepyramine (1 11M) inhibited the histamine (100 llM)-induced production of
inositol phosphates, whereas the H2 antagonist ranitidine (10 11M) and the H3 antagonist
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thioperamide (11JM) did not affect the histamine-induced inositol phosphate response (Fig. 2A
inset).
Table 1 Characterization of [3H]-mepyramine binding to CHOhumH1 cell membranes
pKi
antagonists guinea-pig 1321N1 CHOhumH1
cerebellum cells cells
(+)-cicletanine <5 <5 <5
(-)-cicletanine 7.54 7.74 ± 0.04 7.27 ± 0.06
(d)-chlorpheniramine 8.32 8.35 ± 0.20 8.45 ± 0.04
(l)-chlorpheniramine 6.68 6.78 ± 0.12 6.53 ± 0.06
Membranes of CHOhumH1 cells and 1321N1cells were incubated with 2 nM [3H]mepyramine in the presence
of the indicated drugs at increasing concentrations. Ki values were obtained from the respective IC50 values.
Data shown are the mean ± s.e.mean from three independent experiments. Reported values for [3H]-mepyramine
binding to guinea pig cerebellum (Ter Laale et al.• 1993) are shown for comparison.
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Fig. 2. Signal transduction pathways of the human HI receptor expressed in CHO cells. A, Histamine-
induced production of [3H]-inositol phosphates. Cells were prelabeled overnight with [3H]-myo-inositol, were
washed twice and preincubated for 10 mins in a.MEM containing 10 roM LiCl. Thereafter, cells were incubated
for 10 mins with increasing concentrations of histamine in the same medium. (basal inositol phosphate levels:
2127 ± 371 dpmlwell, histamine induced increases of inositol phosphate production: 23449 ± 2872 dpmlwell, n
=3, mean ± s.e.mean). Mean ± the s.e. values of triplicate determinations of a typical experiment out of three
are shown. (Inset) Effect of the histamine HI antagonist mepyramine (M) (l ~, H2 antagonist ranitidine (R)
(10 IJM) and H3 antagonist thioperamide (n (11JM) on the histamine-induced increase in inositol phosphate
production over basal levels (-) (B) (n = 2). Cells were preincubated for 10 mins with the antagonists. Thereafter,
cells were stimulated with 100 IJM histamine (+). B, Histamine-induced increase in [Ca2+lj in fura-2/AM-Ioaded
CHOhumH1 cells grown on a coverslip. Cells were incubated at 30°C in HBS buffer and exposed to 100 IJM
histamine for 5 mins and washed with HBS buffer. Data shown are from representative experiment (basal
[Ca2+lj: 91 ±4 nM, histamine-induced increase [Ca2+h: 1040 ±53 nM, n =8, mean ± s.e.mean).
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Addition of 100 IlM histamine to fura-2-loaded CHOhumHI cells resulted in a rapid
increase of the intracellular Ca2+ concentration ([Ca2+h) (basal [Ca2+]F 91.4 ± 3.8 nM,
histamine-induced increase [Ca2+h: 1040 ± 53 nM, n = 8, mean ± s.e.mean) (Fig. 2B). The
rapid transient increase was followed by a sustained increase in [Ca2+h (477 ±27 nM) lasting
until the agonist was removed. Preincubation of these cells with 1 JlM of the HI antagonist
mepyramine for a period of 10 min prior to stimulation with histamine (100 JlM), totally
blocked the histamine-induced increase of [Ca2+h (data not shown).
Short-term desensitization ofthe human histamine Hi receptor expressed in CHO cells
Desensitization of the histamine-induced Ca2+ response in CHOhumH1 cells was observed
when the same cells were repeatedly exposed to histamine (Fig. 3). After the first challenge
with 100 IlM histamine for a period of 5 min, cells were washed for 5 mins and re-exposed to
100 IlM histamine for another 5 min. Thereafter, this procedure was repeated once more. In
total therefore 3 histamine-induced Ca2+ responses were recorded. As depicted in Fig. 3 the
consecutive responses we markedly affected by the previous challenges to histamine (basal
[Ca2+]F 91 ± 4 nM, first histamine-induced increase [Ca2+]i: 1040 ± 53 nM, n = 8, second
histamine-induced increase [Ca2+h: 458 ±60 nM (reduction 56 ±6%, n =6), third histamine-
induced increase [Ca2+li: 169 ± 12 nM (reduction of 84 ± 1%, n =6, mean ± s.e.mean).
In CHOhumHI cells 100 JlM ATP also induced a rapid rise of the [Ca2+li, followed by a
sustained increase in [Ca2+h (basal [Ca2+h 78.5 ± 10.5 nM, ATP-induced increase [Ca2+h:
1489 ± 131 nM, n =3, mean ±s.e.mean). Pretreatment of these CHOhumH1 cells with 100
JlM histamine for 5 mins affected the Ca2+ response induced by 100 JlM ATP too. A decrease
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Fig. 3. Desensitization of the histamine-induced Ca2+ transients in CHOhumHl cells. Cells were repeatedly
exposed to 100 J.lM histamine (HA) for a period of 5 mins. After each histamine challenge cells were washed for
5 mins by completely exchanging the buffer. A typical experiment out of 6 is shown.
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of 63 ± 5% (n = 4, mean ± s.e.mean) was observed when CHOHuH1 cells were pretreated for
5 mins with histamine. Preincubation of cells with 100 11M ATP for 5 mins resulted also in a
66 ± 3% (mean ± s.e.mean, n = 3) attenuation of the histamine-induced Ca2+ response.
Caffeine (10 mM) induced a rise in [Ca2+li in CHOhumH1 cells (332 ±23 nM, n = 4, , mean
±s.e.mean). After a 5 mins pretreatment of cells with 100 11M histamine, the caffeine response
was significantly reduced to 45 ± 5% of the control response (n =3, mean ± s.e.mean).
Role ofprotein kinase C in the process ofshort-term desensitization
Pretreatment of CHOhumH 1 cells for 10 mins with 1 11M of the PKC activator PMA, a
concentration shown to be maximally effective in CHO cells (Leurs et ai., 1994) resulted in a
decrease of 46 ± 7% (mean ± s.e.mean, n =3) of the histamine-induced Ca2+ response,
whereas pretreatment with the inactive phorbol ester 4a-phorbol did not affect the histamine-
induced Ca2+ response. The ATP-induced Ca2+ response was also found to be inhibited for
40 ±2% (mean ±s.e.mean, n =3) upon 1 11M PMA pretreatment.
PKC downregulation by 18 hrs incubation of cells with 1 11M PMA did, however, not
affect the histamine~induceddesel}.sitization (control cells: 56 ± 4% desensitization, PKC
downregulated cells: 66 ± 9% desensitization, n =6, mean ± s.e.mean). Moreover, exposure
of cells to the PKC inhibitor staurosporine (100 nM) for 30 mins prior to and during histamine
pretreatment did not inhibit the histamine-induced desensitization of the histamine-induced
Ca2+ reponse (control cells: 56 ±4% desensitization, n =6, staurosporine-treated cells: 73 ±
5% desensitization, n = 4, mean ±s.e.mean, p < 0.05).
Long-term desensitization of the human histamine HI receptor expressed in CHO cells
Incubation of CHOhumH1 cells with 100 11M histamine for periods ranging from 2 to 32 hrs
resulted in a time dependent decrease of [3H]-mepyramine binding (Fig. 4 A). A maximal
reduction (n =3, mean ± s.e.mean) was observed after 24 hrs incubation of cells with 100 11M
histamine. Half-maximal decrease of [3H]-mepyramine binding was recorded after an
incubation period of about 14 hrs. Saturation studies showed that the Kd value of [3H]-
mepyramine was not affected by 24 hrs incubation of cells with 100 11M histamine (Table 2).
Long-term exposure (24 hrs) of CHOhumH1 cells with 100 11M histamine resulted in a
reduction (47 ± 5%, n = 3, mean ± s.e.mean) of the total number of [3H]-mepyramine binding
sites (Bmax) (Table 2). The decrease of [3H]-mepyramine binding was shown to be dose-
dependent, as 24 hrs incubation of CHOhumH1 cells with increasing concentrations of
histamine resulted in a dose-dependent reduction of [3H]-mepyramine binding, with an EC50
of 0.13 ± 0.02 11M (n = 3, mean ± s.e.mean) (Fig. 4B). Exposure of CHOhumH1 cells for 24
hrs with HI agonists (2-pyridylethylhistamine (2-PEA), 2-methylhistamine (2-MeHA) and 2-
thiazoly1ethylamine (2-TEA» also reduced the [3H]-mepyramine binding (inset Fig. 4B).
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Table 2 Characteristics of the [3H]-mepyramine binding to the human histamine HI receptor expressed in
CHO cells pretreated for 24 hrs with or without histamine
pretreatment 24 hrs Kct
(nM)
Bmax
(fmol/mg protein)
control
histamine (I00~)
1.10 ± 0.09
0.98 ± 0.10
861 ± 41
460±46 *
The dissociation constant (Kct) and maximal number of binding sites (Bmax) were determined using non-linear
regression analysis according to a one-site bindillg mode. The data shown represent the mean ± s.e.mean of 3
independent experiments. The asterisk indicates a significant difference (p < 0.05) from control, represented by
untreated cells.
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Fig. 4. Histamine-induced reduction of [3H]-mepyramine binding in CHOhumHl cells. A, CHOhumHl cells
were incubated with 100 J.lM histamine for the indicated times and [3H]-mepyramine binding in membranes was
measured. The [3H]-mepyramine binding is expressed as a percentage of [3H]-mepyramine binding measured in
non-treated cells. The data shown represent the mean ± s.e.mean of 3 independent experiments. B, Dose-
dependent decrease of [3H]-mepyramine binding induced by histamine. CHOhumH1 cells were exposed to
various concentrations of histamine for 24 hrs. The data represent the mean ± s.e.mean of 3 independent
experiments. (Inset) Effect of pretreatment with HI agonists on [3H]-mepyramine binding of CHOhumH1 cells.
CHOhumHl cells were incubated for 24 hrs with histamine (HA, 100 J.lM), 2-PEA (PEA, 100 J.lM), 2-TEA
(TEA, 1OO~) and 2-MeHA (2MH, 100 J.lM). [3H]-mepyramine binding to the membranes was measured as
described above. Data were calculated as the mean ± s.e.mean from at least 3 independent experiments.
Role ofPKC in the process ofhistamine-induced H] receptor downregulation
Exposure of CHOhumHI cells for 24 hrs to 0.1 IlM or IIlM PMA did not affect [3H]-
mepyramine binding (Table 3). Incubations of CHOhumH1 cells with 1 JlM PMA for shorter
periods of time (4 hrs) also did not affect [3H]-mepyramine binding (data not shown). Similar
observations were found for incubation of cells with 1 IlM PdBu. Concurrent exposure of
CHOhumH1 cells to 100 IlM histamine and 1 IlM PMA for 24 hrs caused a significant
reduction of [3H]-mepyramine binding, which was less pronounced than treatment with
histamine alone (Table 3). Co-incubation of cells with PMA (1IlM) and histamine (100 IlM)
for 4 hrs, did not result in reduction of [3H]-mepyramine binding (data not shown). Exposure
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Table 3 Effect of long-term PKC and P2U-receptor activition on [3H]-mepyramine binding of CHOhumH1
cells
compounds % downregulation n
histamine 100 J.!M 41 ± 5 * 11
PMA 0.1 JlM -13 ± 5 6
PMA IJ.!M -5±5 18
PDBu IJ.!M -22± 10 4
histamine (l00 J.!M)+ PMA (1 J.!M) 27 ± 3 * 5
ATP 100 J.!M 15 ± 8 6
CHOhumH1 cells were incubated for 24 hrs with the indicated compounds and [3H]-mepyramine binding to the
membranes was measured. The [3H]-mepyramine binding is expressed as a percentage of downregulation
compared to non-treated cells. Data were calculated as the mean ± s.e.mean from n independent experiments. The
asterisk indicates a significant difference (p < 0.05) from control, represented by untreated cells.
of CHOhumH1 cells to 100 IJM ATP for 24 hI'S did also not induce a change in the number of
[3H]-mepyramine binding sites (Table 3).
Effect oflong-term desensitization on histamine- and ATP-induced Ca2+ signalling
A marked attenuation of the 100 IlM histamine-induced Ca2+ response was observed when the
CHOhumH1 cells were previously exposed to 100 IJM histamine for 24 hI'S (reduction of 57 ±
4%, n =4, mean ±s.e.mean). This treatment also impaired the ATP-induced rise (100 IJM) in
Ca2+ (reduction 32 ± 6%, n =4, mean ± s.e.mean).
Incubation of CHOhumH1 cells that had been exposed to 100 IlM histamine for 24 hI'S, for
10 mins with 11lM PMA resulted in a further attenuation of the 100 IlM histamine- and 100
IlM ATP-induced Ca2+ response (45 ± 4% and 43 ± 6%, respectively, n =3, mean ±
s.e.mean).
Discussion
In the present study we have shown that the human HI receptor eDNA expressed in CHO cells
encodes a classical histamine HI receptor with a pharmacology similar to that of the HI
receptor found in guinea-pig cerebellum (Tel' Laak et al., 1993) and the endogenously
expressed human HI receptor in 1321N1 astrocytoma cells (Nakahata et al., 1985, present
study) (Table 1). The pKi values of different HI receptor antagonists, including their
respective enantiomers, are in accordance with the reported pKi values determined on guinea-
pig cerebellum and values found for 1321N1 astrocytoma cells (Table 1). Similar results were
recently reported for the human HI receptors, expressed into respectively COS-7 and CHO
cells (De Backer et al., 1993, Moguilevsky et al., 1994). Although a few studies on HI
receptor signalling of the cloned guinea-pig (Leurs et al., 1994) and bovine (Iredale et al.,
1993) HI receptor, both expressed in CHO cells, have been reported our study is the first
describing HI receptor signalling after stable transfection of the human HI receptor gene. In
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CHO cells stably expressing the human HI receptor (CHOhumH1>, histamine induced a dose-
dependent rise in inositol phosphates and a rapid increase of [Ca2+h, followed by a sustained
increase of [Ca2+li upon addition of 100 JlM histamine. The inositol phosphate production
was only blocked by an HI antagonist and not by an H2 nor H3 antagonist. In addition, this
cell line, expressing a high density of HI receptors (861 ±41 fmoVmg of protein) allows for
the fIrst time investigation of regulatory phenomena such as receptor downregulation. As such,
the CHOhumH1 cell line may be considered a suitable model system to study HI receptor
regulation and signalling.
The recent cloning of the guinea-pig (Horio et aI., 1993, Traiffort et al., 1994), bovine
(Yamashita et al., 1991), rat (Fujimoto et al., 1993) and human HI receptor (De Backer et
al., 1993, Fukui et aI., 1994, Moguilevsky et al., 1994) has revealed several potential
phosphorylation sites in the amino acid sequence of the HI receptor. Three potential PKC
phosphorylation sites are found in the amino acid sequence of the HI receptor gene, as well as
a potential protein kinase A site. In addition, the third intracellular loop contains many
threonine and serine residues that can be potentially phosphorylated by specific receptor
kinases. As it is well-known for the family of G-protein coupled receptors, that kinases play
important roles in mechanisms such as receptor desensitization and downregulation (Collins,
1993, Lohse, 1993), all these sites may represent possible targets for phosphorylation.
Previous studies have shown that the histamine HI receptor is susceptible to short-term
receptor desensitization. Depending on the cell type both homologous (Cowlen et aI., 1990,
Dickenson and Hill, 1993, Dillon-Carter and Chuang, 1989, Leurs et aI., 1990, McCreath
et al., 1994, Quach et aI., 1981, Smit et aI., 1992) and heterologous (Bristow and Zamani,
1993, Brown et al., 1986, Dickenson and Hill, 1993, McDonough et aI., 1988) HI receptor
desensitization have been observed. In the present study it was shown that short-term exposure
of CHOhumH1 cells to histamine resulted in a decrease of subsequent histamine-induced Ca2+
responses. The histamine-induced desensitization appeared to be heterologous as the ATP-
induced Ca2+ response, mediated by interaction with endogenous purinergic P2U receptors
present on this cell line (Iredale and Hill, 1993, Leurs et aI., 1994), was also found to be
affected. Moreover, pretreatment of CHOhumHl cells with ATP also desensitized the
histamine-induced Ca2+ responses.
The process of heterologous histamine-induced desensitization in CHOhumH1 cells can be
ascribed to an alteration at the level of the intracellular Ca2+ pool, as reported previously for
other model systems (Hishinuma and Uchida, 1988, Leurs et aI., 1990, McDonough et aI.,
1988). The Ca2+ response of caffeine, which releases Ca2+ from intracellular Ca2+ stores
(Palade et al., 1989) was attenuated upon short-term histamine exposure. Ineffective Ca2+-
pump or Ca2+ release mechanisms of the intracellular Ca2+ pool might explain the observed
fIndings.
In various cellular systems PKC has been found to be implicated in negative feedback of
HI receptor signalling (Cowlen et aI., 1990, Dickenson and Hill, 1993, Dillon-Carter and
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Chuang, 1989, Fukui et aI., 1991, Leurs et aI., 1990, McCreath et aI., 1994, Smit et aI.,
1992). Besides attenuation of H1 receptor signalling, direct activation of PKC was also found
to desensitize other phospholipase C-linked receptors present on these cellular systems,
implying that PKC induces heterologous desensitization. In DDT1MF-2 cells, however, PKC-
independent mechanims appeared to be involved in the heterologous desensitization of the
histamine HI and ATP receptor-mediated Ca2+ responses(Dickenson and Hill, 1993). In
CHOhumH1 cells the PKC activator, PMA, was found to inhibit the histamine- as well as the
ATP-induced Ca2+ reponse. At a maximally effective concentration of PMA (Leurs et aI.,
1994), the inhibition of the response was only partially and clearly less effective than
histamine-pretreatment. In contrast, in e.g. cultured astrocytes (Fukui et ai., 1991), human
umbilical vein endothelial cells (McCreath et aI., 1994) and in HeLa cells (Smit et ai., 1992)
H1 receptor mediated responses have been reported to be highly sensitive to PKC activation.
Moreover, in CHOhumH1 cells PKC downregulation induced by long-term exposure to PMA
did not affect the histamine-induced desensitization nor did pretreatment with the PKC inhibitor
staurosporine. These results indicate that in CHOhumH1 cells PKC is probably not involved in
the heterologous desensitization.
The discrepancy regarding the role of PKC in the heterologous desensitization between
CHOhumH1 cells and other cellular systems may be explained by differential expression of
PKC isoenzymes. PKC is known to consist of a family of different PKC isoenzymes
(Nishizuka, 1988). As such, this cell line may be considered as a suitable model system to
investigate the role of different PKC isoenzymes in the negative feedback modulation of the
human HI receptor more closely. Therefore, we stably expressed different PKC isoenzymes
cDNAs (ex, ~I' ~II' 0, e and y) (Ono et ai., 1987) separately into CHOhumH1 cells. Although
clonal cell lines, expressing 1.4 to 3.4 fold [3H]-PdBu binding were obtained (data not
shown), [3H]-mepyramine binding studies revealed disappearance of H1 receptors on
membranes of these clonal CHOhumH 1 cell lines, overexpressing one of the PKC
isoenzymes. Since our co-expression approach was unsuccessful, a detailed knowledge of the
distribution of different PKC isoenzymes in the various cellular systems, as well as the future
availibity of specific PKC isoenzyme inhibitors/activators, could perhaps give more insight in
the contribution of each PKC isoenzyme in the negative feedback of HI receptor signalling.
Thus far, no mechanistic information is available on long-term regulatory mechanisms such
as HI receptor downregulation. Long-term treatment of CHOhumH1 cells with histamine or
other H1 agonists resulted in a time- and dose-dependent decrease in the number of H1
receptor binding sites. In the neuroblastoma cell line NIB-lI5 and neuroblastoma/glioma
hybrid cell line NG108-15, PKC stimulation with phorbolesters was found to induce
downregu1ation of respectively muscarinic receptors (Liles et aI., 1986) and o-opioid receptors
(Gucker and Bidlack, 1992). Yet, neither short-term nor long-term stimulation of the
CHOhumH 1 cells with PMA did affect H1 receptor expression. For the o-opioid receptor
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Gucker and Bidlack showed that simultaneous activation of PKC and the 8-receptor is required
to induce receptor downregulation (Gucker and Bidlack, 1992). Yet, no downregulation was
observed when cells were treated simultaneously with PMA and histamine for a period of 4
hrs. indicating that PKC potentiation is apparently not occuring in CHOhumH1 cells. In
addition. concurrent incubation of cells with PMA and histamine for 24 hrs did not induce a
more pronounced HI receptor downregulation than with histamine alone.
No significant HI receptor downregulation in CHOhumH1 cells was observed upon long-
term ATP exposure. indicating that the HI receptor density is not affected upon activation of
other receptors coupled to phospholipase C. Thus, stimulation of phospholipase C is not
sufficient to induce a reduction of receptor binding sites. These findings are corroborated by
the difference in potency for histamine-induced inositol phosphate production and receptor
downregu1ation (EC50 2.23 flM and 0.13 flM. respectively). Interestingly. the EC50 for the
homologous short-term desensitization of the HI receptor in human umbilical vein endothelial
cells was also found to be lower than the EC50 for inositol phosphate production (McCreath et
al., 1994). Taken together. these data imply that HI receptor downregulation is apparently not
induced by activation of phospholipllSe C or PKC.
To study the possible functional consequences of the HI receptor downregu1ation. we also
measured the Ca2+ responses in histamine-downregulated CHOhumHI cells. We observed
that long-term histamine exposure of CHOHumH1 cells also affected receptor mediated Ca2+
signalling. Long-term treatment of CHOhumH1 cells to 100 flM histamine resulted in
attenuation of both the histamine- as well as the ATP-induced Ca2+ responses. suggesting that
the reduction of the Ca2+ responses is not only caused by HI receptor downregulation. If
PKC stimulation would be responsible for the effects of long-term stimulation on the Ca2+
responses. one would expect based on the partial sensitivity. of the Ca2+ responses towards
PMA that Ca2+ responses of histamine-pretreated (24 hrs) cells would not be further affected
by PMA treatment. Nevertheless, PMA still induced a similar reduction of the histamine-
induced Ca2+ response in CHOhumH1 cells pretreated for 24 hrs with histamine. indicating
that PKC is not responsible for the observed reduction of the histamine and ATP mediated
Ca2+ responses. Although we have no direct evidence. this reduction may be explained by an
alteration at a level distant from the receptor. such as the G-protein or Ca2+ pool. Mullaney et
al. (1993) showed that agonist-induced downregulation of m1 muscarine acetylcholine
receptors expressed in CHO cells was paralleled by a specific downregulation of cellular levels
of the a subunits of G-protein Gq and GIl. For other receptor systems, linked to adenylate
cyclase. similar observations were made with regard to Gas subunit downregulation (see for
references Mullaney et at., 1993). Another possibility is a downregulation of the IF3 receptor
upon long-term receptor activation. In SH-SY5Y human neuroblastoma cells. chronic
muscarinic stimulation was found to suppress the Ca2+ releasing activity of IP3. which was
paralleled by a reduction in the number of IF3 binding sites (Wojcikiewicz et at., 1992).
In conclusion. human HI receptors expressed into CHO cells are susceptible to receptor
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regulation. Short-term activation of the human HI receptor to histamine leads to an
heterologous desensitization of the agonist-induced Ca2+ response, which may be explained
by alterations at the level of the intracellular Ca2+ pool. Long-term exposure of the
CHOhumH I cells results in a dose- and time-dependent downregulation of the human HI
receptor. Both histamine and ATP-induced Ca2+ responses are affected upon long-term
histamine treatment, indicating alterations at a level distant from the receptor. PKC does not
seem to play a role in either the histamine-induced H I receptor desensitization or
downregulation in CHOhumHI cells, which may be explained by differential expression of
PKC isoenzymes in this cell line compared to other cellular systems.
Further detailed investigations are required to elucidate the biological mechanism
underlying H I receptor downregulation. Other phospholipase C-linked receptors, such as the
muscarinic ml receptor, are also downregulated upon long-teon agonist exposure (Shapiro and
Nathanson, 1989). Studies have shown that the third intracellular loop is important for the
agonist-induced muscarine m1 receptor downregulation. The future use of mutant HI
receptors, should give more insight in the structural requirements of HI receptor
desensitization and downregulation.,
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Chapter 4
Rapid desensitization of the histamine H2 receptor
on the human monocytic cell line U937
M. J. Smit, R. Leurs, s. R. Shukrula, A. Bast and H. Timmerman
In the present study we have subjected the histamine H2 receptor on the monocytic cell line U937 to a thorough
pharmacological characterization using a series of selective histamine HI, H2 and H3 receptor agonists and
antagonists. Recent reports have demonstrated the existence of a histamine H2 receptor on HL-60 and HGT-l
cells with a pharmacological proftle distinct from the commonly described histamine H2 receptor (Burde et at.,
1989, Mitsuhashi et at., 1991, Seifert et at., 1992b). U937 cells, however, seem to express classical
histamine H2 receptors. Histamine and dimaprit dose dependently induce the formation of cAMP, whereas
dimaprits inactive analogues, nordimaprit and homodimaprit, show reduced potenties. Histamine HI and H3
receptor agonists do not show histamine H2 receptor activity. Various histamine H2 receptor antagonists are
able to block the histamine-induced production of cAMP with an antagonistic profile comparable to that
observed in the guinea-pig right atrium.
Furthermore, endogenous histamine H2 receptors in U937 cells are found to be susceptible to receptor
desensitization, a mechanism which may become apparent under pathophysiological conditions or during drug
therapy. A 30 mins pre-exposure of U937 cells to histamine (100 IJM) results in a 50% attenuation of the
production of cAMP by a subsequent application of agonist. Desensitization of the histamine H2 receptor in
U937 cells is found to be homologous as the ~-adrenoceptor mediated response remains unaffected.
Introduction
Histamine is a widely occurring endogenous compound, known among others as an
inflammatory mediator, a factor involved in cardiac and gastrointestinal regulation and a
neuroregulator (Leurs et at., 1991, Schwartz and Haas, 1992). Pharmacological analyses,
supported by the availability of selective ligands, have demonstrated the existence of three
major subclasses of histamine receptors, designated as HI, H2 and H3 (Leurs et at., 1991,
Schwartz arid Haas, 1992). The histamine H2 receptor, present in the heart, stomach and
brain, has been shown to be associated with a G-protein mediated stimulation of adenylate
cyclase, causing an increase in cAMP (Hill, 1991). Histamine H2 receptor antagonists have
been proven to be successful in the therapy of gastric ulcers (Bertaccini and Corruzi, 1992).
Recently, also the application of cardioselective histamine H2 receptor agonists during
congestive heart failure has been suggested (Felix et at., 1991).
Under several pathophysiological conditions, e.g. inflammation, histamine is released from
either mast cells or basophils in high quantities. It is conceivable that histamine receptors
present at the site of inflammation may be affected and become desensitized. Desensitization is
a general occurring phenomenon observed for almost all G-protein coupled receptors. It is
characteriZed by an attenuation of the cellular response despite the presence of the agonist This
phenomenon might have serious consequences during various physiological and
pathophysiological processes. Moreover, it may also become apparent during drug therapy
80 Chapter 4
with agonists (Brodde et at., 1990, Motomura et at., 1990, Ghosh et at., 1990).
As for the histamine HI receptors, we and others have demonstrated that these receptors
are rapidly desensitized (see for references Smit et at., 1992). In contrast, few reports have
described desensitization of the histamine H2 receptor (Chan et at., 1982, Johnson and
Sawutz, 1984, Prost et at., 1984, Schreurs et al., 1984). In view of the anticipated use of
histamine H2 receptor agonists during cardiac heart failure (Felix et al., 1991) detailed
knowledge of histamine H2 receptor regulation seems to be essential for the development of
effective drug therapy. One of the underlying mechanisms for the development of cardiac heart
failure was suggested to be ~-adrenoceptor desensitization (Stiles, 1991).
Potential use of histamine H2 receptor agonists during inflammatory processes has also
been suggested (Plaut and Lichtenstein, 1982). The second messenger cAMP is thought to
exert an inhibitory effect on the activity of immune and inflammatory cells through prevention
of antigen-induced release of histamine from leukocytes (Bourne et at., 1974, Kammer, 1988,
Torphy et at., 1992). Thus, under pathophysiological conditions activation of histamine H2
receptors may prevent further release of histamine, leading to an attenuation of the
inflammatory process. However, contributions of the histamine H2 receptors to this effect
could be limited by the occurrence of receptor desensitization.
In order to examine whether endogenous histamine H2 receptors are susceptible to
desensitization we looked for a suitable model system. Due to limited availability of human
tissue we preferred to use an isolated cellular system. The promyelocytic cell line HL-60
(Gespach et at., 1982), the monocytic leukemic cell line U937 (Gespach et at., 1985), and
the gastric carcinoma cell lines HGT-1 (Emani et at., 1983) and MKN-45 (Arima et at.,
1991), all of human origin, can be used as a model system for the human histamine H2
receptor. Yet, recent reports have implied the existence of a histamine H2 receptor on the HL-
60 (Burde et al., 1989, Mitsuhashi et at., 1991, Seifert et at., 1992b) and HGT-1 cell line
(Reyl-Desmars et al., 1991) with a pharmacological profile distinct from the commonly
described histamine H2 receptor. These findings prompted us to use the U937 cell line. As the
histamine H2 receptor had been moderately characterized on the U937 cell line (Gespach et
al., 1985), we first subjected the histamine H2 receptor to a thorough pharmacological
characterization. Histamine H2 receptor activity and specificity were evaluated by means of
measurements of cAMP levels in these cells, using a series of selective histamine HI, H2 and
H3 receptor agonists and antagonists. Thereafter we investigated whether the histamine H2
receptor is susceptible to receptor desensitization.
Materials and methods
Cell culture U937 cells, obtained from the American Type Culture Collection, were cultured at 37°C in a
humidified atmosphere with 5% C02 in RPMI 1640 medium supplemented with 10% heat-inactivated fetal-calf
serum (GIBCO), 2 mM L-glutamine, 50 IV Iml penicillin and 50 I!glml streptomycin (GIBCO). Culture
medium was changed every 3 days.
cAMP assay Pretreatment of cells (desensitization experiments) with histamine was performed in RPM! at
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37°C in a humidified atmosphere with 5% C02' Cells were washed and resuspended in Krebsbuffer
supplemented with I % bovine sermn albumine and I mM isobutyhnethylxanthine (IBMX) at a cell density of
106 cells/ml. Thereafter cells were preincubated for 10 mins at 37°C and exposed to various drugs for 10 mins at
the indicated concentrations. The reaction was stopped by addition of HCI04 (6 N) and cells were stored at ice
for 30 mins. Thereafter cells were centrifuged at 3000 x g for 10 mins. The supernatant was neutralized using
freon/ trioctylamine (1:1) and centrifuged at 3000 x g for 10 mins. The cAMP content (supernatant) was
determined by means of competition with [3H]-cAMP for protein kinase A, according to the method described
by Nordstedt and Fredhohn (1990). Briefly, a protein kinase A containing fraction was isolated from bovine
adrenal glands. Adrenal cortex was homogenized in 10 volumes of 100 mM TrisIHCI, 250 mM NaCI, 10 mM
EDTA, 0.25 M sucrose and 0.1 % 2-mercaptoethanol (pH = 7.4 at 4°C, buffer A) using a Omni-Sorval mixer
(30 s, maximal speed) and a Polytron homogenizer (10 s, maximal speed). The homogenate was centrifuged for
60 mins at 3ססoo g at 4°C. The supernatant, containing protein kinase A, was carefully recovered and frozen in
1 ml aliquots at -80°C. Before use, the binding protein was diluted five-fold in ice-cold buffer A without sucrose
and 2-mercaptoethanol and kept on ice. Subsequently, 200 J.1l of the binding protein was mixed with 100 J.1l of
the U937 homogenate or cAMP standards and 30.000 dpm [3H]-cAMP. After incubation for 150 mins at 4°C
the mixture was rapidly diluted with 3 ml ice-cold 50 mM Tris-HCI (pH 7.4, at 4°C) and filtered through
Whatman GFIB filters using a Brandel cell-harvester (Semat, UK). The radioactivity retained on the filters was
measured by liquid scintillation counting.
Chemicals Histamine dihydrochloride, forskolin, isoprenaline, isobutyhnethylxanthine (IBMX), cAMP and
mepyramine were obtained from Sigma Chemical Company Ltd. (St. Louis, MO, U.S.A.). 1,1,2-
trichlorotrifluoroethane (freon) was purchased from Aldrich Chemical Company. Tri-n-octylarnine was purchased
from Janssen Chimica. [3H]-cAMP (40 C,ilmmo!) was obtained from Amersham. Dimaprit dihydrobromide,
nor- and homodimaprit dihydrobromide, impromidine trihydrobromide, amthamine dihydrobromide, amselamine
dihydrobromide, 2-pyrldylethylamine and thioperamide were taken from laboratory stock.
Gifts of burimamide, metiamide, cimetidine (SmithKline Beecham), tiotidine (hnperial Chemical Industries),
ranitidine (Glaxo), famotidine (Merck Sharp & Dohme), mifentidine (De Angeli) and R(a)-methylhistamine
dihydrobromide (Dr. J.C. Schwartz, Paris) are acknowledged. All other chemicals were of analytical grade.
Data analysis The cAMP production is depicted in absolute values as pmol cAMP produced by 106 cells or
represented as % stimulation compared to the maximum-induced response of 100 J.lM histamine. Antagonistic
properties of the histamine H2 receptor antagonists towards the histamine H2 receptor were analyzed assuming
competitive inhibition, according to the Cheng-Prusoff (1973) equation: Ki = IC50/(1 + L1EC50) where Ki is
the inhibition constant of the antagonist, the EC50 is the dose required to induce 50% of the maximal attained
response, the IC50 the dose required for 50 % inhibition produced by histamine (100 J.lM) and L the
concentration of the ligand, histamine. All data shown are expressed as mean ± s.e.mean of at least three
independent experiments. Statistical analysis was carried out using Student's t-test. P values < 0.05 indicate a
statistically significant difference.
Results
Histamine-induced cAMP production in U937 cells
Addition of 100 J.lM histamine induced a rapid and significant increase of the production of
cAMP in time in the presence of 1 mM of the phosphodiesterase inhibitor IBMX in U937 cells
(Fig. 1A). Already 1 min after application of 100 IlM histamine significant changes in the
cellular cAMP levels were measured (Fig. IA). A maximal response (81 ± 7 pmol/106 cells, an
approximately 11 fold increase of cAMP compared to basal cAMP levels) was observed after
10 mins of incubation of the cells with histamine. No additional production of cAMP was
observed when cells were exposed to histamine for longer incubation periods. The cAMP
production in U937 cells was dose dependently increased when the cells were incubated for 10
mins with increasing concentrations of histamine (Fig. IB). Half maximal stimulation (ECSO)
was observed at 13 ±0.1 J.lM of histamine (Table 1).
82 Chapter 4
A B100 120
§ 80 100
'l::l c
u .12
"
ts 80
'8 "60 ~
"'"~ c- 6040 a.::;:< 40
I "20 -#. 20
0 •0
0 4 8 12 16 20
-8 -7 -6 -5 -4 -3 -2
mins log [histamine]
Fig. 1. Histamine induced cAMP accumulation in U937 cells. A, U937 cells were stimulated with (filled
circles) or without (open circles) histamine (100 IJM) at 37°C in Krebs buffer supplemented with 1 mM IBMX
for various length of time. B, U937 cells were incubated with increasing concentrations of histamine for 10
mins at 37°C in Krebs buffer supplemented with 1 mM IBMX and 1% bovine serum albumin (basal level 7.4 ±
1.2 pmoV106 cells, maximal induced response by histamine (100 IJM) 85 ± 6 pmoVl06 cells). Data shown are
the mean values of triplicate experiments.
Pharmacological characterization ofthe histamine H2 receptor on U937 cells
A wide range of histamine HI. H2 and H3 receptor agonists and antagonists was used to
subject the histamine H2 receptor on U937 cells to a pharmacological characterization (Fig. 2,
3 and Table 1). Dimaprit, a selective histamine H2 receptor agonist was able to induce a dose
dependent increase of cAMP (Fig. 2). The maximum production of cAMP induced by dimaprit
was comparable to the increase of cAMP induced by histamine (Table 1). The pD2 of dimaprit
was 4.79 ± 0.12 IlM. Yet, dimaprit's structural analogues homodimaprit and nordimaprit,
which are devoid of histamine H2 receptor agonist activity (Sterk et al., 1986), failed to
induce a response comparable to that induced by dimaprit (Fig. 2). The pD2 's of the latter
compounds were also markedly reduced. The respective histamine H I and H3 receptor
agonists, 2-pyridylethylamine and R(a.)-methylhistamine, showed weak histamine H2 receptor
agonistic effects only at high concentrations (Table 1).
A wide range of histamine H2 receptor antagonists dose dependently inhibited the
histamine-induced cAMP response (Fig. 3A). Their Ki values are depicted in table 1. In order
to determine whether the antagonists show similar potencies for the histamine H2 receptor
located on U937 cells as well as guinea-pig heart atrium, the Ki values on both systems were
compared. As can be seen in table I the pKi values of the different antagonists showed a good
correlation (r =0.89) with the reported pA2 values against the histamine-induced chronotropic
response of the guinea-pig right atrium (Fig. 3B) (Leurs et al., 1991).The histamine HI and
H3 receptor antagonist, respectively mepyramine and thioperamide, did not show any
antagonistic activity, up to 10 JlM, towards the response elicited by histamine (Table 1).
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Table 1 pKi values of various drugs for inhibition of the histamine (100 flM) induced cAMP response.
Reported pA2 values for guinea-pig right atrium are shown for comparison. pD2 and Emax values of
histaminergic agonists. Data of the Emax values are shown as a percentage of the histamine (100 flM) induced
response.
Drugs
Antagonists
burimamide
cimetidine
metiamide
ranitidine
tiotidine
famotidine
mifentidine
mepyramine
thioperamide
Agonists
histamine
dimaprit
nordimaprit
homodimaprit
2-pyridylethylamine
R(a)-methylhistamine
*Emax value determined at 1 mM.
U937 cells
pKi
5.44 ± 0.14
5.64 ± 0.D7
6.15 ± 0.18
6.89 ± 0.13
7.40 ± 0.30
7.74 ± 0.13
8.17 ± 0.15
<5
<5
pD2
4.89 ± 0.10
4.79 ± 0.12
<4
<4
<4
<4
guinea-pig right atrium
pA2
5.11
6.10
6.04
7.20
7.82
7.60
7.76
Emax (%)
100± 9
117 ± 20
43 ± 5 *
9±2*
Histamine H2 receptor desensitization
In order to investigate whether endogenous histamine H2 receptors on this cell line are
susceptible to receptor desensitization the cells were exposed to 100 J.IM of histamine for
periods ranging from 0.5 to 2 hours in the absence of ffiMX. Thereafter the cells were washed
and exposed to 100 J.IM of histamine in the presence of 1 mM of IBMX for 10 mins to
determine whether the histamine H2 receptors were still able to generate cAMP. As can be seen
in figure 4A, impaired production of cAMP induced by histamine is observed when pre-
exposure time of U937 cells to histamine increases. A reduction of 35 % of the histamine-
induced cAMP response is found when cells are pretreated with 100 11M of histamine for 30
mins. Mter 1 hr pretreatment of cells with histamine, only a minor response is observed (9 ±4
%). Histamine can no longer induce a response when cells are pretreated with 100 11M
histamine for 120 mins. Half maximal desensitization is observed after approximately 35 mins
pre-exposure of cells to histamine. Exposure of cells to increasing concentrations of histamine
for 1 hr led to a dose dependent decrease of the histamine H2 receptor mediated cAMP
response with an EC50 value of 0.67 ± 0.21 11M (Fig. 4B).
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Fig. 2. Dose dependent increase of the cAMP production by dimaprit (filled circles), nordimaprit (open
squares) and homodimaprit (filled triangles). Data are shown as a percentage of the histamine (100 J..lM) induced
response (85 ± 6 pmoVl06 cells) over basal levels (7.4 ± 1.2 pmoVl06 cells). U937 cells were incubated with
the indicated drugs with increasing concentrations for 10 mins at 37°C in Krebs buffer in the presence of 1 mM
ffiMX and 1% bovine serum albumin. Data shown are the mean values of triplicate experiments.
To define the specificity of the histamine-induced desensitization we perfonned some
experiments with forskolin, which directly activates adenylate cyclase. In U937 cells the cAMP
production was dose dependently increased by forskolin (data not shown). Addition of 10 IlM
of forskolin resulted in cAMP production which was 5 times higher than the histamine-induced
cAMP production. As can be seen in fig. 4B the forskolin-induced production of cAMP
remains unaffected after respectively 30 and 60 mins pretreatment of cells with 100 IlM of
histamine.
In order to establish whether the observations of receptor desensitization were confmed to
the histamine H2 receptor, we examined the effects of histamine pretreatment on the B-
adrenoceptor which is also present on U937 cells (Chan et al., 1982). Isoprenaline, a B-
adrenoceptor agonist, dose dependently increased the cAMP production (data not shown).
Exposure of cells to 10 IlM of isoprenaline lead to an increase in cAMP, which was 3 times
higher than the histamine-induced production of cAMP. Fig. 4B shows a unaltered generation
of cAMP after histamine-induced desensitization, indicating that histamine H2 receptor
desensitization is restricted to the histamine H2 receptor.
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Fig. 3. A, Pharmacological characterization of the histamine induced cAMP response in U937 cells. Cells
were incubated for 10 mins at 37°C with 100~ of histamine in the presence of increasing concentrations of
mifentidine (fllied circles), tiotidine (open squares) and cimetidine (filled triangles). Data are shown as a
percentage of the histamine (100 ~) induced response (respectively 88 ± 5, 91 ± 15, 92 ± 14 pmol/106 cells)
over basal levels (7.0 ± 1.6 pmol/l06 cells). Data shown are the mean values of triplicate experiments. B,
Comparison of pKi's values of various dnigs for inhibition of the histamine (100~) induced cAMP response
on U937 cells and reported pA2 values of these drugs on guinea-pig heart atrium (Leurs et al., 1991).
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Fig. 4. Histamine induced desensitization of the histamine H2 receptor. A, U937 cells were incubated for
various length of time with 100~ of histamine. Thereafter cells were washed and stimulated with 100~ of
histamine for 10 mins. Data are shown as a percentage of the histamine (100 ~) induced response (79 ± 7
pmol/106 cells) over basal levels (5.9 ± 2.1 pmol/106 cells) in non pretreated cells. B, U937 cells were
incubated for 1 hr with increasing concentrations of histamine, washed and stimulated with 100~ of
histamine for 10 mins. Data are shown as a percentage of the histamine (100 ~) induced response (98 ± 7
pmol/l06 cells) over basal levels (6.0 ± 2.0 pmol/106 cells) in non pretreated cells. Data shown are the mean
values of triplicate experiments. (Inset) Effect of histamine H2 receptor desensitization on the ~-adrenoceptor and
forskolin induced accumulation of cAMP. U937 cells are preincubated for 60 mins with (open columns) and
without (hatched columns) 100~ of histamine, washed and stimulated with 10~ of isoprenaline (ISO) and
10~ forskolin (FORS). Data are shown as a percentage of respectively the isoprenaline (10 ~, 244
pmol/l06 cells) and forskolin (10~, 407 pmol/106 cells) induced response in non pretreated cells.
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Discussion
The use of isolated cellular systems derived from human tissue for a detailed investigation of
regulatory mechanisms is now quite current. Human cell lines represent a simplified model
system consisting of a homogenous cell population. For the histamine H2 receptor one often
uses the human leukemic cells HL-60, a promyelocytic cell line (Gespach et al., 1982), the
U937 (Gespach et al., 1985), a monocytic cell line, and gastric cell lines HGT-l (Emani et
al., 1983) and MKN-45 (Arima et al., 1991). Ali cell lines show production of cAMP upon
addition of histamine. Yet, the pharmacological profiles of these reported histamine H2
receptors were shown be distinct from the commonly described histamine H2 receptor (Burde
et al., 1989, Mitsuhashi et al., 1989, Reyl-Desmars et al., 1991, Seifert et al., 1992b).
In HL-60 cells histamine was also found to induce rises of the intracellular Ca2+
concentration ([Ca2+Ji) besides the increase in production of cAMP (Mitsuhashi et al., 1989,
Seifert et al., 1992b). Surprisingly, the histamine-induced rise in [Ca2+li appeared to be
primarily mediated via histamine H2 receptors rather than histamine HI receptors. Moreover,
the agonist/antagonist profile of the histamine H2 receptor mediated rise in [Ca2+li did not
correspond to the one observed for the induced cAMP production (Seifert et al., 1992b),
suggesting the existence of different histamine H2 receptor subtypes. Moreover, Burde et al.,
(1989) also described a unique pharmacological profile for the inhibition of the oxidative burst
in these cells. Recently, Seifert et al. (l992a) reported the possible existence of histamine HI
receptors on these cells. There are numerous reports that have shown that histamine HI
receptor agonists appear to potentiate the cAMP response of receptors coupled to adeny1ate
cyclase (see for references, Johnson et al., 1992). It is therefore not clear whether the H2
induced response is affected by the presence of histamine HI receptors. Also in the HGT-1
tumour cell line the pharmacological profile of the histamine H2 receptor appeared to be quite
distinct from the commonly described histamine H2 receptor system; tiotidine showed a rather
low affinity for the histamine H2 receptor (Reyl-Desmars et al., 1991). Based on these
observations we concluded that both the HL-60 and HGT-1 cells are not suitable for detailed
investigation of histamine H2 receptor regulation. Moreover, little information is available on
the pharmacological profile of the histamine H2 receptor on U937 (Gespach et al., 1985) and
MKN-45 cells (Arima et al., 1991). Therefore we examined the histamine H2 receptor on
U937 cells in more detail.
In view of our findings, U937 cells seem to express classical histamine H2 receptors.
Dimaprit, a selective histamine H2 receptor agonist, is as potent as histamine in inducing
formation of cAMP. Yet, its structural analogues nordimaprit and homodimaprit were less
effective in generating cAMP and showed reduced potencies. Variation in chain length by one
methyl group (nordimaprit and homodimaprit) leads to a loss of histamine H2 receptor activity
(Sterk et al., 1986). Moreover, initial experiments with the histamine H2 receptor agonists
amthamine and amselamine, which appear to be potent histamine H2 receptor agonists (Eriks
et al., 1992, Van der Goot et al., 1994), have shown that these new selective histamine H2
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receptor agonists are effective in this model system as well (M.J. Smit, unpublished
observation). In addition, the histamine HI and H3 receptor agonists, 2-pyridylethylamine and
R(a)-methylhistamine, showed weak histamine H2 receptor agonistic effects only at high
concentrations.
Various histamine H2 receptor antagonists were able to block the histamine-induced
production of cAMP. On the other hand the histamine HI and H3 receptor antagonists,
mepyramine and thioperamide, respectively, failed to inhibit the effect induced by 100 ~M
histamine at concentrations up to 10 ~M. The different histamine H2 receptor antagonists
showed an antagonistic profile in U937 cells comparable to that observed in the guinea-pig
right atrium, the commonly accepted histamine H2 receptor reference system. Moreover,
Seifert et al. (1992b) have shown that addition of histamine in these cells does not lead to an
increase in [Ca2+h in U937 cells; cAMP responses are therefore not influenced by cross-talk
with the Ca2+ signalling pathways. Taken together, the U937 cells provide a good model
system for the investigation of human histamine H2 receptor regulation.
Limited information is available on desensitization of the histamine H2 receptor. In the
present study we have found that histamine H2 receptors were susceptible to desensitization.
The histamine H2 receptor mediated cAMP response was found to be time and dose
dependently impaired when cells were pretreated with histamine (100 ~M). The half time for
desensitization was 35 mins. An almost complete reduction of the histamine-induced response
was observed after 1 hr incubation of the cells with histamine. The mechanism remains
restricted to the level of O-protein or receptor protein as forskolin was still able to induce a
response after exposure of cells to histamine. U937 cells also contain ~-adrenoceptors (Torphy
et al., 1992), which couple to the adenylate cyclase pathway. Desensitization of the histamine
H2 receptor seemed to be homologous as the ~-adrenoreceptor mediated responses remained
unaffected after pretreatment with histamine.
Desensitization of the histamine H2 receptor has been reported previously, but the
mechanism responsible for the loss of receptor responsiveness remains to be elucidated. In
HL-60 cells desensitization of putative histamine H2 receptors has been shown to be mainly
homologous, which can not be explained by a loss of receptors nor by the induction of
phosphodiesterase activity (Johnson and Sawutz, 1984). In some experiments prostaglandin
E2 responses were affected, indicating a small heterologous component (Johnson and Sawutz,
1984). The half time of desensitization of the histamine H2 receptor in the HL-60 cell line
appeared to be about 2.5 h (Johnson and Sawutz, 1984). In clonal cytolytic T lymphocytes and
human gastric cancer cell line, HOT-I, histamine (50~ and 1 mM) induced desensitization
with a half-time of 10 mins and 20 mins respectively (Schreurs et al., 1984, Prost et a!.,
1984). Yet, since the actual pharmacological proftle of the histamine receptor is undefined in
the HL-60 and HOT-1 cell lines, these results do not necessarily reflect regulation of the the
classical histamine H2 receptor.
In human mononuclear leukocytes histamine caused a heterologous desensitization of the
H2' ~- and prostaglandin E2 receptor, which could be explained by enhanced
phosphodiesterase activity (Chan et al., 1982, Holden et al., 1987). Also in U937 cells the
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~-adrenoceptor-induced cAMP production was found to be reduced after prolongued exposw'e
(hours) of cells to a ~-agonist. This reduction could also be explained by an increase of
phosphodiesterase activity (Torphy et al., 1992). Since this increased phosphodiesterase
activity was only observed after 3 hours pretreatment, it is therefore unlikely that this effect
may account for the observed histamine-induced histamine H2 receptor desensitization in
U937, which has a half time of 30 mins. Moreover, forskolin and the ~-adrenoceptormediated
cAMP production were not affected, excluding an increased phosphodiesterase activity as
explanation for the observed histamine H2 receptor desensitization.
The mechanism of desensitization of adenylate cyclase-linked receptors has been
characterized best for the ~-adrenoceptor (Hausdorff et al., 1990, Huganir and Greengard,
1990). Desensitization is associated with receptor phosphorylation catalyzed by a specific
kinase called ~-adrenoceptorkinase, which specifically phosphorylates the agonist-occupied
form of the receptor. This kinase is responsible for homologous desensitization. The other
kinase is the cAMP dependent kinase (protein kinase A), which is responsible for heterologous
desensitization. Besides ~-adrenoceptor kinase, another cofactor, called ~arrestin, has been
established to be involved in the process of desensitization (Lohse et al., 1990). In the
meantime other G-protein coupled receptors were also found to be substrates for ~­
adrenoceptor kinase (Benovic et at., 1989, Lefkowitz et at., 1990). To date, up to 6 distinct
cDNAs encoding ~-adrenoceptorkinase isoenzymes, currently referred to as G-protein coupled
receptor kinases and 3 different ~arrestin related proteins have been isolated (see for references
Haribabu and Snyderman, 1993). Apparently this family of G-protein coupled receptor kinases
and ~arrestin related proteins is involved in a general occurring regulatory mechanism for G-
protein coupled receptors.
During the last few years, the genes encoding the canine, rat and human histamine H2
receptor have been cloned (Gantz et al., 1991a, b, Ruat et al., 1991). Several potential
phosphorylation sites appear to exist in the cytop1asmatic tail (Gantz et at., 1991a, b, Ruat et
al., 1991). As the observed histamine-induced histamine H2 receptor desensitization in U937
cells was found to be homologous, these sites might be possible targets for a specific receptor
kinase. Moreover, recently Chuang et at. (1992) have reported the presence of ~-adrenoceptor
kinase in U937 cells, further supporting this possibility. The marked differences between the
observed time course of histamine H2 receptor desensitization in the different cellular systems
may be explained by a difference in distribution of molecular entities, such as specific receptor
kinases or related ~arrestins.
In conclusion, we have shown that the U937 cell line expresses classical histamine H2
receptors which can serve as a suitable model to study receptor regulation. These endogenous
histamine H2 receptors were found to be susceptible to desensitization, a mechanism which
may become apparent under pathophysiological conditions or during drug therapy. Ungerer et
al. (1993) have reported an increased expression of ~-adrenoceptorkinase during cardiac heart
failure. Considering the possible application of H2 agonists during cardiac heart failure (Felix
et al., 1991) it is important to know whether the histamine H2 receptor is also substrate for
this kinase. In view of effective drug therapy detailed knowledge of the mechanism underlying
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histamine H2 receptor desensitization is required.
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Chapter 5
Two distinct pathways for histamine H2 receptor
downregulation
H2 Leu124Ala receptor mutant provides evidence for a cAMP-independent
action of H2 agonists
M. J. Smit, H. Timmennan, E. Roovers, Y. van de Vrede, A. E. Alewijnse and R. Leurs
In the present study we have demonstrated that the rat histamine HZ receptor density in Chinese Hamster Ovary
cells (CHOrHZ cells) is affected by a long-term exposure to HZ agonists. Pretreatment of CHOrHZ cells with
histamine resulted in a time-dependent (tl/Z '" 7 hrs at a concentration of 100 JlM) and dose-dependent (ECso =
18 11M at 24 hrs incubation) HZ receptor downregulation measured as [IZSI]-iodoaminopotentidine binding (44 ±
10% maXimal downregulation). .
Activation of the protein kinase A pathway by cholera toxin (1-100 ng/ml) or forskolin also leads to HZ
receptor downregulation. Forskolin time-dependently (tllZ '" 7 hrs, concentration of 10 JlM) and dose-
dependently (ECSO =0.3 JlM at Z4 hrs incubation) induced HZ receptor downregulation, whereas its inactive
analoguedideoxyforskolin (1-10 JlM) did not. A comparison of the time course and maximum extent of the
histamine and forskolin-induced HZ receptor downregulation suggests the involvement of cAMP in the process
of HZ receptor downregulation. These findings were further supported by the observation that both histamine and
forskolin induced rapid downregulation of HZ receptor mRNA levels, most likely caused by mRNA
destabilization, thereby contributing to the observed decrease of HZ receptor binding sites. Recently, Moro et .
al. (1993) hilVe shown that hydrophobic amino acids in a conserved G-protein coupled receptor motif in the
second intracellular loop are involved in G-protein coupling. To assess the role of cAMP in the process of
agonist-induced HZ receptor downregulation we uncoupled the HZ receptor from the Gs protein by substitution
of the leucine1Z4 in this G-protein coupled receptor motif by an alanine residue. The HZ Leul24Ala mutant
indeed showed an impaired ability of the receptor to physically and functionally couple to its G-protein as
demonstrated by altered agonist-binding parameters (disappearance of high affinity binding site, no detectable
GTPyS shift) and attenuated histamine-induced cAMP production (reduction of ECSO value and decrease of
maximum response). Since the HZ Leu1Z4Ala receptor mutant was downregulated by concentrations of
histamine that did not give rise to cAMP production the agonist-induced downregulation mainly concerns a
cAMP-independent pathway.
Introduction
The introduction of molecular biology in the field of histamine receptor research has greatly
improved the possibilities to study molecular aspects of histamine receptor proteins. In 1991
Gantz et al. cloned the cDNA encoding th~ canine histamine H2 receptor (Gantz et aI.,
1991b), which was followed by the cloning of both the rat and human homologues (Gantz et
al., 1991a, Ruat et al., 1991). The deduced amino acid sequence of the H2 receptor proteins
reveals the existence of seven putative transmembrane domains, indicating that this receptor is a
member of the large family of G-protein coupled reCeptors (GpeRs). This family of receptors
is known to be readily subjected to regulatory processes in order to control receptor signalling,
thus maintaining biological equilibria within the cell (Lohse, 1993). Short-tenn exposure of
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receptors to high concentrations of agonists is often followed by a decrease in cellular
responsiveness, called desensitization (Hausdorff et at., 1991). Long-term exposure, on the
other hand, results in the reduction of receptor number (Collins et at., 1991) and is referred to
as receptor downregulation. Since the histamine H2 receptor is a member of this family of
GPCRs, it is not surprising that this receptor is also susceptible to such regulatory
mechanisms.
Recently, we have shown that in human U937 cells the endogenously expressed histamine
H2 receptors are indeed rapidly desensitized when exposed to histamine (Smit et at., 1994).
Similar observations have been reported in other cellular systems (Arima et al., 1993,
Fukushima et at., 1994). Yet, so far no detailed information is available on long-term
desensitization of the histamine H2 receptor such as receptor downregulation. Such processes
may become apparent under several pathophysiological conditions (e.g. asthmatic attack or
allergic reactions in general), during which histamine is released in large quantities, but might
also occur under normal physiological conditions. Recently, Diaz et at. (1994) suggested e.g.
that in vivo receptor downregulation might explain the inverse relationship between H2
receptor expression and the localizlltion of histamine-synthesizing cells in the rodent gastric
wall. The regulation of H2 receptor expression has further gained interest due to the potential
therapeutical application of H2 receptor agonists in patients sufferering from congestive heart
failure (Felix et al., 1991). Moreover, it has been reported recently that striatal histamine H2
receptor density in brain tissue of patients suffering from Huntington's Chorea is markedly
reduced (Martinez-Mir et at., 1993).
Investigation of the regulation of H2 receptor expression has so far been hampered by the
availability of suitable model systems. Cellular systems (Arima et at., 1993, Fukushima et
at., 1994, Holden et al., 1987, Smit et at., 1994) have been used to investigate second
messenger responses coupled to the histamine H2 receptor stimulation, but the used systems
such as e.g. U937 cells do not express a sufficiently high density of H2 receptors to permit
radioligand binding studies, which are essential for the investigation of long-term regulatory
mechanisms (Smit et al., 1994). Following the recent cloning of cDNAs or genes encoding
histamine H2 receptors, cell lines expressing considerable amounts of histamine H2 receptors
can be obtained (Leurs et al., 1994, Traiffort et al., 1992). Additionally, the availability of
the H2 receptor gene allows the construction of receptor mutants, which can provide
mechanistic insights in phenomena like receptor downregulation.
In the present st.udy we have examined the effects of long-term exposure of the rat
histamine H2 receptor stably expressed in Chinese Hamster Ovary (CHO) cells (CHOrH2)
(Traiffort et at., 1992) to H2 agonists and cAMP mobilizing agents with regard to H2 receptor
protein expression and H2 receptor mRNA levels. In order to get more insight in the
mechanisms underlying H2 receptor regulation, we constructed by means of site-directed
mutagenesis a H2 receptor mutant, in which leucine124 in the second intracellular loop was
substituted by an alanine. This H2 Leu124Ala receptor mutant was as expected partially
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uncoupled from its G-protein and was therefore an excellent tool to investigate the existence of
possible cAMP-dependent and independent pathways in the process of agonist-induced H2
receptor downregulation.
Materials and methods
Cell culture CHO cells expressing the rat histamine H2 receptor (CHOrH2) (Traiffort et at., 1992) and the
mutated H2Leu124Ala receptor (CHOrH2Leu124Ala) were grown at 37°C in a humified atmosphere with 5%
CO2 in Dulbeco's Modified Eagle's Medium (DMEM), containing 10% (vol/vol) dialyzed foetal calf serum
supplemented with 2 mM L-glutamine, MEM amino acids, 50 IU/mI penicillin and 50 Ilg/ml streptomycin.
Site-directed mutagenesis The H2 receptor mutant, in which leucine124 was substituted by alanine
(Leu124Ala) (Fig. 5), was constructed by means of the Polymerase Chain Reaction. The oligonucleotides S1
(5'-GGGAAGCTTGGCCCCAGAATGGAGCCCAATG GCACAGT), corresponding to nucleotides -9 to 21
(Ruat et al., 1991) and a HindIII site (underlined), and AS1 (5'-GGGGGTACCGCGCTGGGT-
CCGTGACAGCGCAGTAGTTG TTCAAGCTGAT CAT), corresponding to nucleotides 358 to 383 of the
complementary strand (Ruat et al., 1991) containing a KpnI site (underlined) with two nucleotide changes,
were synthesized on an Applied Biosystems DNA synthesizer (model 381A). Using 100 ng pSVrH2 (Traiffort
et at., 1992), as a template, 0.4 J.lM Sl, 0.4 J.lM AS2, 40 J.lM dNTP's and 2.5 U Amplitaq according to the
manufacturing protocol (Perkin Elmer) a 392 bases DNA fragment of the H2 Leul24Ala receptor mutant was
amplified in 100 J.lI using 30 cycles at 94°C for 1 min, 56°C for 1 min and 72°C for 1.5 min and a final
extension at 72°C for 10 mins. The obtained PeR product was gel-purified, and restricted with HindIII/KpnI
(Boehringer). This fragment was cloned 'into the plasmid pSP73 (Promega) containing the wild-type rH2
receptor, which was restricted with KpnI and HindIII. Thereafter, the PeR amplified sequence was verified
using the dideoxy-chaintennination method with the Sequenase kit (USB). Subsequently, the coding sequence of
the mutated H2Leu124Ala receptor was subcloned into the eukaryotic pSV expression vector. CHO cells,
deficient in dihydrofolate reductase, were stably transfeeted with 15 Ilg of pSVrH2Leu124Ala using Transfectam
(Promega).
Membrane preparation CHOrH2 and CHOrH2Leu124Ala cells were washed three times with cold phosphate
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCI, 10.1 mM Na2HP04, 1.8 mM KH2P04) and harvested
with a cell scniper and recovered by a 10 min centrifugation at 5OOg. Cells were homogenized in ice-cold 50 mM
Na2/K-phosphate buffer (pH =7.4) with a Polytron homogenizer (5 secs, maximal speed) and used for
radioligand binding studies. Protein concentrations were detennined according to Bradford using bovine serum
albumin as a standard (Bradford, 1976).
Histamine H2 receptor binding The radiolabelled H2 receptor antagonist [125I]-iodoaminopotentidine ([1251]_
APT) was synthesized as described previously (Leurs et al., 1994). Triplicate assays were performed in
polyethylene tubes in 50 mM Na2/K phosphate buffer containing ~Iatine (0.1%) to prevent adsorption of the
radioligand. In saturation studies increasing concentrations of [1 5I]_APT were incubated with 5-10 Ilg of
membrane proteins in the absence or presence of 1 J.lM tiotidine in a total volume of 400 Ill. Mter 90 mins at
30°C the incubations were stopped by rapid dilution with 3 mI ice-cold 20 mM Na2/K phosphate buffer (pH =
7.4) supplemented with 0.1% bovine serum albumin. The bound radioactivity was subsequently separated by
filtration with a Brandel cell harvester (Semat, United Kingdom) through Whatman GFIB glass fibre ftlters that
had been treated with 0.3% polyethyleneimine. Filters were washed twice with 3 mI buffer and radioactivity
retained on the filters was counted with a LKB-y-counter at an efficiency of 63%. The binding data were
evaluated by use of LIGAND, a non-linear, weighted, least squares curve-fitting procedure (Munson and
Rodbard, 1980). Changes in H2 receptor density were denoted as a percentage downregulation compared to non-
treated control cells. During the 24 hrs incubation of cells with various histamine ligands or other compounds,
cells were maintained in medium without foetal calf serum.
Cyclic AMP production CHOrH2 and CHOrH2Leu124Ala cells were seeded in 24-well plates and cultured
overnight in culture medium. Cells were washed twice with DMEM, supplemented with 50 mM HEPES (pH =
7.4 at 37°C) and preincubated for 30 mins at 37°C. Thereafter, the medium was aspirated, appropriate drugs in
DMEMIHEPES supplemented with 300 J.lM of the phosphodiesterase inhibitor isobutylmethylxanthine (IDMX)
were added and the cells were incubated for 10 mins at 37°C. The reaction was stopped by the rapid aspiration of
the culture medium and the addition of 200 III of 0.1 N cold HCI. The cells were kept on ice and disrupted by
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sonification (5 secs, 50 Watt, Labsonic 1510, Braun-Melsungen, Gennany). The resulting homogenate was
frozen at -20°C or directly neutralized with 1 N NaOH and assayed for the presence of cAMP.
Cyclic AMP assay The amount of cAMP in the CHOrH2 and CHOrH2Leu124Ala cells was detennined
according to Nordstedt and Fredholm (Nordstedt and Fredholm, 1990), with some minor modifications. Briefly,
a protein kinase A containing fraction was isolated from bovine adrenal glands. Adrenal cortex was homogenized
in 10 volumes 100 mM TrisIHCI, 250 mM NaCl, 10 mM EDTA, 0.25 M sucrose and 0.1% 2-mercaptoethanol
(pH =7.4 at4°C, buffer A) using an Omni-Sorval mixer (30 secs, maximal speed) and a Polytron homogenizer
(10 sees, maximal speed). The homogenate was centrifuged for 60 mins at 30,ooog at 4°C. The supernatant,
containing protein kinase A, was carefully recovered and frozen in 1 ml aliquots at -80°C. Before use, the
binding protein was diluted five-fold in ice-cold buffer A without sucrose and 2-mercaptoethanol and kept on ice.
Subsequently, 200 ~ of the binding protein was mixed with 50-100 ~ of the CHO homogenate or cAMP
standards and 30.000 dpm [3H]-cAMP. After incubation for 150 mins at 4°C the mixture was rapidly diluted
with 3 ml ice~cold 50 mM TrislHCI (pH = 7.4 at 4°C) and filtered through Whatman GFIB filters using a
Brandel cell-harvester (Sernat, UK). The radioactivity retained on the filters was measured by liquid scintillation
counting.
RNA slot blot analysis RNA was analyzed by means of mRNA slot blot assay as described by Zhang et al.
(1994), with minor modifications. Briefly, RNA was isolated according to the method of Chomczynski and
Sacchi (Chomczynski and Sacchi, 1987), using Trizol reagent@ (GillCQ BRL), and RNA was slot blotted on
a nitrocellulose filter (GeneScreen plus, NEN) and prehybridized for 2 hrs at 65°C in 7% SDS, 0.5 M
Na2HP04, 1 mM EDTA (pH 7.2). Thereafter, filters were hybridized overnight with a radioactive labelled 48-
mer antisense rat H2 receptor oligonucleotide (5'-GATGGTGGCTGCCTTCCAGGAGCTGATGTG-
GTTGATCCGTTTGGCCTG-3', corresponding to nucleotides 631 to 678) or antisense rat ~-actin
oligonucleotide (5' -CTCCTGCTTGCTGATCCACATCTGCTGGAAGGTGGACAGTGAGGCCAG-3' ,
corresponding to nucleotides 3040 to 3087) at 65°C in 7% SDS, 0.5 M Na2P04 and 1 mM EDTA (pH 7.2).
The rat H2 receptor oligonucleotide (1.5 pmol) was [32p]-labelled by 3' -end tailing using 16 pmol of [a._32p]_
dATP (3000 Cilmmol; Amersham) and 1 unit of terminal deoxynucleotidyl transferase (Boehringer) for 20 min
at 37°C. The ~-actin oligonucleotide (5 pmol) was labelled using 10 pmol of [y_32p]_dATP (3000 Cilmmol;
Amersham) and 4 units of polynucleotide kinase (Boehringer) for 30 mins at 37°C. The blots were washed twice
for 5 mins at room temperature in 2xSSC (0.3 M NaCl, 0.03 M Na3C6H507.2H20) supplemented with 0.1%
SDS, which was followed by two 45 mins washes at 65°C with 2xSSC supplemented with 0.1% SDS. The
blots were exposed to a phosphorscreen (Molecular Dynamics) and signals were quantified with a
phosphorimager 425 (Molecular Dynamics) using the computer program ImageQuant (Molecular Dynamics).
H2 receptor mRNA levels were expressed as the ratio of the values of the H2 receptor mRNA signals and the
corresponding ~-actin signals.
Analysis of H2 receptor mRNA stability H2 receptor mRNA levels were determined after incubation of the
CHOrH2 cells with actinomycine D to block transcription as described previously (Rodgers et ai., 1985). Cells
were preincubated with or without 100 IJM histamine or with 10 IJM forskolin for 1 hr in DMEM. Thereafter,
actinomycin D (10 ~g/ml) was added. Cells were harvested from 0 to 90 mins after addition of actinomycin D.
Total RNA was extracted at each time point and H2 receptor mRNA was-quantified by means of the mRNA slot
blot assay as described above.
Chemicals Histamine dihydrochloride, isobutylmethylxanthine (illMX), cyclic AMP (cAMP), forskolin, 1,9
dideoxyforskolin, cholera toxin and GTPyS were obtained from Si~ma Chemical Company (USA). Actinomycin
D was purchased from Boehringer (Mannheim, Gennany). [2,8- H]-cAMP (40 Cilmmol) was obtained from
Amersham. Dimaprit dihydrobromide, homo- and nordimaprit dihydrochloride, amthamine dihydrobromide,
amselamine dihydrobromide and aminopotentidine were taken from laboratory stock. Gifts of cimetidine
(SmithKline Beecham, United Kingdom), ranitidine dihydrochloride (Glaxo, United Kingdom), tiotidine (Imperial
Chemical Industries, United Kingdom), CHO cells expressing the rat H2 receptor and pSVrH2 vector (Dr J.C.
Schwartz) are greatly acknowledged.
Statistical analysis All data shown are expressed as mean ± standard error (mean ± s.e.mean) of at least three
independent experiments. Statistical analysis was carried out by Student's t-test P-values < 0.05 were considered
to indicate a significant difference.
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Results
Histamine-induced H2 receptor downregulation
Exposure of CHOrH2 cells (Traiffort et at., 1992) to 100 IlM of histamine for prolonged
periods of time resulted in a time-dependent decrease of [1251]-iodoaminopotentidine ([1251]_
APT) binding (Fig. 1A). Maximum reduction of [1251]-APT binding was observed after 16
hrs incubation of cells with 100 IlM of histamine. Under this condition, histamine induced 44
± 10% (p < 0.05) reduction of [1251]-APT binding. Half maximum reduction of the [1251]_
APT binding was recorded at an incubation period of approximately 7 hrs. A 24 hrs incubation
of CHOrH2 cells with increasing concentrations of histamine led to a dose-dependent reduction
of [1251]-APT binding (EC50 value =18 ±6 nM, mean ±s.e.mean, n =7) (Fig. 1B). The
observed reduction of [1251]_APT binding was not reflected by a change in affinity of [1251]_
APT for the H2 receptor, as its dissociation constant (Kct), determined by means of saturation
studies, remained unaffected in CHOrH2 cells incubated with 100 IlM histamine for 24 hrs
(Table 1). Exposure of CHOrH2 cells to histamine resulted only in a marked decrease of the
total number of [1251]-APT binding sites (Bmax) (Table 1).
The recently described selective H2 receptor agonists amselamine and amthamine (Eriks et
at., 1992, Van der Goot et al., 1994) induced cAMP production in CHOrH2 cells, with
EC50 values lower and maximal responses comparable to histamine (Table 2). Long-term
exposure (24 hrs) of CHOrH2 cells to 100 IlM of amselamine or 100 IlM of amthamine
resulted in a decrease of [1251]-APT binding of 41 ± 1% and 56 ± 6% respectively. As shown
in Table 2, 24 hrs incubation of CHOrH2 cells with 100 IlM of dimaprit, which generates
cAMP slightly less efficient compared to histamine induced 33 ±7% decrease of [1251]-APT
binding sites. Dimaprit's structural analogues, homodimaprit and nordimaprit showed strongly
reduced capacities to generate cAMP with EC50 values of 1.4 ±0.91lM and higher than 10
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Fig. 1. Time- and dose-dependent decrease of [12SII-APT binding in CHOrH2 cells by histamine. A,
CHOrH2 cells were incubated with 100 J.lM of histamine for the indicated times and [12SI]_APT binding in
membranes was measured. The [12SII-APT binding is expressed as a percentage of [12SI]_APT binding measured
in non-treated cells. The data shown represent the mean ± s.e.mean of 4 independent experiments. B, Dose-
dependent decrease of [12SII-APT binding induced by histamine. CHOrH2 cells were exposed to various
concentrations of histamine for 24 hrs. The data represent the mean ± s.e.mean of 7 independent experiments.
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J.lM respectively (Table 2). The reduced ability of these dimaprit analogues to induce a cAMP
response was paralleled by a lack of H2 receptor downregulation after 24 hrs incubation of
CHOrH2 cells with 100 J.lM of the analogues (Table 2).
Table 1 Characteristics of the [125I]_APT binding to the rat histamine H2 receptor expressed in CHO cells
pretreated for 24 hrs with or without histamine or forskolin
[125I]-APT binding
pretreatment 24 hrs
control
histamine (100 IJM)
forskolin (10 IJM)
K<J
(nM)
0.43 ± 0.06
0.42 ± 0.05
0.29 ± 0.03 *
Bmax
(fmoUmg protein)
975 ± 12
468 ± 129 *
324± 59 *
The dissociation constant (K<J) and maximum number of binding sites (Bmax) were determined using non-linear
fitting according to a one-site binding mode. The data shown represent the mean ± s.e.mean of 3 independent
experiments. The asterisk indicates a significant difference (p < 0.05) from control, represented by untreated cells
Table 2 EC50-values and the percentage'ofmaximally-induced production <Emax) of different H2 agonists for
production of cAMP and the effect of 24 hrs incubation of these compounds (100 IJM) on [1251]-APT binding
in CHOrH2 cells
cAMP response
EC50 %Emax % downregulation
histamine 66.1 ± 29.1 nM l00± 4 41 ±6 *
amselamine 14.5 ± 5.9 nM 88 ± 10 41 ± 1 *
amthamine 5.3 ±0.7 nM 89 ± 6 56± 6 *
dimaprit 0.20 ± 0.07 J.lM 122± 8 33± 7 *
nordimaprit >10 J.lM 70±3# 7±9
homodimaprit 1.35 ± 0.85 J.lM 38± 1 11 ± 5
Data of the Emax values are shown as a percentage of the histamine (100 J.lM)-induced response. The effect of
24 hrs of incubation of CHOrH2 cells with the different compounds on [125I]_APT binding is expressed as the
percentage of H2 receptor downregulation. The data shown represent the mean ± s.e.mean of4 to 8 independent
experiments. The asterisk indicates a significant difference (p < 0.05) from control, represented by non-treated
cells. #; The Emax value of nordimaprit was determined using a concentration of 1 mM.
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Role ofcAMP in the process ofH2 receptor downregulation
Forskolin, which directly activates adenylyl cyclase, dose-dependently induced the formation
of cAMP in CHOrH2 cells (Fig. 2A). Prolonged exposure (incubation periods ranging from 4
to 32 hrs) of CHOrH2 cells with 10~ of forskolin led to a marked reduction of 58 ±2% of
[125I]-APT binding (Fig. 2B). Again, no major change in affinity of [125I]-APT for the H2
receptor was apparent, only a decrease in Bmax was observed when CHOrH2 cells were
incubated for 24 hrs with 10~ offorskolin (Table 1). Maximum and half-maximum down-
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Fig. 2. Forskolin- and 1,9-dideoxyforskolin-induced cAMP production and decrease of [125I]_APT binding in
CHOrH2 cells. A, Dose-dependent increase of the cAMP production by forskolin (filled circles) and 1,9-
dideoxyforskolin (open circles). CHOrH2 cells were incubated with the indicated drugs with increasing
concentrations for 10 mins at 37°C in DMEM in the presence of 300 ~M of IBMX and 25 mM of Hepes, pH
7.4. Data represent the mean ± s.e.mean of 6 independent experiments. B, Forskolin-induced decrease of [1251]_
APT binding in CHOrH2 cells. CHOrH2 cells were incubated with 10~ of forskolin for the indicated times
and [125I]_APT binding was measured. The [125I]_APT binding is expresseq as a percentage of [125I]_APT
binding measured in non-treated cells. C, Dose-dependent decrease of [125I]_APT binding in CHOrH2 cell
membranes induced by forskolin. CHOrH2 cells were exposed to various concentrations of forskolin for 24 hrs.
The H2 receptor density was determined as described. D, Effect of 1,9 dideoxyforskolin and forskolin on [1251]_
APT binding. CHOrH2 cells were exposed to 1 and 10~ of 1,9 dideoxy forskolin (filled bars) and forskolin
(open bars) respectively for 24 hrs and examined for [125I]_APT binding. The asterisk indicates a significant
difference (p < 0.05) from control, represented by the [125I]_APT binding measured in untreated cells. Data from
B, C and D were calculated as mean ± s.e.mean from 4 independent experiments.
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regulation was recorded after 16 hrs and approximately 7 hrs of incubation of CHOrH2 cells
with 10 IlM forskolin respectively (Fig. 2B). The H2 receptor binding sites appeared to be
dose-dependently downregulated by increasing concentrations of forskolin, with an ECSO
value of 0.3 ± 0.06 IlM (mean ± s.e.mean, n = 4) (Fig. 2C). Concentrations up to 10 IlM of
the inactive analogue 1,9-dideoxy-forskolin, which does not generate cAMP in CHOrH2 cells
(Fig. 2A), did not attenuate the H2 receptor density after 24 hrs of pretreatment (Fig. 2D).
Cholera toxin (CTX), which irreversibly activates theGs protein, thereby generating
cAMP, also induced a dose-dependent decrease of [12SI]-APT binding sites when incubated
for 24 hrs (ECSO = 32 ± 1 ng/ml, mean ± s.e.mean, n=4, Fig. 3). CTX pretreatment of
CHOrH2 cells resulted in a maximum downregulation of H2 receptors of 46 ± 3%. Finally,
exposure of CHOrH2 cells for 24 hrs to 300 IlM of ffiMX, a cAMP phosphodiesterase
inhibitor, also resulted in an attenuation of [12SI]-APT binding (26 ± 7% H2 receptor
downregulation, n = 4, mean ± s.e.mean, p < O.OS).
H2 receptor mRNA levels and stability in control, histamine-treated andforskolin-treated
CHOrH2 cells
Exposure of CHOrH2 cells to 100~ of histamine for increasing periods of time resulted in a
rapid transient decrease of H2 receptor mRNA (maximal reduction of 71 ± 4%, mean ±
s.e.mean, n = 4) (Fig. 4). This effect was at its peak after 4 hrs of incubation of cells with
histamine (l00 IlM), while the amount of H2 receptor mRNA returned to approximately SO%
of control after 12 hrs of histamine-treatment. Long-term incubation of CHOrH2 cells with 10
IJ.M of forskolin also induced a time-dependent transient decrease (maximal reduction: 7S ±7%
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Fig. 3. Effect of long-term treatment with CTX on [125I]_APT binding in CHOrH2 celIs. The CHOrH2 cells
were treated with increasing concentrations ofCTX for 24 hrs. [125I]_APT binding is expressed as a percentage
of [125I]_APT binding measured in non-treated cells studied under the same conditions and was measured as
described earlier. The data shown represent the mean ± s.e.mean of4 independent experiments.
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mean ± s.e.mean, n = 4) of H2 receptor mRNA to levels similar to those observed after
histamine-treatment (Fig. 4).
To study the role of mRNA stability CHOrH2 cells were incubated for 1 hr in the absence
or presence of histamine (100 11M) or forskolin (10 JlM), whereafter actinomycin D (10 l1g1ml)
was added to block mRNA transcription. Cells were collected at different time intervals ranging
from 0 to 90 mins after addition of actinomycin D and were analyzed for H2 receptor mRNA
content The H2 receptor mRNA in non-treated cells was hardly affected during the 90 mins of
incubation with actinomycin D (Inset Fig. 4). Incubation of cells with 100 11M of histamine,
however, resulted in a significant breakdown of H2 receptor mRNA levels (Inset Fig. 4).
Similar results were obtained after forskolin treatment (Inset Fig. 4).
As can be seen in Fig. 4, 4 hrs of incubation of cells with 100 11M of histamine resulted in
a marked downregulation (71 ± 4%) of the H2 receptor mRNA, whereas after 4 hrs of
incubation of CHOrH2 cells and direct measurement of (125I]-APT binding no significant
downregulation of H2 receptors was observed (Fig. 1A).Yet, when CHOrH2 cells were
incubated with 100 IlM of histamine for 4 hrs, extensively washed and further incubated in
serum-free medium without histamine for another 20 hrs, a significant reduction of 60 ± 1%
(mean ± s.e.mean, n = 4) of the H2 receptor binding sites was observed.
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Fig.4. Histamine- and forskolin-induced modulation of HZ receptor mRNA levels. CHOrHZ cells were
incubated for the indicated times with 100 11M of histamine (filled circles) or 1O!JM of forskolin (open circles)
and mRNA quantified by means of a RNA slot blot assay as described under "Experimental procedures". The
results are the mean ± s.e.mean of two separate experiments, performed in duplicate. Inset, Effect of histamine-
treatment and forskolin-treatment 011 HZ receptor mRNA stability. CHOrHZ cells were incubated with (open
circles) or without (open squares) 100 11M of histamine or with 10 !JM of forskolin (filled squares) for 1 hr,
before actillomycin D (10 I1g/ml) was added. Cells were harvested at 0, 15, 30,60 and 90 mins after the additioll
of actinomycin D. The data are the mean ± s.e.mean of three experiments, each performed in duplicate. The
asterisk indicates a sigllificant difference (p < 0.05) from cOlltrol, represented by untreated cells.
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Fig. S. Schematic representation of the rat histamine H2 receptor. The leucine (1.) at position 124, located in
the second intracellular loop, was mutated to an alanine (A) by site-directed mutagenesis as described under
Materials and methods.
Functional analysis ofthe Leu124Ala mutation ofthe rat histamine H2 receptor
Using the polymerase chain reaction the leucine124 in the second intracellular loop of the rat
histamine H2 receptor (Fig. 5) was mutated into an alanine residue. Transfection of the
H2Leu124Ala receptor eDNA into CHO cells. resulted in the formation of several clonal cell
lines expressing [125I]-APT binding sites. A clonal cell line expressing amounts of [125I]_
APT binding comparable to those of the CHOrH2 cells was chosen for further analysis and
referred to as CHOrH2Leu124Ala (CHOrH2 cells: 975 ± 12 fmoUmg of protein,
CHOrH2Leu124Ala cells: 980 ±7 fmoUmg of protein, mean ±s.e.mean, n = 3). There were
no major differences in the binding of the H2 antagonists to the wild-type receptor or the
mutated receptor. The affinity of [125I]-APT for the mutatedi:eceptor was hardly affected (Kct
of [125I]-APT in CHOrH2 cells: 0.43 ± 0.06 nM, in CHOrH2Leu124Ala cells: 0.61 ± 0.03
nM, mean ± s.e.mean, n =3). Moreover, cimetidine and ranitidine had similar Ki values for
both receptors (Table 3). In contrast, the introduced Leu124Ala mutation significantly affected
the agonist binding characteristics. In CHOrH2 cells, histamine displacement curves were
shallow and could be analysed best by a two site model (Fig. 6, Table 3). The addition of 10
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~ GTPyS resulted in a steepening and a right-ward shift of the histamine displacement curve,
which could be analysed best by a single site model with a Ki value of 0.18 ± 0.02 mM (Fig.
6). In CHOrH2Leu124Ala cells, however, the displacement curve of histamine was analysed
best by a single site model, leading to a Ki value (0.21 ± 0.02 mM) that corresponded to the
low affinity site of the wild-type receptor (Fig. 6, Table 3). The addition of 10 JlM of GTPyS
did not result in a right-ward shift of the displacement curve of histamine (Fig. 6, Table 3).
Moreover, the Leu124Ala mutation also affected the ability of histamine to induce the
formation of cAMP in CHOrH2Leu124Ala cells (fig. 7A). The EC50 value of the histamine-
induced cAMP response in CHOrH2Leu124Ala cells was approximately 162-fold higher (11 ±
3 JlM, mean ± s.e.mean, n = 7) than the observed EC50 value of the histamine-induced cAMP
response in CHOrH2 cells (66 ±29 nM, mean ±s.e.mean, n = 6) measured under the same
conditions. The maximum histamine-induced reponse was also found to be affected in
CHOrH2Leu124Ala cells (Emax in CHOrH2 cells: 40 ± 4 pmol/well, Emax in
CHOrH2Leu124Ala cells: 18 ± 1 pmol/well).
Histamine-induced downregulation ofrat H2 Leu124Ala receptors
Long-term exposure (24 hrs) of CHOrH2Leu 124Ala cells to increasing concentrations of
histamine resulted in a dose-dependent reduction of [1251]-APT binding sites (Fig. 7B).
Whereas in CHOrH2 cells an EC50 of 18 ±6 nM (mean ±s.e.mean, n = 7) was observed for
histamine, in CHOrH2Leu124Ala cells histamine induced downregulation with an EC50 value
of 288 ± 89 nM (mean ± s.e.mean, n = 4). Comparing the histamine-induced cAMP
production and H2 Leu124Ala receptor downregu1ation (Fig. 7B), a discrepancy in dose-
relationships is observed. Almost 40-fold higher concentrations of histamine are required to
induce cAMP production, compared to receptor downregulation. Pretreatment of
CHOrH2Leu124Ala cells for 24 hrs with 1 JlM of histamine resulted in a significant degree of
H2 receptor downregulation (51 ± 2%, mean ± s.e.mean, n = 4), whereas no significant
cAMP production was observed after 10 mins of incubation (Fig 7B). Also after 24 hrs of
incubation of CHOrH2Leu124Ala cells with 1 JlM of histamine, no significant increase in
cAMP was observed (M.J. Smit, unpublished observations). Moreover, even at 0.1 ~ of
histamine significant H2 receptor downregulation was observed. The mRNA levels of the
H2Leu124Ala mutant were not decreased upon 24 hrs incubation with 1~ of histamine (101
± 19% vs non-treated cells, mean ± s.e.mean, n = 4). A 24 hrs incubation of CHOrH2 cells
with 1~ of histamine, on the other hand, resulted in a significant decrease of H2 receptor
mRNA levels (45 ± 2% vs non-treated cells, mean ± s.e.mean, n=4).
In the CHOrH2Leu124Ala cells the maximum histamine-induced downregulation was more
pronounced (68 ± 4%, mean ± s.e.mean, n = 4) than was observed for the CHOrH2 cells (43
±4%, mean ± s.e.mean, n = 7). The forskolin (10 JlM)-induced H2 receptor downregu1ation
was also found to be more pronounced in the CHOrH2Leu124Ala cells (67 ± 1%, mean ±
s.e.mean, n = 3) than in CHOrH2 cells (58 ± 2%, mean ± s.e.mean, n = 4).
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Table 3 Pharmacological characterization of [1251]_APT binding to CHOrH2 and CHOrH2Leu124Ala cell
membranes
compounds
cimetidine
ranitidine
histamine
+ 10~ GTPyS
804± 53 nM
232±45 nM
Ki, high = 3.5 ± 1.0~ (39 ± 7%)
Ki, low =0.24 ± 0.04 mM (61 ± 7%)
0.18 ± 0.02 mM (100%)
766± 73 nM
173 ± 20 nM
0.21 ± 0.02 mM (100%)
0.23 ± 0.03 mM (100%)
Membranes of CHOrH2 and CHOrH2Leu124Ala cells were incubated with 0.3 nM [1251]_APT in the presence
of the indicated drugs at increasing concentrations. Ki values were obtained from the respective IC50 values.
Data shown are mean ± s.e.mean from at least three independent experiments. Values in parentheses indicate the
relative densities of the high/low affinity binding site.
120
~ 100
:a
.S 80
.0
~ 60
I
;:::;'
'" 40M
"t....o
~ 20
o+--r--r--r--r--r--r--r--r--r--r--r---r--..--
-8 -7 -6 -5 -4 -3 -2 -1
log [histamine]
Fig. 6. Binding of histamine to the wild-type and H2Leu124Ala receptor. Displacement of binding of 0.3 nM
of [1251]_APT by increasing concentrations of histamine in the presence (open symbols) and absence (filled
symbols) of 10 J.lM of GTPyS in CHOrH2 cells (circles) and CHrH2Leu124Ala cells (squares). Mean values of
triplicate determinations of a typical experiment out of at least three are shown.
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Fig. 7. Effects of Leu124Ala mutation on histamine-induced cAMP production and downregulation. A, Dose-
dependent increase of the cAMP production by histamine in CHOrH2 cells (filled circles) and
CHOrH2Leu124Ala cells (open circles). Cells were incubated with increasing concentrations of histamine for 10
mins at 37°C in DMEM in the presence of 300~ of mMX and 25 mM of Hepes, pH 7.4. The data shown
represent the mean ± s.e.mean for respectively, 6 and 7 independent experiments. B, Effects of Leu124Ala
mutation on histamine-induced H2 receptor downregulation (open circles) and cAMP production (filled circles,
see also above). CHOrH2Leu cells were exposed to increasing concentrations of histamine for 24 hrs and [1251]_
APT binding in membranes was measured. The [1251]_APT binding is expressed as a percentage of [125I]_APT
binding measured in non-treated cells. The data shown represent the mean ± s.e.mean of 4 experiments. The
asterisk and # indicate a significant difference (p < 0.05) from control, represented by untreated cells and basal
cAMP levels respectively.
Discussion
So far studies addressing regulation of the histamine H2 receptor function have focused in
particular on rapid agonist-induced desensitization. These reports show that the histamine H2
receptor is rapidly desensitized upon agonist exposure (Arima et al., 1993, Fukushima et aI.,
1994, Smit et aI., 1994). In contrast, no information is available on molecular mechanisms
operating after prolonged periods of time (hours) of agonist stimulation.
In the present study we have demonstrated that the rat histamine H2 receptor density in
CHO cells is reduced about 50% by long-term exposure to histamine or selective H2 agonists.
Long-term treatment ofCHOrH2 cells with histamine resulted in a time-dependent (t1l2 "" 7 hrs
at a concentration of 100 11M) and dose~dependent (EC50 =18 nM at 24 hrs of incubation)
decrease in the number of H2 receptor binding sites. Yet, incubation of CHOrH2 cells with
homo- and nordimaprit, two side chain homologues of the H2 agonist dimaprit with weak H2
agonistic activity «Sterk et al., 1987, present study), did not significantly reduce the number
of H2 receptors. These findings show that the observe.d H2 agonist-induced downregulation is
a H2 receptor-mediated process.
As was found for the ~2-adrenergic receptor (~2AR) (Bouvier et aI., 1989), a cAMP-
dependent pathway can also regulate the H2 receptor density. Forskolin, generating cAMP
upon addition, time-dependently (t1l2 "" 7 hrs at a concentration of 10 11M) and dose-
dependently (EC50 = 0.3 11M at 24 hrs of incubation) induced H2 receptor downregulation.
CTX and IBMX, agents that also elevate intracellular levels of cAMP in CHOrH2 cells,
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induced downregulation of the H2 receptor as well. Thus, the H2 receptor does not need to be
stimulated by an agonist in order to be downregulated. This mechanism might be involved in
heterologous H2 receptor downregulation as previously shown for other GPCRs (see for
references Collins, 1993, Lohse, 1993). The time course of the forskolin-induced decrease of
H2 receptor number in CHOrH2 cells parallels the time-dependent decrease of H2 receptors
induced by histamine. For both histamine and forskolin, half-maximum H2 receptor
downregulation is reached after approximately 7 hrs of incubation. Moreover, the maximum
decrease ofH2 receptor numbers induced by forskolin is comparable to the maximum agonist-
mediated H2 receptor downregulation.
Agonist-induced receptor downregulation is a commonly occurring regulatory process of
the large family of GPCRs (see for references reviews Collins, 1993, Lohse, 1993).
Enhanced degradation and/or decreased synthesis of the receptor protein are thought to
contribute to receptor downregulation (Collins, 1993, Lohse, 1993). Agonist-induced
downregulation of GPCRs is often accompanied by a decline of receptor mRNA levels,
presumably contributing to the overall reduction in receptor number and responsiveness
(Hadcock and Malbon, 1993). Indeed, incubation of CHOrH2 cells with histamine or
forskolin resulted in a transient decrease of H2 receptor mRNA levels (70% reduction) within 4
hrs, which was followed by a gradual increase of H2 receptor mRNA to 50% of control
mRNA levels in the following hours. The initial 70% reduction of H2 receptor mRNA is
sufficient to explain the 50% reduction of the H2 receptor numbers, since a relatively short 4
hrs treatment of CHOrH2 cells with histamine followed by 20 hrs of wash-out already led to
50% H2 receptor downregulation. The reduced H2 receptor mRNA levels, 50% of the control
levels, at later time points represent a new steady-state level of receptor mRNA to maintain the
downregulated state of H2 receptors. The reduction of H2 receptor mRNA is most likely
explained by post-transcriptional events, such as receptor mRNA destabilization. For e.g. the
~2AR and thrombin receptor in DDTIMF-2 smooth muscle cells, the endothelin ETB receptor
in ROSI7/2 rat osteosarcoma cells, and also for the ~2AR and muscarine ml receptor
expressed into CHW and CHO cells respectively, the decline in receptor mRNA has been
ascribed to destabilization of the mRNA (Bouvier et ai., 1989, Hadcock and Malbon, 1989,
Lee et al., 1994, Sakurai et ai., 1992, Tholanikunnel et al., 1995). In the presence of
actinomycin D, breakdown of the H2 receptor mRNA in CHOrH2 cells was significantly
stimulated upon histamine-treated and forskolin-treatment compared to non-treated cells.
Recently, it was shown that a so-called Mr 35,000 ~-adrenergic receptor mRNA-binding
protein (~-ARB), involved in the destabilization of ~2-adrenergic receptor mRNA, also
recognizes other GPCR transcripts (Tholanikunnel et al., 1995). As such, our observations of
H2 receptor mRNA destabilization fits well in an apparently general mechanism of ~-ARB­
mediated regulation of GPCR mRNA (Port et al., 1992, Tholanikunnel et ai., 1995).
For the ~2AR, the most extensively studied GPCR, receptor downregulation is ascribed to
two pathways: an agonist-dependent, PKA-independent, and a PKA-dependent process
(Collins, 1993, Lohse, 1993). Evidence for a PKA-independent pathway was obtained by
studies which showed unaffected profiles of ~2AR downregulation in mutant S49 mouse
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lymphoma cells defective in signal transduction components (Allen et al., 1989, Mahan et
al.• 1985, Shear et al.• 1976, Su et al.. 1980). Receptor-Gs-coupling seems to be important
for the process of 132AR downregulation, since defects in this coupling introduced by
mutations of the receptor or Gs-protein have lead to impaired 132AR downregulation (Campbell
et al., 1991, Hadcock and Malbon. 1988, Mahan et al., 1985, Shear et al.• 1976, Su et
al., 1980). Agents responsible for the elevation of intracellular levels cAMP, such as forskolin
and IBMX, or cAMP analogues, e.g. dibutyrylcAMP, were shown to induce 132A R
downregulation as well, providing evidence for the existence of cAMP-dependent receptor
downregulation (Bouvier et al.. 1989, Collins, 1993, Hadcock and Malbon, 1988). In
CHW cells the time course of the cAMP-promoted downregulation of the 132AR was much
slower than the 13-agonists-induced downregulation, suggesting that distinct pathways can lead
to downregulation of the 132AR (Bouvier et al., 1989). Yet, PKA-dependent phosphorylation
of the 132AR appears to enhance downregulation, since receptor mutants lacking PKA
phosphorylation sites showed impaired agonist-induced downregulation (Bouvier et al..
1989). Taken together, 132AR receptor downregulation seems to require receptor-Gs coupling
for the initial loss of receptor binding sites, while the cAMP-dependent decrease of receptor
mRNA levels serves to maintain the downregulated state by establishing a new steady-state of
receptor expression (Collins. 1993). The underlying biochemical mechanisms responsible for
each of these events is, however, unclear so far.
In our study on CHOrH2 cells, comparable time courses and a maximum extent of
histamine-induced and forskolin-induced H2 receptor downregulation as well as H2 mRNA
downreguiation suggest the involvement of cAMP in the process of agonist-induced H2
receptor downregulation. In order to assess the role of cAMP in the process of agonist-induced
H2 receptor downregulation, we constructed a mutant H2 receptor which showed impaired G-
protein coupling. Recently, Moro et al. (1993) have shown that hydrophobic amino acids
within a highly conserved GPCR motif DRYXXV(I)XXPL (X is any amino acid and L is
leucine or other lipophilic amino acid) in the second intracellular loop are involved in receptor-
G-protein coupling (Moro et al., 1993). In the H2 receptor protein a DRYCAVTDPL
sequence is found at an equivalent position of the highly conserved motif (Ruat et al., 1991).
Substitution of the Leu124 residue to by an alanine residue had no effect on H2 receptor
expression nor on H2 antagonist binding properties. However, the mutation induced a marked
impairment of the ability of the receptor to physically couple to its G-protein as assessed by
alterations in its agonist-binding parameters (disappearance high affinity binding site, no
detectable GTPyS shift). The physical uncoupling of the H2Leu124Ala mutant was paralleled
by a functional uncoupling, characterized by an impairment of the histamine-induced cAMP
production (160-fold reduction of the EC50 value and 55% decrease of the maximal cAMP
response). These findings are in agreement with the functional uncoupling reported by Moro
et al. (1993) after mutation of a hydrophobic amino acid at similar position in the muscarine
m1, m3 and 132-adrenergic receptor.
Interestingly, long-term exposure of CHOrH2Leu124Ala cells to O.IIlM and IIlM of
histamine, concentrations that do not elicit cAMP production, resulted in a significant
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reduction of [125I]-APT binding sites, indicating that a cAMP-independent pathway is
involved in the observed agonist-induced H2 receptor downregulation in CHOrH2Leu124Ala
cells. Previous findings in mutant S49 mouse lymphoma cells defective in signal transduction
components also showed the existence of cAMP-independent pathways in the agonist-induced
downregulation (Allen et al., 1989, Mahan et al., 1985, Shear et al., 1976, Su et aI.,
1980). However, it should be noted that the EC50 value of histamine-induced-H2 receptor
downregulation was shifted 16-fold to the right for the H2Leu124Ala receptor compared to the
wild-type receptor. These data suggest that agonist-induced H2 receptor downregulation
depends on intact receptor-G-protein coupling. As already stated earlier, previous findings for
the /32AR have shown that defective receptor-Gs coupling leads to impaired receptor
downregulation (Campbell et al., 1991, Hadcock and Malbon, 1988, Mahan et aI., 1985,
Shear et al., 1976, Su et aI., 1980).
Moreover, no decrease in H2Leu124Ala mRNA levels was observed after 24 hrs
incubation of CHOrH2Leu124Ala cells with 1 IlM histamine. These data indicate that the
reduction of H2 receptor mRNA levels in CHO cells is cAMP-dependent, as generally accepted
(Hadcock and Malbon, 1989). Remarkably, both the maximum histamine-induced and
forskolin-induced downregulation of H2Leu 124Ala receptor were found to be more
pronounced than for the wild-type H2 receptor, suggesting that the mutated receptor has
become more susceptible to receptor downregulation. Although we do not have an explanation
for this finding, we hypothesize that the Leu124Ala mutation induces a conformational change
in the second intracellular loop of the H2 receptor protein, causing an uncoupling from the Gs
protein but also an increase of the accessibility of molecular entities involved in receptor
degradation. Recent studies with the parathyroid hormone receptor (Huang et aI., 1995) and
/31-adrenergic receptor (Green and Liggett, 1994) support this hypothesis. Small changes in
the conformation of intracellular receptor domains have been shown to augment receptor
internalization (Green and Liggett, 1994, Huang et al., 1995). Unfortunately, no data on
receptor downregulation are available for these mutant receptors (Green and Liggett, 1994,
Huang et al., 1995).
In conclusion, for the first time we have demonstrated that the histamine H2 receptor is
downregulated by prolonged treatment with H2 agonists. Elevation of cAMP by long-term
incubation of CHOrH2 cells with forskolin, CTX and IBMX, is also shown to induce H2
receptor downregulation. These data suggest the involvement of protein kinase A in the process
of H2 receptor downregulation and provides a mechanism for heterologous H2 receptor
regulation. Also H2 receptor mRNA levels were rapidly downregulated upon both histamine-
treatment and forskolin-treatment, thereby contributing to the observed decrease of H2 receptor
binding sites. Substitution of the hydrophobic amino acid leucinel24, located within the highly
conserved G-protein coupling motif DRYXXV(I)XXPL in the second intracellular loop of the
H2 receptor, by an alanine generated a mutant receptor with impaired ability to couple to its G-
protein. Interestingly, the H2 Leu124Ala mutant receptor was still downregulated by
histamine, at concentrations which showed no increase of cAMP, thereby providing evidence
for a cAMP-independent pathway in the process of agonist-induced H2 receptor
Downregulation ofthe H2 receptor 107
downregulation. Thus, H2 receptor downregulation appears to be induced by two distinct
pathways, a cAMP-dependent and cAMP-independent pathway.
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The C-terminal tail of the histamine H2 receptor
contains positive and negative signals important for
signal transduction and receptor regulation
M. J. Smit, H. Timmerman, J. Blauw, M. W. Beukers, E. Roovers and R. Leurs
In the present study we constructed 3 different truncated HZ receptor mutants to examine the role of the C-
terminal tail in HZ receptor regulation. Stable transfection of HZ receptor mutants, truncated at position 307 and
341 (HZT307 and HZT341), in Chinese Hamster Ovary (CHO) cells resulted in detectable [IZ51]_
iodoaminopotentidine ([ IZ51]_APl) binding, whereas no detectable [IZ51]_APT binding of the HZ receptor
truncated at position Z95 (HZT295) was observed in CHO nor after transient transfection in HEK-Z93 cells.
Thus the amino acids prior to position 307 appear to be necessary for proper receptor transport or folding.
Ligand binding properties of the tested HZ antagonists and histamine (formation of a ternary complex) and
histamine-induced signalling were not affected by truncation of the C-terminal tail by 51 amino acids,
supporting previous findings that the ligand binding domain mainly resides in the transmembrane domains of
the HZ receptor protein. Yet, removal of only 17 amino acids of the C-terminal tail generated a mutant receptor
(HZT341) which was able to form a ternary complex but was unable 10 fully activate the Gs-protein upon
histamine exposure (70% reduction of the maximal histamine-induced cAMP response).
Desensitization, characterized by attenuated production of cAMP upon increase of the histamine incubation
time, was not affected by C-terminal tail truncation of the HZ receptor, suggesting that the serine and threonine
residues in the C-terminal tail are not implicated in the mechanism underlying short-term HZ receptor
desensitization. Truncation of the C-terminal tail of the HZ receptor by 51 amino acids, in contrast to most
other GPCRs resulted in the generation of a mutant HZ receptor (HZT307) which was more susceptible to
agonist-induced receptor dowuregulation, but not to the cAMP-dependent HZ receptor dowuregulation. These data
indicate that the cAMP-dependent and independent pathways of HZ receptor dowuregulation appear to be mediated
by different regulatory processes. Taken together, in this study we identified regions in the C-terminal tail of the
HZ receptor, which appear to act as positive and/or negative signals in HZ receptor signalling and HZ receptor
regulation.
Introduction
Recent studies have shown that the histamine H2 receptor, like other G-protein coupled
receptors (GPCRs), is susceptible to receptor regulation (Arima et ai., 1993, Fukushima et
al., 1994, Smit et ai., 1994, Chapter 4, 5). At least three mechanistically and temporarily
distinct processes contribute to the overall phenomenon of desensitization of the GPCRs
(Collins, 1993, Lohse, 1993, Savarese and Fraser, 1992). The first involves a rapid (sees to
mins) uncoupling of these receptors from their effector system (desensitization), the second is
characterized by the translocation of these receptors away from the cellular surface within
minutes (internalization) and the third is characterized as a reduction of receptor binding sites
occurring after hours of agonist exposure (downregulation) (for references see reviews
Collins, 1993, Lohse, 1993, Savarese and Fraser, 1992).
In view of the potential use of H2 agonists in patients sufferering from congestive heart
failure (Felix et ai., 1991) detailed investigation of H2 receptor regulation has gained interest.
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However, knowledge regarding H2 receptor regulation is limited and has only recently become
available. The endogenous histamine H2 receptor in the human U937 lymphoma cell line and
the human gastric carcinoma cell line MKN-45 as well as the canine H2 receptor expressed in
Chinese Hamster Ovary cells (CHO cells) were found to undergo rapid receptor desensitization
upon agonist exposure (Arima et al., 1993, Fukushima et al., 1994, Smit et al., 1994).
Furthermore, long-term exposure of the rat histamine H2 receptor expressed in CHO cells to
histamine was shown to result in dose- and time-dependent H2 receptor downregulation
(Chapter 5). The process of agonist-induced H2 receptor downregulation appeared to be
mediated both by cAMP-dependent and cAMP-independent pathways, as was shown by
studies with H2 receptor mutants (Chapter 5).
The molecular entities and H2 receptor domains involved in H2 receptor regulation are still
unknown. Yet, the involvement of various domains and specific amino acids in GPCR
regulation has been studied for several other members of the family of GPCRs. In particular
the third intracellular loop and the C-terminal tail of the GPCRs are important for receptor
regulation (see reviews Collins, 1993, Lohse, 1993, Savarese and Fraser, 1992). These
domains contain various serine 'and threonine residues which may serve as potential
phosphorylation sites for serine/threonine kinases. Phosphorylation of serine and threonine
residues in the carboxyl terminal region of many GPCRs by specific receptor kinases and in the
third intracellular loop and/or carboxyl terminus by second messenger-dependent kinases is
thought to direct rapid uncoupling from the signal transduction pathway (Bouvier et al., 1988,
Hausdorff et al., 1989, Hausdorff et al., 1991, Lattion et al., 1994, Liggett et al., 1989,
Roth et al., 1991, Takano et al., 1994). Also for agonist-induced receptor internalization the
importance of serine/threonine-rich regions in the C-terminal tail of the GPCRs has been
reported, suggesting that a phosphorylation-driven mechanism participates in this process
(Benya et al., 1993, Hausdorff et al., 1991, Hunyady et al., 1994, Nussenzveig et al.,
1993, Thomas et al., 1995). Finally, the C-terminal tail of many GPCRs appears to be an
important structural determinant for the process of receptor downregulation. Truncation or site-
directed mutagenesis of serine-, threonine- or tyrosine residues of the C-terminal tail of, for
example, the ~2-adrenergic receptor and muscarine m3 receptor were shown to decrease the
rate of receptor downregulation (Bouvier et al., 1989, Campbell et al., 1991, Cheung et al.,
1989, Valiquette et al., 1990, Yang et al., 1993). In addition, isoforms of the somatostatin
(mSSTR2A and mSSTR2B) (Vanetti et al., 1993) or of the prostaglandin E2 receptor (EP3a
and EP3~)' which differ in their C-terminal tail (Negishiet al., 1993), showed different
patterns of receptor downregulation upon exposure to the respective agonist The role of the C-
terminal tail in receptor downregulation appears to be complex. For the avian ~l-receptor the
C-terminal tail seems to prevent receptor downregulation as truncation of the receptor
eliminates the insensitivity of the ~l-adrenergic receptor towards receptor downregulation
(Hertel et al., 1990, Parker and Ross, 1991).
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In view of the above findings the C-terminal tail should be considered as an important
structural domain for GPCR regulation. Especially serine/threonine containing domains appear
to be involved in the various processes of GPCR regulation (Benya et ai., 1993, Bouvier et
ai., 1988, Bouvier et ai., 1989, Hausdorff et ai., 1989, Hausdorff et ai., 1991, Hunyady
et ai., 1994, Liggett et ai., 1989, Nussenzveig et ai., 1993, Roth et ai., 1991, Thomas et
ai., 1995, Yang et ai., 1993). Since the H2 receptor contains 11 serine and threonine residues
in the C-terminal tail, we found it tempting to speculate that this structural element is involved
in the observed H2 receptor regulation. We therefore constructed three receptor mutants
truncated at different positions of the C-terminus and we stably expressed them in CHO cells
(Fig. 1). The H2 receptor mutant truncated at position 295 lacks all serine/threonine residues
localized in the C-terminus of the receptor, whereas the H2 receptor mutant truncated at
positions 307 and 341 lack 10 and 3 of these residues respectively. Using these receptor
mutants we first examined whether truncation affected ligand binding and the H2 receptor-
mediated signal transduction. Various reports have shown that C-terminal truncation resulted in
decreased G-protein coupling (Josiah et ai., 1994, Kosugi and Mori, 1994, Ohyama et ai.,
1992, Sasakawa et ai., 1994), whereas others showed no effect on ligand binding nor signal
transduction (Benya et ai., 1993, Bouvier et ai., 1988, Koch et ai., 1994, Nussenzveig et
ai., 1993, Thomas et ai., 1995, Zhu et ai., 1993). Finally, we examined whether the C-
terminus of the H2 receptor is a structural domain crucial for agonist-, cAMP-independent as
well as cAMP-induced receptor regulation.
Materials and methods
Cell culture CHO cells expressing the rat histamine H2 receptor (CHOrH2) (Traiffort et al., 1992) and the
truncated Hi receptors (CHOrH2TI41 and CHOrH2TI07) were grown at 37°C in a humified atmosphere with
5% CO2 in Dulbeco's Modified Eagle's Medium (DMEM), containing 10% (vol/vol) dialyzed foetal calf serum
and supplemented with 2 mM L-glutamine, MEM amino acids, 50 IU/ml penicillin and 50 Ilg/ml streptomycin.
Site-directed mutagenesis eDNA's encoding truncated H2 receptor proteins were constructed by means of the
Polymerase Chain Reaction (PeR), using the gene of the rat H2 receptor as a template (Ruat et aI., 1991).
Different 3' primers were designed to introduce a stop-codon at the desired position (amino acid position 295,
307 and 341) followed by a BglII site. The oligonucleotide SI (5'-GGGAAGCTTGGCCCCAGAATGGA-
GCCCAATGGCACAGT), corresponding to nucleotides -9 to 21 (Ruat et al., 1991) and a HindIll site
(underlined) and oligonucleotides, AT341 (5' -CGGAGATCTTTAGAGCTTCAAGGGCTTCTCCTC),
corresponding to nucleotides 1003-1026 of the complementary strand, ATI07 (5' -CGGAOATClTrATGCGA-
ACTTGCAGTGGAAGAG), corresponding to nucleotides 901-921 of the complementary strand and AT295 (5'-
CGGAGATCTTTAGCGGAAGTCTCTGTTGAGAGC), corresponding to nucleotides 865-885 of the
complementary strand, all containing a BglII site (underlined) with one or two nucleotide changes to introduce a
stop codon were synthesized on an Applied Biosystems DNA synthesizer (model 381A). Using 100 ng pSVrH2
(Traiffort et al., 1992) as a template, 0.4 JlM SI, 0.4 JlM AT341, 200 JlM dNTP's and 2.5 U Amplitaq
(Perkin Elmer) a 1035 bases DNA fragment of the H2TI41 receptor mutant was amplified in 100 Jll using 20
cycles at 95°C for 1 min, 56°C for 1 min and noc for 1 min and a fmal extension at noc for 10 mins. Similar
conditions were used to amplify respectively a 930 and 894 bases fragment for the construction of the H2T307
and H2T295 receptor mutants. The obtained PeR products were gel-purified and restricted with HindlIl/BglllI
(Boehringer) and cloned into the plasmid pSP73 (Promega) in order to verify the complete nucleotide sequence
using the dideoxy-chain termination method with the Sequenase kit (USB). Subsequently, the coding sequence of
H2T341, H2T307 and H2T295 receptor was subcloned into the eukaryotic pSV expression vector. CHO cells,
deficient in dihydrofolatc reductase, were stably transfected with 15 Ilg expression vectors pSVrH2T341,
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pSVrH2T307 and pSVrH2T295 using Transfectam (Promega).
Biochemical measurements The determination of H2 receptor binding and levels of cAMP were performed as
described in Chapter 5.
RNA slot blot analysis RNA was analyzed as described in Chapter 5.
Statistical analysis All data shown are expressed as mean ± standard error (mean ± s.e. mean) of at least three
independent experiments. Statistical analysis was carried out by Student's t-test. P-values < 0.05 were considered
to indicate a significant difference.
Chemicals Histamine dihydrochloride, isobutylmethylxanthine (IDMX), cyclic AMP (cAMP), forskolin, were
obtained from Sigma Chemical Company (USA). [2,S)H]-cAMP (40 Cilmmol) was obtained from Amersham.
Aminopotentidine was taken from laboratory stock. Gifts of cimetidine (SmithKline Beecham, United Kingdom)
and ranitidine dihydrochloride (Glaxo, United Kingdom) are gratefully ackJiowledged.
Results
Pharmacological characterization ofthe trU1U:ated H2 receptor mutants
A series of cDNAs, encoding rat histamine H2 receptor proteins truncated at the C-terminus
(Fig. 1), were constructed by PCR and stably expressed in CHO cells as described in the
section "Methods". Individual clones were isolated and assayed for [125I]-APT binding. With
the exception of the shortest construct (H2T295) the other receptor mutants were functionally
expressed. Transient expression of the H2T295 mutant, inserted into a pRK5 vector, in human
embryonal kidney HEK-293 cells did not show detectable [125I]-APT binding either (data not
shown). H2 mRNA studies, on the other hand, revealed synthesis of H2T295 mRNA in
transiently transfected HEK-293 cells (data not shown). For the other mutants clonal cell lines
expressing comparable amounts of [125I]-APf binding as CHOrH2 cells, expressing the wild-
type rat H2 receptor, were chosen for further analysis and referred to as CHOrH2T341 and
CHOrH2T307.
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Fig. 1. Schematic representation of the rat histamine H2 receptor. The histamine H2 receptor was truncated at
positions 341 (H2T34l), 307 (H2T307) and 295 (H2T295) by insertion of a stop codon by site-directed
mutagenesis as described under "Methods". Solid circles indicate the presence of either a serine or a threonine.
The assumed palmitoylation and membrane anchorage of Cys304 is indicated.
C-terminal truncation ofthe H2 receptor 113
The dissociation constant of [125I]-APT for the truncated receptors (H2T341 and H2T307)
was comparable to that of the wild-type receptor (Table 1). Moreover, the Ki values of
aminopotentidine, cimetidine and ranitidine for the truncated receptors were not significantly
different compared to the wild-type H2 receptors (Fig. 2A, Table 2). The histamine
displacement curves in CHOrH2, CHOrH2T341 and CHOrH2T307 cells were shallow and
could all be best analyzed by a two site model (Table 2, Fig. 2B, C), indicating the presence of
high and low afftnity binding sites. Note, however, that the percentage of high afftnity binding
sites for the H2T341 mutant is signiftcantly increased compared to the wild-type receptor (Fig.
2B, Table 2).
Table 1 Characteristics of [12511_APT binding to CHOrH2. CHOrH2T341 and CHOrH2T307 cell membranes
Kd Bmax
CHOrH2 (nM) (fmolJmg protein)
WI' 0.71 ± 0.08 1172 ± 286
T341 0.60 ± 0.08 616± 195
1'307 0.56 ± 0.12 1041 ± 152
T295 not detectable
The dissociation constant (~) and maximum number of binding sites (Bmax) was determined by using non-
linear fitting according to a one-site binding mode. The data shown represent the mean ± s.e. mean of four
independent experiments.
Table 2 Pharmacological characterization of [125II-APT binding to CHOrH2. CHOrH2T341 and
CHOrHZT307 cell membranes
Ki-value
CHOrHZ CHOrHZT341 CHOrHZT307
aminopotentidine 5.8 ± 0.9 nM 6.4± 1.1 nM 6.6 ± 1.0 nM
cimetidine 804±53 nM 935± 195 nM 837 ± 17 nM
ranitidine Z32±45 nM 194±39 nM 244± 54nM
histamine Ki. high 3.5 ± 1.0~ 4.8 ± 1.5~ 7.7 ± 3.2~
(39 ± 7%) (60± 5%) * (36± lZ%)
Ki.low 0.3 ± 0.04 mM 0.6± O.ZmM 0.4 ± 0.08 mM
(61 ± 7%) (40±5%) * (64± lZ%)
Membranes ofCHOrHZ' CHOrHZT341 and CHOrHZT307 cells were incubated with 0.3 nM [IZ5II-APT in the
presence of the indicated drugs at increasing concentrations. Ki values were obtained from the respective IC50
values. Data shown are mean ± s.e.mean from at least three independent experiments. Values in parentheses
indicate the relative densities of the respective sites. The asterisk indicates a significant difference (p < 0.05)
compared to CHOrHZ cells.
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Fig.2. Pharmacological profile of [125I]_APT binding on CHOrH2. CHOrH2T341 and CHOrH2T307 cell
membranes. Displacement of 0.3 nM [125I]_APT binding by increasing concentrations of cimetidine (A) and
histamine (B, C) in CHOrH2 (ftlled circles), CHOrH2T341 (open circles) and CHOrH2T307 (open squares) cell
membranes. Data shown are mean values of triplicate determinations from a typical experiment. Similar
experiments were obtained in three other independent experiments.
cAMP accumulation ofcAMP in CHOrH2, CHOrH2T341 and CHOrH2T307 cells
In order to confirm that the truncated receptors stimulate the signal transduction pathway, we
determined the ability of histamine to induce a rise in cAMP in these cell lines. In all cell lines
histamine elicited an increase in cAMP production (Table 3). Yet, the maximal increase of
cAMP in CHOrH2T341 cells was markedly impaired (- 70% reduction). The observed
reduction in cAMP production in CHOrH2T341 cells cannot be ascribed to a decrease in
adenylyl cyclase activity as 10 11M forskolin induced a cAMP response comparable to that in
CHOrH2 cells (Table 3). The ECSO values for the histamine-induced cAMP response in
CHOrH2T341 and CHOrH2T307 cells, were the same, however, as measured in CHOrH2
cells (Table 3).
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Table 3 Histamine- and forskolin-induced cAMP production in CHOrH2' CHOrH2T341 and CHOrH2T307
cells
CHOrH2 CHOrH2T341 CHOrH2T307
histamine
basal (pmollwell) 3±1 2± 0.4 1 ± 0.5 *
EC50(nM) 36± 2 42± 12 56± 14
Emax (pmollwell) 48 ± 8 15 ± 3 * 53 ± 5
10 IJM forskolin 59 ± 10 54±4 34± 1 *
(pmollwell)
Cells were incubated with increasing concentrations of histamine or 10 IJM forskolin for 10 mins at 37°C in
DMEM in the presence of 300 IJM IBMX and 25 mM Hepes, pH 7.4. Data represent the mean ± s.e.mean of
six to seven independent experiments. The asterisk indicates a significant difference (p < 0.05) from CHOrH2
cells.
When CHOrH2 cells were exposed to 100 IlM histamine, cAMP accumulated within 10
mins, which was followed by an attenuation of the cAMP response at later time points (Fig.
3A). The lack of increase in cAMP production at later time points cannot be ascribed to
impaired adenylyl cyclase activity, as 10 IlM forskolin continued to elevate the production of
cAMP to levels higher than observed for histamine (Fig. 3A). The decline in 100 IlM
histamine-induced cAMP accumulation in time was also observed in CHOrH2T341 and
CHOrH2T307 cells.
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Fig. 3. Time course of the histamine-induced cAMP accumulation in CHOrH2' CHOrH2T341 and
CHOrH2T307 cells. A, CHOrH2 cells were incubated with DMEM (fIlled circles), 100 IJM histamine (open
circles) or 10 IJM forskolin (fIlled squares) for increasing periods of time at 37°C in the presence of 300 IJM
IBMX. B, CHOrH2' (open circles) CHOrH2T341 (open squares) and CHOrH2T307 (fIlled circles) cells were
incubated with 100 IJM histamine for increasing periods of time at 37°C in the presence of 300 IJM IBMX. Data
shown are mean values ± s.e. mean of three to four independent experiments determined in triplicate.
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Histamine-induced downregulation ofthe wild-type and truncated H2 receptors
As was shown in previous studies (Chapter 5) exposure of CHOrH2 cells to 100 J.lM of
histamine for prolonged periods of time resulted in a time-dependent decrease of [125I]-APT
binding sites of 46 ± 8% (mean ± s.e.mean, n =3) (Fig. 4). Similar results were obtained
when incubating CHOrH2T341 cells for increasing periods of time with 100 J.lM histamine
(Fig. 4) (reduction 62 ± 5%, mean ± s.e.mean, n = 3). Remarkably, a significantly more
pronounced reduction in [125I]-APT binding sites was observed (80 ± 3%, mean ± s.e.mean,
n = 3, p < 0.05) when CHOrH2T307 cells were exposed to 100 11M histamine for increasing
periods of time, although the time course of receptor downregulation remained the same (Fig.
4). Also the potency of histamine to induce H2 receptor downregulation was not affected by
the truncation. Long-term exposure of CHOrH2 cells, CHOrH2T341 and CHOrH2T307 cells
to increasing concentrations of histamine resulted in a dose-dependent decrease of [125I]_APT
binding sites, with comparable EC50 values (Table 4).
The H2 receptor needs not to be activated by an agonist in order to be downregulated (Inset
Fig. 4) (Chapter 5). Also in CHOrH2T341 and CHOrH2T307 cells 10 11M forskolin induced
downregulation of the H2 receptor (Inset Fig. 4). The extent of H2 receptor downregulation
was similar in the three cell lines.
Downregulation OfH2 receptor mRNA levels in CHOrH2 and CHOrH2T307 cells
Earlier studies have demonstrated that agonist-induced H2 receptor downregulation in
CHOrH2 cells is accompanied by a decrease in H2 receptor mRNA levels (Chapter 5). In order
to investigate whether the increased downregulation observed in CHOrH2T307 cells is a result
from increased attenuation of H2 receptor mRNA levels, H2T307 receptor mRNA levels were
determined at different time intervals. Incubation ofCHOrH2 and CHOrH2T307 cells with 100
J.lM histaniine resulted for both cell lines in a transient decrease of H2 receptor mRNA levels
within 4 hrs, followed by a gradual increase of H2 receptor mRNA levels to 50% of control in
the following hours (Fig. 5). No change in H2 receptor mRNA downregulation could be
observed in the CHOrH2T307 cells when compared to the CHOrH2 cells.
Table 4 Histunine-induced decrease of [125I]_APT binding in CHOrH2' CHOrH2T341 and CHOrH2T307
cells
EC50(nM)
Emax (%)
18 ± 6
46±8
20±6
62± 5
28± 2
80± 3*
CHOrH2 cells, CHOrH2T341 and CHOrH2T307 cells were exposed to increasing concentrations of histamine
for 24 hrs and the [125I]_APT binding in membranes was measured. The maximmn extent of decrease of [1251]-
APT binding is expressed as a percentage of [1251]_APT binding measured in non-treated cells <Emax %). The
data represent the mean ± s.e.mean of three to seven independent experiments.
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Fig. 4. Time-dependent decrease of [125I]-APT binding in CHOrH2, CHOrHZT341 and CHOrHZT307 cells
by histamine. CHOrHZ (filled circles), CHOrHZT341 (open circles) and CHOrHZT307 (open squares) cells were
incubated with 100 JlM histamine for the indicated time periods and [lZ5Il-APT binding in membranes was
measured. The [lZ5Il-APT binding is expressed as a percentage of [lZ5Il-APT binding measured in non-treated
cells (*: p < 0.05). The data shown represent the mean ± s.e.mean of three independent experiments Inset,
Forskolin-induced decrease of [lZ5Il-APT binding sites in CHOrHZ' CHOrHZT341 and CHOrHZT307 cells.
Cells were incubated with 10 JlM forskolin for 24 hrs and [125Il-APT binding in the membranes was measured.
The data shown represent the mean ± s.e. mean of4 independent experiments.
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Fig. S. Histamine-induced modulation of HZ receptor mRNA levels in CHOrHZ and CHOrHZT307 cells.
CHOrHZ (filled circles) and CHOrHZT307 (open circles) cells were incubated for the indicated times with 100
JlM histamine. Cells were harvested, total RNA was extracted and HZ receptor mRNA expression was quantified
by means of a RNA slot blot assay as described in Chapter 5. Data shown are the mean values of duplicate
determinations from a typical experiment. Similar results were obtained in another independent experiment.
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Discussion
Recent reports have shown that the H2 receptor is susceptible to short- and long-term receptor
regulation (Arima et al., 1993, Fukushima et al., 1994, Smit et al., 1994) (Chapter 5). As
C-terminal domains are considered to be important for GPCR regulation (see reviews Collins,
1993, Lohse, 1993, Savarese and Fraser, 1992), we constructed 3 different truncated H2
receptor mutants to examine the role of the C-terminal tail in H2 receptor regulation. Stable
transfection of H2 receptor mutants, truncated at positions 307 and 341 (H2T307 and
H2T341), in CHO cells resulted in detectable [125I]-APT binding, whereas no detectable
[1251]-APT binding of the H2 receptor truncated at position 295 (H2T295) was observed in
CHO nor after transient transfection in HEK-293 cells. Although no [1251]-APT binding of the
H2T295 mutant was detected, synthesis of H2T295 mRNA in HEK-293 cells was observed,
suggesting that the H2T295 receptor protein is not efficiently transported and/or inserted into
the membrane. Similar observations or lowered receptor expression were reported after C-
terminal tail truncation of various other GPCRs, indicating that the region adjacent to
transmembrane (TM7) may serve as a general domain critical for GPCR expression in the
membrane (Alblas et al., 1995, Cheung et aI., 1989, Josiah et aI., 1994, Klos et al., 1994,
Moro et aI., 1993, Schneider et aI., 1994, Thomas et al., 1995). In most GPCRs a highly
conserved cysteine residue is found in this domain (position 304 in the H2 receptor) (Savarese
and Fraser, 1992). For several GPCR members this residue has been shown to be
palmitoylated (Kennedy and Limbird, 1994, Ng et aI., 1993, Ng et aI., 1994, Ovchinnikov
et aI., 1988) and this structural modification is thought to result in membrane anchorage of the
C-terminal tail and thereby in the formation of an additional intracellular loop (O'Dowd et al.,
1989). Based on the observed loss of receptor expression after truncation of the C-terminal tail
prior to the conserved cysteine, one might speculate that the elimination of this membrane
anchorage is responsible for an incorrect positioning of TM7 in the membrane or for an
incorrect initial insertion of the receptor into the membrane. However, there are also studies
describing that C~terminal tail truncation prior to the cysteine residue (Nussenzveig et aI.,
1993, Takano et al., 1994) did not affect receptor expression. Moreover, some GPCRs, like
the (X,2C4 receptor, do not even possess a cysteine in their C-terminal tail (Eason et al., 1994).
The reason for this apparent discrepancy between different members of the GPCR family is not
clear at this moment, but suggests that perhaps other structural features adjacent to TM7
(residues 295-307) are of importance for proper receptor expression.
The C-terminal region of the H2 receptor from amino acid position 307 does not seem to be
important for the binding of H2 receptor ligands to the receptor as the binding properties of
various H2 antagonists and histamine were unaffected. These results confirm previous findings
that the binding of histamine to the histamine receptors mainly occurs in the transmembrane
domains (Gantz et aI., 1992, Leurs et al., 1994, Ohta et al., 1994). The C-terminal tail of
some GPCRs appears to be involved in G-protein coupling, as G-protein coupling was found
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to be reduced upon tmncation of the C-terminal tail (Josiah et al., 1994, Kosugi and Mori,
1~94, Ohyama et ai., 1992, Sasakawa et al., 1994). For the H2 receptor, no difference in the
ability of histamine to stimulate the H2T307 was observed, suggesting that the major Palt of
the C-terminal region (SI amino acids) is not involved in the activation of the signal
transduction pathway. Surprisingly, however, tmncation of the C-terminal tail with only 17
amino acids (H2T341) attenuated the capacity of histamine to induce production of cAMP (-
70% reduction), even though high affmity binding for histamine was observed. Even a small
increase in the percentage of high affinity binding for the H2T341 receptor was observed. Yet,
the ECSO value of the histamine-induced cAMP response in CHOrH2T341 cells (42 nM) did
not significantly differ from the ECSO value recorded in CHOrH2 cells (36 nM). The observed
decrease in the maximum cAMP production cannot be attributed to a lower receptor expression
(616 fmoVmg protein vs 1172 fmoV mg protein for CHOrH2 cells), as CHO cells expressing
the wild-type receptor at a density of -SOO fmoVmg of protein showed a similar maximum
histamine-induced response as that in CHOrH2 cells (M.J. Smit, unpublished observations).
Detection of high affinity binding sites for GPCR agonists is considered to reflect the formation
of a ternary agonist-receptor-G-protdn complex (De Lean et ai., 1980). Formation of such a
ternary complex is usually thought to lead to a dissociation of the G-protein subunits which
results in an effective activation of the signal transduction cascade. Our findings, however,
indicate that the formation of a high affinity agonist-receptor-G-protein complex is not
sufficient enough to fully activate the Gs-protein. Instead, an additional stimulatory signal
appears to be required. The existence of distinct molecular determinants involved in physical
coupling to and functional activation of the Gs-protein has also been reported for the 132-
adrenergic receptor upon deletion of the C-terminal region of the third intracellular loop
(Hausdorff et al., 1990). Also some rhodopsin receptor mutants were found to bind
transducin, but they were found to be defective in catalysing the GDP dissociation from
transducin (Ernst et ai., 1995). Since histamine was capable to fully activate the H2T307
receptor, the region encompassing amino acids 307 to 341 seems to contain a signal motif that
impairs proper Gs-protein activation. The last 17 amino acids of the H2 receptor appear to
prevent this impairment by the 307-341 region, thereby serving as a positive signal for Gs-
mediated signal transduction. These findings indicate that this region of the C-terminal tail of
the H2 receptor is important for Gs-protein activation. The presence of such positive and
negative signals in the C-tenuinal tail has also been reported for the parathyroid hormone
receptor (Huang et al., 1995). Different domains were found to act as stimulators, while other
domains as inhibitors of the process of internalization (Huang et al., 1995). Future site
specific mutagenesis studies should further define which amino acids in the region
encompassing 307 and 341 of the H2 receptor are responsible for the impaired Gs-protein
activation.
Subsequently, we were interested to find out whether C-terminal tmncation affected H2
receptor regulation. Previous studies have shown that both the human H2 receptor in U937 or
120 Chapter 6
MKN-45 cells and the canine H2 receptor expressed in CHO cells are rapidly desensitized
upon short-term histamine exposure (Arima et al., 1993, Fukushima et a/., 1994, Smit et
al., 1994). Receptor desensitization of GPCRs often leads to blunting of agonist-induced
cAMP production or inositol phosphate production in time as shown, for example, for the ~2­
adrenergic receptor and the neurokinin-2 receptor (Alblas et aI., 1995, Liggett et a/., 1989).
Elimination of potential phosphorylation sites in the ~2-adrenergic receptor and truncation of
the neurokinin-2 receptor have been reported to result in a sustained stimulation of the
respective effector enzymes compared to the transient activation seen in cells expressing wild-
type receptors (Alblas et a/., 1995, Liggett et al., 1989). We also found that the wild-type H2
receptor response is desensitized in time upon agonist exposure. In our studies, a similar
pattern of desensitization was observed in time in CHOrH2T341 and CHOrH2T307 cells,
implying that phosphorylation of serine/threonine residues by kinases in the C-terminal tail of
the H2 receptor is not responsible for the observed desensitization. Previously, truncation of
the C-terminus of the luteinizing hormone (Zhu et al., 1993) and angiotensin II ATIA
(Thomas et al., 1995), both containing various serine- and threonine residues, did not affect
the pattern of agonist-induced dese~sitization either, indicating that the C-terminal tail of these
receptors has no apparent role in desensitization. As such, different receptor domains appear to
be involved in agonist-induced GPCR desensitization. The third intracellular loop of the H2
receptor contains four more potential phosphorylation sites, which might be implicated in the
observed agonist-induced desensitization. Substitution of these phosphorylation sites and/or
direct phosphorylation studies with co-expression of specific receptor kinases should give
more insight in the phenomenon of agonist-induced H2 receptor desensitization.
Former studies have also shown that the H2 receptor is susceptible to long-term receptor
activation, resulting in H2 receptor downregulation (Chapter 5). Two mechanisms seem to be
involved in the process of H2 receptor downregulation, a cAMP-dependent as well as agonist-
dependent, cAMP-independent (Chapter 5). As already stated in the Introduction, the C-
terminal tail of many GPCRs appears to be a structural determinant for receptor downregulation
(see reviews Collins, 1993, Lohse, 1993, Savarese and Fraser, 1992). In CHOrH2T341
cells histamine induced a time- and dose-dependent decrease of [1251]-APT binding sites
comparable to that in CHOrH2 cells, even though the histamine-induced cAMP production was
found to be attenuated in the mutant receptor. These data further support our previous findings
(Chapter 5) describing a cAMP-independent pathway inducing H2 receptor downregulation.
The last 17 amino acids do not seem to be implicated in the process of histamine-induced H2
receptor downregulation, although they function as a positive signal in the process of signal
transduction.
The cAMP-dependent downregulation of the wild-type H2 receptor, induced by forskolin,
did not alter upon truncation of either 17 or 59 amino acids, which indicates that the C-terminal
tail of the H2 receptor is not involved in the process of the cAMP-dependent H2 receptor
downregulation. It is remarkable that in CHOrH2T307 cells the observed agonist-induced H2
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receptor downregulation was more pronounced than in CHOrH2 cells (80% vs 44%).
Downregulation of the wild-type H2 receptor can be partly ascribed to an increased H2 mRNA
breakdown (Chapter 5). However, the increased downregulation of the H2T307 receptor
cannot be explained by an increased H2T307 mRNA breakdown, since no change in the
pattern of H2T307 mRNA downregulation was observed compared to the wild-type H2
receptor. These findings are confirmed by the lack of a more pronounced effect induced by
long-term forskolin treatment, assuming that H2 mRNA downregulation process is cAMP-
mediated, as generally accepted (Hadcock and Malbon, 1993, Chapter 5). The increased
downregulation in CHOH2T307 cells was rather unexpected and in contrast with the reports
of, for example, the ~2-adrenergic receptor and muscarine m3 receptor, here removal of serine,
threonine or tyrosines from the C-terminal tail resulted in a decrease of receptor downregulation
(Bouvier et aI., 1989, Campbell et al., 1991, Chueng et aI., 1989, Valiquette, et aI., 1990,
Yang et aI., 1993). The only studies showing increased downregulation upon C-terminal
truncation are those of the avian ~1-adrenergic receptor (Hertel et aI., 1990, Parker and Ross,
1991). This avian receptor has a C-terminal tail which is 59 amino acids longer than the
mammalian ~1-adrenergic receptor. The authors suggested that the additional 59 amino acids
act as an anchorage of the receptor to the cytoskeleton, thereby blocking signal transduction
efficacy and regulatory mechanisms such as internalization and downregulation (parker et al.,
1995, Wang and Ross, 1995). In view of these findings we hypothesize that the region which
contains the amino acids 307 to 341 and which is found to act as a negative signal in the
histamine-induced signalling, also impairs receptor downregulation. Truncation of the H2
receptor with 51 amino acids is considered to increase the accessibility of molecular entities
involved in the process of agonist-induced H2 receptor downregulation.
In conclusion, this study has provided information whether the C-terminal tail of the H2
receptor is involved in ligand binding, signal transduction and receptor regulation. The amino
acids prior to position 307 appear to be necessary for a proper receptor transport or folding.
Ligand binding properties of the tested H2 antagonists and histamine were not affected by
truncation, indicating that their binding domain mainly resides in the transmembrane domains
of the H2 receptor protein. Truncation of the major part of the C-terminal tail (51 amino acids)
did not affect the histamine-induced production of cAMP, whereas removal of only 17 amino
acids resulted in the formation of a receptor capable of coupling to G proteins, but unable to
fully activate the Gs-protein upon histamine exposure. These data suggest that this region of
the C-terminal tail of the H2 receptor is important for G-protein activation. Truncation of the C-
terminal tail did not influence the agonist-induced desensitization, indicating that the serine and
threonines residues are not involved in the mechanism underlying short-term H2 receptor
desensitization. The C-terminal tail does not appear to be important in the cAMP-dependent
pathway of H2 receptor downregulation, whereas truncation of the last 51 amino acids
enhanced the observed agonist-, cAMP-independent H2 receptor downregulation. These data
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suggest that the cAMP-dependent and -independent pathways of the H2 receptor
downregulation are mediated by different regulatory processes. Taken together, our findings
show that the C-terminal tail of the H2 receptor contains regions which act as positive or
negative signals important for signal transduction and receptor regulation. In order to determine
the exact role of various amino acids and/or receptor domains in the C-terminal tail of the H2
receptor in these different processes, investigations including site directed mutagenesis are
required.
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Chapter 7
Pharmacological characterization of the human
histamine H2 receptor stably expressed in Chinese
Hamster Ovary cells
M. J. Smit, R. Leurs, W. M. B. P. Menge and H. Timmerman
In the present study the gene encoding the human histamine H2 receptor was stably expressed in Chinese
Hamster Ovary (CHO) cells and characterized by [125IJ-iodoaminopotentidine binding studies. Thereafter, the
coupling of the expressed receptor protein to a variety of signal transduction pathways was investigated. After
cotransfection of CHO cells with pCMVhumH2 and PUT626 a phleomycine-resistant clonal cell line
(CHOhumH2) was isolated that ex~ressed 565 ± 35 finol/mg protein binding sites with high affinity (0.21 ±
0.02 nM) for the H2 antagonist [12 I]-iodoaminopotentidine. The encoded protein was indistinguishable from
the H2 receptor identified in human brain membranes and guinea-pig right atrium as the ~-values of a variety of
H2 antagonists correlated well (c2 = 0.996 and 0.920 respectively). Displacement studies with histamine showed
that a limited fraction (32 ± 6%) of the binding sites showed a high affinity for histamine (2 ± 1.2 ~); the
shallow displacement curves were reflected by a Hill-coefficient significantly different from unity (nH =0.58 ±
0.09). The addition of 100~ Gpp(NH)p resulted in a steepening of the displacement curve (nH =0.79 ± 0.02)
and a loss of high affinity sites for histamine. The recently developed specific H2 agonists amthamine and
amselamine showed an approximately 4-5 fold higher affinity for the hmnan H2 receptor than histamine.
Stimulation of CHOhumH2 cells with histamine resulted in a rapid rise of the intracellular cAMP levels
(EC50-value 7 ± 1 nM) which was effectively blocked by tiotidine and cimetide (Krvalues of 8 ± 1 nM and
0.56 ± 0.24~ respectively). Stimulation of CHOhumH2 cells with histamine neither inhibited the A23187-
induced release of [3H]-anlchidonic acid nor changed the intracellular IP3 1evels.
These results show that the cloned human gene encodes an histamine H2 receptor that is indistinguishable
from the H2 receptor identified in human brnin tissue. This receptor is functionally coupled to the adenylate
cyclase in CHO cells, but does not influence the inositol phosphate turnover or arachidonic acid release.
Introduction
Following the original observations of Ash and Schild (1966) of possible histamine receptor
heterogeneity, Black et aI. (1972) initiated a successful search for histaminergic ligands that
could selectively block or mimic the actions of histamine on cardiac and stomach function. It
was the development of burimamide and various analogues (Black et aI., 1972) that finally
provided evidence for the existence of at least two different histamine receptor subtypes. With
the availability of suitable pharmacological tools (for a review see Leurs et aI., 1991) the role
of the H2 receptor in human (patho)physiology has been studied in detail. The receptor protein
is present in e.g. various distinct human brain areas (Traiffort et ai., 1992a, Martinez-Mir et
aI., 1993), human heart (Bristow et ai., 1982, Du et aI., 1993, Zerkowski et aI., 1993),
human airway preparations (Barnes, 1992), human blood vessels (Keitoku et aI., 1990, Toda,
1990), human uterus (Martinez-Mir et aI., 1992) and human stomach (Bertaccini and Corruzi,
1992). As can be anticipated from this localization the H2 receptor subtype has been identified
as an important target for (potential) pharmacotherapy. Besides a role of H2 receptor
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antagonists in gastric acid secretion (Bertaccini and Corruzi, 1992) also application of
cardioselective H2 receptor agonists in congestive heart failure has been suggested (Felix et
ai., 1991). Moreover, recently, a role for the H2 receptor has been suggested in some
neurological diseases (Deutsch et ai., 1993, Kaminsky et al., 1990, Martinez-Mir et ai.,
1993), indicating that also CNS-active H2ligands might have therapeutic potential. Due to
these perspectives, the search for more potent and selective H2 receptor agents still continues
and has, for instance, recently resulted in the development of the new and highly specific H2
receptor agonists amthamine and amselamine (Eriks et ai., 1991, Timmerman, 1992, Van der
Goot et ai., 1994).
Despite the interesting therapeutic potential of the H2 receptor, detailed studies of the human
histamine H2 receptor have been hampered by the lack of suitable model systems. Human
tissue is not widely available for pharmacological studies and only a few human cell lines have
been reported to contain histamine H2 receptors (Arima et al., 1991, Emani et al., 1983,
Gespach et al., 1985). Yet, the reported pharmacology of the histamine receptor present on
these cells is not always clear (Burde et ai., 1989, Mitsuhashi et ai., 1991, Reyl-Desmars et
ai., 1991, Seifert et al., 1992). O~y in human monocytic U937 cells pharmacologically
clearly defined H2 receptors are present, but the density of receptor sites is too low for detailed
receptor binding studies (Smit et ai., 1994).
The recent introduction of molecular biology in the field of G-protein coupled receptor research
has greatly improved the knowledge of molecular aspects of these receptor proteins. Following
the cloning of the gene encoding the hamster beta2 receptor by Dixon et ai. (1986), a wide
variety of genes encoding G-protein coupled receptors have been cloned by various techniques.
Also in the field of histamine research the molecular biological approach has recently been
successful. Using degenerated oligonucleotides based on conserved transmembrane regions of
the receptor family and mRNA of canine parietal cells, Gantz et ai. (1991a) succeeded in
cloning the gene encoding a putative canine histamine H2 receptor. Using the canine nucleotide
sequence, soon thereafter a rat (Ruat et ai., 1991) and human homologue (Gantz et ai.,
1991b) were cloned. The rat gene was expressed in Chinese Hamster Ovary cells and was
shown to be a typical H2 receptor (Traiffort et al., 1992b). For the proteins encoded by the
canine and human gene no detailed information is available yet for the pharmacological profile
of the encoded proteins.
A cellular system expressing the human histamine H2 receptor protein would be very useful for
the development of new histaminergic ligands and would also allow detailed investigation of
the regulation of the histamine H2 receptor function. For the study of HI receptor regulation
isolated cell systems have already proven to be extremely useful (see e.g. Smit et al., 1992).
In view of the anticipated use of histamine H2 receptor agonists in congestive heart failure
(Felix et al., 1991) and the reported increase in beta-receptor kinase expression in heart tissue
of patients with congestive heart failure (Ungerer et al., .1993), a detailed study of the
molecular mechanisms underlying the regulation of histamine H2 receptor function is of great
Stable expression ofthe human H2 receptor 127
importance. Therefore, we decided to stably express the reported human gene in Chinese
Hamster Ovary cells and to perform a molecular pharmacological characterization of the
encoded protein. Besides receptor binding studies with a wide range of histaminergic agents
we also investigated the signal transduction pathways that can be activated by the receptor
protein in these cells.
Materials and methods
Cell culture CHO cells deficient in dibydrofolate reductase were maintained at 37°C in a humified atmosphere
with 5% CO2 in Dulbeco's Modified Eagle's Medium (DMEM), containing 10% (vol/vol) fetal calf serum and
supplemented with 2 mM L-glutamine, hypoxanthine, thymidine, MEM amino acids, 50 IU/ml penicilline and
50 Jlg/ml streptomycine. CHO cells were stably transfected with the eukaryotic expression vector
pCMVhumH2neo (Gantz et al., 1991b) and the plasmid pUT626, containing the Sh ble gene, conferring
resistance to the antibiotic phleomycine (Cayla, France), using Lipofectine (Gibco BRL, The Netherlands). After
two weeks of selection in the presence of 50 Jlglml phleomycine, surviving CHO colonies were isolated by ring
cloning and further expanded in culture medium supplemented with phleomycine.
CHO cells expressing the guinea-pig histamine HI receptor (CHOgpH1, Leurs et ai., 1994) were grown at
37°C in a humified atmosphere with 5% CO2 in Dulbeco's Modified Eagle's Medium (DMEM), containing
10% (vol/vol) dialysed fetal calf serum and supplemented with 2 mM L-glutamine, MEM amino acids, 50
IU/ml penicilline and 50 Jlg/ml streptomycine.
Biochemical measurements The determinations of H2 receptor binding and levels of cAMP were performed as
described in Chapter 5.
[3H)-Arachidonic acid release CHOhumH2 cells were seeded in 24-well plates and cultured overnight in culture
medium, containing 0.5 JlCi/ml [3H]-arachidonic acid ([3H1-AA). To remove unincorporated [3H1-AA cells were
washed twice with 1 ml DMEM supplemented with 0.2% bovine serum albumin (fatty acid free). Thereafter the
cells were incubated at 37°C for 30 mins with the appropriate drugs in 1 ml of DMEM with 0.2% bovine serum
albumin. In some experiments CHOhumH2 cells were preincubated with histamine for 10 mins before the
release of [3H]-AA was stimulated. The release of [3H]_AA was determined by liquid scintillation counting of
0.5 ml sample of the incubation medium. Previously, it has been shown that over 90% of the released
radioactivity corresponds to authentic [3H1-AA (Traiffort et al., 1992b).
Inositol phosphate production CHOhumH2 or CHOgpHl cells were seeded in 24-well plates and cultured
overnight in culture medium. Cells were washed twice with DMEM, supplemented with 50 mM HEPES (pH =
7.4 at 37°C) and preincubated for 30 mins at 37°C. Thereafter the medium was aspirated, 100 JlM histamine in
100 JlI DMEMIHEPES was added and the cells were incubated for the indicated time at 37°C. The reaction was
stopped by the addition of 100 Jll of 10% cold HCI04. The cells were disrupted by sonication (5 sec, 50 Watt,
Labsonic 1510, Braun-Melsungen) and kept on ice for 10 mins The cell homogenate was centrifuged for 5 min
in Eppendorf tubes at 11.000 g. The supernatant (190 Jll) was transfered to another tube and 47.5 JlI 10 mM
EDTA (pH = 7.4) was added. The samples were neutralized with 300 Jll of a freon:tri-octylamine mixture (1:1,
vol/vol, freshly prepared). The samples were vortexed and centrifuged for 2 mins at 11,000 g. The neutralized
upper phase (150 Jll) was mixed with 37.5 Jll1 M NaHC03 and assayed for the presence of 1P3 using a IP3-
mass assay system (Amersham).
In some experiments cells were labelled overuight in culture medium supplemented with 1 JlCilml [3H]_
inositol. Reactions were terminated with 1 ml cold CHCl3/methanoi and the [3H]-inositol phosphates were
isolated by anion exchange chromatography (Godfrey, 1992).
Chemicals Histamine dihydrochloride, A23187, isobutylmethylxanthine, cyclic AMP, haloperidol and
mepyramine were obtained from Sigma Chemical Company (USA). [3H1-cAMP (40 Cilmmol), [3H]-inositol
(18.8 Cilmmol) were obtained from Amersham, whereas [3H]-arachidonic acid (232 Cilmmol) was purchased
from New England Nuclear. Dimaprit dibydrobromide, amthamine dibydrobromide, amselamine dibydrobromide,
impromidine trihydrobromide, aminopotentidine and thioperamide were taken from laboratory stock. Gifts of
burimamide, metiamide, cimetidine, icotidine, zolantidine (SmithKline Beecham), tiotidine (ICI), ranitidine
(Glaxo), famotidine (MSD), mianserin (Organon) and the human H2 cDNA (Dr.!. Gantz) are acknowledged.
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Results
Pharmacological characterization ofthe human H2 receptor using [12S/j_APT
Cotransfection of CHO cells with the plasmid pCMVhumH2 and pUT626 resulted after 10-12
days of selection in culture medium supplemented with 50 Ilglml phleomycine in the formation
of several clonal cell lines, which expressed [125I]-APT binding sites. Untransfected cells did
not show any specific [1251]_APT binding (data not shown). For subsequent experiments a
cell line (CHOhumH2) stably expressing [1251]_APT binding sites was further analysed.
Saturation experiments performed with CHOhumH2 cell membranes indicated the expression
of a single [1251]_APT binding site (nH =1.0 ±0.1) with a dissociation constant (Kd) of 0.21
± 0.02 nM (n =3, mean ± s.e.mean) and a maximal density of 565 ± 35 fmol/mg protein (n =
3, mean ± s.e.mean) (Fig. I).
The specific binding of 0.2 nM [125I]-APT represented more than 95% of the total binding
and was monophasically (nH not significantly different from unity) inhibited by a variety ofH2
receptor antagonists but was unaffected by the HI and H3 antagonists mepyramine and
thioperamide (Fig. 2A, Table 1). The Ktvalues of the H2 antagonists correlated well with their
biological activities at the H2 receptor of the guinea-pig right atrium (Leurs et al., 1991) (c2 =
0.920, n =10, Table 1) and the Ki-values determined for the H2 receptor on post-mortem
human brain membranes (Traiffort et al., 1992a) (r2 =0.996, n =6, Table 1). The
antidepressant mianserine and the neuroleptic haloperidol also interacted with the cloned human
H2 receptor protein, although at only moderate concentrations (Table 1).
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Fig. 1. Concentration dependent binding of [125JJ-APT to CHOhumH2 cell membranes. Specific radioligand
binding (open circles) was determined by substracting the binding in the presence of 1~ of tiotidine (filled
squares) from the total binding (filled circles). Mean values of triplicate determinations of a typical experiment
out of three are shown.
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Table 1 Ki-values of various histaminergic antagonists for competition of [125I]_APT binding to
CHOHurnH2 membranes
CHOHurnH2 human brain guinea-pig atrium
compounds Ki nH Ki KB
APT 15 ± 5 nM -0.99 ± 0.6
Burirnarnide 3.9 ± 1.2 JlM -1.10 ± 0.04 1.6JlM 7.8 JlM
Cirnetidine 0.66 ± 0.22 JlM -0.89 ± 0.02 0.27 JlM 0.79 JlM
Farnotidine 16±3 nM -0.92 ± 0.07 16nM
Metiarnide 0.67 ± 0.16 JlM -0.95 ± 0.03 0.92 JlM
Ranitidine 85±4nM -0.96 ± 0.06 38nM 63nM
Tiotidine 17±6nM -0.88 ± 0.01 5nM 15nM
Zolantidine 40±8nM -L05 ± 0.06 35nM
Iootidine 15± 2nM -I!01 ± 0.04 60nM
Haloperidol 1.5± 0.3 JlM -0.'98 ± 0.03 0.65 JlM 0.87 JlM
Mianserine 0.56 ± 0:51 'JlM -1.08 ± 0.04 0.10 JlM 0.11 JlM
Mepyrarnine > 10 JlM
Thioperarnide > 100 JlM
Reported values for [125I]_APT binding to human brain membranes (Traiffort et ai., 1991a) and antagonism of
histamine-induced chronotropic responses of guinea-pig right atrium (Leurs et ai., 1991) are shown for
comparison. Data shown are mean ± s.e.mean of three to four independent experiments, each performed in
triplicate.
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Fig. 2. Pharmacological profile of the [I25I]APT binding site on CHOhumH2 cell membranes. Displacement
of [125I]_APT binding by (A) APT (filled circles), ranitidine (open circles), burlmarnide (fIlled squares) or (B)
histamine in the absence (filled circles) or presence (open circles) of 100 JlM of Gpp(NH)p is shown. Data
shown are the mean values of triplicate determinations from a typical experiment. Similar results were obtained
in 2-4 other independent experiments.
Table 2 Ki-values of various histaminergic agonists for competition of [125Il_APT binding to CHOHumH2 membranes in the absence or presence of 100 J.IM
Gpp(NH)p. Reported values for agonist-induced chronotropic responses of guinea-pig right atrium (Eriks et al., 1991, Van der Goot, 1994) are shown for comparison.
Values between parentheses indicate the relative densities of the respective sites. Data shown are mean ± SEM of three to five independent experiments, each performed
in triplicate
.....
w
o
-Gpp(NH)p + Gpp(NH)p
guinea-pig right atrium
compounds Ki; high (JIM) Ki, low (JIM) nH Ki (JlM) nH EC50 (JIM)
Histamine 2.0 ± 1.2 81 ± 15 -0.58 ± 0.09 45 ±4 -0.79 ± 0.02 0.72
(32± 6%) (68±6%)
Amthamine 0.15 ± 0.14 6.9 ± 0.8 -0.68 ± 0.03 7.0 ± 1.7 -0.88 ± 0.01 0.62 ~(23 ±6%) (76 ± 6%) "i:::j
~
""t
Amselamine 0.13 ± 0.09 9.6± 0.7 -0.73 ± 0.02 10 ± 1 -1.02 ± 0.11 0.39 ""l
(l8± 3%) (82± 3%)
Dimaprit ND 25 ± 5 -0.79 ± 0.02 24±5 -0.96 ± 0.09 1.1
(100%)
lmpromidine 0.023 ± 0.028 0.38 ± 0.09 -0.73 ± 0.04 0.47 ± 0.03 -0.95 ± 0.04 0.016
(31 ± 15%) (69 ± 16%)
NO = not detectable
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Various histamine H2 agonists displaced the specific [125I]_APT binding to CHOhum H2
cell membranes too (Fig. 2B, Table 2). Yet, histamine displacement curves were shallow (nH
= 0.58 ± 0.09, n = 5, mean ± s.e.mean) and could be best analysed according to a two site
model (Fig. 2B). Simultaneous fitting of the five independent expedments resulted in an
affinity of 2.0 ± 1.2 IlM and 81 ± 15 IlM for respectively the high- and low affmity binding
site. The addition of 100 IlM Gpp(NH)p resulted in a steepening and a dghtward shift of the
histamine displacement curve (Fig. 2B), which was best analysed according to a single site
model, leading to a Ktvalue of 45 ±4 IlM (Table 2). The percentage high affinity sites for
histamine was rather low (Fig. 2B, Table 2) and not always obvious. Similar observations
were made for the other H2 receptor agonists. Under control conditions shallow displacements
curves were obtained, which, with the exception of the data for dimapdt, were best fitted
according to a two sites model (Table 2). In the presence of Gpp(NH)p the specific agonists
amthamine (Eriks et al., 1991), amselamine (Van der Goot et al., 1994), dimapdt and
impromidine all displaced [125I]-APT binding to CHOhumH2 membranes monophasically and
showed a higher affinity for the human H2 receptor compared to histamine (Table 2).
cAMP production in CHOhumH2 cells
In untransfected CHO cells histamine (100 JlM) did not affect the cellular cAMP level (data not
shown). Stimulation of the CHOhumH2 cells in the absence of the cAMP phosphodiesterase
inhibitor isobutylmethylxanthine (IBMX) with 11lM histamine for 10 mins resulted in a slight
but significant increase of the basal cAMP level of 6.6 ± 1.0 pmoVwell to 10.7 ± 1.1 pmoVwell
(p < 0.05, mean ± s.e.mean, n = 3). In the presence of increasing concentrations of IBMX,
histamine stimulation resulted in a massive increase of the cellular cAMP levels, which
appeared to be maximal with 300-600 JlM IBMX (data not shown). In subsequent experiments
the cAMP accumulation was measured in the presence of 300 JlM IBMX.
Under these conditions addition of 1 IlM histamine resulted in the rapid production of
cellular cAMP (inset Fig. 3A). Already 2 mins after the application of histamine, increased
levels of cAMP were found. Maximal stimulation of the cellular cAMP levels (approximately
10-fold) was observed after 10 mins (inset Fig. 3A). Stimulation of CHOhumH2 cells with
increasing concentrations of histamine for 10 mins resulted in a concentration dependent
increase in cellular cAMP levels. At relatively low concentrations histamine stimulated the
cAMP production (Fig. 3A); the EC50-value of histamine for this response was 7 ± 1 nM (n =
5, mean ± s.e.mean). This histamine-induced (0.3 IlM) cAMP response was effectively
inhibited by the H2 receptor antagonists tiotidine and cimetidine (Fig. 3B), resulting in Kt
values of 8 ± 1 nM and 0.56 ± 0.24 IlM (n = 4, mean ±s.e.mean) respectively. These Ki-
values correspond well with the Ktvalues obtained from the [125I]_APT displacement studies
(Table 1). The histamine-induced cAMP response was not affected by the HI and H3 receptor
antagonists mepyramine and thioperamide in concentrations up to 100 JlM (Fig. 3B).
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Fig. 3. Histamine-induced cAMP accumulation in CHOhumH2 cells. (A) CHOhumH2 cells were stimulated
with increasing concentrations of histamine for 10 mins at 37°C in the presence of 300~ of IBMX. Data
shown are the mean values of a typical experiment out of 6. In untransfected cells histamine did not alter the
intracellular cAMP concentration. Inset: CHOhumH2 cells were stimulated with DMEM (dotted line) or 1~
of histamine (solid line) for various lengths of time at 37°C in the presence of 300~ of IBMX. Data shown
are the mean values of a typical experiment out of 3.(B) Pharmacological characterization of the histamine-
induced cAMP response in CHOhum~ cells. Cells were incubated for 10 mins at 37°C with 0.3~ of
histamine in the presence of increasing concentrations of tiotidine (filled circles), cimetidine (open circles),
mepyramine (f1l1ed squares) and thioperamide (open squares) and 300~ of IBMX. A typical experiment out of
4 is shown.
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Fig. 4. Effect of histamine on the basal and A23187-induced release of [3H]-AA from prelabelled CHOhumH2
cells. Cells were incubated with DMEM (open column), 1~ (hatched column) or 100~ (filled column) of
histamine in the absence or presence of 1~ of A23187 for 30 mins at 37°C, whereafter the released
radioactivity was counted in the medium. A typical experiment out of 4 is shown. * indicates a significant
difference compared to stimulation with DMEM.
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Arachidonic acid release in CHOhuml!2 cells
In CHOhumH2 cells prelabelled with [3H]-AA application of the Ca2+ ionophore A23l87 led
to a massive increase of [3H]-AA release (Fig. 4). Whereas under basal conditions the [3H]-
AA release amounted to 389 ± 17 dpm (n =4, mean ± s.e.mean), stimulation of CHOhumH2
cells with 111M of the Ca2+ ionophore A23l87 led to an elevation of the [3H]-AA release to
3156 ± 88 dpm (n =4, mean ± s.e.mean). Histamine (111M and 100 11M) did not affect the
basal [3H]-AA release, whereas the A23l87 (111M) induced [3H]-AA release was slightly
increased by 100 11M of histamine (Fig. 4). In some experiments CHOhumH2 cells were
preincubated with histamine in order to study its effect on the A23l87-induced [3H]-AA
release. Also under these conditions histamine had no inhibitory effect on the A23l87 response
(data not shown).
Inositol phosphate production in CHOhuml!2 cells
In CHOhumH2 cells prelabelled overnight with [3H]-inositol application of lOO!!M histamine
in the presence of 20 mM LiCl for 10 mins at 37°C did not result in an increase of the
intracellular accumulation of [3H]-inositol phosphates (107 ±7% of the basal accumulation,
mean ± s.e.mean, n = 3). Yet, stimulation of the endogenous P2-purinergic receptor of
CHOhumH2 cells (Iredale and Hill, 1993, Traiffort et ai., 1992b) with 100 11M of ATP
resulted in an increase of 580 ± 110% (mean ± s.e.mean, n =3) of the basal release of [3H]_
inositol phosphates. Since this approach might be too insensitive for small increases in the
levels of inositol-1,4,5-trisphosphate (IP3)' we analysed the effects of histamine in more
detail. Using an IP3 mass assay we measured the intracellular IP3 levels in CHOhumH2 and
CHOgpH1 cells after stimulation with 100 11M histamine. As can be seen in Fig. 5, histamine
had no effect on the basal levels of IP3 in CHOhumH2 cells. In CHOgpH1 cells 100 11M
histamine rapidly elevated, as expected, the cellular IP3 levels; within 10 secs the IP3 levels
were more than doubled. This rise was transient and dropped to a lower level, which remained
elevated up to 1 min of stimulation (Fig. 5). In accordance with these findings we were unable
to find any effect of histamine on the intracellular calcium levels in fura-2loaded CHOhumH2
cells, although in the same population of cells 100 !!M of ATP resulted in a rapid rise of the
basal level of 97 ± 12 nM to a peak value of 406 ± 55 nM (mean ± s.e.mean, n =3).
Discussion
In this paper we present evidence that the receptor protein encoded by the putative human
histamine H2 receptor gene (Gantz et al., 1991b) is indistinguishable from the
pharmacologically characterized H2 receptor at the guinea-pig atrium (Leurs et ai., 1991) or
human brain tissue (Traiffort et ai., 1992a). In the initial paper on the cloning of the human
gene (Gantz et al., 1991b), some indications of the H2 nature of the encoded receptor protein
were presented; transfected cells bound the H2 receptor antagonist [3H]-tiotidine, whereas
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Fig. 5. Effect of 100 J.l.M of histamine on the 1P3 production in CHOhumH2 (filled circles) and CHOgpH1
cells (open circles). Cells were incubated for the indicated times with histamine at 37°C, homogenized and the
IP3 levels were determined by radioreceptor assay. Data shown are the mean ± s.e.mean of a typical experiment
out of 4.
histamine was found to induce a cimetidine-sensitive cAMP accumulation (Gantz et al.,
1991b). In view of the reported pharmacological discrepancies of human H2 receptor-like
proteins in various cell systems (Burde et al., 1989, Reyl-Desmars et al., 1991, Seifert et
al., 1992) the observed actions of cimetidine and tiotidine do, however, not unambiguously
define the encoded human receptor protein.
In human gastric HGT-1 tumour cells Reyl-Desmars et al. (1991) reported the presence of
an H2 receptor with a rather low affmity for tiotidine. The pharmacological proflle of the
reported binding site was therefore quite different from the proflle of standard H2 receptor
systems (Reyl-Desmars et al., 1991) and still remains undefined. Nevertheless, functional H2
receptors have been observed in the same cell line (Emaui et aI., 1983). Similar observations
are made in human HL-60 promyelocytic leukemia cells. Also in these cells functional H2
receptors have been described (Burde et aI., 1989, Mitsuhashi et al., 1991, Seifert et aI.,
1992). Yet, the pharmacological definition of the various functional responses is not always
clear. A unique agonist/antagonist proflle is reported for the inhibition of the oxidative burst
(Burde et al., 1989) and the increase of cytosolic calcium in HL-60 cells (Mitsuhashi et aI.,
1991, Seifert et al., 1992).
In view of these data and the lack of suitable systems for the study of the pharmacological
properties of the human H2 receptor and the regulation of its fuction, we stably expressed the
cloned human gene (Gantz et al., 1991b) in CHO cells. Our detailed pharmacological
characterization of the encoded protein was performed with the highly specific H2 receptor
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antagonist [lZ51]-iodoaminopotentidine (Ruat et al., 1990). This radiolabel has previously
successfully been used for the labelling of the human HZ receptor in brain tissue (Traiffort et
al., 199Za) and shows many advantages over [3H]-tiotidine. From our results with
CHOhumHZ cells the HZ nature of the encoded receptor protein is clear. Affinity constants
calculated from displacement studies with 11 structurally different HZ receptor antagonists
perfectly match the pharmacological profile of the HZ receptor from guinea-pig right atrium
(Leurs et al., 1991) and human brain (Traiffort et al., 199Za); regression coefficients of 0.9Z
and 0.99 respectively are obtained when the various ~-values are correlated. It can therefore
be concluded that the cloned gene (Gantz et al., 1991b) encodes a classical human HZ
receptor.
In this study a complicated interaction of histamine with the [1Z5I]-iodoaminopotentidine
([1Z5I]-APT) binding site on CHOhumHZ cell membranes is observed. Shallow displacement
curves with Hill-coefficients of 0.58 were obtained, whereas the inclusion of the non-
hydrolysable GTP analogue Gpp(NH)p resulted in a steepening of the curves. Approximately
30% of the [lZ5I ]_APT binding sites showed high affinity for histamine (Z 11M). The biphasic
nature of the displacement curves of,histamine indicate the coupling of the human HZ receptor
to G-proteins.
As far as we know, the coupling of the human HZ receptor to a G-protein has not been
reported before on the basis of radioligand binding studies. Yet, besides its deduced amino acid
structure, adenylate cyclase studies with human heart tissue (Bristow et al., 198Z) and
radioligand binding studies with the rat HZ receptor expressed in CHO cells (Traiffort et al.,
199Zb) also indicate the interaction of the HZ receptor with G-proteins. Remarkable is the
discrepancy between the results from the displacement studies with histamine using
CHOhumHZ cell membranes and post-mortem human brain membranes (Table 1). In human
brain tissue histamine was found to display a to-fold higher affinity (4 11M) compared to
guinea-pig brain tissue (Traiffort et al., 199Za). The affinity of histamine for the high affinity
site on CHOhumHZ cell membranes is remarkably close to the reported affmity of histamine on
human brain membranes (Traiffort et al., 1992a). Unfortunately no data regarding GTP
sensitivity were reported in the latter. Yet, the observed differences between guinea-pig and
human brain tissue were suggested to be related to species differences or post-mortem or
aging-induced changes in receptor characteristics (Traiffort et al., 199Za). Based on the
present findings we conclude that the previously reported high affinity of histamine in human
brain membranes does not reflect a natural higher sensitivity of the human HZ receptor to this
neurotransmitter, but could be due to either conservation problems inherent to the use of post-
mortem human samples or due to aging related changes in receptor or G protein
characteristics; it is possible that only high affinity HZ receptor sites have been measured in the
post-mortem human brain membranes (Traiffort et aI., 199Za).
Following the characterization of the binding characteristics of the expressed protein we
investigated the signal transduction pathways of the human HZ receptor in CHO cells.
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Previously, it has been reported that H2 receptors can elevate the cAMP levels in a variety of
human tissues (Arima et ai., 1991, Bristow et ai., 1982, 1989, Emani et ai.• 1983,
Platshon et ai., 1978, Whitehead et al., 1988). We found that also in stably expressed CHO
cells stimulation of the human H2 receptor results in the rapid intracellular accumulation of
cAMP. Histamine is highly effective in this respect; the high potency in relation to its low
affinity reflects a large receptor reserve for histamine and therefore a highly efficient coupling
of the H2 receptor to the adenylate cyclase system in the CHO cells. The histamine-induced
cAMP production in CHOhumH2 cells was pharmacologically characterized as an H2 receptor
mediated process; the response was not inhibited by the HI and H3 receptor antagonists
mepyramine and thioperamide but could potently be inhibited by the H2 antagonists tiotidine
and cimetidine. The resulting Ktvalues obtained from the cAMP inhibition experiments (8 nM
and 0.56 JlM) were quite similar to the Ktvalues obtained from the radioligand binding studies
(17 nM and 0.66 JlM) for tiotidine and cimetidine respectively.
In some systems histamine H2 receptor stimulation has been suggested to be linked to other
signal transduction mechanisms (Delvalle et ai., 1992, Mitsuhashi et al., 1989, Seifert et ai.,
1992, Traiffort et al., 1992b). In HL-60 cells (Mitsuhashi et ai., 1989, Seifert et al., 1992)
and rat HEPA cells transfccted with the canine H2 receptor cDNA (Delvalle et ai., 1992) H2
receptor stimulation has been reported to result in an increase of the intracellular Ca2+
concentration. In HEPA cells this response was clearly correlated with an increase of the IP3
levels and appeared to be independent from the cAMP production (Delvalle et al., 1992).
Moreover, in CHO cells rat H2 receptor stimulation inhibited A23187-induced arachidonic acid
release via a cAMP independent mechanism (Traiffort et ai., 1992b). These data indicate that
H2 receptors might interact with a variety of different G proteins in the membrane.
In CHOhumH2 cells we were unable to observe a coupling to the phospholipase C and
phospholipase A2 pathway. In total agreement with our findings a linkage of the rat H2
receptor with the phospholipase C pathway could not be found either (Traiffort et al., 1992b).
These conflicting observations can be explained by assuming different G protein and/or
phospholipase C isoenzyme distribution in CHO and HEPA cells. In contrast to the rat H2
receptor (Traiffort et al., 1992b) the human H2 receptor was not able to reduce the A23187-
induced arachidonic acid release from CHOhumH2 cells either. Instead, a slight stimulation
was obtained, which can be explained by the reported modulation of arachidonic acid release
from CHO cells by protein kinase A (Piomelli and Di Marzo, 1993). An explanation for the
observed lack of inhibition could be found in the difference in receptor expression. For the rat
H2 receptor a CHO clone expressing 1.4 pmoVmg protein was used for the arachidonic acid
release experiments (Traiffort et ai., 1992b), whereas in the present study the human H2
receptor was expressed at a more physiological level (± 600 fmol/mg protein). It is also
possible that the observed sequence differences between the rat (Ruat et ai., 1991) and human
gene (Gantz et ai.• 1991) are responsible for the difference in signal transduction. It is known
that intracellular receptor domains are involved in the intemction of G protein coupled receptors
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with different G proteins (Probst et at., 1992). Although the rat and human H2 receptor genes
share a high degree of overall homology, especially in the intracellular parts of the receptor
proteins differences are found (Gantz et at., 1991b, Ruat et at., 1991).
In conclusion, we have stably expressed the human H2 receptor in CHO cells. The receptor
protein is pharmacologically similar to the human H2 receptor in brain tissue and is very
efficiently coupled to the adenylate cyclase system. The availability of a cell system expressing
the human H2 receptor will playa key role in the development of new and selective ligands for
this protein, an important target for today's human pharmacotherapy (Bertaccini and Corruzi,
1992, Felix et aZ., 1991). Screening of large series of compounds for their affinities for the
human H2 receptor is possible now, whereas also the regulation of the human H2 receptor
function can be studied in detail.
H2 receptor agonists are investigated for future development for application in patients with
congestive heart failure (Felix et at., 1991). In this pathophysiological condition the cardiac
adrenergic neurotransmission is strongly reduced. This is probably the result of an increase in
the expression of the beta-adrenergic receptor kinase, which is responsible for the
phosphorylation and desensitization of the beta2 adrenoceptor (Ungerer et aZ., 1993).
Recently, we observed a rapid desensitization of the human H2 receptor-mediated cAMP
production in U-937 cells (Smit et aZ., 1994). Yet, the use of this cell line for detailed
biochemical investigations is limited since the density of H2 receptors is very low (±1O
fmol/mg protein, MJ. Smit, unpublished observations). The use of the described CHOhumH2
cells will therefore be also of great importance for future mechanistic studies of the
desensitization and regulation of H2 receptor expression.
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Chapter 8
Visualization of agonist-induced internalization of
histamine H2 receptors
M. J. Smit, H. Timmerman, A. E. Alewijnse, M. Pounine, I. M. van den Nieuwenhof,
J. Blauw, J. van Minnen and R. Leurs
Histamine H2 receptors were tagged at the N-tenninus with the eight amino acid Flag epitope to allow the
immunological identification of the receptor peptide with the monoclonal anti-Flag M2 antibody. The
introduction of the epitope did not modify the binding of several H2 ligands to the H2 receptor, nor the ability
of histamine to stimulate the H2 receptor mediated cAMP production in HEK-293 cells. Western blots revealed
a major protein band of 57 ± 1 kDa, whereas a second band of 31 ± 1 kDa was probably the result of a
proteolytic breakdown of the 57 kDa band. lmmunofluorescence measurements of stably transfected HEK-293
cells revealed the presence of anti-Flag-immunoreactivity in the plasma membrane. This immunoreactivity
completely disappeared after a one hour treatment with histamine. The receptor internalization was reversible and
blocked by the endocytosis inhibitor phenylarsine oxide. Forskolin did not induce H2 receptor internalization,
indicating that histamine causes H2 recepto~ internalization via a cAMP-independent pathway.
Introduction
Molecular biological studies indicate that the histamine H2 receptor belongs to the large
multigene family of G protein coupled receptors (GPCR) (Gantz et at., 1991, Gantz et at.,
1991, Ruat et at., 1991, Traiffort et at., 1995). Excessive stimulation of receptor proteins
belonging to the GPCR family often leads to an attenuation of the receptor responsiveness
(Collins, 1993, Lohse, 1993). Three major mechanisms are currently acknowledged to be
involved in the process of GPCR regulation (Collins, 1993, Lohse, 1993). Initially, GPCRs
are uncoupled from their respective G proteins due to phosphorylation by serine/threonine
kinases, resulting in a desensitization of the receptor responsiveness (Collins, 1993, Lohse,
1993). Thereafter, GPCRs can be translocated from the plasma membranes to intracellular
endosomes, where they are inaccessible to hydrophylic ligands like biogenic amines (Collins,
1993, Lohse, 1993). Finally, the GPCRs can be degradated to obtain a lower expression level
at the plasma membrane for a prolonged period of time (Collins, 1993, Lohse, 1993).
Despite the wide therapeutic use of H2 antagonists for gastric ulcers (Bertaccini and
Coruzzi, 1992) and the potential application of H2 agonists in cardiac heart failure (Felix et
at., 1991), only limited information is available on the regulation of the H2 receptor
responsiveness. Previously, we and others showed that the H2 receptor mediated cAMP
response is rapidly desensitized in various cell types (Arima et at., 1993, Fukushima et at.,
1994, Johnson and Sawutz, 1984, Prost et at., 1984, Schreurs et at., 1984, Smit et at.,
1994). With the availability of the nucleotide sequence encoding the H2 receptor (Gantz et at.,
1991, Gantz et at., 1991, Ruat et at., 1991, Traiffort et at., 1995) detailed molecular
investigations of H2 receptor regulation are now feasible. Cellular systems, expressing
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sufficient amounts of H2 receptor proteins for the detection with radioligands, have been
reported (Fukushima et al., 1994, Leurs et al., 1994, Traiffort et al., 1992) and shown to be
highly suitable for the study of H2 receptor regulation.
We previously reported on the agonist-induced H2 receptor downregulation in CHO cells,
expressing the rat histamine H2 receptor (Chapter 5). Our data indicate that the general scheme
of regulation of GPCR responsiveness is probably also applicable to the H2 receptor.
Currently, no studies on H2 receptor internalization have been reported. This is mainly due to
the lack of suitable hydrophylic radioligands and anti-H2 receptor antibodies. Again, the
cloning of the H2 receptor cDNAs and genes (Gantz et al., 1991, Gantz et al., 1991, Ruat et
al., 1991, Traiffort et al., 1995) has provided means to overcome this latter problem.
Recently, an anti-H2 receptor peptide antibody has been described (Fukushima et al., 1994),
whereas in the present study we describe the construction of epitope-tagged H2 receptors as a
tool to identify the H2 receptor protein by Western blotting and immunofluorescence
microscopy. This approach allows us to demonstrate the process of H2 receptor internalization
for the first time.
Materials and Methods
Epitope-tagging HZ receptor The nucleotide sequence encoding the epitope-tagged human H2 receptor was
constructed by PCR, using the synthetic oligonucleotide S'·TGCAGATCTGCCACCATGGACTACAA-
GGACGACGATGACAAGGCACCCAATGGCACAGCCTCT (nucleotides 4 to 24 of the human H2 receptor
(Gantz et al., 1991), a nucleotide sequence encoding the Flag peptide DYKDDDD, a methionine, a Kozak
sequence and a Bgill linker site) and the oligonucleotide S'-TGCAGATCTTTACCTGTCTGTGGCTCCCT
(nucleotides 1061-1080 and a Bgill linker site). For the rat H2 receptor similar oligonucleotides S'-
GGGAAGCTIGCCACCATGGACTACAAGGACGACGATGACAAGGAGCCCAATGGCACAGTICATand
S'-CGGAGATCTACAACCTrfACCTGATIGGGT were used. Using 100 ng pSVratH2 (Ruat et al., 1991) or
pCMVhumH2 (Gantz et al., 1991) as template, 0.4 j.lM of the respective oligonucleotides, 200 j.lM of each
nucleotide and 2.S U Pfu DNA polymerase (Promega), the desired fragments were amplified in 100 IJl using 2S
cycles at 94°C for 1 min, S6°C for 1 min and 72°C for 1 min and a final extension at 72°C for 10 min. The
DNA fragments were gel-purified, restricted with the appropriate enzymes and ligated in the plasmid pSP73
(Promega). The complete nucleotide sequence of the receptor mutant was verified using Sequenase (USB) and
subcloned into the expression vectorpRKS'
Cell culture and transfection Human embryonic kidney cells (HEK-293 cells) were grown at 37°C in a
humified atmosphere with S% CO2 in Dulbeco's Modified Eagle's Medium (DMEM), containing 10% (v/v)
foetal calf serum and supplemented with 2 mM L-glutamine, SO IU/ml penicillin and SO Jlg/ml streptomycin.
HEK-293 cells were transiently transfected with the eukaryotic expression vectors pRKS' pRKShumH2,
pRKShumH2Flag and pRKSratH2Flag using calcium phosphate precipitation (Chen and Okayama, 1987).
HEK-293 cells (10 cm dish) were stably cotransfected with the eukaryotic expression vectors pRKSratH2Flag
(14 Jlg) and pSV2neo (I Jlg) using Transfectam (Promega) (Leurs et al., 1994). Stable cell lines were
maintained in culture medium, supplemented with SOO Jlg/ ml G418.
Biochemical measurements The determination of the cAMP levels and the H2 receptor binding assays were
performed as described previously (Leurs et aI., 1994). In some experiments membrane proteins were
solubilized (Ruat et al., 1990) and resolved by electophoresis through a 10% polyacrylamide/SDS gel and
transferred to nitrocellulose (BA8S, Schleicher and Schuell). Immunoblotting was performed overnight at 4 °C
with the anti-Flag M2 antibody (0.6 Jlg/ml) and an incubation with a horseradish peroxidase conjugated goat-
anti-mouse secondary antibody (Biorad, 1:20.000). Immunoreactivity was visualized by chemiluminescence
using the Amersham ECL detection kit
Immunofluorescence microscopy HEK-293 cells were grown on glass coverslips. Following the various
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treatments cells were fixed with 4% paraformaldehydeIPBS for 30 mins at room temperature (Rl) and blocked in
PBS/O.l% BSA for Ihr at RT. For detection of immunofluorescence inside the cell, cells were permeabilzed
using 0.5% Nonidet P40 (Boehringer)/PBS for 30 mins at RT and blocked with PBS/O.l %BSAlO.4%
Tritonxloo. Receptor antigen detection was performed with 9 Ilg/ml anti-Flag M2 antibody for 2 hrs in
PBS/1%BSA. After washing in PBS the coverslips were incubated with a fluorescein isothiocyanate-conjugated
rabbit-anti-mouse secondary antibody (DakopaU 1:100) for 1 hr in PBS/1 % BSA. Immunofluorescence
microscopy was performed with an inverted (Axiovert 135) Zeiss 410 confocal laser scan microscope. The
standard ftlter combination for FlTC fluorescence microscopy (FT 510, BP 515-565) was used. The FlTC was
excited using the 488 line of an Argon laser. The parameters of the microscope (laser intensity, pinhole,
scantime, contrast, brightness) were kept constant during the experiments, allowing to compare fluorescence
levels of cells during the different experimental conditions.
Chemicals Histamine.2HCl, forskolin, phenylarsine oxide, isobutylmethylxanthine were obtained from
Sigma Chemical Company (USA). [3H]-cAMP (40 Cilmmol) was obtained from Amersham. Aminopotentidine
was taken from laboratory stock. Generous gifts of tiotidine (Imperial Chemical Industries) and burimamide
(SmithKline Beecham) are greatly acknowledged. The mouse anti-Flag M2 monoclonal antibody was obtained
from International Biotechnology Inc.
Results·
Transient expression ofthe human and rat histamine H2Flag receptor in HEK-293 cells
Forty-eight hrs after transient transfection of HEK-293 cells with the expression vectors
pRK5humH2 and pRK5humH2Flag a high expression of the respective H2 receptor proteins
was detected with the H2 receptor antagonist [125I]-iodoaminopotentidine ([125I]-APT). The
eight amino acid epitope had no effects on either the receptor expression levels (humH2: Bmax
= 3.2 ± 0.7 pmoVmg protein, humH2Flag: Bmax = 2.8 ± 0.4 pmoVmg protein) or the Kd value
for [125I]_APT (Table 1). Moreover, the ~ values for other H2 antagonists and histamine did
also not markedly differ between the two receptor proteins (Table 1).
The Flag epitope did not affect the signalling properties of the receptor protein in transiently
transfected HEK-293 cells either. Stimulation of HEK-293 cells expressing the human H2Flag
receptor with 10 nM or 11lM histamine induced respectively 98 ± 2 % (n =4) and 105 ± 8 %
(n = 4) of the cAMP accumulation in HEK-293 cells expressing the wild-type receptor induced
by the same concentrations of histamine.
Table 1 Analysis of the binding of several H2ligands to membranes of HEK-293 cells expressing the human
wild-type or H2Flag receptor protein. Data shown are mean ± s.e.mean of three independent experiments.
Ki values
compound
[1251]_APT*
aminopotentidine
tiotidine
burimamide
histamine
*Kct value
wild-type H2
0.34 ± 0.03 nM
12± 2nM
14± 3 nM
21 ± 5 11M
89 ± 5 11M
0.35 ± 0.07 nM
9±2nM
12± 2nM
22 ± 10 11M
181 ± 19 11M
144 Chapter 8
The Flag epitope allowed the detection of the human and rat H2Flag receptor by the mouse
anti-Flag M2 monoclonal antibody. Western blots of a 10 % SDS-PAGE gel of solubilized
membranes of HEK-293 cells transiently transfected with pRKS' pRKShumH2 or
pRKshumH2Flag revealed only immunoreactive bands with cells, expressing the human
H2Flag receptor (Fig. 1). Two major immunoreactive bands of 57 ± I kDa and 31 ± 1 kDa
were detected (Fig. 1). Two minor bands at 53 and 50 kDa and various bands smaller than 21
kDa were also identified (Fig. 1). Similar results were obtained with HEK-293 cells expressing
the rat H2Flag receptor (data not shown). The specificity of the anti-Flag M2 monoclonal
antibody was confirmed by the measurement of cellular immunofluorescence. Neither pRKs-
nor pRKShumH2 transfected HEK-293 cells showed considerable immunoreactivity. In
contrast, HEK-293 cells transiently expressing the human or rat H2Flag receptor showed a
clear immunofluorescence signal in the plasma membrane (data not shown). Permeabilization
of the transiently expressed 293 cells with the human as well as rat H2Flag receptor also
showed immunofluorescence in the cytoplasm in areas corresponding to the Golgi apparatus
(cover thesis).
Stable expression ofthe rat histamine H2Flag receptor in HEK-293 cells
In view of our interest in the regulation of the rat H2 receptor expression (Chapter 5 and 6), the
rat H2Flag receptor was stably expressed in HEK-293 cells. Cotransfection of HEK-293 cells
with the plasmids pRKsratH2Flag and pSV2neo by lipofection resulted after 10 to 14 days of
selection in culture medium, supplemented with 500 Ilglml G418, in the formation of several
clonal cell lines. A clone (293rH2Flag) that expressed 1594 ± 17 fmol/mg protein [12SI]_APT
binding sit:es (mean ±s.e.mean, n =3) was selected. Initial experiments indicated again that the
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Fig. 1. Western blot of human H2Flag receptors in pRKS- (lane A), pRKSH2 (lane B) and pRKSH2Flag(lane C) transfected HEK-293 cells. Solubilized membrane proteins were subjected to 10 % SDS/PAGE
electrophoresis and immunoblotted using the mouse monoclonal anti-Flag M2 antibody. Molecular weight
markers are indicated. Similar results were obtained in two other experiments.
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Flag-epitope did not alter the pharmacological characteristics of the H2 receptor protein (M. J.
Smit, unpublished observations). In the 293rH2Flag cells the H2Flag receptor was functionally
coupled to adenylate cyclase. A 10 mins incubation with histamine resulted in a maximal
increase of the intracellular cAMP levels from 51 ± 12 pmo1!well to 805 ± 202 pmo1!well
(mean ± s.e.mean, n = 6), with a pD2 value of 7.3 ± 0.06 (mean ± s.e.mean, n = 3).
Prolonged incubation (24 hrs) of the 293rH2Flag cells with 1 or 100 IlM histamine resulted in
a dose-dependent reduction of the H2 receptor expression (Fig. 2). Stimulation of 293rH2Flag
cells with 10 IlM forskolin also resulted in a marked increase of cellular cAMP (991 ± 293
pmo1!well), but only a moderate reduction of the H2 receptor expression was observed after a
24 hrs incubation with 10 IlM forskolin (Fig. 2).
Using the anti-Flag M2 monoclonal antibody the H2Flag receptor could be visualized in the
membranes of 293rH2Flag cells (Fig. 3 A, B). Permeabilization of the 293rH2Flag cells also
showed immunofluorescence in the cytoplasm (data not shown). One hr pretreatment of the
293rH2Flag cells with 100 IJ.M histamine at 37 °C resulted in an almost complete disappearance
of the immunoreactivity in the cell membrane (Fig. 3 C). Yet, at this time point no effective
receptor downregulation was observed. After 1 hr treatment with 100 IlM histamine the [1251]_
APT binding remained unchanged (103 ± 7 % compared to non-treated 293rH2Flag cells,
mean ± s.e.mean, n =4). Immunofluorescence of epitope-tagged H2 receptors was already
detected inside the cell and it was impossible to identify a further increase of the intracellular
immunofluorescence.
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Fig. 2. Downregulation of the rat H2Flag receptor stably expressed in 293rH2Flag cells. Cells were
incubated with the compounds for 24 hrs and analysed for [125I]_APT binding. The binding was expressed as the
percentage of non-treated 293rH2Flag cells. Data shown are mean ± s.e.mean of six independent experiments.
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Fig. 3. Internalization of the rat H2Flag receptor in 293rH2Flag cells as visualized by immunofluorescence.
Panel A and B show the immunofluorescence and light microscopic image of the same group fixed control
293rH2Flag cells respectively. Panel C and D show the immunofluorescence after treatment of 293rH2Flag cells
with 100 J.IM histamine at 37°C for I he and the same treatment with histamine after 10 mins preincubation
with 80 J.IM phenylarsine oxide respectively. Data shown are a representative example of three independent
experiments. The bar represents 15 fJ.IIl.
The rapid histamine-induced disappearance of the Flag-immunoreactivity was effectively
blocked by a 10 mins pretreatment of 293rH2Flag cells with 80 jlM phenylarsine oxide (Fig. 3
D). In a separate set of experiments the reversibility of the observed disappearance of Flag-
immunoreactivity was investigated. After a one hr incubation of 293H2Flag cells with 100 IlM
histamine at 37°C the cells were extensively washed with DMEM/50 mM HEPES (pH =7.4).
Thereafter the cells were allowed to recover for two hrs at 37°C in the same medium. This
procedure allowed the detection of the recovery of Flag-immunoreactivity in the cell
membranes (compare Fig. 4 A, C). Finally, we investigated the effect of forskolin pretreatment
on H2Flag receptor internalization. A one hr incubation of 293H2Flag cells with 10 IlM
forskolin at 37°C did not lead to important changes of the membrane-localized Flag
immunoreactivity (compare Fig. 4 A, B and D).
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Fig. 4. Internalization of the rat H2F!ag receptor in 293rH2Flag cells as visualized by immunofluorescence.
Panel A shows the immunofluorescence of fixed control 293rH2F1ag cells, whereas in panel B the
immunofluorescence after treatment of 293rH2Flag cells with 100 f.lM histamine at 37°C for 1 hr is shown. In
panel C the cells were treated as. in B but extensively washed and incubated for additional two hrs at 37°C. In
panel D 293rH2Flag cells were treated with 10 f.lM forskolin at 37°C for 1 hr. Data shown are a representative
example of three independent experiments. The bar represents 15 J.Ull.
Discussion
In the present study we epitope-tagged the H2 receptor to detect the receptor protein by
Western blotting and immunohistochemistry. As shown by [125I]_APT binding studies and
cAMP measurements the introduction of the Flag peptide at the N-terminus did not modify the
pharmacological properties of the H2 receptor, validating our experimental approach. The Flag
epitope allowed the immunological detection of the H2 receptor protein. Using HEK-293 cells
expressing the wild-type receptor no immunoreactive bands were observed on a Western blot,
whereas with cells expressing the H2F1ag receptor two main bands of 57 and 31 kDa peptides
were found to be labelled. Some minor bands at 53-50 kDa were also found and probably
represent partially glycosylated receptors, whereas the 31 kDa peptide is likely the result of a
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proteolytic breakdown of the 57 kDa peptide, since omittance of protease inhibitors largely
increased the intensity of this band (data not shown). In literature some conflicting results have
been reported on the molecular identification of the H2 receptor proteins (Fukushima et al.,
1994, Ruat et aI., 1990). Using [125I]-iodoazidopotentidine Ruat et al. (1990) reported the
photoaffinity labelling of 87,59,51 and 32 kDa proteins in guinea-pig brain membranes. Only
the labelling of the 59 and 32 kDa bands was prevented by coincubation with H2 antagonists
(Ruat et aI., 1990). In another study an anti-peptide antibody directed against the C-terminus
of the canine H2 receptor was used to probe Western blots of CHO cells transfected with the
canine H2 receptor (Fukushima et aI., 1994). The antibody recognized a broad band with an
apparent molecular mass of 63-95 kDa (Fukushima et al., 1994), which is substantially higher
than the molecular mass found in the present study. Yet, the results obtained after photoaffinity
labelling (Ruat et al., 1990) correspond well with our results with the anti-Flag antibody. The
reasons for the discrepancy with the results obtained with the anti-peptide antibody (Fukushima
et al., 1994) are not clear, but are probably due to technical'differences in the solubilization
step. In the present study we used the same protocol as Ruat et al. (1990), but in preliminary
experiments we observed that the migration of Flag-immunoreactive bands was dependent on
the solubilization protocol used (M. J. Smit, unpublished observations).
The introduction of the Flag peptide allowed us to demonstrate H2 receptor internalization
for the first time. A short incubation of stably transfected HEK-293 cells with histamine at
37°C resulted in the rapid disappearance of Flag immunoreactivity in the plasma membrane.
Apparently, agonist stimulation of the H2 receptor results in the rapid translocation of the H2
receptor to intracellular domains, which are inaccessible for the anti-Flag antibody. Our data
indicate that under these conditions these receptor proteins are not degraded, but recycled. The
internalization was rapidly reversed by washing and incubation at 37°C, whereas [125I]-APT
binding studies did not reveal major changes in the total number of H2 receptors after a one hr
treatment with histamine. The loss of Flag-immunoreactivity was moreover effectively
inhibited by preincubation with the endocytosis inhibitor pheny1arsine oxide. This compound is
reported to inhibit endocytosis of e.g. recycling epidermal growth factor receptors (Hertel et
al., 1985), but more interesting also inhibits the internalization of the ~2-adrenergic and
substance P NK1 receptors (Feldman et al., 1986, Garland et al., 1994, Hertel et aI., 1985).
Treatment of the 293rH2 Flag cells with forskolin did not result in H2 receptor internalization,
although production of cAMP and H2 receptor downregu1ation was observed. These data
indicate that the process of H2 receptor internalization in HEK-293 cells is cAMP-independent,
as previously has been found for the ~2-receptor (Bouvier et al., 1989). Moreover, the
different extents of H2 receptor downregulation by forskolin and histamine also indicates a
cAMP-independent mechanism of H2 receptor downregulation in these cells. Recently, we
observed similar mechanisms in CHO cells, transfected with mutant H2 receptors (Chapter 5),
substantiating the hypothesis of cAMP-independent pathways of H2 receptor regulation.
The exact fate of the internalized H2 receptors is not clear, but internalization via clathrin-
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coated pits and recycling to the plasma membrane of receptors of e.g transferrin and the
epidermal growth factor has been shown (Hertel et al., 1985, Von Zastrow and Kobilka,
1992). Recently, Von Zastrow and Kobilka provided evidence that the P2-receptor is
internalized and recycled via such a pathway (Von Zastrow and Kobilka, 1992). The
functional role of GPCR internalization is not completely resolved, but there is strong evidence
that internalization of the P2-receptor is required for receptor resensitization. Sibley et al.
(1986) reported that high phosphatase levels were associated with sequestered vesicles.
Consequently, the sequestered Prreceptors were phosphorylated to a lesser extent than
desensitized P2-receptors (Sibley et al., 1986). Moreover, inhibition of GPCR internalization
resulted in an inhibition of receptor resensitization (Barak et al., 1994, Palmer et aI., 1994,
Pippig et aI., 1995, Yu et al., 1993), corroborating the suggestion that internalization is
required for receptor dephosphorylation and resensitization. Homologous desensitization of the
H2 receptor responsiveness has been shown previously (Arima et aI., 1993, Fukushima et
al., 1994, Schreurs et al., 1984, Smit et al., 1994), but H2 receptor phosphorylation and
resensitization has so far not been studied. Our approach of epitope-tagging of the H2 receptor
should allow to investigate this process. This approach should also enable to investigate which
structural elements of the receptor protein are implicated in H2 receptor internalization.
Serine/threonine-rich domains in the third intracellular loop or C-terminus and a highly
conserved NP(X)Y motif in the seventh transmembrane domain have been shown to be
involved in the internalization of GPCRs (Barak et al., 1994, Campbell et aI., 1991,
Hunyady et al., 1994, Lameh et aI., 1992). Similar structural features are found in the rat H2
receptor amino acid sequence (Ruat et al., 1991), but the assignment of their role awaits site-
directed mutagenesis studies.
In conclusion, receptor internalization is a prominent mechanism of H2 receptor regulation.
This process is rapid, reversible, cAMP-independent and is probably responsible for the
resensitization of desensitized H2 receptors.
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Chapter 9
Inverse agonism of histamine H2 antagonists leads to
antagonist-induced upregulation of the histamine H2
receptor
M. J. Smit, H. Timmerman, A. E. Alewijnse, J. Blauw, G. P. Van Nieuw Amerongen, E.
Roovers and R. Leurs
In the present study we have demonstrated that the wild-type rat histamine H2 receptor density in Chinese
Hamster Ovary celIs (CHOrH2WT cells) is affected by long-term exposure to some H2 antagonists. Prolonged
treatment of CHOrH2WT cells with cimetidine resulted in time-dependent (tIl2 = 3.5 hrs, concentration of 100
J.lM cimetidine) and dose-dependent (EC50 = 6.0 J.lM at 24 hrs incubation) increase of [1251]_
iodoaminopotentidine ([125I]-APT) binding, referred to as H2 receptor upregulation (68 ± 2% maximum
upregulation). Yet, the cimetidine analogue VUF 8299, which is devoid of H2 receptor antagonistic activity on
the guinea-pig right atrium, induced no H2 receptor upregulation. No change in H2 receptor density was
observed either after long-term treatment Of CHOrH2WT celIs with the HI antagonist triprolidine or the H3
antagonist thioperamide.
Basal levels of cAMP and forskolin-induced formation of cAMP were shown to increase upon elevation of
H2 receptor density (286 fmol/mg protein and higher), indicating that the wild-type H2 receptor displays
properties resembling those of constitutively active GPCR mutants. Interestingly, the agonist-independent H2
receptor activity in CHOrH2WT was accompanied by the occurrence of inverse agonism exerted by cimetidine,
whereas its inactive structural analogue VUF 8299 did not show negative intrinsic activity. Cimetidine did uot
display inverse agonism in CHOrH2Leu124Ala (CHO celIs expressing the mutant H2Leu124Ala receptor which
was previously found to be uncoupled from its Gs-protein (Chapter 5» and CHOrH2WT6 cells (density 96 ± 26
fmol/mg protein), both showing reduced basal and forskolin-induced levels of cAMP compared to CHOrH2WT
cells. Accordingly, cimetidine only induced H2 receptor upregulation in CHOrH2WT (density 975 ± 12
fmol/mg protein) and CHOrH2WT9 (density 286 ± 52 fmolfmg protein) celIs and not in CHOrH2Leul24Ala or
CHOrH2WT6 cells. Moreover, not all H2 antagonists displayed negative intrinsic activity. Burimamide, for
example, acted as a neutral antagonist as no major changes in basal cAMP levels or in H2 receptor density were
observed after incubation with burimamide.
Based on these fmdings we conclude that at physiological H2 receptor densities H2 receptors are precoupled
and that several H2 antagonists, previously thought to act as competitive antagonists, may actually function as
inverse agonists. The displayed inverse agonism of some H2 antagonists appears to be the mechanistic basis for
the H2 antagonist-induced H2 receptor upregulation in CHOrH2WT cells. Moreover, it may also explain the
previously reported observations after long-term H2 antagonist treatment of gastric ulcers, such as increased
sensitization of the H2 receptor, increased intragastric hyperacidicity and loss of antisecretory effect. Our data
imply a careful reconsideration of the pharmacological activity of the clinically used H2 antagonists. In some
instances neutral antagonists may be favoured.
Introduction
G-protein coupled receptors (GpeRs) are known to undergo receptor down- or upregulation
after excessive stimulation or prolonged blockade respectively. These processes have been
observed in vivo (Elfellah and Reid, 1989, Homey et at., 1991, Motomura et al., 1990,
Reid et at., 1994, Yoburn et at., 1994) and have been suggested to have consequences for
drug therapy (Brodde et al., 1990, Ghosh et al., 1991, Homey et at., 199J, Motomura et
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al., 1990, Stiles, 1991).
In Chapter 5 we describe that histamine H2 receptors are affected by long-term agonist-
exposure, as shown by H2 receptor downregulation in transfected Chinese Hamster Ovary
(CHO) cells. Moreover, Diaz et al. (1994) suggested that in vivo receptor downregulation
might explain the inverse relationship between H2 receptor expression and the localization of
histamine-synthesizing cells in the rodent gastric wall.
Clinically, histamine H2 antagonists are of great importance. These drugs (cimetidine,
ranitidine, famotidine, nizatidine) are widely used in the treatment of gastric ulcers (Bertaccini
and Coruzzi, 1992), whereas the reported beneficial effect of famotidine in schizophrenia
(Deutsch et al., 1993, Kaminsky et al., 1990) might further boost their therapeutic use.
Interestingly, in vivo modulation of H2 receptor responsiveness and H2 receptor density after
treatment of H2 antagonists has also been reported (Bertaccini and Coruzzi, 1992, Coruzzi
and Bertaccini, 1989, Martinez-Mir et al., 1993, Merki and Wilder-Smith, 1994, Nwokolo
et al., 1991). Chronic treatment of conscious cats with ranitidine resulted in increased parietal
cell sensitivity (Coruzzi and Bertaccini, 1989). Furthermore, abrupt withdrawal of histamine
H2 receptor blockade (ranitidine,cimetidine, nizatidine) in humans was shown to lead to
intragastric hyperacidity (Nwokolo et al., 1991). Others reported a loss of antisecretory effect
after prolonged infusions of ranitidine (Merki and Wilder-Smith, 1994). As for alterations in
H2 receptor expression, it has been reported that the histamine H2 receptor expression in brain
tissue (globus pallidus) of schizophrenic patients which receive chronic neuroleptic treatment is
increased (Martinez-Mir et al., 1993). Some neuroleptics show considerable affinity for
human H2 receptors (Leurs et al., 1994, Traiffort et al., 1992), indicating the possible in
vivo regulation of H2 receptor expression upon treatment with neuroleptics.
Despite the therapeutical importance of H2 antagonists so far no detailed insights on the
modulation of H2 receptor function by H2 antagonists have been obtained. According to
classical models for drug-GPCR interaction, competitive antagonists are believed to simply
inhibit the binding of agonists to the receptors (De Lean et al., 1980). Their physiological
effect, including receptor upregulation, is therefore attributed to their ability to prevent
activationldownregulation of receptors by endogenous hormones or neurotransmitters.
However, there is now substantial evidence that contradicts this notion (Lefkowitz et al.,
1993, Schlitz and Freissmuth, 1992). For some GPCRs some antagonists were shown to
induce effects opposite to those observed by agonists, thereby displaying negative intrinsic
activity, also referred to as inverse agonism (Lefkowitz et al., 1993, Schlitz and Freissmuth,
1992). Consequently, unoccupied receptors were proposed to spontaneously isomerize
between 'inactive' and 'activated' states (Costa et al., 1992, Lefkowitz et al., 1993, Onaran
et al., 1993). Agonists were shown to favour the active state of the receptor (coupled to the G-
protein), whereas inverse agonists would favour the inactive state of the receptor. Initial
conclusive evidence of inverse agonism by GPCR antagonists came from experiments with
constitutively active GPCR mutants (<XlB-, <X2-ClO- and B2-adrenergic receptors) (Cotecchia
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et at., 1990, Kjelsberg et al., 1992, Ren et al., 1993, Samama et at., 1994). These GPCR
mutants were shown to activate signal transduction pathways without agonist stimulation
(Cotecchia et al., 1990, Kjelsberg et al., 1992, Ren et al., 1993, Samama et at., 1994).
Intriguingly, this spontaneous activity could be reduced by receptor antagonists. Thereafter,
wild-type serotonine 5-HT2C (Barker et at., 1994), <x'2D-adrenergic (Tian et al., 1994), ~2­
adrenergic (Chidiac et at., 1994), dopamine DlB (Tiberi and Caron, 1994) and bradykinin
B2 receptors (Leeb-Lundberg et al., 1994) were shown to display agonist-independent activity
as well. These observations suggest that the agonist-independent activity may be a natural
feature of some GPCRs. Consequently, a dramatic change in our views on the pharmacological
activity of some GPCR antagonists will be needed.
In the present study we examined the effects of H2 antagonists on rat histamine H2
receptor activity and H2 receptor expression in transfected CHO cells (Traiffort et at., 1992).
Using CHO cell lines expressing different levels of H2 receptor proteins and a CHO cell line
expressing a mutant H2 receptor, which was previously (Chapter 5) shown to be uncoupled of
its Gs-protein, we have evidence that several H2 antagonists act as inverse agonists and
consequently cause H2 receptor I.1;pregulation. These observations might have important
therapeutical consequences for the currently available H2 antagonists and the future
development of effective drug therapy.
Materials and methods
Cell culture and transfection CHO cells, deficient in dihydrofolate reductase, were maintained in a humidified
atmosphere with 5% CO2 in Dulbeco's Modified Eagle's Medium (DMEM), containing 10% (vol/vol) foetal
calf serum, supplemented with 2 mM L-glutamine, MEM amino acids, 50 IU/ml penicillin, 50 ~g/ml
streptomycin and hypoxanthine. CHO cells were stably transfected with 15 ~g of the eukaryotic expression
vector pSVrH2 using Transfectam (Promega). After two weeks of selection in medium without hypoxanthin and
thymidine and with 10 % dialyzed foetal calf serum, surviving CHO colonies were isolated by ring cloning.
Two clones expressing 96 ± 26 and 286 ± 52 fmol H2 receptors/mg protein, referred to as CHOrH2WT6 and
CHOrH2WT9 respectively, were selected and grown at 37°C in a humified atmosphere with 5% CO2 in
DMEM, containing 10% (voVvol) dialyzed foetal calf serum, supplemented with 2 mM L-glutamine, MEM
amino acids, 50 IU/ml penicillin and 50 ~g/ml streptomycin. The same medium was used for CHO cells
expressing the wild-type rat histamine H2 receptor (CHOrH2WT) (975 ± 12 fmoVmg protein) (Traiffort et al.,
1992) and rat histamine H2Leu124Ala (CHOrH2Leu124Ala) (980 ± 7 fmoVmg protein) (Chapter 5).
Biochemical measurements The determination of H2 receptor binding and levels cAMP were performed as
described in Chapter 5. Instead of seeding the cells in 24-well plates, CHOrH2WT, CHOrH2WT6,
CHOrH2WT9 and CHOrH2Leu cells were seeded in 12-well plates for the measurement of basal cAMP
production.
RNA slot blot analysis RNA was analyzed as described in Chapter 5.
Chemicals Histamine dihydrochloride, isobutylmethylxanthine (IBMX), cyclic AMP (cAMP), forskolin and
triprolidine dihydrochloride was obtained from Amersham. Aminopotentidine, VUF 8299 and thioperamide
maleate were taken from laboratory stock. Gifts of cimetidine and burimamide (SmithKline Beecham, United
Kingdom), tiotidine (Imperial Chemical Industries, United Kingdom), ranitidine dihydrochloride (Glaxo, United
Kingdom) and famotidine (Merck Sharp & Dobme, The Netherlands) are greatly acknowledged.
Statistical analysis All data shown are expressed as mean ± standard error (mean ± s.e.mean) of at least three
independent experiments. Statistical analysis was carried out by Student's t-test P-values < 0.05 were considered
to indicate a significant difference.
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Results
Effect of long-term incubation of H2 antagonists on r1251]-APT binding in CHOrH2WT
cells
As we showed in previously (Chapter 5) exposure of CHOrH2WT cells to 100~ of
histamine for prolonged periods of time resulted in a time-dependent decrease of [1251]_
iodoaminopotentidine ([1251]-APT) binding sites (44 ± 10%, mean ± s.e.mean, n = 4, P <
0.05) (Fig. 1). The histamine-induced downregulation (24 hrs incubation with 100 I.lM of
histamine) was blocked by co-incubation of CHOrH2WT cells with 10 I.lM of the H2
antagonist tiotidine, as no change in [125I]-APT binding sites was observed (Inset Fig. 1).
Remarkably, exposure of CHOrH2WT cells to tiotidine (10 ~) alone surprisingly resulted in
a significant increase in [1251]-APT binding (82 ± 6%, n =4, mean ± s.e.mean, p < 0.05,
Inset Fig. 1, Table 1). Pretreatment of CHOrH2WT cells for 24 hrs with other H2 antagonists,
such as cimetidine, ranitidine and aminopotentidine, possessing distinct structural properties
led to similar observations (Table 1). Pretreatment of CHOrH2WT cells with different H2
receptor antagonists resulted in a significant increase in [1251]-APT binding (Table 1). The
observed increase of [125I]-APT binding was ascribed to an increase in the maximal number of
[1251]-APT binding sites when CHOrH2WT cells were incubated with 10 I.lM
aminopotentidine for 24 hrs (Table 2).
120
I:lIl 100
;§
] 80
~ 60
I
~
'" 40
'"~
~ 20
0
0
*
HA HAfTIO 110
5 10 15 20 25 30 35
time (hrs)
Fig. 1. Histamine-induced decrease of [l25I]-APT binding in CHOrH2WT cells. CHOrH2WT cells were
incubated with 100 J.IM histamine for the indicated times and [125I]_APT binding in membranes was measured.
The [125I]_APT binding is expressed as a percentage of [1251]_APT binding measured in non-treated histamine.
The data shown represent the means ± s.e.mean of 4 independent experiments. Inset Effect of the H2 antagonist
tiotidine on the histamine-induced H2 receptor dowuregulation and [125I]_APT binding. CHOrH2wT cells were
incubated in the presence of 100 J.IM histamine (HA), 10 J.IM tiotidine (TIO) together with 100 J.IM histamine
and 10 J.IM tiotidine alone for 24 hrs. Data shown are means ± s.e.mean of 4 independent experiments.
Significant differences from control, represented by the number of [1251]-APT binding sites measured in non-
treated cells, at p < 0.05 (Student's (-test) are indicated by the asterisks.
Upregulation ofthe H2 receptor 157
Table 1 Effect of 24 hrs incubation of HI, H2 and H3 antagonists on [125Il-APT binding in CHOrH2WT
ceils
Antagonist
Tiotidine
Cimetidine
Aminopotentidine
Triprolidine
Thioperamide
(10 J.lM)
(100 J.lM)
(10 J.lM)
(1 J.lM)
(1 J.lM)
% upregulation
82±6 *
68 ± 9 *
79± 9 *
-3 ± 10
12± 11
CHOrH2WT were incubated for 24 hrs with the indicated drugs and [125Il_APT binding in membranes was
measured. The [1251]-APT binding is expressed as a percentage of upregulation compared to non-treated cells.
Data were calculated as means ± s.e.mean from at least 3 experiments. The asterisk indicates a significant
difference (p <0.05) from control, represented by non-treated cells.
Table 2 Characteristics of [125Il-APT binding to rat histamine H2 receptors expressed in CHO cells
pretreated for 24 hrs with or without aminopotentidine (APT)
pretreatment 24 hrs
control
APT (10 J.lM)
Kq
(oM)
0.43 ± 0.06
0.54 ± 0.02
Bmax
(fmoVmg protein)
975 ± 12
1768 ± 85 *
The dissociation constant (~) and maximal number of binding sites (Bmax) was determined by using a non-
linear fitting according to a one-site binding mode. The data shown represent the means ± s.e.mean of 3
independent experiments. The asterisk indicates a significant difference (p < 0.05) from control, represented by
non-treated cells.
Table 3 Effect of 24 hrs incubation of CHOrH2WT cells with respectively 100 J.lM cimetidine and 100 J.lM of
the inactive analogue of cimetidine VUF 8299 on [1251]_APT binding to CHOrH2WT membranes
cimetidine
VUF8299
pA2 (atrium)
6.2 ± 0.1
<4
% upregulation
85 ± 9*
-3 ± 27
The antagonistic activity, depicted by a pA2 value, of cimetidine and VUF 8299 was detennined on the guinea-
pig atrium (Sterk et ai.• 1987). CHOrH2WT were incubated for 24 hrs with 100 J.lM cimetidine and 100 J.lM of
VUF 8299 and [1251]_APT binding in membranes was measured. The [125Il-APT binding is expressed as a
percentage of upregulation compared to non-treated cells. The values are means ± s.e.mean of 3 independent
determinations. The asterisk indicates a significant difference (p < 0.05) from control, represented by non-treated
cells.
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Pretreatment of CHOrH2WT cells for 24 hrs with 100 ~M VUF 8299, a structural
analogue of cimetidine devoid of H2 antagonistic activity at the guinea-pig right atrium (Sterk
et aI., 1987), did not affect the [1251]-APT binding (Table 3), suggesting that the observed
effects of cimetidine were related to its H2 antagonistic properties. Moreover, cimetidine had
no effect on the density of guinea-pig HI receptors (gpH1) expressed in CHO cells (untreated
cells: 100 ± 2% gpHl receptors, cimetidine-treated cells: 91 ± 4% gpHl receptors, mean ±
s.e.mean, n = 4) using the same pSV expression vector. In addition, the histamine HI and H3
antagonists, triprolidine (1 ~M) and thioperamide (l ~M) did not affect the amount of H2
receptors of CHOrH2WT cells after 24 hrs incubation (Table 1).
Incubation of CHOrH2WT cells for 24 hrs with increasing concentrations of cimetidine led
to a dose-dependent increase of [1251]-APT binding (Fig. 2A). The EC50 was found to be 6.0
± 1.1 ~M (mean ± s.e.mean, n =4). Exposure of CHOrH2WT cells to 100~ of cimetidine
for prolonged periods of time resulted in a time-dependent increase of [1251]-APT binding
(Fig. 2B). A maximal increase of [1251]_APT binding of 68 ±2% (mean ± s.e.mean, n =3)
compared to non-treated cells (mean ±s.e.mean, n =3, p < 0.05) was observed after 12 hrs
incubation of cells with 100~ cimetidine. Half maximal increase of [1251]_APT binding was
recorded at an incubation period of approximately 3.5 hrs.
H2 receptor mRNA levels in cimetidine-treated CHOrH2WI cells
Exposure of CHOrH2WT cells to 100~ of cimetidine for increasing periods of time resulted
in a rapid significant transient increase of H2 receptor mRNA (maximal increase of 32 ± 8%,
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Fig. 2. A, Dose-dependent increase of [125I]_APT binding induced by cimetidine in CHOrH2WT cells.
CHOrH2WT cells were exposed to various concentrations of cimetidine for 24 hrs. The data represent the mean
± s.e.mean of 4 independent experiments. B, Time-dependent increase of [125I]_APT binding in CHOrH2WT
cells by 100 J.1M cimetidine. CHOrH2wT cells were incubated with 100 J.1M cimetidine for the indicated times
and [125I]_APT binding in membranes was measured. The [125I]_APT binding is expressed as a percentage of
[125I]_APT binding measured in non-treated histamine. The data shown represent the mean ± s.e.mean of 3
independent experiments. Inset. Cimetidine-induced modulation of H2 receptor mRNA levels in CHOrH2WT
cells. CHOrH2WT cells were incubated for the indicated times with 100 J.1M of cimetidine. Cells were harvested,
total RNA was extracted and quantified by means of a RNA slot blot assay as described in Chapter 5. The results
displayed are the mean ± s.e.mean of three separate experiments, performed in duplicate.
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mean ± s.e.mean, n =6, P < 0.05) (Inset Fig. 2B). This effect was at its peak after 0.5 hrs of
incubation of cells with cimetidine (l00 IlM). Thereafter, the amount of H2 receptor mRNA
returned to control mRNA levels.
Basal cAMP levels andforskolin-inducedformation ofcAMP in untransfected CHO cells and
CHO cell lines expressing H2 receptors
In order to examine whether the H2 antagonist-induced upregulation of [125I]-APT binding
sites can be ascribed to an inhibition of basal H2 receptor activity we determined the basal
levels and forskolin-induced formation of cAMP in CHO cells expressing different levels of rat
histamine H2 receptors. As can be seen in Table 4 the basal level of cAMP in untransfected
CHO cells is the lowest and rises upon an increase of expressed H2 receptors. The forskolin
(10 1lM)-induced formation of cAMP was also found to increase upon elevation of the H2
receptor density (Table 4). In contrast, basal levels and forskolin-induced formation of cAMP
in CHO cells expressing a mutant H2 receptor, which was previously found to be uncoupled
from its Os protein (H2Leu124Ala, see Chapter 5), were found to be significantly lower than
those recorded in CHOrH2WT cells, expressing the same amount of H2 receptors (Table 4).
Table 4 Basal cAMP levels and forskolin-induced formation of cAMP in untransfected cell lines and cell lines
expressing H2 receptors and effect of long-term incubation of these cells with cimetidine on [125I]_APT binding
cell line H2 receptor density cAMP (pmoUmg protein) % upregulation
(fmoUmg protein)
basal 10 IJM forskolin
CHO 0 37 ±4 2148 ± 169
CHOrH2WI'6 96±26 42± 7 2054 ± 393 0±3
CHOrH2Wf9 286 ± 52 62± 5 * 2472 ± 130 * 83 ± 9 *
CHOrH2WI' 975 ± 12 198 ± 17 * 2945 ± 132 * 68 ± 9 *
CHOrH2Leul24A1a 980± 7 44± 3 ** 2123 ± 71 ** 18 ± 8 **
The basal cAMP levels and forskolin (10 IJM)-induced formation of cAMP in different CHO cell lines was
determined for 10 mins at 37°C in DMEM in the presence of 300 IJM IBMX and 25 mM Hepes, pH 7.4. Data
represent the mean ± s.e.mean of at least 3 independent experiments performed in duplicate. The asterisk and the
double asterisk indicate a significant difference (p < 0.05) from untransfected CHO cells and CHOrH2WT cells
respectively. Column %upregulation; the different CHO cell lines were incubated for 24 hrs with 100 IJM
cimetidine and [125I]_APT binding in membranes was measured. The [125I]-APT binding is expressed as a
percentage of upregulation compared to non-treated cells. Data were calculated as means ± s.e.mean from at least
3 experiments. The asterisk and double asterisk indicate a significant difference (p < 0.05) from non-treated cells
and CHOrH2WT cells respectively.
Effect ofcimetidine on basal cAMP levels in various CHO cell lines
In view of the observed increase of basal activity in CHOrH2WT6 and CHOrH2WT9 and
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CHOrH2WT cells compared to untransfected CHO cells we were interested to see whether
cimetidine was able to exhibit negative intrinsic activity by reducing the basal levels of cAMP.
Incubation of CHOrH2WT cells with increasing concentrations of cimetidine resulted in a
dose-dependent decrease of levels of cAMP (Fig. 3A). The EC50 value of this effect was 1.2 ±
0.3~ (mean ± s.e.mean, n =4). Cimetidine decreased the basal activity in CHOrH2WT cells
for 72 ± 6%. The inactive cimetidine VUF 8299, on the other hand, exhibited negative intrinsic
activity at a concentration of 100~ only (Fig. 3A).
Basal levels of cAMP (62 ± 5 pmol cAMP/mg of protein, mean ± s.e.mean, n =5) in
CHOrH2WT9 cells were also found to be significantly reduced by 100 IlM cimetidine (48 ±5
pmollmg of protein, 23% reduction, mean ± s.e.mean, n =3), while no effect was observed
when CHOrH2WT6 cells were exposed to 100 IlM cimetidine (basal cAMP level: 42 ± 7
pmollmg of protein, level of cAMP after cimetidine treatment: 46 ±9 pmollmg of protein, mean
± s.e.mean, n =4). In CHOrH2Leu124Ala cells, cimetidine did not exhibit any negative
intrisic activity either (Fig. 3B). Moreover, no effect on basal cAMP levels was observed when
untransfected CHO cells were exposed to 100 IlM cimetidine (basal cAMP level: 37 ± 4
pmollmg of protein, level of cAMP ,after cimetidine treatment: 39 ± 2 pmollmg of protein, mean
± s.e.mean, n =5)
Effect of cimetidine on [125[J-APT binding in various CHO cell lines, expressing H2
receptors
As observed earlier (Fig. 2A, B, Table 1,3),24 hrs incubation ofCHOrH2WT cells with 100
IlM cimetidine resulted in a marked increase of [1251]-APT binding sites. Similarly, 24 hrs
incubation ofCHOrH2WT9 cells with 100 JlM cimetidine led to a significant increase in
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Fig. 3. A, Effect of cimetidine and inactive analogue VUF 8299 on basal levels of cAMP in CHOrH2WT
cells. CHOrH2WT cells were exposed to increasing concentrations of cimetidine (filled circles) or VUF 8299
(open circles) for 10 mins at 37°C in DMEM in the presence of 300 fJM IBMX and 25 mM Hepes, pH 7.4.
Data represent the mean ± s.e.mean of 4 independent experiments. B, Effect of cimetidine on basal levels of
cAMP in CHOrH2WT cells and CHOrH2Leu124Ala cells. CHOrH2WT (filled circles) and CHOrH2Leu124Ala
cells (open circles) were exposed to increasing concentrations of cimetidine for 10 mins at 37°C in DMEM in
the presence of 300 fJM IBMX and 25 mM Hepes, pH 7.4. Data represent the mean ± s.e.mean of4 independent
experimentso
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[125I]-APT binding sites (83 ± 9% upregulation) (Table 4). Yet, in CHOrH2WT6 and
CHOrH2LeuI 24Ala cells no significant increase in [125I]-APT binding sites was recorded
after long-tenn incubation (24 hrs) with 100 IlM cirnetidine (Table 4).
Effect ofH2 antagonists on basal cAMP levels and on [125/J-APT binding in CHOrH2WT
cells
Besides cimetidine other H2 antagonists were tested for their ability to induce negative intrinsic
activity. As can be seen in Fig. 4, a dose-dependent decrease of basal cAMP levels was
observed when CHOrH2WT cells were incubated with increasing concentrations of ranitidine
(maximum decrease 88 ± 3%, EC50 value: 0.1 ± 0.08 IlM, mean ± s.e.mean, n = 4) and
famotidine (famotidine-induced maximum decrease 89 ±3%, EC50 value: 42 ±8 nM, mean ±
s.e.mean, n =4). Remarkably, burimamide did not display negative intrinsic activity (Figs. 4,
5). As can be seen in Fig. 5, 100 IlM burimamide was able to inhibit the histamine (30 nM)-
induced cAMP production in CHOrH2WT cells significantly. In addition, 100 JlM burimamide
was able to significantly inhibit the cimetidine (l IlM)-induced reduction of basal levels of
cAMP (Fig. 5).
Accordingly, long-tenn incubation (24 hrs) ofCHOrH2WT cells with 10 JlM ranitidine and
10 JlM famotidine was shown to induce an increase in [125I]-APT binding sites (ranitidine: 55
± 3% upregulation, mean ± s.e.mean, n =6, p < 0.05, famotidine: 59 ± 7% upregulation,
mean ± s.e.mean, n =7, p < 0.05), whereas burimamide (1 mM) did not induce a significant
change in H2 receptor density (burimamide: -4 ± 1% upregulation, mean ± s.e.mean, n = 7).
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Fig.4. Effect of H2 antagonists on basal levels of cAMP in CHOrH2WT cells. CHOrH2WT cells were
exposed to increasing concentrations of ranitidine (filled circles), famotidine (open circles) or burimamide (open
squares) for 10 mins at 37°C in DMEM in the presence of 300 JlM IBMX and 25 roM Hepes, pH 7.4. Data
represent the mean ± s.e.mean of 4 independent experiments.
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Fig. 5. Effects of burimamide, histamine and cimetidine on basal levels of cAMP in CHOrH2WT cells.
CHOrH2WT cells were exposed to either 100 J.IM burimamide (Bur), 30 nM histamine (HA) or 1 J.IM
cimetidine (Cim) or a combination of two of each for 10 mins at 37°C in DMEM in the presence of 300 J.IM
IBMX and 25 mM Hepes, pH 7.4. Data represent the mean ± s.e.mean of 3 independent experiments.
Discussion
In the present study we have shown that prolonged exposure (24 hrs) of cells expressing wild-
type H2 receptors to some H2 antagonists affected the H2 receptor density. Long-term
incubation (24 hrs) of CHOrH2WT cells with several H2 antagonists resulted in a marked
increase of [12SI]-APT binding, referred to as H2 receptor upregulation. Prolonged treatment
of CHOrH2WT cells with cimetidine resulted in time-dependent (t112 =3.5 hrs, concentration
of 100 J.IM cimetidine) and dose-dependent (ECSO =6.0 IlM at 24 hrs incubation) H2 receptor
upregulation. Moreover, the lack of H2 receptor upregulation induced by VUF 8299, a
structural analogue of cimetidine which is devoid of H2 receptor activity, indicates that this
process is confined to an H2 antagonistic effect. In addition, cimetidine had no effect on CHO
cells expressing HI receptors using the same expression vector. Furthermore, no change in H2
receptor density was observed after long-term treatment of CHOrH2WT cells with the HI
antagonist triprolidine or the H3 antagonist thioperamide.
The observed effect of these H2 receptor antagonists might be ascribed to an inhibition of
the agonist-induced receptor activity. The antagonist-induced upregulation of the m2- and m3-
muscarinic receptors in cultured granule cells (Fukamauchi et at., 1993) was suggested to be
explained by a tonic activation of these receptors due to spontaneous synaptic activity between
interacting neurons. Nevertheless, there are other reports describing antagonist-induced
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upregulation of GPCRs, which cannot be explained by an endogenous agonist-induced
receptor activity (Motomura et al., 1990, Yoburn et aI., 1994). As for the H2 receptor
expressed in CHO cells, it is unlikely that histamine, leading to a histamine-induced H2
receptor activity, is present in the medium. Cells were grown in medium with dialyzed foetal
calf serum and 24 hrs incubations were performed in serum-free DMEM. Moreover, incubation
of CHOrH2WT cells with 1 nM of histamine was shown to result in a significant elevation of
cAMP levels (basal cAMP level: 2.5 ± 0.6 pmol/well, histamine (l nM)-induced cAMP
formation: 9 ± 4 pmol/well), indicating that concentrations of histamine in the medium seem to
be lower than 1 nM. In addition, no change in basal cAMP levels were observed when
CHOrH2WT cells were extensively washed and incubated in HBSS medium. The observed
H2 antagonist-induced H2 receptor upregulation can therefore not be caused by an antagonism
of histamine-induced H2 receptor stimulation.
Interestingly, as already stated in the Introduction, several laboratories have provided
evidence for the existence of precoupling of some wild-type GPCRs to G-proteins, thereby
exhibiting spontaneous, agonist-independent activity (Barker et aI., 1994, Chidiac et ai.,
1994, Leeb-Lundberg et ai., 1994, Tian et ai., 1994). Antagonists, shown to favour binding
to the inactive state of the receptor, provoke the dissociation of these spontaneously occurring
receptor-G-protein complexes, thereby inhibiting basal receptor activity (Chidiac et aI., 1994,
Samama et ai., 1994). These antagonists are referred to as inverse agonists. Antagonists
which do not distinguish between the active and inactive state of the receptor do not affect basal
receptor activity and are referred to as neutral antagonists. In view of these findings we studied
w~ether the CHOrH2WT cells exhibited basal, agonist-independent H2 receptor activity as a
consequence of H2 receptor expression. Moreover, we investigated whether the used H2
antagonists acted as inverse agonists, thereby causing H2 receptor upregulation.
As shown in this study, both the basal levels of cAMP and the forskolin-induced cAMP
formation increased upon elevation of H2 receptor density. These observations demonstrate
that the wild-type H2 receptor displays properties resembling those of precoupled GPCRs
(Adie and Milligan, 1994a,b, 1994, Barker et aI., 1994, Chidiac et aI., 1994, Eason et ai.,
1992, Kim et ai., 1995, Leeb-Lundberg et ai., 1994, Samama et aI., 1993, Tian et aI.,
1994) and constitutively active GPCR mutants (Cotecchia et aI., 1990, Kjelsberg et aI.,
1992, Ren et aI., 1993, Samama et aI., 1994). It should be noted, however, that in the
published cellular systems, expressing GPCRs coupled to Gs proteins, increased basal and
forskolin-induced adenylyl cyclase activity were only recorded at receptor densities exceeding
expression levels of 1 pmollmg protein (Adie and Milligan, 1994a,b, 1994, Kim et ai.,
1995, Samama et aI., 1993). As such, we show that for the H2 receptor already at a density of
286 fmol/mg protein a significant increase of basal and forskolin-induced cAMP formation is
noticed. It is therefore likely that agonist-independent H2 receptor activity may also be
observed at physiological H2 receptor densities (200-300 fmol/mg protein). Evidence of H2
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receptor precoupling was further supported by experiments using the H2Leu124Ala receptor
mutant. Previously, we observed that this mutation resulted in a loss of agonist high-affinity
binding sites and a concomitant loss of histamine potency to induce the production of cAMP
(Chapter S). CHO cells expressing this H2 receptor mutant (CHOrH2Leu124Ala cells)
displayed reduced basal levels and forskolin-induced formation of cAMP, even though
expression levels were comparable to those in CHOrH2WT cells.
Interestingly, the agonist-independent H2 receptor activity in CHOrH2WT and
CHOrH2WT9 cells was accompanied by the occurrence of inverse agonism exerted by
cimetidine. Its structural analogue VUF 8299, which did not show H2 antagonism or H2
receptor upregulation, did not display any negative intrinsic activity in CHOrH2WT cells.
Moreover, in CHOrH2Leu124Ala and CHOrH2WT6 cells, both displaying reduced basal
levels and forskolin-induced formation of cAMP compared to CHOrH2WT and CHOrH2WT9
cells, cimetidine did not show any negative intrinsic activity. Based on these findings we
conclude that binding of cimetidine provokes dissociation of the H2 receptor-G-protein in those
cell lines displaying increased basal adenylyl cyclase activity. As observed earlier (Chapter S),
H2 receptordensity is readily reguJated upon receptor stimulation. We therefore hypothesize
that the observed inverse agonism displayed by cimetidine could be a mechanistic basis for the
observed H2 receptor upregulation. This hypothesis was supported by the absence of
cimetidine-induced H2 receptor upregulation in CHOrH2WT6 and CHOrH2Leu124Ala cells.
Moreover, not all H2 antagonists appeared to act as inverse agonists. Interestingly, burimamide
was shown to act as a neutral antagonist, as no major changes in basal cAMP levels were
observed or in the H2 receptor density upon 24 hrs incubation. According to the characteristics
of a neutral antagonist, burimamide blocked the histamine-induced formation of cAMP and also
the cimetidine-induced decrease of basal levels of cAMP. Moreover, the lack of upregulation
by burimamide furthermore excludes the possibility that the H2 receptor upregulation is caused
by a competitive antagonism of histamine-induced H2 receptor stimulation. Famotidine and
ranitidine displayed like cimetidine negative intrinsic activity with ECSO values that correlate
with their respective Ki values (Chapter S, Traiffort et aI., 1992) (ranitidine: ECSO value 0.11
~M, Ki value 0.23 ~M; famotidine: ECSO value 42 oM, Ki value 12 nM; cimetidine: ECSO
value 1.2 ~M, Ki value 0.80 ~M).
The mechanism underlying the inverse agonist-induced H2 receptor upregulation may be
attributed to a rapid transient increase of H2 mRNA levels observed after O.S hr cimetidine-
treatment. Experiments using protein synthesis inhibitors should give more insight in the
mechanism underlying H2 receptor upregulation.
H2 antagonists are widely used for the treatment of gastric ulcers (Bertaccini and Coruzzi,
1992). They are considered as one of the safest classes of compounds that has ever been
introduced (Deakin and Williams, 1992). However, as already stated in the Introduction, there
are some reports that describe observations after long-term H2 antagonist treatment in vivo,
which may be explained by the findings obtained in this study (Bertaccini and Coruzzi, 1992,
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Coruzzi and Bertaccini, 1989, Martinez-Mir et aI., 1993, Merki and Wilder-Smith, 1994,
Nwok010 et at., 1991). The inverse agonism displayed by ranitidine, which was paralleled by
an increase of H2 receptors in CHOrH2WT cells, may explain the increase of parietal cell
sensitivity towards dimaprit observed after chronic ranitidine treatment (Coruzzi and
Bertaccini, 1989). Moreover, the inverse agonism may also explain the loss of antisecretory
effect after prolonged infusions of ranitidine (Merki and Wilder-Smith, 1994) and the
observed increase of intragastric hyperacidicity after abrupt ranitidine or cimetidine withdrawal
(Nwokolo et aI., 1991). Furthermore, neuroleptics, shown to induce an increase of H2
receptors in brain tissue of schizophrenic patients (Martinez-Mir et at., 1993) and shown to
display considerable affinity for H2 receptors (Leurs et at., 1994, Traiffort et at., 1992), may
actually behave as inverse H2 agonists. Preliminary results in our laboratory have shown that
some neuroleptics indeed behave as inverse agonists in CHOrH2WT cells (M.J. Smit,
unpublished observations), possibly explaining the observed increase in H2 receptor density.
Precoupling of H2 receptors, revealing inverse agonism of H2 antagonists, is not
necessarily dependent on H2 receptor expression levels, but may also be induced by G-protein
overexpression (Burstein et aI., 199;5). Recently, overexpression of Gq was shown to induce
constitutive activity of muscarine m3 receptors, which was blocked by muscarinic antagonists
(Burstein et aI., 1995). Moreover, H2 receptor precoupling properties may be tissue-specific
and differ among species and even individuals. The latter may explain why H2 antagonists
usually do not display signs of inverse agonism in the human heart. However, some groups
have described negative inotropic effects by H2 antagonists in some model systems (e.g.
guinea-pig atria) and some even in patients, for which so far no explanation could be given
(Bertaccini et at., 1993, Hinrichsen and Kirch, 1994). The occurrence of precoupling of H2
receptors could be a possible explanation.
Taken together, this study shows that at physiological H2 receptor densities H2 receptors
are precoupled and that several H2 antagonists, previously thought to act as competitive
antagonists, may actually function as inverse agonists. The inverse agonism of H2 antagonists
appears to be a mechanistic basis for the observed H2 antagonist-induced H2 receptor
upregulation in CHO cells. Moreover, it may also explain the previously reported observations
after long-term H2 antagonist treatment of gastric ulcers such as increased sensitization of the
H2 receptor, increased intragastric hyperacidicity after ranitidine and cimetidine withdrawal and
loss of antisecretory effect after ranitidine infusions (Bertaccini and Coruzzi, 1992, Coruzzi
and Bertaccini, 1989, Merki and Wilder-Smith, 1994, Nwokolo et at., 1991). It is clear that
the therapeutically important class of H2 antagonists needs reclassification, which may have
important clinical consequences. Neutral H2 antagonists would be favoured in the treatment of
gastric ulcers, since increased sensitivity and intragastric hyperacidicity upon withdrawal or
loss of H2 antagonistic effect can then perhaps be avoided.
166 Chapter 9
References
Adie, E.I. and Milligan, G. (1994a) Agonist regulation of cellular G(s) alpha-subunit levels in neuroblastoma x
glioma hybrid NGI08-15 cells transfected to express different levels of the human beta 2 adrenoceptor.
Biochem. J., 300, 709-715.
Adie, E.J. and Milligan, G. (1994b) Regulation of basal adenylate cyclase activity in neuroblastoma x glioma
hybrid, NGI08-15, cells transfected to express the human beta 2 adrenoceptor: Evidence for empty receptor
stimulation of the adenylate cyclase cascade. Biochem. J., 303, 803-808.
Barker, E.L., Westphal, R.S., Schmidt, D. and Sanders-Bush, E. (1994) Constitutive active 5-
hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J. Bioi. Chent,
269, 11687-11690.
Bertaccini, G. and Coruzzi, G. (1992). Histamine receptors in the digestive system, In: The histamine receptor
J.C. Schwartz and H. L. Haas (eds.), pp. 193-231. New York: Wiley-Liss.
Bertaccini, G., Poli, E. and Coruzzi, G. (1993) Histamine H2 Receptor Antagonists and the Cardiovascular
System. Pharmacol. Res., 28, 301-316.
Bradford, M. M. (1976) A rapid and sensitive method for the quantification of microgram quantities of protein
utilizing the principle of protein dye-binding. Anal. Biochem., 72, 248-254.
Brodde, O.E., Daul, A., Micheireher, M., Boomsma, F., Veld, A.I.M.I., Schlieper, P. and Michel, M.C.
(1990) Agonist-induced desensitization of beta-adrenoceptor function in humans - Subtype-selective
reduction in beta-l-adrenoceptor or beta-2-adrenoceptor mediated physiological effects by xamoterolor
procaterol. Circulation, 81, 914-921.
Burstein, E.S., Spalding, T.A., Braiiner-Osborne, H. and Brann, M.R. (1995) Constitutive activation of
muscarinic receptor by the G-protein'Gq. FEBS Lett., 363, 261-263.
Chidiac, P.,Hebert, T.E., Valiquette, M., Dennis, M. and Bouvier, M. (1994) Inverse agonist activity of~­
adrenergic antagonists. Mol. Pharamcol., 45, 490-499.
Coruzzi, G. and Bertaceini, G. (1989) Increased parietal cell sensitivity after chronic treatment with ranitidine in
the consious cat. Agents and Actions, 28,215-217.
Costa, T., Ogino, Y., Munson, P. J., Onaran, O. and Rodbard, D. (1992) Drug efficacy at guanine nucleotide-
binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of
receptor activity in the absence of ligand. Mol. Pharmacol., 41, 549-560.
Cotecchia, S.,. Exum, S., Caron, M.G. and Lefkowitz, R.I. (1990) Regions of the <Xl-adrenergic receptor
involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function.
Proc. Natl. Acad. Sci. USA, 87, 2896-2900.
De Lean, A., Stadel, J.M. and Lefkowitz, R.I. (1980) A ternary complex model explains the agonist-specific
binding properties of the adenylyl cyclase-coupled ~-adrenergic receptor. J. Bioi. Chem, 255, 7108-7117.
Deakin, M. and Williams, J.G. (1992) Histamine H2 receptor antagonists in peptic ulcer disease. efficacy in
healing peptic ulcers. Drugs, 44, 709-719.
Deutsch, S.I., Rosse, R.B., Kendrick, K.A., Faymccarthy, M., Collins, J.P. and Wyatt, R. J. (1993)
Famotidine Adjunctive Pharmacotherapy for Schizophrenia - Preliminary Data. Clin. Neuropharmacol.,
16, 518-524.
Diaz, 1., Vizuete, M.L., Traiffort, E., Arrang, J.M., Ruat, M. and Schwartz, J.C. (1994) Localization of the
histamine H2 receptor and gene transcripts in rat stomach: back to parietal cells. Biochem. Biophys .Res.
Commun., 198, 1195-1202.
Eason, M.G., Kurose, H., Holt, B.D., Raymond, J.R. and Liggett, S.B. (1992) Simultaneous coupling of <X2-
adrenergic receptors to two G-proteins with opposing effects. J. Bioi. Chem.,267, 15795-15801.
Elfellah, M.S. and Reid, J. L. (1989) Regulation of ~1-and ~2-adrenoceptors following chronic treatment with
~-adrenoceptor antagonists. Eur. J. Pharmacol., 173, 85-92.
Fnkamauchi, F., Saunders, P.A., Hough, C. and Chuang, D.M. (1993) Agonist-induced down-regulation and
antagonist-induced up-regulation of m(2)-muscarine and m(3)-muscarinic acetylcholine receptor messenger
RNA and protein in cultured cerebellar granule cells. Mol. Pharmacol., 44, 940-949.
Ghosh, S.K., Vos De, C., Mcilroy, I. and Patel, K.R. (1991) Effects of cetirizine on histamine-and lenkotriene
D4 induced brochoconstriction in patients with atopic asthma. J. All. Clin. lmmunol., 87, 1010-1013.
Hinrichsen, H. and Kirch, W. (1994) Cardiovascular Side Effects of H-2-Receptor Antagonists. Dtsch Med
Wochenscllr, 119, 525-530.
Upregulation ofthe H2 receptor 167
Homcy, C.I., Varner, S.F. and Vatner, D.E. (1991) Beta adrenergic receptor regulation in the heart in
pathophysiological states: abnormal adrenergic responsiveness in cardiac disease. Annu. Rev. Physiol.,
53, 139-157.
Kaminsky, R., Moriarty, T.M., Bodine, J., Wolf, A.E. and Davidson, M. (1990) Effect of famotidine on deficit
symptoms of schizophrenia. Lancet, 335, 1351-1352.
Kim, G.D., Carr, I.C. and Milligan, G. (1995) Detection and analysis of agonist-induced fonnation of the
complex of the stimulatory guanine nucleotide-binding protein with adenylate cyclase in intact wild-type
and beta 2-adrenoceptor-expressing NGI08-15 cells. Biochem. J., 308, 275-281.
Kjelsberg, M.A., Cotecchia, S., Ostrowski, J., Caron, M.G. and Lefkowitz, R.I. (1992) Constitutive activation
of the alB-adrenergic receptor by all amino acid substitutions at a single site. J. Bioi. Chem., 267,
1430-1433.
Leeb-Lundberg, L.M.F., Mathis, S. A. and Herzig, M.C.S. (1994) Antagonists of bradykinin that stabilize a G-
protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J. BioI. Chem.,
269, 25970-25973.
Lefkowitz, R. J., Cotecchia, S., Samama, P. and Costa, T. (1993) Constitutive activity of receptors coupled to
guanine nucleotide regulatory proteins. Trends Phannacol. Sci., 14, 303-307.
Leurs, R., Smit, M.I., Menge, WM.B.P. and Timmennan, H. (1994) Pharmacological characterization of the
human histamine H2 receptor stably expressed in Chinese Hamster Ovary cells. Br. J. Pharmacol., 112,
847-854.
Martinez-Mir, M.I., Pollard, H.,Moreau, J., Traiffort, E., Ruat, M., Schwartz, J.C. and Palacios, J.M. (1993)
Loss of striatal histamine H2 receptors in Huntington's Chorea but not in Parkinson's disease: Comparison
with animal models. Synapse, 15, 209-~20.
Merki, H.S. and Wilder-Smith, C.H. (1994) Do continuous infusions of omeprazole and ranitidine retain their
effect with prolongued dosing? Gastroenterology, 106, 60-64.
Motomura, S., Deighton, N.M., Zerkowski, H.R., Doetsch, N., Michel, M.C. and Brodde, O.E. (1990)
Chronic Beta-l-adrenoceptor antagonist treatment sensitizes beta-2-adrenoceptors, but desensitizes M2-
muscarinic receptors in the human right atrium. Br. J. Pharmacol., 101, 363-369.
Nwokolo, C.D., Smith, J.T.L., Sawyer, A.M. and Pounder, R.E. (1991) Rebound intragastric hyperacidity after
abrupt withdrawal of histamine H2 receptor blockade. Gut, 32, 1455-1460.
Onaran, 0., Costa, T. and Rodbard, D. (1993) ~r-subunits of guanine nucleotide-binding proteins and regulation
of spontaneous receptor activity: thennodynamic model for the interaction between receptors and guanine
nucleotide-binding protein subunits. Mol. Pharmacol., 43, 245-256.
Reid, K., Hayashi, Y., Guo, T.Z., Correasales, C., Nacifcoelho, C. and Maze, M. (1994) Chronic
administration of an alpha(2) adrenergic agonist desensitizes rats to the anesthetic effects of
dexmedetomidine. Pharmacol. Biochem. Behav., 47, 171-175.
Ren, Q., Kurose, H., Lefkowitz, R.I. and Cotecchia, S. (1993) Constitutively active mutants of the a2-
adrenergic receptor. J. Bioi. Chem.,268, 16483-16487.
Samama, P., Cotecchia, S., Costa, T. and Lefkowitz, RJ. (1993) A mutation-induced activated state of the ~2­
adrenergic receptor. J. Bioi. Chem., 268, 4625-4636.
Samama, P., Pei, G., Cosat, T., Cotecchia, S. and Lefkowitz, R.I. (1994) Negative antagonists promote an
inactive confonnation of the beta(2)-adrenergic receptor. Mol. Pharmacol., 45, 390-394.
Schlitz, W. and Freissmuth, M. (1992) Reverse intrinsic activity of antagonists on G protein-coupled receptors.
Trends Phannacol. Sci., 13, 376-380.
Sterk, G.J., van der Goot, H. and Timmennan, H. (1987) Studies on histaminergic compounds VI. Synthesis
and structure-activity relationships of a series of cimetidine and impromidine congeners. Eur. J. Med.
Chem.,22, 427-432.
Stiles, G. L. (1991) Adrenergic receptor responsiveness and congestive heart failure. Am. J. Cardiol.,67, 13-
17.
Tian, W.N., Duzic, E., Lanier, S.M. and Deth, R.C. (1994) Detenninants of alpha(2)-Adrenergic Receptor
Activation of G-Proteins - Evidence for a Precoupled Receptor G-Protein State. Mol. Pharmacol., 45,
524-531.
Tiberi, M. and Caron, M.G. (1994) High agonist-independent activity is a distinguishing feature of the
dopamine DlB receptor subtype. J. Bioi. Chem.,269, 27925-27931.
Traiffort, E., Ruat, M., Arrang, J.M., Leurs, R., Piomelli, D. and Schwartz, J.C. (1992) Expression of a
168 Chapter 9
cloned rat histamine H2 receptor mediating inhibition of arachidonate release and activation of cAMP
accumulation. Proc. Natl. Acad. Sci. USA, 89, 2649-2653.
Yoburn, B.C., Duttaroy, A.. Shah, S. and Davis, T. (1994) Opioid antagonist-induced receptor upregulation:
effects of concurrent agonist administration. Brain Research, 33, 237-240.
169
Chapter 10
Summary and final considerations
Regulation of receptor function appears to be an integral part of transmembrane signalling of
many G-protein coupled receptors (GPCRs) and is important for proper cellular
communication (Chapter 1, section 1.3). Moreover, receptor regulation may also have
consequences for the development of effective drug therapy. One distinguishes three
mechanistically and temporarily distinct regulatory processes. The first involves a rapid (secs to
mins) uncoupling of GPCRs from their effector system (short-term desensitization), the second
is characterized by the translocation of these receptors away from the cellular surface within
minutes (internalization) and the third as a reduction of recel?tor binding sites occurring after
hours of agonist exposure (downregulation or long-term desensitization). These processes are
thought to be associated with post-translational modification of the receptor by phosphorylation
by kinases, such as protein kinase A (PKA), protein kinase C (PKC) and specific GPCR
kinases (GRKs).
Regulation of histamine HI and H2 receptors, both belonging to the class of GPCRs, has
not only been observed in vitro but also in vivo under pathophysiological conditions (e.g.
asthmatic attack or allergic reaction). In addition, in vivo modulation of the HI and H2
receptor function has also been observed after antagonist treatment. In view of these findings
and the widespread use of HI antagonists (treatment of allergies) and H2 antagonists (treatment
of gastric ulcers) and the proposed use of H2 agonists (treatment of congestive heart failure),
detailed knowledge of the regulation of the histamine receptors is indispensable. Isolated cell
lines and transfected cell lines appear to be excellent model systems for the investigation of
(histamine) receptor regulation. Both contain a homogeneous population of either HI or H2
receptors and allow the study of the pharmacological and biochemical properties of these
receptors. Additionally, the use of transfected cell lines allows the expression of receptor
mutants, which can provide mechanistic insights in phenomena like receptor regulation.
Short-term desensitization ofthe histamine H] andH2 receptors
In our initial studies we used isolated cell lines of human origin expressing endogenous HI or
H2 receptors as model systems to examine the phenomenon of short-term receptor
desensitization. For the histamine HI and H2 receptors, the HeLa cell line, a uterine carcinoma
cell line, and U937 cell line, a monocytic cell line, were chosen respectively. The HI receptors
in the HeLa cell line appeared to be readily desensitized upon short-term exposure to histamine
as shown by a reduction of the release and influx component of the histamine-induced Ca2+
response (Chapter 2). The short-term desensitization of the HI receptor was associated with a
selective reduction of the release component, mediated by a PKC-independent pathway, and a
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non-selective inhibition of the Ca2+ influx, activated by a PKC-dependent pathway. As such,
short-term desensitization of the histamine H I receptor in HeLa cells evolves from two
different processes: a PKC-dependent and a PKC-independent pathway (Chapter 2). Similarly,
the histamine H2 receptor-mediated cAMP response in U937 cells was found to be time- and
dose-dependently impaired when cells were pretreated with histamine (Chapter 4). The
observed H2 receptor desensitization appeared to be homologous, as ~-adrenoceptor-mediated
responses remained unaffected.
During the course of these investigations the genes encoding the HI and H2 receptor were
cloned. Their deduced amino acid sequences revealed the existence of the commonly reported
features of GPCRs: seven putative hydrophobic transmembrane domains, separated by
hydrophilic intra- and extracellular loops. Interestingly, the third intracellular loop and
cytoplasmatic tail of both receptors were found to contain several serine and threonine residues
serving as potential phosphorylation sites for GRKs, as shown for other GPCRs. As such, the
observed homologous desensitization of the H I and H2 receptor may be caused by the
phosphorylation of these potential phosphorylation sites by GRKs. The development of cell
lines expressing epitope-tagged histamine H I or H2 receptors (Chapter 8), thereby allowing
direct phosphorylation studies by means of immunoprecipitation, and coexpression of GRKs
will provide more insight in the phenomenon of short-term, agonist-induced H I and H2
receptor desensitization. Moreover, the use of histamine HI and H2 receptor mutants, with
deletions in the third intracellular loop or truncation of the C-terminal tail (Chapter 6) might
give more insight in the structural domains involved in this phenomenon.
Downregulation ofthe histamine H] andH2 receptors
Initial studies in our laboratory (1991-1992) have shown that the HeLa cell line does not
express sufficient levels of H I receptor nor does the U937 cell line express sufficient H2
receptors (- 60 and - 10 fmoVmg protein respectively) to determine the effect of long-term
histamine exposure on H I or H2 receptor expression. With the cloning of the geneslcDNAs
encoding the HI and H2 receptor proteins, cellular systems expressing sufficient amounts of
H I or H2 receptors are currently available. As for the HI receptor, CHO cells were transfected
with the recently cloned human H I receptor, obtaining a CHO cell line expressing human HI
receptors (CHOhumHI cells) at a density of 861 fmoVmg protein (Chapter 3). The human HI
receptor gene expressed in CHO cells was found to encode a classical H I receptor with
properties similar to that of the H I receptor found in guinea-pig cerebellum and the
endogenously expressed human HI receptor in 132INI astrocytoma cells (Chapter 3). This
receptor was also found to be susceptible to short-term receptor desensitization as shown by a
decrease of the histamine-induced Ca2+ response after histamine exposure. Long-term
exposure of the CHOhumH I cells to histamine resulted in a dose- and time-dependent
downregulation of the human H I receptor. As a result of long-term histamine exposure, both
histamine- and ATP-induced Ca2+ responses were affected, indicating modulations at a level
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distant from the receptor too. PKC does not seem to playa role in either the histamine-induced
HI receptor desensitization or downregulation in CHOhumH1 cells, which may be explained
by a differential expression of PKC isoenzymes in this cell line compared to other cellular
systems. Currently, no detailed information is available on the structural domains involved in
H I receptor downregulation. However, the generation of HI receptor mutants analogous to
those described for the H2 receptor (Chapter 5, 6 and 8) will provide more insight in this
phenomenon.
Likewise, long-term histamine-exposure of CHO cells expressing the rat histamine H2
receptor (CHOrH2 cells, 975 fmoVmg protein) resulted in a dose-and time-dependent reduction
of the number of H2 receptors. H2 receptor downregulation was also observed upon long-term
incubation of CHOrH2 cells with agents elevating the intracellular cAMP concentration, such
as forskolin and cholera toxin. Both histamine and forskolin induced rapid downregulation of
H2 receptor mRNA levels, most likely caused by mRNA destabilization, thereby contributing
to the observed decrease of H2 receptor binding sites. A comparison of the time course and the
maximum extent of the histamine- and forskolin-induced H2 receptor and H2 mRNA
downregulation suggested the in'volvement of cAMP in the process of H2 receptor
downregulation. However, two H2 receptor mutants displaying impaired ability to induce
cAMP upon histamine exposure (H2Leul24Ala (Chapter 5) and H2T341 (Chapter 6»
provided evidence for a cAMP-independent pathway in the process of agonist-induced H2
receptor downregulation. Both H2 receptor mutants were shown to be downregulated by
histamine, while no or little increase of cAMP was observed. Thus, H2 receptor
downregulation appears to be induced by two distinct pathways, a cAMP-dependent and a
cAMP-independent pathway.
Recent studies have shown that besides inducing H2 receptor downregulation long-term
(24 hrs) exposure of CHOrH2 cells (975 fmoVmg protein) to histamine (100 I..lM) resulted in a
rightward shift of the dose-response curve of histamine-induced cAMP production (Fig. 1).
The observed shift cannot be ascribed to decreased adenylyl cyclase activity as forskolin-dose
response curves remained unaffected after a long-term histamine exposure (data not shown in
this thesis). The shift cannot be explained either by the decrease in H2 receptor expression, as
the EC50 value of the histamine-induced cAMP response in CHO cells expressing rat H2
receptors at a density of approximately 500 fmoVmg protein (50% of density in CHOrH2 cells)
was similar to the value recorded in CHOrH2 cells (MJ. Smit, unpublished observations). The
observed shift might be attributed to a decrease in Os-protein expression, as was previously
reported for other OPCRs upon long-term agonist-exposure. Quantification of Os-protein
levels in histamine-treated cells (24 hrs) should give more insight in the above-mentioned.
Thus, histamine-induced H2 receptor downregulation does not seem to have an immediate
effect on H2 receptor signalling. These experiments, however, suggest modification of e.g.
Os-protein expression upon long-term histamine-exposure, indicating the complexity of
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agonist-induced receptor regulation.
These findings do not mean that H2 receptor downregulation has no physiological
meaning. In preliminary studies we observed in CHO cells that the EC50 value for the
histamine-induced cAMP production is highly correlated with the H2 receptor density up to
200 fmol/mg protein. (M.J. Smit. unpublished observations). Histamine-induced H2 receptor
downregulation may thus have a marked effect on H2 receptor signalling in cells expressing
low levels of the H2 receptor protein.
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Fig.I. Effect of long-term treatment of CHOrH2 cells with histamine on H2 receptor signalling. CHOrH2
cells were treated with (open circles) or without (fJ.Iled circles) 100 J.lM histamine for 24 hrs in DMEM without
foetal calf serum. Thereafter, cells were washed several times and incubated for 1hr with DMEM supplemented
with 25 mM Hepes, pH 7.4. CHOrH2 cells were subsequently incubated with increasing concentrations of
histamine for 10 mins at 37°C in DMEM in the presence of 300 J.lM IBMX and 25 mM Hepes, pH 7.4. The
levels of cAMP were determined as described in chapter 5.
For several GPCRs the C-terminal tail is considered to be an important structural domain
for GPCR regulation. Truncation of the C-terminal tail of the H2 receptor by 51 amino acids.
in contrast to most other GPCRs. resulted in the generation of a mutant H2 receptor (H2T307.
Chapter 6) which was more susceptible to agonist-induced receptor downregulation. but not to
the cAMP-dependent H2 receptor downregulation. Thus. this region of the C-terminal tail
seems to impair agonist-induced H2 receptor downregulation. Accordingly. the region
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encompassing the amino acids 307 to 341 of the H2 receptor was found to inhibit histamine-
induced signalling, suggesting the presence of positive and negative signals in the C-terminal
tail of the H2 receptor for signal transduction and receptor downregulation. Furthermore, these
data again indicate that the cAMP-dependent and cAMP-independent pathways of H2 receptor
appear to bemediated by different regulatory processes.
Internalization ofthe histamine H2 receptor
Due to a lack of suitable radioligands and anti-H2 receptor antibodies no studies on H2 receptor
internalization have been reported so far. In· order to study the process of H2 receptor
internalization rat and human histamine H2 receptors were tagged at the N-terminus with the
eight amino acid Flag epitope to allow the immunological identification of the receptor peptide
with the monoclonal anti-Flag M2 antibody (Chapter 8). Initially, we tried to express the
epitope-tagged H2 receptor in CHO cells. However, no clones expressing the epitope-tagged
H2 receptor were obtained when we used various transfection methods. As such, we stably
transfected the epitope-tagged H2 receptor in human embryonal 293 kidney cells
(293rH2Flag). Importantly, the introduction of the epitope did not affect H2 agonist or H2
antagonist binding nor did it affect histamine-induced signalling. Immunofluorescence
measurements of 293rH2Flag cells revealed the presence of anti-Flag-immunoreactivity in the
plasma membrane (Chapter 8). Permeabilization of the 293rH2Flag cells also showed
immunofluorescence in the cytoplasm in areas corresponding to the Golgi apparatus
(unpublished observations). Using this technique we observed after a one-hour histamine-
treatment a complete disappearance of immunoreactivity in the membrane, indicating H2
receptor internalization. As immunofluorescence of epitope-tagged H2 receptors was already
detected inside the cell it was impossible to identify a further increase of the intracellular
immunofluorescence. The receptor internalization was reversible and blocked by the
endocytosis inhibitor phenylarsine oxide. Forskolin did not induce H2 receptor internalization,
which indicates that histamine causes H2 receptor internalization via a cAMP-independent
pathway. Internalization of other GPCRs was found to be associated with phosphorylation of
serine and threonine domains in the C-terminal tail by kinases other than the second-
messenger-dependent kinases. As such, by using an epitope-tagged truncated H2 receptor
mutant (H2T307, Chapter 6) it would be interesting to investigate whether these serines and
threonine residues are involved in the process of H2 receptor internalization. Moreover, it is as
yet not clear whether GPCR internalization requires G-protein coupling. To study the latter, the
use of an epitope-tagged uncoupled H2 receptor mutant (H2Leu124Ala, Chapter 5) might
elucidate whether G-protein coupling is a prerequisite in the process of H2 receptor
internalization.
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Antagonist-induced histamine H2 receptor upregulation
In the chapters 2 to 8 we have shown that the HI and H2 receptors are susceptible both to
short-term and long-term desensitization, which results in a decrease of HI and H2 receptor
responsiveness and downregulation respectively. In Chapter 9 we demonstrate that also several
H2 antagonists may affect the H2 receptor function as shown by H2 antagonist-induced H2
receptor upregulation. At physiological H2 receptor densities H2 receptors were found to be
precoupled in CHO cells. Several H2 antagonists which were previously thought to act as
competitive antagonists were shown to inhibit basal H2 receptor activity, displaying negative
intrinsic properties also referred to as inverse agonism. As shown in Chapter 5, H2 receptors
are regulated upon receptor stimulation; inverse agonism of H2 antagonists may be a
mechanistic basis for the observed H2 receptor upregulation. This hypothesis is supported by
both the lack of H2 receptor upregulation in cells which do not show precoupling
(CHOrH2Leu124Ala and CHOrH2WT6) and the lack of upregulation by neutral H2
antagonists (e.g. burimamide). Our findings may explain the previously reported observations
after long-term H2 antagonist treatment of gastric ulcers. Several authors reported increased
sensitization of the H2 receptor, increased intragastric hyperacidicity and loss of antisecretory
effect after prolonged H2 receptor blockade.
So far there are no reports describing inverse agonism by H2 antagonists in other in vitro
or in vivo pharmacological models. However, H2 receptor precoupling properties may be
tissue-specific, differ among species and even individuals. In this respect the level of H2
receptor expression is important. but also other factors (e.g. G protein levels) might contribute
to this phenomenon. It is clear, however, that the therapeutically important class of H2
antagonists needs a pharmacological reclassification, which may have important clinical
consequences. These findings await studies defining the structural components of H2
antagonists and structural determinants within the H2 receptor protein responsible for inverse
agonism.
While studies on rat histamine H2 receptor regulation were in progress, also the human H2
receptor was cloned. Subsequently, this receptor was stably expressed in CHO cells in our
laboratory (Chapter 7). Pharmacological studies showed that the cloned human gene encoded a
histamine H2 receptor that is indistinguishable from the H2 receptor identified in human brain
tissue and showed functional coupling to the adenylate cyclase in CHO cells (Chapter 7).
Long-term exposure of CHO cells expressing human H2 receptors to histamine or H2
antagonists was also found to induce H2 receptor downregulation or upregulation (M.J. Smit,
unpublished observations), validating the use of CHO cells expressing rat H2 receptors as our
model system. Moreover, the use of this model system has emphasized the importance of H2
receptor mutants (Chapter 5, 6, 8 and 9) in the investigation of mechanisms involved in H2
receptor signalling and H2 receptor regulation. However, one should not exclude the
investigation of these phenomena in more appropriate models, such as primary cultures or
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tissues which more accurately reflect the situation in vivo. In order to elucidate the
mechanisms underlying histamine receptor function, a combination of both model systems is
indispensable.
In conclusion, histamine HI and H2 receptors are susceptible to dynamic receptor regulation.
Detailed knowledge of the molecular entities involved in histamine receptor regulation, along
with the knowledge regarding both their cellular distribution and their expression levels is
required for the development of effective drug therapy.
To be continued!!
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Samenvatting en discussie
Signaaltransductie door G-eiwit-gekoppelde receptoren speelt een belangrijke rol bij de
communicatie tussen cellen. Voor een effectief verloop van deze communicatie is een goede
regulatie van de receptorfunctie essentieel.
Tot de klasse van G-eiwit-gekoppelde receptoren behoren ook de histamine Hl- en H2-
receptor. Regulatie van deze receptoren wordt niet alleen in vitro. maar onder
pathofysiologische condities (astmatische aanval, allergische reactie) ook in vivo
waargenomen. Bovendien worden in vivo veranderingen gezien in H1- en H2-receptorfunctie
na behandeling met histamine-antagonisten. Deze antagonisten worden onder meer gebruikt
voor de behandeling van allergieen (H1) en van maagzweren (H2). Sommige auteurs stellen
voor H2-agonisten toe te dienen aan patienten met hartinsufficientie. Omdat medicijnen
receptorregulatie kunnen geven, is inzicht in de mechanismen die daaraan ten grondslag liggen
onmisbaar voor de ontwikkeling van effectieve therapieen.
We onderscheiden drie verschillende regulatiemechanismen, die onderling verschillen in
tijdsverloop en karakter. Het eerste mechanisme noemen we kortdurende desensitisatie. Dit
mechanisme wordt gekarakteriseerd door een snelle (seconden tot minuten) ontkoppeling van
de G-eiwit-gekoppelde receptoren van hun effectorsysteem. Het tweede mechanisme,
internalisatie, uit zich in een translocatie van receptoren aan het celoppervlak naar het
cytoplasma. Het derde mechanisme tot slot speelt zich pas na uren af en resulteert in een
afname van het aantal receptoren. Dit mechanisme noemen we downregulatie. Kinases, zoals
prote'ine kinase A (PKA), prote'ine kinase C (PKC) en specifieke G-eiwit-gekoppelde
receptorkinases blijken bij de verschillende regulatiemechanismen betrokken te zijn.
Ge'isoleerde en getransfecteerde celsystemen zijn uitermate geschikt als modelsysteem voor
het onderzoek naar de regulatie van histamine H1- en H2-receptoren. Beide bezitten een
homogene populatie van histamine-receptoren, waardoor farmacologische en biochemische
eigenschappen goed kunnen worden bestudeerd. Bovendien kunnen receptormutanten, die
essentieel zijn voor de opheldering van regulatiemechanismen, in getransfecteerde celsystemen
tot expressie worden gebracht en daarna functioneel worden onderzocht.
Kortdurende desensitisatie van histamine Hj- en H2-receptoren
Het onderzoek is gestart met ge'isoleerde celsytemen van humane afkomst, die endogene H1-
of endogene H2-receptoren tot expressie brengen. Voor onderzoek naar de HI-receptor was dit
de HeLa-cellijn, een uit de baarmoeder afkomstige carcinome cellijn, en voor de H2-receptor de
U937-cellijn, een monocytachtige. De Hl-receptoren op de HeLa-cellijn blijken na toediening
van histamine snel te desensitiseren, hetgeen zich uit in een verminderde Ca2+-respons. Deze
desensitisatie is geassocieerd met een selectieve reductie van de 'Ca2+-release' veroorzaakt
door een PKC-onafhankelijk mechanisme, en een niet-selectieve vermindering van de 'Ca2+-
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influx', veroorzaakt door een PKC-gemedieerd mechanisme (hoofdstuk 2). Desensitisatie van
de HI-receptor wordt dus gemedieerd door twee verschillende routes: een PKC-onafhankelijke
en PKC-afhankelijke.
Bij de H2-receptor treedt een vergelijkbaar proces op: de histamine-gernduceerde cAMP-
respons in U937-cellen vermindert op een tijds- en dosisafhankelijke wijze (hoofdstuk 4). Deze
desensitisatie is homoloog: de j3-receptor gemedieerde respons blijft gelijk.
Andere onderzoekers kloneerden in de loop van het onderzoek de genen die coderen voor
de H1- en de H2-receptor. Uit de aminozuurvolgorde van beide receptoreiwitten blijkt dat deze
inderdaad tot de klasse van G-eiwit-gekoppelde receptoren behoren. Beide receptoren zijn
opgebouwd uit zeven transmembraandomeinen, die door drie intra- en drie extracellulaire loops
worden verbonden. Wat opvalt is dat er zowel in de derde intracellulaire loop als in de C-
terminale staart van beide receptoren potentiele serine- en threonineresiduen zitten, die wellicht
gefosforyleerd kunnen worden door specifieke receptorkinases. Deze fosforyleringen zouden
de homologe desensitisatie van de receptoren kunnen verklaren. Het creeren van een cellijn
waarin H1- of H2-receptoren met een epitoop eraan (hoofdstuk 8) tot expressie worden
gebracht, maakt het mogelijk om -, met immuunprecipitaties - directe fosforylering van het
desbetreffende receptor-eiwit aan te tonen. Coexpressie van specifieke receptorkinases met
deze epitoop-receptoren kan meer inzicht geven in de agonist-gelnduceerde H1- en H2-
receptordesensitisatie. Daarnaast zal het gebruik van gemuteerde H1- of H2-receptoren,
bijvoorbeeld met een deletie in de derde intracellulaire loop of zonder cytoplasmatische staart,
veel kunnen verhelderen.
Downregulatie van histamine Hj- en H2-receptoren
De dichtheid van de Hl-receptoren in de HeLa- en de dichtheid van de H2-receptoren in de
U937-cellijnen (respectievelijk -60 en -20 mg fmol/mg eiwit) zijn voor onderzoek naar
downregulatie niet hoog genoeg. Tijdens het onderzoek publiceerden andere onderzoekers de
nucleotide-sequenties die voor deze receptoren coderen. Met deze kennis konden cellijnen met
voldoende hoge expressie worden verkregen.
Het gen dat codeert voor de humane HI-receptor werd tot expressie gebracht in ovaria
cellen van de Chinese hamster (CHO-cellen), wat een cellijn met een dichtheid van 861
fmol/mg eiwit opleverde (CHOhumHl-cellen). De receptoren bleken dezelfde farmacologische
eigenschappen te hebben als H l-receptoren in het cerebellum van de cavia en de humane
endogene H l-receptoren in de 1321Nl astrocytomacellen (hoofdstuk 3). De receptor was
verder gevoelig voor desensitisatie, gezien de afname van de Ca2+-respons na toediening van
histamine. Langdurige blootstelling aan histamine leidde tot een dosis- en tijdsafhankelijke
afname van het aantal receptoren (downregulatie). Tevens was zowel de door histamine als de
door ATP gernduceerde Ca2+-respons verminderd, hetgeen aangeeft dat modulatie ook
plaatsvindt op andere niveaus dan die van de receptor. PKC blijkt echter geen rol te spelen,
noch in de desensitisatie, noch in de downregulatie van de HI-receptor in CHOhumHl-cellen.
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Dit kan verklaard worden door een verschil in expressie van PKC-iso-enzymen in
CHOhumH l-cellen en in andere celsystemen. Er is nog geen informatie over de structurele
Hl-receptordomeinen die bij de downregulatie betrokken zijn. Mutanten kunnen meer inzicht
geven in downregulatie van de HI-receptor, zoals ook voor de H2-receptor is gedaan
(hoofdstuk S, 6 en 8).
Op eenzelfde wijze werd in CHO-cellen de H2-receptor van de rat tot expressie gebracht
(CHOrH2-cellen). Langdurige toediening van histamine leidde tot een dosis- en
tijdsafhankelijke downregulatie van H2-receptoren. Langdurige blootstelling aan stoffen die de
intracellulaire cAMP-concentratie verhogen, zoals forskoline en cholera-toxine, leidde eveneens
tot een afname van het aantal H2-receptoren. Verder zorgen histamine en forskoline voor een
snelle downregulatie van mRNA, mogelijk veroorzaakt door destabilisatie van het mRNA. Het
verloop en de mate van downregulatie lopen voor de door histamine en forskoline geYnduceerde
vermindering gelijk, zowel voor de receptoren als voor het mRNA. Oit wijst erop dat cAMP
een belangrijke rol speelt bij de downregulatie van H2-receptoren. Twee mutanten van de H2-
receptor, H2Leu124Ala (hoofdstuk S) en H2T307 (hoofdstuk 6), toonden echter ook een
cAMP-onafhankelijke route aan. Bij beide mutanten was de cAMP-produktie na toediening van
histamine minder sterk vergeleken met de wild-type receptor. Toch kon bij concentraties die
nog geen verhoging van cAMP veroorzaakten weI een downregulatie worden waargenomen.
Downregulatie van de H2-receptor blijkt dus te worden gemedieerd door twee verschillende
routes: een cAMP-afhankelijke en een cAMP-onafhankelijke.
Recente studies hebben aangetoond dat bij langdurige blootstelling (24 uur) van CHOrH2-
cellen aan histamine (100 11M) de dosis-respons-curve van de door histamine geYnduceerde
cAMP-respons naar rechts verschuift (Fig. 1). Deze verschuiving kan niet verklaard worden
door verminderde activiteit van het adenylaatcyclase, omdat de curve van de door forskoline
geYnduceerde cAMP-respons gelijk bleef (niet gepubliceerde resultaten). Downregulatie is
evenmin een verklaring: de ECso-waarde van de curve van de door histamine geYnduceerde
cAMP-respons blijft gelijk in CHO-cellen die slechts SOO fmol H2-receptoren per mg eiwit tot
expressie brengen (SO% van het aantal H2-receptoren in CHOrH2-cellen; niet gepubliceerde
resultaten). WeI zou een verminderde expressie van het Gs-eiwit de verschuiving kunnen
verklaren. Dit is ook beschreven voor andere G-eiwit gekoppelde receptoren. Kwantificering
van Gs-eiwit-niveaus na behandeling met histamine gedurende 24 uur kan hierin meer inzicht
geven.
De door histamine geYnduceerde downregulatie van H2-receptoren blijkt dus geen direct
effect te hebben op de signaaltransductie van de H2-receptor. Deze experimenten laten zien hoe
complex het proces van agonist-geYnduceerde receptor downregulatie is. De downregulatie is
toch fysiologisch belangrijk. Preliminaire studies lieten zien dat de ECso-waarde van de
histamine-gemduceerde cAMP dosis-respons-curve afhankelijk is van de dichtheid van de H2-
receptor tot 200 fmoVing eiwit (niet gepubliceerde resultaten). De door histamine geYnduceerde
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Fig.I. Effect van langdurige histamine behandeling op de H2-receptor signaaltransductie in CHOrH2-celien.
CHOrH2-celien werden met (open cirkels) of zonder (gevulde cirkels) 100 j.IM histamine gedurende 24 uur
voorbehandeld in DMEM zonder foetaal kalf serum. Vervolgens, werden cellen vele malen gewassen en
geincubeerd voor 1 uur in DMEM met 25 mM Hepes, pH 7.4. CHOrH2-celien werden daama gemcubeerd met
oplopende concentraties histamine gedurende 10 minuten bij 37°C in DMEM in aanwezigheid van 300 j.IM
IBMX en 25 mM Hepes, pH 7.4. De cAMP niveaus werden bepaald zoals beschreven in hoofdstuk 5.
downregulatie van H2-receptoren heeft dus weI degelijk effect op de signaaltransductie in
cellen met een Iage dichtheid H2-receptoren.
Voor verschillende G-eiwit-gekoppeide receptoren is gebleken dat de C-terminale staart een
belangrijke rol speeit in receptorregulatie. Truncatie van 51·aminozuren van de C-terminale
staart van de H2-receptor genereert een mutant (H2T307, hoofdstuk 6) die een sterkere
agonist-afhankelijke downregulatie geeft, terwiji de cAMP-afuankelijke downregulatie gelijk
blijft Veel andere G-eiwit-gekoppeide receptoren Iaten in dat gevaljuist mindel' downregulatie
zien. Dit gedeeite van de C-terminale staart van de H2-receptor belemmert dus agonist-
gelnduceerde downregulatie. Op vergelijkbare wijze is de regio in de C-terminale staart van
aminozuur 307 tot aminozuur 341 betrokken bij de remming van de door histamine
gelnduceerde signaaltransductie. Oit suggereert dat de C-terminale staart van de H2-receptor
zowel positieve als negatieve signalen bevat voor de signaaltransductie en de downregulatie.
Bovendien laat deze H2-receptormutant zien dat de cAMP-afhankelijke en cAMP-
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onafuankelijke H2-receptor downregu1atie via verschillende regulatieprocessen verlopen.
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Internalisatie van histamine H2-receptoren
Omdat geschikte radioliganden en antilichamen ontbreken is de intemalisatie van H2-receptoren
tot nu toe niet onderzocht. Om dit fenomeen toch te kunnen bestuderen werd een epitoop van
acht aminozuren (Flag) aan de N-terminale zijde van de H2-receptor vastgemaakt. Daardoor
kan de receptor met een monoklonaal anti-Flag-antilichaam worden gedetecteerd (hoofdstuk 8).
Het bleek niet mogelijk om de receptor-met-Flag in CHO-cellen tot expressie te brengen. Dit
1ukte weI in humane embryonale niercellen (293rH2Flag-cellen). Onderzoek heeft uitgewezen
dat de p1aatsing van een Flag-eiwit aan de H2-receptor geen invloed heeft op de
bindingseigenschappen van H2-agonisten en -antagonisten. Ook de histamine-geYnduceerde
signaaltransductie verloopt normaal.
Met behu1p van immunofluorescentiemetingen werd op het membraan van de 293rH2Flag-
cellen anti-Flag immunofluorescentie waargenomen (hoofdstuk 8). Permeabilisatie van deze
cellen gaf ook immunofluorescentie te zien in het cytoplasma, in regio's waar zich het Golgi-
apparaat bevindt. Na behandeling van de cellen met histamine (1 uur) was de
immunofluorescentie in het membraan geheel verdwenen. Dit duidt op intemalisatie van de H2-
receptoren. Omdat ook onder normale omstandigheden (rlelen van) receptoren in de eel
aanwezig zijn, is het helaas niet mogelijk om verhoging van internalisatie met
immunofluorescentie aan te tonen.
H2-receptor-internalisatie is reversibel. Het proces kan geblokkeerd worden door de
endocytose-remmer fenylarsine-oxide. Forskoline was niet in staat om de internalisatie te
induceren, hetgeen bewijst dat het proces cAMP-onafuankelijk is.
Internalisatie van andere G-eiwit-gekoppe1de receptoren gaat gepaard met de fosforylering
van serine- en threonineresiduen in de C-terminale staart, door nog niet geYdentificeerde
kinases. Het zou daarom interessant zijn een getrunceerde (H2T307, hoofdstuk 6) H2-
receptor-Flag te gebruiken om te onderzoeken of ook in dit geva1 de serine- en
threonineresiduen in de C-terminale staart bij de internalisatie betrokken zijn. Het is overigens
nog niet duidelijk of G-eiwit-koppeling nodig is voor internalisatie. Het gebruik van de
ontkoppelde H2-receptormutant (H2Leu124Ala, hoofdstuk 5) met daaraan een Flag-epitoop
kan hierin helderheid brengen.
Antagonist-gei"nduceerde upregulatie van H2-receptoren
De hoofdstukken 2 tim 8 laten zien dat H1- en H2-receptoren onderhevig zijn aan kort- en
langdurige desensitisatie. Dit uit zich in een afname van de receptorrespons en in receptor-
downregulatie. Hoofdstuk 9 beschrijft dat ook H2-antagonisten effect hebben op H2-
receptorexpressie. Langdurige blootstelling van CHOrH2-cellen aan H2-antagonisten
resulteerde in een upregulatie van H2-receptoren. Bij fysiologische dichtheden van de H2-
receptor in CHO-cellen zijn de receptoren geprekoppeld. Verschillende H2-antagonisten, die
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voorheen als competitief beschouwd werden, blijken nu negatieve intrinsieke activiteit te
vertonen: ze zijn in staat om de basale H2-receptor activiteit te blokkeren. Dit fenomeen wordt
ook weI 'invers agonisme' genoemd.
Zoals reeds getoond in hoofdstuk 5 worden H2-receptoren na stimulatie gedownreguleerd.
Invers agonisme van sommige antagonisten kan dus aan de waargenomen upregulatie ten
grondslag liggen. Deze hypothese wordt verder ondersteunddoor het feit dat cellen die geen
H2-receptor prekoppeling vertonen (CHOrH2LeuI24Ala en CHOrH2WT6) geen upregulatie
geven. Ook neutrale antagonisten zoals burimamide doen dit niet. Deze resultaten kunnen
eerdere publikaties verklaren inzake langdurige behandeling van maagzweren met H2-
antagonisten: sommige onderzoekers zagen in dat geval een verhoogde gevoeligheid van de
H2-receptoren, een verhoogde zuurgraad en een verlies van de remmende werking van H2-
antagonisten. Prekoppeling van receptoren, hetgeen aanleiding geeft tot invers agonisme, is
niet noodzakelijk afhankelijk van receptor-expressie, maar kan ook veroorzaakt worden door
overexpressie van G-eiwitten. Prekoppeling-eigenschappen kunnen dus specifiek zijn voor het
weefsel en per individu verschillen. Het is duidelijk dat de therapeutisch zeer belangrijke H2-
antagonisten opnieuw geclassificyerd dienen te worden, hetgeen belangrijke klinische
consequenties kan hebben. Verder onderzoek is nodig naar de structurele componenten van de
H2-antagonisten en de structurele domeinen van het H2-receptor-eiwit die voor invers
antagonisme verantwoordelijk zijn.
In de loop van het onderzoek kloneerden andere auteurs ook het gen dat codeert voor de
humane H2-receptor. Met deze kennis kon de humane H2-receptor in CHO-cellen tot expressie
worden gebracht (CHOhumH2-cellen) (hoofdstuk 7). Een uitgebreide karakterisering van deze
receptor liet zien dat de humane H2-receptor dezelfde eigenschappen heeft als de H2-receptor in
humane hersenen (hoofdstuk 7). Langdurige blootstelling van CHOhumH2-cellen aan
histamine en H2-antagonisten resulteerde ook in downregulatie, respectievelijk upregulatie (niet
gepubliceerde resultaten). Dit valideert het gebruik van het modelsysteem (CHOrH2-cellen).
Het modelsysteem benadrukt bovendien het belang van het gebruik van H2-receptormutanten
in het onderzoek naar H2-receptorregulatie (hoofdstuk 5, 6, 8 en 9). Het is zinvol om de
modelsystemen die meer de in vivo situatie benaderen, zoals primaire culturen of weefsels, in
het onderzoek naar regulatieprocessen te betrekken. Een combinatie van in vitro- en meer in
vivo-systemen komt het onderzoek naar de regulatiemechanismen van de histamine H1- en
H2-receptor sterk ten goede.
Samenvattend: histamine H1- en H2-receptoren zijn onderhevig aan een dynamische
receptorregulatie. Voor de ontwikkeling van effectieve therapieen is een gedetailleerde kennis
van de eiwitten die hierbij betrokken zijn, als ook meer inzicht in hun cellulaire distributie en
expressieniveaus noodzakelijk. Wordt vervolgd!!
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